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Abstract 
 
Overweight dogs have a reduced life expectancy and increased risk of chronic disease.  
During obesity development, adipose tissue undergoes major expansion and remodeling, but the 
biological processes involved are not well understood.  The objective of study 1 was to analyze 
global gene expression profiles of adipose tissue in dogs, fed a high-fat (47% kcal/g) diet, during 
the transition from a lean to obese phenotype.  Nine female beagles were randomized to ad 
libitum (n=5) feeding or body weight maintenance (n=4).  Subcutaneous adipose tissue biopsy, 
skeletal muscle biopsy and blood samples were collected, and dual x-ray absorptiometry 
measurements were taken at 0, 4, 8, 12, and 24 wk of feeding.  Ad libitum feeding increased 
(P<0.05) body weight, body fat mass, adipocyte size and serum leptin concentrations.  
Microarrays displayed 1,665 differentially expressed genes in adipose tissue over time in the ad 
libitum fed dogs.  Alterations were observed in many homeostatic processes including 
metabolism, oxidative stress, mitochondrial homeostasis, and extracellular matrix.  Our data 
implies that during obesity development subcutaneous adipose tissue has a large capacity for 
expansion, which is accompanied by tissue remodeling and short-term adaptations to the 
metabolic stresses associated with ad libitum feeding.  Gene expression changes between 12 and 
24 wk indicate the end of an initial adaptive response to ad libitum feeding and the onset of a 
chronic obese state. 
The objective of study 2 was to identify differentially expressed genes and enriched 
functional pathways between subcutaneous and gonadal adipose of lean and obese dogs at 24 wk 
of the animal experiment described in study 1.  Subcutaneous adipocytes of obese dogs were 
larger than obese gonadal and lean subcutaneous and gonadal adipocytes.  A total of 946 and 703 
transcripts were differentially expressed between gonadal and subcutaneous adipose tissue in 
   iii 
obese and lean dogs, respectively.  Both lean and obese dog gene lists had enrichment of the 
complement and coagulation cascade, lysosomal and systemic lupus erythematosus pathways.  
Obese dogs had enrichment of extracellular matrix-receptor interaction and renin-angiotensin 
system pathways.  Lean dogs had enrichment of glutathione metabolism, focal adhesion, 
synthesis and degradation of ketone bodies and amino sugar metabolism.  This study 
demonstrates that there are a core set of genes that differentiate adipose tissue depots regardless 
of obesity status, that may underlie differences in depot metabolism and inflammation.   
Skeletal muscle, as a large and insulin-sensitive tissue, is an important contributor to 
metabolic homeostasis and energy expenditure. Only a limited number of studies have compared 
skeletal muscle gene expression of lean and obese dogs.  The objective of study 3 was to identify 
genes and functional classes differentially expressed between lean and obese dog skeletal muscle 
at 24 wk of the animal experiment described in study 1.  Microarrays displayed 77 differentially 
expressed skeletal muscle transcripts between lean and obese dogs.  Alterations were observed in 
genes pertaining to the functional classes of signaling, transport, protein catabolism and 
proteolysis, protein modification, development, transcription and apoptosis, cell cycle and 
differentiation.  The small amount of differentially expressed genes in skeletal muscle indicates 
that adipose tissue expansion may buffer skeletal muscle from the metabolic stresses associated 
with ad libitum feeding.   
In study 1, zinc-alpha2 glycoprotein (ZAG) was highly expressed (up to 60-fold vs. 
baseline) in subcutaneous adipose tissue during weight gain, with increased expression at 4, 8, 
and 12 wk.  At 24 wk, however, ZAG expression had returned to basal levels.  Studies in both 
humans and rodents suggest that adipose tissue ZAG expression is down-regulated during 
obesity.  Therefore, the objective of study 4 was to determine if ZAG was increased with 
   iv 
increasing body weight and body condition score in a clinical population of dogs.  The clinical 
population studied had a narrow body condition score range (2-6), but wide body weight range 
(3.0-29.5 kg).  ZAG expression (ZAG/cycophilin A) ranged from 0.68-3.13, but there was no 
influence (P>0.05) of body condition score or body weight on its expression.  Gonadal adipose 
tissue expression of ZAG was not influenced by body condition score in this clinical population, 
which could be due to the depot measured or lack of obese dogs in this population. Our results indicate that adipose tissue has a large capacity to store and adapt to excess calories during the transition from a lean to obese phenotype.  The capacity for adipose tissue to expand may buffer skeletal muscle from the effects of excess calories during this period.  Even though large phenotypic differences were noted between lean and obese dogs, transcriptome analysis revealed a core set of genes differentiating subcutaneous and gonadal adipose tissue in both groups. 
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CHAPTER 1 
Introduction 
 Dog obesity rates vary from 20-40% in Westernized societies [1].  Obesity in dogs 
reduces lifespan and increases risk for numerous chronic diseases [2, 3].  Common causes of 
obesity include overfeeding and lack of exercise [4].  Although obesity seems to be a simple 
imbalance between energy intake and expenditure, it induces changes in multiple tissues and 
organ systems, which contribute to metabolic dysfunction and disease risk.  High-fat feeding and 
overfeeding total calories increase body fat and lead to insulin resistance and hyperlipidemia in 
the dog [5, 6].  Both liver and skeletal muscle becomes insulin-resistant during canine obesity.  
Non-esterified fatty acids (NEFA) cause hepatic and muscular insulin resistance [7, 8].  Visceral 
adipose tissue has increase lipid metabolic activity and may be the source of NEFA and 
inflammatory mediators causing liver and skeletal insulin-resistance.  Skeletal muscle plays an 
important role in insulin-stimulated glucose disposal and insulin resistance in skeletal muscle 
shifts glucose to other metabolically active tissues such as the liver and adipose tissue.   
Adipose tissue releases NEFA, and increased NEFA release as a result of adipose tissue 
dysfunction could play a causative role in metabolic perturbations associated with obesity.  
Mechanisms of adipose tissue dysfunction are relatively unexplored in the dog, compared to 
humans and rodents.  During diet-induced obesity in C57BL/6 mice, adipose tissue is infiltrated 
by macrophages, which dispose of lipid droplets from dead adipocytes [9].  The uptake of lipid 
droplets is important for adipose tissue remodeling, which is associated with changes in insulin 
sensitivity [10].  However, macrophages infiltrating adipose tissue also secrete cytokines that 
contribute to systemic low-grade inflammation associated with obesity.  Canine adipocytes 
express inflammatory cytokines, which are increased by treatment with tumor necrosis factor-α 
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or lipopolysacchride [11].  Inflammatory cytokines, along with NEFA, are known to reduce 
insulin sensitivity in multiple tissues and play a causative role in metabolic perturbations 
associated with obesity. 
 Whole genome microarrays have been utilized to determine adipose tissue and skeletal 
muscle functional differences between lean and obese rodents and humans.  These studies have 
been informative, but many unanswered questions remain.  Most studies have focused on 
differences between lean and obese individuals, without regard to the biological processes and 
changes that occur over the course of obesity development.   
The overall objective of this dissertation was to use microarray technology to identify 
differentially expressed genes and functional pathways during early weight gain in the dog, and 
to relate these changes in gene expression to circulating hormones and metabolites.  The 
objective of study 1 was to identify genes and functional gene classes differentially expressed 
over 24 wk of ad libitum feeding in the dog.  We hypothesized that over this time course, adipose 
tissue would have increased expression of transcripts associated with macrophages and 
inflammation, extracellular matrix production, and oxidative stress response.  The objective of 
study 2 was to identify genes and functional gene classes differentially expressed between 
subcutaneous and gonadal adipose tissue in lean and obese dogs.  We hypothesized that gonadal 
adipose tissue would have increased expression of carbohydrate and lipid metabolism genes and 
inflammatory markers, and these differences would be larger in obese as compared to lean 
animals.  The objective of study 3 was to identify genes and functional gene classes differentially 
expressed in skeletal muscle between lean and obese dogs.  We hypothesized that obese dogs 
would have gene expression patterns indicative of metabolic dysfunction.  Subcutaneous adipose 
tissue zinc-alpha2 glycoprotein (ZAG) mRNA was highly increased during weight gain.  The 
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objective of study 4 was to determine how ZAG expression is affected by body weight and body 
condition score in a clinical population.  We hypothesized that dogs with a higher body condition 
score would have increased expression of ZAG, but extremely obese dogs would have reduced 
ZAG expression. 
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CHAPTER 2 
Literature Review 
 Obesity is a major problem in pet dogs.  Obesity is diagnosed in dogs when body weight 
exceeds ideal body weight by 15-30% or when body condition score is > 8 on a 9-point scale [1].  
Worldwide, overweight and obesity rates vary between 20 and 40% in dogs [2].  Obesity is 
caused by an imbalance of caloric intake and energy expenditure.  The regulation of body weight 
is a complex process.  Some studies highlight the complex interactions between breed genetics, 
environment and aging, while other studies indicate that most obesity risk lies with the pet owner 
[2, 3].  Exercise-associated behaviors are particularly important with obesity risk, most likely due 
to effects on energy expenditure [4].  Weight loss is achievable through energy restriction, and 
increased dietary fiber improves weight loss [5]. 
Table 2.1: Obesity-associated chronic disease risk in dogs and humans 
Disease Species 
  Dog Human 
Insulin Resistance Increased Increased 
Type II diabetes - Increased 
Hyperlipidemia Increased Increased 
Hypertension Not of clinical significance Increased 
Atherosclerosis - Increased 
Orthopeadic Increased Increased 
Cancer Increased Increased 
Urogenital Increased Increased 
Life expectancy Decreased Decreased 
* Rodent models have been used to study all of these disease states 
 
As in humans, obesity increases the risk of chronic disease in dogs.  Obesity in dogs 
predisposes pets to a multitude of diseases (Table 1) that reduce quality of life including 
orthopedic disorders, cancer, urinary tract problems, endocrine disorders, and dyslipidemia [6].  
Lawler et al. performed a caloric restriction study on Labrador retrievers [7].  In that study, 
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restricted-fed dogs received 25% less food than overweight controls, resulting in an average 
body condition score of 4 versus 6.5, respectively [7].  That study found that calorically 
restricted dogs had decreased body weight and fat mass, improved glucose homeostasis, delayed 
onset of chronic disease (e.g., musculoskeletal and cancer), and a 2 yr increase in median life 
expectancy [Figure 1; 7].  Even though overweight control dogs were not allowed to become 
morbidly obese, being overweight had dramatic effects on lifespan and the incidence and onset 
of chronic disease.  Although changes in serum lipids, insulin-resistance, and inflammatory 
mediators have been documented in the obese dog, it is unclear how molecular changes in 
adipose tissue during obesity increase the risk of chronic disease.  The time course of molecular 
events leading to increased risk of chronic disease during the progression from a lean to an obese 
phenotype is also unknown. 
Figure 2.1: The effect of caloric restriction on life expectancy in the dog 
 
Both overfeeding and increasing dietary fat, in an iso-caloric manner, alter body 
composition in dogs [8, 9].  MRI images revealed that in response to 12 wk of feeding an iso-
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diet), there was an increase in omental (76%) and subcutaneous (182%) body fat as compared to 
baseline levels [8].  Obese dogs have increased concentrations of blood triglycerides, cholesterol, 
glucose and insulin as compared to normal weight controls [9-11].  Both hyperinsulinemia and 
increased fasting triglycerides are important components of the metabolic syndrome in people.  It 
should be recognized that even though the dog becomes insulin-resistant, this often does not lead 
to glucose intolerance [12].  This has led some laboratories to use pharmacological methods to 
create a state of type 2 diabetes in the dog through the combination of a high-fat diet and 
adminstration of a low dose of streptozotocin [13]. 
Inflammatory mediators, such as tumor necrosis factor-α (TNFα), and NEFA are 
contributors to obesity-associated insulin resistance and metabolic derangement.  During obesity 
development, the expansion of visceral adipose tissue is of particular interest due to its 
anatomical location.  Visceral adipose tissue is comprised of the gonadal, mesenteric, omental, 
and retroperitoneal depots.  Each of these depots likely have differing local and systemic 
physiological influences.  Mesenteric adipose tissue, which surrounds the intestines, and the 
omental depot have prime opportunities to alter systemic metabolism because their metabolites 
(e.g. NEFA), adipokines and cytokines drain into the splanchnic circulation and liver.  In dogs, 
the metabolic activity of omental adipose tissue is thought to exceed that of subcutaneous 
adipose, with high-fat-fed (42%) dogs having a higher ratio of omental : subcutaneous 
expression of enzymes involved in lipid synthesis and turnover as compared to chow-fed (35% 
fat) control dogs [14].  These differences in adipose tissue metabolic activity, have been 
proposed to result in increased release of NEFA and subsequent liver insulin resistance with 
high-fat fed dogs [15].  The importance of omental adipose tissue in controlling insulin 
sensitivity has been demonstrated by the removal of omental fat from normal healthy dogs, 
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which improved insulin sensitivity, but resulted in limited changes in body composition, fasting 
liver glucose production, blood glucose, insulin and NEFA concentrations [16]. 
In addition to secreting NEFA, adipose tissue also secretes adipokines and cytokines.  
Adipokines and cytokines contribute to systemic metabolism and inflammation.  In obese dogs, 
serum leptin and TNFα concentrations are increased [9, 17].  Obese dogs have lower serum 
adiponectin concentrations as compared to lean dogs [18].  Leptin and TNFα have both been 
implicated as causing insulin resistance, while adiponectin promotes insulin sensitivity [19].  The 
chronic effect of altered serum adipokine concentrations associated with the obese state is 
thought to be reduced insulin sensitivity, and insulin resistance.  In the obese state, it is not 
known if NEFA or adipokines and cytokines have predominant effects over each other, but are 
likely contributors to systemic insulin resistance and metabolic dysfunction. 
The liver is one of the most important target organs of cytokines and NEFA released 
from adipose tissue.  How adipose tissue influences liver function is an active research area.  In 
the dog, increases in fasting serum insulin concentrations associated with increased visceral 
adipose tissue mass are not due to changes in pancreatic insulin output, but rather due to 
decreased insulin extraction by the liver [20].  Hepatic insulin resistance precedes the 
development of peripheral insulin resistance and is a causative factor in fasting hyperinsulinemia 
in the dog [8].  The factors mediating adipose tissue and hepatic insulin resistance are unknown 
at this time, but NEFA and adipokines are likely involved.  NEFA are good candidates because 
they are known to cause insulin resistance, but NEFA concentrations are unaltered in fasted 
high-fat-fed (44%) dogs, which are insulin resistant [8].  This led Kim et al. to examine 
differences in 24 hr circadian profiles of glucose, insulin, NEFA, glycerol, and triglycerides [21].  
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Interestingly, the 24 hr profile of serum insulin showed increased concentrations in the morning 
hours, which was preceded by a nighttime increase of NEFA and glycerol concentrations. 
Skeletal muscle is important for overall metabolic homeostasis because of its large 
influence on energy expenditure and its role in glucose disposal as an insulin-sensitive tissue. 
Kolka et al. demonstrated that during moderate-fat (control diet supplemented with 6 g/kg bacon 
grease) feeding, insulin uptake into skeletal microvascular beds was decreased as compared to 
control dogs, resulting in reduced insulin exposure to myocytes [22].  A prime candidate 
mediating decreased skeletal muscle insulin uptake is NEFA, the infusion of which limits insulin 
absorption into this tissue [23].  TNFα has also been associated with reduced insulin sensitivity 
in obese humans, and in myocytes, because it directly affects insulin signaling by increasing 
serine phosphorylation and reducing tyrosine phosphorylation of insulin receptor substrate 1 
(IRS-1) [24].  Thus in obese animals, NEFA and inflammatory mediators are contributors to 
increased skeletal muscle insulin resistance and metabolic dysfunction.   
Changes in blood hormones, adipokines and metabolites are very informative in that they 
reflect tissue changes in metabolism and may provide diagnostic information on the obese state.  
NEFA and adipokines are markers of metabolic dysfunction.  In the dog, molecular mechanisms 
linking adipose and skeletal muscle tissue metabolic dysfunction to changes in serum hormones 
and metabolites are yet to be elucidated.  By understanding the molecular mechanisms mediating 
these events, future nutritional and pharmaceutical interventions may be devised to prevent the 
pathogenic processes of obesity-associated diseases. 
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Adipose tissue: 
Obesity, by definition, is a state characterized by excess adipose tissue.  Proper adipose 
tissue function is critical for whole body metabolic homeostasis.  Adipose tissue also functions 
as an innate immune organ, and adipose tissue dysfunction is associated with systemic low-grade 
inflammation [25].  As a tissue that supports both metabolism and immune function, adipose 
tissue is complex, consisting of pre-adipocytes and adipocytes, immune cells, endothelial cells 
and mesenchymal stem cells.  Pre-adipocytes and adipocytes are important for both metabolism 
and immune function.  As in other animals, canine adipose tissue produces and secretes 
adipokines and cytokines, which are responsive to inflammatory status and treatment with 
peroxisome proliferator activated receptor-γ (PPARγ) agonist, Rosiglitazone (GlaxoSmithKline, 
Philadelphia, PA).  Ryan et al. demonstrated that treatment of cultured canine adipocytes with 
lipopolysaccharide or TNFα increased gene expression of TNFα, monocyte chemoattractant 
protein-1 (MCP-1) and interleukin-6 (IL-6), while treatment with rosiglitazone lowered TNFα, 
MCP-1 and IL-6 gene expression [26].  As discussed above, obese dogs exhibit increased serum 
TNFα, and the results of Ryan et al. [26] indicate that adipose tissue could be the source of 
TNFα.  Canine adipose tissue differs from that of rodents and humans because it is the primary 
site of lipogenesis [27].  The effect of this difference on adipose tissue function and lipid storage 
is unclear, but could be an explanation for species differences in obesity-associated disease. 
The capacity of adipose tissue to expand and buffer other tissues from nutrient excess 
may be a large determinant of obesity-associated co-morbidities.  It has been noted that insulin-
sensitive obese humans have reduced visceral fat mass and adipocyte cell size, increased serum 
adiponectin and adipocyte insulin sensitivity, and reduced infiltration of macrophages into 
visceral adipose tissue, as compared to insulin-resistant obese humans [28].  That study 
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highlights the importance of regional adipose tissue depots, and how subjects matched by obesity 
status can have varied responses depending upon where and how they store excess body fat.  
Both adipocyte size and expression of lipid droplet proteins are important in controlling adipose 
tissue lipolysis.  Larger adipocytes in C57BL/6 mice have increased basal NEFA release [29].  
Indeed, adipose tissue of obese humans as increased basal lipolysis, which is accompanied by 
larger adipocytes and lower concentrations of the lipid droplet associated protein, perilipin, as 
compared to lean controls [30]. 
Pre-adipocytes and adipocytes are able to produce mediators of the innate immune 
response, including adipokines, cytokines, and complement proteins [26, 31].  Thus, adipose 
tissue is a crossroads of immune function and metabolism.  Its dual role in both of these 
physiologically important processes is highlighted by its complement expression.  Whole adipose 
tissue expresses complement proteins including complement C3, which is an important mediator 
of the alternative complement pathway.  When activated, it leads to the formation of the 
membrane attack complex and cell lysis.  In adipose tissue, it also has another role.  It can be 
converted into C3adesARG, through the removal of arginine.  C3adesARG, also known as 
acylation stimulating protein, has both local adipose tissue-specific metabolic effects ( e.g., 
increasing triglyceride synthesis) and systemic effects highlighted by C3 knockout mice, which 
are resistant to obesity development [32].  Cytokines also have similar roles in both energy 
metabolism and inflammation.  For example, TNFα is a potent mediator of inflammation, but 
also leads to lipolysis, as it has been noted to be one of the mediators of decreased muscle mass 
and adipose tissue loss during cancer cachexia [33]. 
A variety of immune cells have been identified in adipose tissue, including macrophages, 
T- and B-cells, and natural killer cells.  In two seminal publications, the presence of adipose 
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tissue macrophages was demonstrated to be increased by obesity and associated with insulin 
resistance in rodents [34, 35].  Interestingly, macrophages in adipose tissue form crown-like 
structures that surround adipocytes [36].  The adipocytes within crown-like structures are dead, 
no longer staining positive for perilipin [37].  The function of these macrophages surrounding the 
lipid droplet appears to be phagocytosis and clearance of the lipid droplet contents [37].  
Macrophages also have roles outside of this phagocytotic role, because they have been shown to 
have a direct effect on adipose tissue, increasing lipolysis during fasting and actively secreting 
matrix remodeling enzymes [38, 39].  Macrophage populations of adipose tissue appear to 
fluctuate, because recruitment increases during obesity and fasting [39, 40].  The precise roles of 
these macrophage populations are unknown, but during obesity they contribute to adipose tissue 
inflammation, remodeling, and metabolism as noted above. 
 
Adipose tissue regional differences: 
In humans, increased visceral adipose tissue is associated with higher rates of 
cardiovascular disease and type 2 diabetes, possibly due to its increased metabolic activity and 
proinflammatory environment [41].  Visceral adipose tissue is more metabolically active having 
a greater capacity for glucose uptake and NEFA release [42, 43].  A higher activity of 
glucocorticoid receptors makes visercal adipose more sensitive to glucocorticoid induced lipid 
accumulation than subcutaneous adipose tissue [44].  A greater expression of beta3-adrenergic 
receptors, makes it more responsive to sympathetic nervous system induced lipolysis [45].  In 
response to these hormonal stress signals visceral adipose tissue has a greater capacity to expand 
and release NEFA, which may underlie the association of increased visceral adiposity with 
increased chronic disease risk.  
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Obesity is a state of low-grade inflammation.  In addition to NEFA, increases in 
proinflammatory cytokines may play a role in obesity-associated co-morbidities.  Adipose tissue 
produces proinflammatory cytokines, and visceral adipose tissue in particular has greater levels 
of inflammation than subcutaneous adipose tissue.  Increased inflammation in visceral adipose 
tissue is associated with a greater presence of macrophages, the exact function of which is 
unknown [46].  Though increased macrophage populations are associated with inflammation, 
macrophages in adipose tissue also contribute to adipose tissue remodeling.  During diet-induced 
obesity in C57BL/6 mice, there is a remarkable remodeling response in visceral adipose tissue 
over 20 wk, while subcutaneous adipose tissue is unaffected [40].  The adipocyte death rate in 
visceral adipose tissue reached 80%, while that of subcutaneous adipose tissue was only 4% over 
that 20 wk study.  Visceral adipose tissue remodeling peaked at 16 wk, and this was associated 
with the greatest degree of insulin resistance.  At 20 wk, visceral adipose tissue cell number had 
increased 3-fold and insulin tolerance test performance had decreased by 40% as compared to 16 
wk.  That study was key in showing how adipocyte characteristics and adipose tissue remodeling 
influence insulin sensitivity and inflammation.  Because macrophages play such an important 
role in this process, it is necessary to understand the mechanisms by which they act to influence 
adipose tissue function and metabolic homeostasis in obese animals.  
Differnces in depot function are relatively unknown in the dog.  Both subcutaneous and 
visceral adipose tissue expand in response to increased dietary fat and food intake in the dog.  
Only a limited number of studies have examined protein and gene expression of different adipose 
depots in the dog at the tissue level.  As compared to subcutaneous adipose tissue, canine 
omental adipose tissue has increased gene expression of enzymes pertaining to metabolism (e.g., 
hormones sensitive lipase, lipoprotein lipase, PPARγ) with high-fat feeding [14].  Weight loss 
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has a much larger effect on lipid metabolizing enzymes (e.g., sterol regulatory element-binding 
protein 1, fatty acid synthase, perilipin) in visceral as compared to subcutaneous adipose tissue 
[47].  The differences in gene expression among adipose depots may underlie depot-specific 
responses to the macronutrient composition of the diet, overfeeding, and weight loss.  It is 
unknown how populations of inflammatory cells differ between depots and change during diet-
induce obesity in the dog.  Future studies targeting how depot differences in protein and mRNA 
expression differ and if they have influence on the development of obesity-associated disease are 
needed in the dog.  Of interest is the variability in immune cell composition and inflammation 
among depots because immune cells directly affect the metabolic state of adipocytes in rodent 
models.  
Figure 2.2: Epididymal adipose tissue remodeling in C57BL/6 mice 
 
 
Mechanisms of adipose tissue dysfunction: 
 Recruitment of macrophages during obesity is likely due to cellular stress associated with 
adipocyte hypertrophy, adipocyte death, and other undefined factors.  During adipocyte 
expansion, oxidative stress, endoplasmic reticulum (ER) stress, and extracellular matrix 
remodeling increase.  During obesity development, adipose tissue plays an important role in 
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buffering other tissues from excess lipid storage and NEFA exposure.  Lipid storage in skeletal 
muscle and liver during obesity is associated with impaired insulin sensitivity in these organs, 
and disrupts overall macronutrient metabolism.  Liver and muscle dysfunction are likely linked 
to excessive adipocyte lipolysis and exposure to NEFA, which can activate inflammatory 
signaling cascades.  Thus, the capacity of adipose tissue to expand and buffer other tissues from 
nutrient excess may determine the appearance of obesity-associated co-morbidities.  Changes in 
adipose tissue immune cell composition, and the balance of adipocyte hypertrophy vs. 
hyperplasia are important for adipose tissue homeostasis during times of expansion. 
The capacity of adipose tissue to expand is determined by adipocyte hypertrophy and 
hyperplasia.  Adipocyte hypertrophy occurs with overfeeding, but cells only have a finite 
capacity to grow before dying and becoming engulfed by macrophages.  Prolonged high-fat 
feeding in C57BL/6 mice leads to reduction in adipose tissue mass due to increased adipocyte 
cell death and reduced recruitment of preadipocytes, causing repartitioning of energy to fat-free 
mass [48].  The capacity for adipocyte growth may be a determinant of adipose tissue function, a 
fact illustrated by C57BL/6 mice with an adipose tissue-specific overexpression of adiponectin 
[49].  These mice have increased adipocyte size, but their adipose tissue remains insulin-
sensitive even with larger adipocytes and increased fat mass.  The capacity for expansion is 
likely influenced not only by adiponectin, but also extracellular matrix components.  The 
extracellular matrix of adipose tissue undergoes a biphasic progression during differentiation in 
cell culture, starting with fibrillar collagens and ending with production of laminar collagens.  
Collagen VI is a component of fibrillar collagen, and is increased with adipose tissue fibrosis in 
ob/ob mice compared to controls [44].  Collagen VI knockout mice fed a high-fat (60%) diet 
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have increased insulin sensitivity compared to wild type controls, despite having increased 
adipose tissue mass and adipocyte size [50].   
Though adipose tissue extracellular matrix profile changes over the course of 
adipogenesis, transitioning from the formation of fibrillar to laminar collagen synthesis, this may 
not be the reason for altered expression of extracellular matrix components in adipose tissue 
during obesity [51].  One of the drivers of these changes in extracellular matrix composition may 
be hypoxia.  As adipocytes expand, the distance between adipocytes and capillaries increases, 
leading to decreased oxygen exposure [52].  A hypoxic environment promotes reactive oxygen 
species formation and oxidative stress.  Hypoxia inducible factor 1 α is induced by low oxygen 
concentrations and is essential in controlling the transcriptional and homeostatic response to 
hypoxia.  In mice, constitutive over expression of hypoxia inducible 1 α in adipose tissue leads 
to adipose tissue fibrosis and reduced insulin sensitivity [53].  Along with extracellular matrix 
changes, hypoxia is also a known activator of macrophages, and an inhibitor of pre-adipocyte 
differentiation, and thus may impact both the inflammatory response and capacity to store 
additional fat [54]. 
 Obesity is associated with many stresses at the cellular and tissue level including 
inflammation, ER stress and oxidative stress.  Though oxidative stress is known to occur in 
adipose tissue, the etiology and consequences of this stress are not well-studied.  4-
hydroxynonenal (4-HNE) is a reactive aldehyde produced during times of oxidative stress.  4-
HNE is an important compound because once formed it is either detoxified or goes on to modify 
proteins, leading to inactivation or altered function.  Adipose tissue of C57BL/6 high-fat-fed 
(30% and 58%) mice has increased reactive oxygen species formation and increased 
concentration of carbonylated proteins [55, 56].  Using a proteomics approach, Grimsrud et al. 
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demonstrated carbonylation of numerous protein in adipose tissue of high-fat-fed (58%), obese 
as compared to low-fat-fed (10%) C57BL/6 mice [57].   Of interest, proteins modified by 
carbonylation pertained to functionally important pathways including lipid and carbohydrate 
metabolism, signal transduction, and oxidation-reduction homeostasis.  Antioxidant proteins 
(e.g., glutathione-S-tranferases) are responsible for clearing 4-HNE and mitigating oxidative 
stress.  Inactivation of antioxidant proteins by carbonylation may create a vicious cycle of 
increased oxidative stress and reduced quenching of reactive oxygen species and removal of 
toxic oxidation by-products (e.g., 4-HNE).  Glutathione-S-transferase A4 (GSTA4) is modified 
by carbonylation in adipose tissue, and in the mouse seems to be particularly important for 
detoxifying 4-HNE [56].  Adipose tissue knockdown of GSTA4 in C57BL/6 mice increases 
protein carbonylation, oxidative stress and mitochondrial dysfunction in both lean and obese 
mice as compared to normal C57BL/6 mice [57]. 
 The ER is the intracellular site of protein folding.  The accumulation of unfolded protein 
induces ER stress and activates the unfolded protein response, which increases synthesis of 
protein chaperones and enzymes involved with ER protein folding and degradation.  
Subcutaneous adipose tissue of obese humans has increased markers of ER stress (e.g., calnexin 
and glucose-regulated protein 78) [58].  The ER stress response is induced in cultured 
subcutaneous human adipocytes by saturated fatty acids, lipopolysaccharide, and high glucose, 
all of which have increased blood concentrations during obesity [58].   
The functional consequences of ER stress, oxidative stress, and inflammation are an 
activation of stress-associated signals including c-jun N-terminal kinases (JNK) and extracellular 
signal-regulated kinases (ERK) signaling.  JNK and ERK function during the stress response to 
increase synthesis of proinflammatory cytokines, and also influence insulin resistance by 
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increasing serine phosphorylation of IRS-1 and IRS-2 [59, 60].  Deletion of JNK1 and ERK1 are 
both protective against weight gain and subsequent insulin resistance in mouse models of high 
fat diet-induced obesity [61, 62].  The interplay of metabolic stress experienced by adipocytes 
during obesity and adipose tissue inflammation as a whole is not well understood.  Activation of 
stress induced pathways by ERK and JNK signaling likely contributes to the inflammatory 
response of adipose tissue during obesity, but the time course of such events and relative 
contributions of these signals to adipose tissue dysfunction is unknown. 
 
Mechanisms of skeletal muscle dysfunction: 
Skeletal muscle is one of the primary organs contributing to overall energy expenditure.  
Due to its role in metabolism, skeletal muscle is likely a major contributor to the dysregulated 
metabolism of metabolic syndrome. When skeletal muscle is unable to metabolize glucose, 
glucose utilization is shifted to lipogenic tissues resulting in increased de novo lipogenesis and 
subsequent increases in blood lipid concentrations.  Liver insulin resistance precludes that of 
skeletal muscle in the obese dog, but both play significant roles in nutrient partitioning and 
metabolism [8].   
Skeletal muscle insulin resistance can be induced by cytokines and NEFA, which have 
overlapping signaling [23, 24].  Signaling pathways activated by NEFA and cytokines include 
TLR4 and map kinase signaling, respectively.  After activation, these kinases can directly affect 
IRS phosphorylation by enhancing inhibitory serine phosphorylation or decreasing tyrosine 
phosphorylation, and also increase expression of proinflammatory genes that interfere with 
glucose uptake [24].  Lipid metabolites also may play a role in insulin resistance.  It has been 
noted that skeletal muscle insulin resistance is associated with increased accumulation of lipids 
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in the tissue, but at the same time, endurance athletes accumulate skeletal muscle lipids [63].  
Obviously, the accumulation of skeletal muscle lipid is not harmful, but is a useful energy source 
in such instances.  The difference between these two groups of humans may, however, be the 
turnover time, utilization of lipid stores, and the accumulation of toxic lipid metabolites [63].  
 Microarray technology has been useful in determining changes in canine skeletal muscle 
function due to both diet and age, but has not been used to define differences between lean and 
obese dogs [64].  Microarray profiling of skeletal muscle of insulin-resistant as compared to 
insulin-sensitive obese Pima Indians revealed global gene expression differences in functional 
categories pertaining to metabolism, transcription regulation and signaling, indicating that these 
differences may be contributing to the insulin-resistant phenotype within this population [65].  
Though these data are informative, cause and effect cannot be proven using this study design.  A 
time course of obesity-induced changes during high-fat (45%) feeding in APOE3 Leiden 
transgenic mouse skeletal muscle revealed a down-regulation of genes pertaining to lipid 
metabolism, acute phase response and inflammation [66].   
Although the previous studies indicate a role of skeletal muscle gene expression in 
insulin resistance and metabolism, many studies have had contrary results.  In C57BL/6 mice (9 
wk of age), 8 wk of high-fat (45%) feeding resulted in minor changes in skeletal muscle gene 
expression as compared to a low-fat (10%) control [67].  Interestingly, in that same study, the 
effects of age (8 wk vs. baseline) revealed larger changes in skeletal muscle gene expression than 
those of diet (8 wk: high-fat vs. low-fat).  Similar results have been observed in obese humans.  
Brons et al. fed a high-fat (60%), high-calorie (150% of caloric requirement) diet for 5 days to 
26 young, healthy men and observed no alterations in peripheral insulin sensitivity or skeletal 
muscle gene expression, even though subjects had increased fasting serum glucose 
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concentrations and increased hepatic glucose production [68].  Gene expression profiling, using 
cDNA microarrays, was used to compare myotubes isolated from obese patients with type 2 
diabetes vs. healthy obese controls (normal glucose tolerance and no family history of diabetes) 
[69].  In that study, expression profiles were not different, indicating that either insulin resistance 
associated with type 2 diabetes was not due to changes at the gene expression level or that 
skeletal muscle was not driving the process.  These data indicate that liver insulin resistance may 
drive changes that occur with over-feeding and that changes in peripheral insulin sensitivity 
occur later. 
 
Role of zinc-alpha 2 glycoprotein 1 (ZAG) in obesity: 
Zinc-alpha 2 glycoprotein is an adipokine produced by adipose tissue, that was first 
identified in the urine of patients with cancer cachexia, a state characterized by severe muscle 
wasting and fat loss [70].  It is a beta3-adrenergic receptor agonist [71].  Beta3-adrenergic 
agonists have been of interest in livestock production because they repartition energy from fat to 
muscle, resulting in leaner, more muscular animals.  In obese humans and rodents, adipose tissue 
ZAG gene expression is decreased as compared to lean controls [72, 73].  Conversely, peripheral 
administration of ZAG to ob/ob mice decreases blood glucose, increases insulin sensitivity, and 
increases muscle and brown adipose tissue mass [74].  It also has the ability to increase brown 
adipose tissue and skeletal muscle energy utilization.  Cell culture studies demonstrate that 
adipose tissue ZAG expression is induced by PPARγ and glucocorticoids, and is suppressed by 
TNFα [75, 76].  Thus, decreased ZAG expression during obesity, when adipose tissue is 
inflamed, would be expected.   
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 Zinc-alpha 2 glycoprotein expression, along with other adipokines, may be a bellweather 
of adipose tissue function.  It is well known that circulating leptin concentrations rise during 
obesity, due to increased adipose tissue mass.  Conversely, circulating adiponectin 
concentrations decrease during chronic obesity.  Adiponectin is an important metabolic mediator, 
which mantains insulin sensitivity and promotes fatty acid oxidation.  Adiponectin circulates in a 
number of complexes ranging from a trimeric form to a multimeric high molecular weight form.  
High molecular weight adiponectin has been identified having the highest correlation to insulin 
sensitivity.  In the dog, Bronson et al. identified adiponectin complexes of low and medium 
molecular weight, but high molecular weight complexes were not detected [77].  Circulating 
blood ZAG concentrations and ZAG adipose tissue gene expression were positively correlated to 
circulating adiponectin concentrations and adiponectin adipose tissue gene expression [72].  This 
is not surprising because adiponectin gene expression, like ZAG, is induced by PPARγ and 
inhibited by TNFα.  Together, these two proteins may indicate the inflammatory state of adipose 
tissue, with higher expression levels reflecting a metabolically healthy tissue, and low expression 
levels indicating increased adipose tissue inflammation and metabolic dysfunction. 
 
Summary: 
Changes in blood hormones and metabolites are associated with obesity in dogs.  The 
time course of obesity development has largely been ignored, especially at the level of tissue 
gene expression.  Even though we know characteristics of the obese state, it is unclear what the 
molecular drivers of metabolic dysfunction are.  Adipose tissue-specific changes occurring 
during obesity in the dog are relatively unexplored.  The process of adipose tissue expansion 
requires adaptation at many levels, including tissue and adipocyte structure, and adaptation to 
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metabolic stresses.  The time course of such changes is important because it may be associated 
with the appearance of co-morbidities.  By first identifying the time course by which changes in 
adipose tissue function occur, future dietary or pharmacological treatments can be designed for 
either rescuing lost functions (e.g., detoxification enzymes) or preventing the occurrence of 
negative changes (e.g., mitochondrial stress and inflammation). 
 Variation among adipose depots also is important when considering the links between 
obesity and chronic disease.  Because adipose tissue depots are located in different areas of the 
body and have unique microenvironments, each likely contributes to the obese state in a unique 
way.  No global transcriptome examination of how adipose depots differ has been reported in the 
dog.  In rodents and humans, visceral adipose tissue appears to mediate disease processes and 
progression, while fat storage in subcutaneous adipose tissue may be less pathogenic.  Visceral 
adipose tissue in the dog may play a causative role in reduced insulin sensitivity, but the extent 
of functional differences between depots and how they vary by obesity status are unkown. 
 Changes in skeletal muscle gene expression with weight gain and obesity have also 
received limited attention in the dog.  Skeletal muscle becomes insulin-resistant during obesity in 
dogs, but the contribution of gene expression changes to insulin resistance is unknown in the 
dog.  It could be that NEFA are the primary mediators of skeletal muscle insulin resistance, but it 
is more likely a combination of changes induced by increased NEFA exposure and altered gene 
expression leading to insulin resistance.  Thus, identifying gene expression differences between 
lean and obese dogs, and determining at what physiologic state these changes begin to occur 
would be useful in determining the cause of muscle metabolic dysfunction during obesity. 
By understanding the relationships between physiologically relevant blood hormones and 
metabolites with tissue gene expression, processes can be targeted either to reduce disease risk or 
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to aid in weight management.  Thus, the objective of this dissertation was to identify when 
adipose tissue and skeletal muscle gene expression changes occur and how they relate to 
systemic markers of metabolism.   
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CHAPTER 3 
Adipose tissue transcriptome changes during obesity development in female dogs1 
 
Abstract 
During the development of obesity, adipose tissue undergoes major expansion and remodeling, 
but the biological processes involved in this transition are not well understood.  The objective of 
this study was to analyze global gene expression profiles of adipose tissue in dogs, fed a high-fat 
diet, during the transition from a lean to obese phenotype.  Nine female beagles (4.09 ± 0.64 y; 
8.48 ± 0.35 kg) were randomized to ad libitum feeding or body weight maintenance.  
Subcutaneous adipose tissue biopsy, blood, and dual x-ray absorptiometry measurements were 
collected at 0, 4, 8, 12, and 24 wk of feeding.  Serum was analyzed for glucose, insulin, 
fructosamine, triglycerides, non-esterified fatty acids, adiponectin and leptin.  Formalin fixed 
adipose tissue was used for determination of adipocyte size.  Adipose RNA samples were 
hybridized to Affymetrix Canine 2.0 microarrays.  Statistical analysis, using repeated measures 
ANOVA, showed ad libitum feeding increased (P<0.05) body weight (0 wk: 8.36 ± 0.34 kg; 24 
wk: 14.64 ± 0.34 kg), body fat mass (0 wk: 1.36 ± 0.24 kg; 24 wk: 6.52 ± 0.24 kg), adipocyte 
size (0 wk: 114.66 ± 17.38 μm2; 24 wk: 320.97 ± 0.18.17 μm2), and leptin (0 wk: 0.8 ± 1.0 
ng/ml; 24 wk: 12.9 ± 1.0 ng/ml).  Microarrays displayed 1,665 differentially expressed genes in 
adipose tissue as weight increased.   Alterations were observed in adipose tissue homeostatic 
processes including metabolism, oxidative stress, mitochondrial homeostasis, and extracellular 
matrix.  Adipose transcriptome changes highlight the dynamic and adaptive response to ad 
libitum feeding and obesity development. 
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Introduction 
 Obesity in dogs, as in humans, has large effects on morbidity and mortality.  It is 
associated with increased incidence of orthopedic disorders, urinary tract and reproductive 
disorders, diabetes mellitus, and cancer rates [1].  Lean dogs live longer than overweight dogs 
and have decreased incidence of chronic disease [2].  In the laboratory setting, obese dogs 
exhibit insulin resistance, hypertension, and increased blood lipids [3, 4, 5, 6].  Increased food 
intake and increased dietary fat, in an isocaloric diet, have been shown to increase body fat and 
lead to insulin resistance as measured by hyper-insulinemic euglycemic clamp [5, 7].   
Obesity is regarded as a state of low-grade inflammation where dysfunctional adipose 
tissue is a major source of circulating pro-inflammatory cytokines in the blood.  Canine 
adipocytes both express and secrete adipokines and cytokines, including leptin, adiponectin, and 
tumor necrosis factor-α (TNFα) [8].  Stimulation of canine adipocytes with lipopolysaccharide 
or TNFα decreased adiponectin expression, while enhancing expression of interleukin 6 (IL-6), 
TNFα and monocyte chemoattractant protein 1 (MCP-1) [8].  Obese canines have higher 
concentrations of circulating leptin and lower concentrations of adiponectin [9, 10].  Weight loss, 
by itself, reduces circulating leptin concentrations, but has not been shown to increase circulating 
adiponectin concentrations [11].  Adiponectin circulates in a number of different multimers of 
different molecular weights, and the ratio of high molecular weight adiponectin to total 
adiponectin is more highly correlated to insulin resistance in humans than total adiponectin 
concentrations [12].  Smaller circulating multimer complexes of adiponectin have been detected 
in the dog, but higher molecular weight adiponectin has not been detected [13].  Because 
circulating hormones and metabolites are often times used to clinically assess disease states, it is 
important to link adipose tissue gene expression with relevant blood hormones and metabolites. 
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The use of transcriptomics, particularly whole genome microarrays, in obesity research 
has led to an increased understanding of adipose biology and begun to link mRNA changes to the 
physiological state of obesity.  Data compiled from such studies is useful in understanding global 
gene networks, and identifying novel genes and functional gene classes altered during obesity 
development and progression.  Though transcriptomics has been useful for understanding the 
differences in lean and obese animals, there has been a limited amount of research analyzing 
transcriptome profiles during the transition from a lean to obese phenotype.  Analyzing this 
transition period will be useful in differentiating transcriptome changes leading to the obese state 
from those that occur as a response to obesity, allowing us to identify causative factors for 
obesity-induced metabolic dysfunction and inflammation in adipose tissue. 
This is the first prospective study to examine adipose tissue transcriptome profile changes 
during the transition from a lean to obese phenotype in dogs.  We hypothesized that by gaining 
weight over a 24 wk time course, dogs would have increased insulin, leptin, and triglyceride 
concentrations and reduced total adiponectin concentrations.  Along with the changes in 
circulating hormones and metabolites, we hypothesized that gene expression profiles of adipose 
tissue would indicate increased recruitment and activation of macrophages, oxidative and 
endoplasmic reticulum stress, as well as metabolic adaptations to ad libitum feeding.   
 
Methods 
Animals and diet  
The University of Illinois Animal Care and Use committee approved all animal care 
procedures prior to initiation of this experiment.  Nine intact female beagles (4.09 ± 0.64 y; 8.48 
± 0.35 kg) were used in this experiment.  Dogs were housed in temperature-controlled rooms 
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(22.2°C) in individual kennels (1.06 m × 1 m), with a 12h light: 12h dark cycle at the Edward R. 
Madigan Laboratory on the University of Illinois campus.  Dogs were weighed and given a body 
condition score (9 point scale; 1= extremely thin; 9=morbidly obese) weekly, and daily food 
intake was recorded  [14].  After a baseline period of 4 wk, dogs were randomized to either ad 
libitum feeding (n=5) or weight maintenance (control, n=4).  All dogs were fed Purina® Pro 
Plan® Performance Formula, which includes chicken and corn gluten meal as the main protein 
sources, brewers rice and whole grain corn as the main carbohydrate sources, animal fat 
preserved with mixed tocopherols as the main fat source, and corn bran as the main dietary fiber 
source.  AOAC International methods were used to determine dietary dry and organic matter, 
ash, and total crude protein [15].  Acid hydrolyzed fat concentration was determined using 
methods from the American Association of Cereal Chemists and Budde [16, 17].  Total dietary 
fiber was determined using methods described by Prosky et al. [18].  The diet contained 24.3% 
acid hydrolyzed fat, 32.0% crude protein, and 6.7% total dietary fiber on a dry matter basis.  
Using modified Atwater Factors, it was estimated that the diet contained 4.67 kcal metabolizable 
energy/g on a dry matter basis. 
 
Blood and tissue collection   
At baseline and after 4, 8, 12, and 24 wk, blood was collected after an overnight fast via 
jugular venipuncture (Fig. 3.1).  Blood was immediately transferred to appropriate Vacutainer 
tubes (Becton Dickinson, Franklin Lakes, NJ, USA) for plasma and serum.  After collection, 
plasma samples were placed on ice until they were centrifuged at 3,000 x g for 15 min at 4°C. 
 After blood collection, dogs were sedated with 0.2 mg/kg butorphanol, 0.2 mg/kg 
medetomidine and 0.04 mg/kg atropine for subcutaneous adipose tissue biopsy collection.  
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Anesthesia was maintained and isoflurane in 100% oxygen was used if necessary until the 
procedure was finished.  An incision was made along the dorsal side of the body and 
subcutaneous adipose tissue was collected.  Samples were flash frozen in liquid nitrogen and 
stored on dry ice until being transferred to -80°C where they were stored until further analysis. 
 
Blood analysis  
Blood samples were analyzed for hormones and metabolites at each time point.  Serum 
non-esterified fatty acids (NEFA), triglycerides (TG) and fructosamine concentrations were 
determined by the University of Illinois Veterinary Diagnostic Laboratory (Urbana, IL) using a 
Hitachi 911 clinical chemistry analyzer (Roche Diagnostics, IN).  Plasma insulin was determined 
using a rat specific enzyme immunoassay (Cayman Chemical, Ann Arbor, MI) that has 100% 
reactivity with canine insulin.  Plasma adiponectin was determined using the Canine Adiponectin 
ELISA kit (Millipore, St. Charles, MO).  Plasma leptin was determined using the Canine Leptin 
ELISA kit (Millipore).  
 
Adipose tissue RNA extraction   
Total cellular RNA was extracted from adipose tissue samples using Trizol (Invitrogen, 
Carlsbad, CA).  Samples were cleaned with the RNeasy mini kit and DNase treated (Qiagen, 
Valencia, CA).  RNA concentration and purity was determined using an ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, DE), and RNA quality was assessed 
using a 2100 Bioanalyzer (Agilent, Santa Clara, CA). 
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Microarray analysis   
Microarray analysis was done at the W. M. Keck Center for Comparative and Functional 
Genomics.  All RNA samples were analyzed by cDNA hybridization to the Affymetrix 
GeneChip® Canine Genome 2.0 Arrays (Affymetrix, Santa Clara, CA).  Hybridization reactions 
were performed using Affymetrix GeneChip Expression 3′-Amplification Reagents (One-Cycle 
Target Labeling and Control Reagents package) according to manufacturer instructions and as 
described by Swanson et al. [19].  After hybridization, the microarray chips were washed and 
stained using a streptavidin-conjugated phycoerythrin dye (Invitrogen) enhanced with 
biotinylated goat anti-streptavidin antibody (Vector Laboratories, Burlingame, CA) using an 
Affymetrix GeneChip Fluidics Station 450 and Genechip Operating Software.  Images were 
scanned using an Affymetrix GeneChip scanner 3000. 
 
Quantitative real-time polymerase chain reaction (qRT-PCR)   
qRT-PCR was used to validate a subset of differentially regulated genes based on 
microarray results.  Gene-specific primers were designed using Primer Express 2.0 Software 
(Perkin Elmer, Boston, MA; Table 3.1).  RNA was converted to cDNA using the ABI cDNA 
Archive kit (Applied Biosystem, Foster City, CA) and amplified using SYBR green real time 
qRT-PCR on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems).   
 
Adipocyte sizing   
Adipose tissue was fixed in formalin and embedded in paraffin wax.  Two 5 µm sections 
were stained with hemotoxylin and eosin.  Adipocyte area was calculated using Axiovision AC 
software and an AxioCam MRc5 (Zeiss, Obercochen).   
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Statistical analyses   
qRT-PCR and blood hormone and metabolite data were analyzed using a repeated 
measures analysis in the Mixed Models procedure of SAS (SAS Institute, Cary, NC).  For 
adipocyte size, the fixed effects of treatment, time, and treatment x time were tested and animals 
and number of cells counted per animal were included as a random effect.  For blood hormones 
and metabolites, the fixed effects of treatment, time, and treatment x time were tested and animal 
was included as a random effect. Ten leptin samples (0 wk, 5 samples; 4 wk, 2 samples; 8 wk, 2 
samples; 12 wk, 1 sample) were undetectable.  After baseline, obese dogs had detectable leptin 
concentrations at every time point.  Multiple time points in the weight maintenance treatment 
had only 2 detectable samples.  Thus, for leptin, the fixed effect of time was tested in the ad 
libitum group, and baseline data was pooled for both treatments.  For qRT-PCR, the fixed effect 
of time was tested and animal was included as a random effect in the ad libitum group to mirror 
statistics used in microarray analysis.  A probability of P<0.05 was considered statistically 
significant and P<0.10 was considered a trend.  The mixed procedure was used to determine 
pooled standard error of the means (SEM). 
All quality control assessments, data processing and statistical analyses for microarray 
data were done in R using packages from the Bioconductor project as indicated below [20, 21].  
All microarray data have been deposited in the Gene Expression Omnibus repository at the 
National Center for Biotechnology Information archives (http://www.ncbi.nlm.nih.gov/geo) 
under accession #GSE24099.  Quality control assessment (affycoretools) showed that all arrays 
were of acceptable quality; surprisingly there was no individual dog effect, although there was a 
slight effect of processing batch [22]. This batch effect was accounted for in the statistical model 
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(described below).  The raw probe-level data were processed with the GCRMA algorithm, which 
performs a GC-based background-correction, does a quantile normalization between arrays and 
summarizes the multiple probes into one probe set value using a median polish algorithm [23].  
To be considered for statistical testing, a probe set had to be called “present” (Affymetrix’s Call 
Detection Algorithm) on at least 1 array or “marginal” on at least two arrays, and have a mean 
GCRMA value greater than 3.  A total of 23,835 probe sets out of the 42,860 present on the array 
passed these filters [24]. 
Testing for differential gene expression was done using the limma package to fit a mixed 
linear model while adjusting for the correlation due to the processing batch effect [25, 26].  Pair-
wise comparisons between the zero time point (baseline) and each of the other 4 time points for 
the ad libitum treatment were pulled as contrasts from the model. The results for the four pair-
wise comparisons were used to compute an overall F-test for “change over time” in the ad 
libitum treatment.  After correcting for multiple hypothesis testing using the FDR method, 1,665 
probe sets changed significantly (FDR P-value < 0.05) over time due to the ad libitum feeding 
[27].  
To evaluate the expression patterns due to ad libitum feeding over time, a heatmap was 
made of the 1,665 significant probe sets. The zero time point of the control group was added to 
represent the expression in the control dogs (Fig. 3.2).  Hierarchical clustering was used to 
elucidate the similarity in expression patterns, and determination of distinct clusters was done 
using the dynamicTreeCut package using the hybrid method with minClusterSize=4 and 
deepSplit=2 [28]. 
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Results 
Food intake, body weight, body composition, body condition and adipocyte size   
Food intake was increased (P<0.01) in ad libitum animals (Table 3.2; Fig. 3.3).  A 
significant treatment x time interaction (P<0.01) was present, with food intake peaking at 4 wk in 
the ad libitum group and remaining elevated (P<0.01) at 8, 12 and 24 wk.  Body weight, fat 
mass, bone mineral mass and body condition score were increased (P<0.01) in ad libitum fed 
dogs over the entire 24 wk period.  Body weight, fat mass, bone mineral mass and body 
condition score presented significant treatment x time interactions (P<0.01), exhibiting a rapid 
rise from 0 to 4 wk and then moderate increases until 24 wk.  Feeding efficiency (weight gain 
(kg) : food intake (kg)) was increased in obese dogs and a treatment x time interaction (P<0.01) 
was observed.  Feeding efficiency was increased (P<0.05) in ad libitum as compared to control 
dogs at 4 and 8 wk, but then, though numerically greater, were not different than the efficiency 
of control dogs at 12 and 24 wk.  Lean body mass was not different (P>0.10) in control versus ad 
libitum fed dogs.  Adipocyte size was increased (P=0.02) in ad libitum fed dogs and had a 
significant treatment x time interaction (P<0.01), rising to 3.15 times that of baseline 
measurements (Fig. 3.4). 
 
Blood metabolites, hormones and adipokines   
NEFA concentrations tended to be increased (P=0.06) in ad libitum fed dogs (Table 3.3; 
Fig. 3.5).  Serum TG concentrations had a significant treatment x time interaction (P<0.01), 
which was driven by a large TG increase in ad libitum fed dogs at the 24 wk time point.  Fasting 
blood glucose concentrations were increased (P<0.05) in ad libitum dogs, however, they were 
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within normal limits and there were no differences (P>0.10) in either insulin or fructosamine 
concentrations with weight gain.  Plasma leptin concentrations were increased (P<0.01) in ad 
libitum fed dogs over time (0 wk: 0.84±1.52, 4 wk: 2.79±1.35, 8 wk: 4.53±1.35, 12 wk: 
5.02±1.35, 24 wk: 12.94±1.35), as expected with an expanding adipose tissue depot.  Total 
adiponectin concentrations in ad libitum fed dogs numerically increased from 0 wk to 12 wk and 
then decreased from 12 wk to 24 wk producing a group x time interaction (P=0.05), but there 
was no main effect of treatment.  Serum c-reactive protein (CRP) concentrations were not 
biologically different between treatments, and the majority of serum TNFα concentrations were 
below the limit of detection as measured by ELISA (data not shown). 
 
Adipose tissue microarrays   
A total of 1,665 (~4% of array probe sets) differentially-expressed (FDR P<0.05) gene 
transcripts were detected within the ad libitum treatment over time (Fig. 3.2; Appendix A).  After 
removal of duplicate transcripts, a total of 1,378 probe sets were differentially expressed in 
subcutaneous adipose tissue over 24 wk.  Of these non-redundant transcripts, 962 were annotated 
genes, while 416 were unknown gene transcripts.  Annotated, non-redundant genes were then 
classified into functional classes using SOURCE (http://smd.stanford.edu/), Database for 
Annotation, Visualization and Integrated Discovery (DAVID) [29, 30] and NCBI resources 
(http://www.ncbi.nlm.nih.gov; Fig. 3.6; Table 3.4-3.6; Appendix A).  Although many transcript 
expression patterns were up-regulated or down-regulated over the entire study, others had 
variable expression patterns, having increased and decreased expression at different time points.  
Extracellular matrix (transcripts up: 18, down: 1, variable: 5), oxidation-reduction (transcripts 
up: 21, down: 8, variable: 7), and protein folding (transcripts up: 11, down: 0, variable: 5) had a 
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predominance of up-regulated transcripts.  DNA metabolism (transcripts up: 4, down: 3, 
variable: 19), immune response (transcripts up: 5, down: 2, variable: 13), protein degradation 
(transcripts up: 19, down: 6, variable: 34), translation and ribosome (transcripts up: 3, down: 13, 
variable: 34), RNA processing (transcripts up: 7, down: 18, variable: 37), and protein 
modification (transcripts up: 4, down: 1, variable: 9), had a predominance of transcripts that were 
both up- and down-regulated depending on the time point (e.g., level of obesity).  Interestingly, 
there were no functional classes that had a predominance of down-regulated transcripts over the 
entire study. 
 
Adipose tissue qRT-PCR   
The expression of 10 genes belonging to 5 functional classes [metabolism (ELOVL 
family member 6, elongation of long chain fatty acids (ELOVL6), pyruvate dehydrogenase 
kinase, isozyme 4 (PDK4), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (PFKFB1), zinc‐alpha2 glycoprotein (ZAG), oxidation reduction (glutathione peroxidase 7 (GPX7), 
glutathione S-transferase pi (GSTP)), immune (chemokine (C-C motif) ligand 5 (CCL5), 
triggering receptor expressed on myeloid cells 2 (TREM2)), extracellular matrix (lysyl oxidase 
(LOX)), and mitochondrial fusion (optic atrophy 1 (OPA1))] was confirmed using qRT-PCR 
(Fig. 3.7 and 3.8).  There was general agreement between expression patterns as measured by 
microarrays and qRT-PCR.  PFKFB-1 was an exception, showing increased expression over time 
as measured by qRT-PCR and decreased expression over time as measured by microarrays.  
Expression of GPX7 expression was similar in microarray and qRT-PCR until 24 wk, where 
microarrays exhibited a pattern of decreased expression and qRT-PCR showed increased 
expression.  Microarray data tended to show more dramatic changes in gene expression than 
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qRT-PCR, which was especially evident for ZAG, ELOVL6 and LOX expression.  This is most 
likely due to the background correction and normalization required for microarray analysis. 
 
Discussion  
  This study is the first to describe transcriptome changes over the course of diet-induced 
obesity in the dog.  We have noted large changes in the subcutaneous adipose tissue 
transcriptome particularly in the functional classes of metabolism, oxidation-reduction, 
extracellular matrix and immune response.  Adipose tissue is complex and contains many 
different cell types including: adipocytes, pre-adipocytes, immune cells, endothelial cells and 
fibroblasts.  Our data are from whole adipose tissue biopsies, so gene expression differences 
cannot be attributed to different cellular fraction or types but represents changes in gene 
expression of whole adipose tissue.   
 Ad libitum fed beagles had a large, but variable increase in food intake.  Food intake 
peaked at 4 wk, and then decreased, but remained elevated, thereafter.  Estrogen is known to 
interact with both orexigenic and anoroxigenic neuropeptides promoting decreased food intake, 
so the variable food intake in our study may be a response specific to females [31].  Along with 
increased food intake, there was a very large increase (~4.8x) in whole body adipose tissue mass, 
which was accompanied by an increase in adipocyte size.  As expected with large changes in 
body composition and adipose tissue mass, ad libitum feeding resulted in large effects on genes 
associated with metabolism in subcutaneous adipose tissue.  With weight gain, blood glucose 
increased and adipose tissue appeared to adapt to excessive substrates entering glycolysis, as 
many genes associated with carbohydrate metabolism were altered.  Hexokinase-1 expression 
was increased at all time points, a change that would commit more glucose to glycolysis, while 
  46 
the catalytic subunit of glucose 6-phosphatase expression was decreased.  Glucose-6-
phosphatase dephosphorylates glucose-6-phosphate.  Glucose-6-phosphatase does not have a 
defined role in adipose, a non-gluconeogenic tissue, but is critical for gluconeogenesis in the 
liver.  Decreased expression of the catalytic subunit of glucose 6-phosphatase would likely lead 
to decreased glucose leaving adipocytes and increase the amount of glucose committed to the 
glycolytic pathway, but the physiological relevance of such changes is unclear.  Pyruvate 
dehydrogenase kinase-4 regulates the pyruvate dehydrogenase complex and, thus, glycolytic flux 
into acetyl-CoA.  Pyruvate dehydrogenase kinase-4 expression was decreased until 24 wk, where 
it returned to baseline levels.  The importance of pyruvate dehydrogenase kinase-4 in glucose 
homeostasis has been demonstrated in pyruvate dehydrogenase kinase-4 -/- mice fed a high fat 
diet, which had a 28% decrease in fasting blood glucose levels and a 10% reduction in glucose 
area under the curve during intraperitoneal glucose tolerance testing [32].  In our study, 
subcutaneous adipose tissue in ad libitum fed beagles may have compensated for excessive 
calorie consumption and increased blood glucose by committing more glucose to the glycolytic 
pathway, and increased conversion of pyruvate to acetyl-CoA.  This may be important in dogs 
because unlike humans and rodents, adipose tissue is the primary site of de novo lipogenesis 
[33]. 
 Increased substrates moving through glycolysis would be expected to increase TCA cycle 
intermediates and substrates for both energy production and de novo fatty acid synthesis.  We, 
however, found that acetyl-CoA carboxylase-A (ACACA) was down-regulated over the entire 
study.  Human studies also have shown decreased ACACA expression in both subcutaneous and 
visceral adipose tissue during obesity [34, 35].   Ortega et al. [35] hypothesized that adipose 
tissue down-regulation of ACACA during long-term, chronic obesity could limit adipose tissue 
  47 
expansion, whereas during dynamic obesity, when adipose tissue is actively expanding, this 
down-regulation does not occur.   This is in contrast to our data that shows down-regulation of 
ACACA in subcutaneous adipose tissue, while adipose tissue is still undergoing a remarkable 
expansion.  Decreased ACACA expression may be a response by adipocytes to excess calorie 
exposure and metabolic load during ad libitum feeding.   Our data does, however, show a 
consistent increase of ELOVL6, which elongates 16C fatty acids from de novo lipogenesis and 
the diet.  Interestingly, ELOVL6 and ACACA are both regulated by SREBP1, but our data 
implies that under our study conditions ELOVL6 and ACACA are differentially regulated [36, 
37].  ELOVL6 -/- mice on a high-fat diet are insulin sensitive, even though they are obese and 
present increased concentrations of liver triglycerides [38].  Insulin sensitivity improvements in 
these mice are related to changes in liver function by restoring Akt and insulin receptor substrate 
2 (IRS-2) phosphorylation [38].  The role of ELOVL6 in adipose tissue is unclear and warrants 
further investigation.   
 Adipose tissue, an important regulator of energy homeostasis, releases adipokines and 
free fatty acids that modify energy metabolism of other tissues.  Adipose tissue lipolysis is 
responsive to both norepinephrine and glucagon.  β-adrenergic receptors are known to increase 
lipolysis, while α-adrenergic receptors decrease lipolysis.  Ad libitum fed beagles had decreased 
expression of ADRA2c (α-receptor) at 4, 12 and 24 wk, while ADRB2 (β-receptor) expression 
was decreased over the entire study.  These gene expression changes are likely essential for 
controlling lipolytic response to norepinephrine with increased adipose tissue mass.  ZAG is an 
adipokine identified as a contributor to excessive lipolysis during cancer cachexia [39, 40].  
Injections of ZAG into obese mice normalize blood glucose, increase insulin sensitivity, and 
increase muscle mass [41].  In this study, ZAG had increased (fold change>21.0) expression at 4, 
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8, and 12 wk, but then decreased (fold change=1.02) to baseline levels at 24 wk.  Adipose tissue 
ZAG gene expression is known to decrease with obesity in both humans and rodents [42, 43, 44].  
In Simpson-Golabi-Behmel syndrome adipocytes, ZAG is most highly induced by the 
peroxisome proliferator activated receptor gamma (PPARγ) agonist roglitazone and is most 
highly suppressed by treatment with TNFα [43].  Our data indicate that although a down-
regulation of ZAG may occur during chronic obesity, its expression may be increased during 
adipose tissue expansion, depending upon the degree of and/or duration of obesity.  Interestingly, 
in humans, ZAG expression is positively correlated with serum adiponectin concentrations, and 
negatively correlated with serum TG concentrations [45].  In our study, there were no significant 
group differences in adiponectin, but we found a significant interaction, whereby 24 wk serum 
adiponectin concentrations decreased from 12 wk concentrations in obese dogs.  The lack of an 
effect of weight gain on adiponectin may be specific to dogs and modified by study duration and 
sex.  TG concentrations were increased as compared to baseline in ad libitum fed beagles at 24 
wk.   These 24 wk changes in adiponectin and TG coincide with ZAG mRNA expression levels 
returning to baseline, following its large increase with initial weight gain.  Taken together, 24 wk 
ZAG expression and adiponectin and TG concentrations may represent the beginnings of 
obesity-induced decrements in whole body metabolism.  The local and peripheral roles that ZAG 
played during obesity development in our study are unknown, but metabolic changes occurring 
at the 24 wk time point could be indicative of the end of a short-term adaptive response and the 
beginning of a chronic deleterious response to chronic overfeeding. 
Obesity is associated with increased oxidative stress in adipose tissue.  To buffer 
oxidative stress, cells induce antioxidant and detoxification enzymes.  Glutathione-S-transferases 
(GST) play a role in decreasing oxidative stress by conjugating glutathione to electrophilic 
  49 
molecules leading to their disposal.  GSTA4 in mice has proven essential in maintaining 
oxidative status, mitochondrial function and insulin sensitivity during high-fat feeding, however, 
the role of other redox sensitive enzymes is unclear [46].  Glutathione peroxidase 1 (GPX1), 
NAD(P)H dehydrogenase, quinone 1 (NQO1) and GPX7 scavenge free radicals.   In ob/ob mice, 
GPX1 and GPX7 expression are decreased [47]. NQO1 expression positively correlates with 
adipocyte size and is reduced by weight loss [48].  In the current study, GSTP, GPX1 and NQO1 
were induced in ad libitum fed dogs at all time points, while GSTM4, GSTT2, GSTO1 and 
GPX7 displayed increased expression at 4 and 8 wk, which then decreased to baseline levels or 
lower at 12 and 24 wk.  Interestingly, the greatest food consumption occurred at 4 and 8 wk, so 
the induction of GSTM4, GSTT2, GSTO1 and GPX7 might be associated with the metabolic 
stresses during rapid adipose tissue expansion and lipid storage.  In cancer cells, GPX7 has been 
shown to decrease PUFA oxidation [49].  The induction of antioxidant enzymes observed in our 
study should have buffered oxidative stress, however, it may not be sustainable in chronic 
obesity.   Reduction in GSTs have been noted during obesity and decreased expression could 
lead to increased oxidative stress [50, 51].   
Oxidative stress is a factor that contributes to metabolic dysfunction and inflammation 
within adipose tissue during obesity [52, 53].  Increased oxidative stress leads to mitochondrial 
dysfunction.  PPAR-coactivator receptor 1 alpha (PGC1α) and beta (PGC1β) are known to play 
important roles in mitochondrial biogenesis and in maintaining mitochondrial function.   In the 
current study, expression of PGC1α was decreased until 12 wk, but then increased to basal levels 
at 24 wk, while PGC1β expression was decreased over the entire study.  3T3-L1 cells treated 
with high glucose, NEFA, or both have increased reactive oxygen species formation and 
decreased expression of PGC1α and PGC1β [54].  3T3-L1 cells also have a decrease in the 
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mitochondrial fusion protein mitofusin 1 during high NEFA exposure and high exposure to 
glucose and NEFA combined [54].  In the current study, ad libitum fed beagles displayed 
decreased expression of mitofusin 1 until 12 wk, but increased expression at 24 wk.  Another 
mitochondrial fusion protein, optic atrophy 1, also displayed decreased expression at 8 and 12 
wk, but increased expression at 24 wk.  The physiological relevance of mitofusin1 and optic 
atrophy 1 in adipose tissue is unclear, however optic atrophy 1 has been shown to have a role in 
the maintenance of mitochondrial inner membrane integrity and mitochondrial autophagy [55].  
Expression of PGC1α and PGC1β, along with changes in mitochondrial fusion proteins, 
indicates that there could be an alteration in mitochondrial homeostasis during rapid weight gain. 
 Adipose tissue of obese humans and rodents has increased numbers of macrophages and 
other immune cells.  Macrophages group together to form crown-like structures that surround 
dead adipocytes [56].  The exact role of adipose tissue macrophages is unclear, however recent 
advances indicate they are involved in adipose tissue remodeling and phagocytosis of lipid 
droplets of dead adipocytes, and regulation of adipocyte lipolysis in the fasting state [57, 58, 56, 
59].  CCL5, a monocyte chemoattractant, and TREM2, a marker of macrophages recruited from 
the circulation, increased at 4, 8, 12 and 24 wk, and 8, 12, and 24 wk respectively, in ad libitum 
fed beagles of the current study.  CCL5 and TREM2 expression in the current study suggest 
active recruitment of monocytes to subcutaneous adipose tissue during rapid weight gain.  Along 
with macrophage recruitment, gene expression changes indicate an increase in the innate 
immune response, with decreased expression of complement factor H and I, both inhibitors of 
the complement cascade, at 8 wk, while complement component 8, gamma polypeptide, a 
component of the membrane attack complex, was elevated over the entire study.  Expression of 
CD97, a recognized mediator of inflammation in arthritis [60], was increased at 4, 12 and 24 wk.  
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In contrast, mucosa associated lymphoid tissue lymphoma translocation gene 1 had decreased 
expression at 4, 8, and 12 wk, but then returned to basal expression levels at 24 wk.  Although 
our data suggests increased innate immune system activation, we did not detect any changes in 
cytokine mRNA, such as increased TNFα or IL-6 using microarrays.  Interestingly, our data 
demonstrate a trend towards decreased inflammatory response with increased anti-inflammatory 
proteins (TREM2; interleukin 10 receptor, beta), although suppressor of IKBKE 1 had decreased 
expression until 12 wk and then returned to basal expression levels.  Gene expression differences 
of immune response genes may not be limited to immune cells solely, as canine adipocytes are 
responsive to inflammatory stimuli [8].  Our data indicate that although there is active 
recruitment of macrophages to adipose tissue, it is not accompanied by the characteristic adipose 
tissue inflammatory response.  One explanation for this could be that the adipose tissue was 
collected from the subcutaneous depot, which is generally considered to have less inflammation 
than the visceral depot.  It could also be that because weight gain occurred over a relatively short 
period of time in this study, our results represent an acute adaptive response rather than one that 
is chronic and deleterious.   
During obesity development, extracellular matrix (ECM) supports expanding lipid-laden 
adipocytes.  Extracellular matrix remodeling is associated with insulin sensitivity [57].  
Adipocytes in cell culture are noted to undergo a biphasic ECM development whereby there is a 
transition from a fibrillar to laminar ECM [61].  In vivo adipose tissue fibrosis is associated with 
metabolic dysfunction and adipose tissue inflammation [62, 63].  Gene expression of ad libitum 
fed dogs indicated enhanced ECM biosynthesis, particularly components associated with laminar 
ECM.  Ad libitum fed beagles exhibited increased synthesis of basement membrane components, 
including collagen IV A1, collagen IV A2, nidogen 1, nidogen 2 and laminin alpha 3.  Along 
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with increased basement membrane transcript expression, there was also increased collagen 
XXIII A1 and fibromodulin expression.  Fibromodulin expression in tendons is associated with 
tendon rigidity, and has been proposed to be a critical factor in early fibril formation [64].  
Fibromodulin and asporin are both members of the small leucine repeat rich protein family.  
Unlike fibromodulin, asporin expression was reduced at 4 and 8 wk, but then increased at 12 and 
24 wk.  Asporin inhibits TGF-beta, which is involved with increasing ECM formation and 
angiogenesis [65].  ADAM metallopeptidases and lysyl oxidase are involved in ECM remodeling 
and have been implicated in obesity.  LOX expression was increased >7 fold and ADAM 
metallopeptidase with thrombospondin type 1 motif, 2 was increased >3 fold over the entire 24 
wk study.  Mice over-expressing hypoxia inducible factor-1 alpha have increased LOX 
expression and adipose tissue fibrosis [63].  Subcutaneous adipose tissue of ad libitum fed 
beagles compensates for increased adipocyte cell size by increasing extracellular matrix 
production and remodeling enzymes. 
The ubiquitin proteosome pathway is induced by the accumulation of unfolded proteins 
and is involved with protein turnover.  Proteins are targeted for proteosomal degradation by 
polyubiquitin chains and before entry into the proteosome, ubiquitin is removed from target 
proteins. The ubiquitin proteosome pathway is the predominant pathway for cellular protein 
catabolism.  Ubiquitin mediated degradation has been implicated in regulation of insulin 
signaling through degradation of IRS-1, adipogenesis through degradation of PPARγ, and 
lipogenesis through degradation of ACACA [66, 67, 68]. In general, our data demonstrated that 
proteosome subunits followed a pattern of increased expression until 8 wk.  At 12 wk, expression 
returned to basal levels and then decreased below basal expression levels at 24 wk.  Along with 
proteosome subunits, 2 E2 ligases, 10 E3 ligases and 7 deubiquitinating enzymes were 
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differentially expressed.  Interestingly, unlike proteosome gene expression, 14/19 genes involved 
in ubiquitin dependent protein degradation had expression that peaked or plateaued at 24 wk. 
This indicates that proteosome gene expression may be responsive to the large increase in food 
intake at the beginning of the study, while the genes involved with ubiquitin dependent 
degradation may be more responsive to chronic overfeeding and the associated increase in 
adipose tissue mass. 
 Both adipocyte hypertrophy and hyperplasia occur in adipose tissue.  The commitment of 
pre-adipocytes to fully differentiated adipocytes is a tightly regulated and well-described process.  
Wnt and bone morphogenetic protein (BMP) signaling modulate adipogenesis.  Our data 
demonstrated a general increase in expression of WNT signaling pathway inhibitory proteins and 
a decrease in transcription factor 7-like 2 (TCF7L2) expression, which was most highly 
decreased at 8 wk.  BMP signaling regulates the conversion of pre-adipocytes to mature 
adipocytes.  The BMP2 signaling pathway (BMP2, SMAD family member 5 (SMAD5), inhibitor 
of DNA binding 3 (ID3)) was down regulated at all time points.  Reduced expression of runt-
related transcription factor 1 (RUNX1T1), nucleolar complex associated 3 homolog (NOC3L), 
xanthine oxidoreductase (XOR), and the BMP signaling pathway indicate a trend toward 
decreased adipogenesis.  It is unclear what the overall effect these gene expression changes have 
on adipose tissue function, however it has been suggested that pre-adipocytes in obese humans 
have increased proliferation but decreased differentiation into mature adipocytes [69]. 
 The application of our study to adipose tissue physiology is limited.  As mentioned 
previously, we are unable to attribute changes to certain cell types or fractions.  Additionally, 
changes in the amount of certain cell types (e.g., increased pre-adipocytes or macrophages) could 
alter gene expression data without any differences in gene expression in specific subsets of cells.  
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Our results do, however, do represent relevant whole tissue changes.  Future studies comparing 
isolated cell fractions would be useful for determining the cell type origins of the gene 
expression differences in our study.  The correlation of mRNA and protein expression is not 1:1 
and has a range between 0.45 and 0.74 in different studies, and protein and mRNA expression 
differences may not reflect differences in protein activity [70].  The dogs used were female 
beagles, and many differences exist in response to obesity between male and female animals.  
Lastly, our study cannot separate the effects of the response to increased energy and 
macronutrient intake, from growing adiposity.  This study does provide a comprehensive 
analysis of the complex changes in adipose tissue gene expression that occur as a response to ad 
libitum feeding and subsequent weight gain. 
 
Conclusion 
 Our study highlights the dynamic nature of the global transcriptional response to ad 
libitum feeding and rapid weight gain. The strength of our study lies in tracking transcriptome 
changes over time during the transition from a lean to obese phenotype.  In this study, adipose 
tissue expansion during ad libitum feeding led to metabolic and adipose gene expression changes 
associated with macronutrient utilization, induction of antioxidant proteins, matrix remodeling 
and increased proteosome expression.  The first 12 wk of the study highlight the high capacity of 
dogs to expand adipose tissue depots during times of abundant energy intake.  By 24 wk, 
however, even though adipose stores were still expanding, adipose tissue gene expression and 
circulating blood hormones and metabolites were beginning to show changes that may have been 
the beginning of a chronic deleterious response.  In the future, targeting specific functional 
classes and genes identified during this transition period may prove useful for understanding 
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causative factors for adipose tissue dysfunction.   In particular, understanding how early 
alterations in oxidation-reduction, macrophage recruitment, lipid synthesis and handling, and 
extracellular matrix remodeling influence chronic obesity and co-morbidities may prove useful.  
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Figure 3.1:  Study design: After a 4wk baseline, dogs were randomized to either ad libitum 
feeding or body weight maintenance.  At 0, 4, 8, 12 and 24 wk subcutaneous adipose tissue, 
blood serum and plasma, and dual x-ray absorptiometry images were collected.  
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Figure 3.2:  Heat Map of 1,665 differentially expressed gene transcripts in subcutaneous adipose 
tissue of ad libitum fed dogs over 24 wk.  Log2 fold-changes for each group were calculated 
using the mean expression value across all arrays as the baseline.  Hierarchical cluster analysis 
was used to create the dendrogram. 
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Figure 3.3:  Food intake, body weight, body fat mass and feeding efficiency profiles of control 
(n=4) and ad libitum (n=5) fed dogs. P-values are provided for the group, time and interaction 
effects. 
 
  69 
  
Figure 3.4:  Adipocyte size of ad libitum (n=4-5) and control (n=3-4) dogs.  P-values are 
provided for the group, time and interaction effects of adipocyte size data. 
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Figure 3.5:  Blood hormone, metabolite and adipokine profiles of control (n=4) and ad libitum 
(n=5) fed dogs.  P-values are provided for the group, time and interaction effects. 
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Figure 3.6:  Major functional gene classes in subcutaneous adipose tissue affected by ad libitum 
feeding.  Functional classification was determined using SOURCE, DAVID and NCBI 
resources.  Each functional class had a minimum of 11 annotated, non-redundant genes.  
Transcription (130) Transport (94) Metabolism (89) Signaling (69) Cell cycle, differentiation, proliferation and growth (53) RNA  processing (52) Protein degradation (45) Translation and ribosome (35) Oxidation, reduction and detoxiOication (25) DNA metabolism and repair (22) Apoptosis (18) Cytoskeleton (18) Extracellular matrix (15) Immune response (15) Protein modiOication (12) Cell adhesion (12) Phosphorylation (12) Protein folding (11) 
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Figure 3.7:  Gene expression profile comparisons of selected metabolism genes in ad libitum fed 
dogs using microarray and qRT-PCR assays.  P-values are provided for the time effect of qRT-
PCR data (n=5). Figure 5: Gene expression profile comparisons of selected oxidation-reduction, 
immune response, extracellular matrix and mitochondrial fusion genes in ad libitum fed dogs 
using microarray and qRT-PCR assays.  P-values are provided for the time effect of qRT-PCR 
data (n=5). 
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Figure 3.8: Gene expression profile compari4sons of selected oxidation-reduction, immune 
response, extracellular matrix and mitochondrial fusion genes in ad libitum fed dogs using 
microarray and qRT-PCR assays.  P-values are provided for the time effect of qRT-PCR data 
(n=5).
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Table 3.1: Forward (F) and reverse (R) primers used for quantitative reverse transcriptase-PCR analysis 
 
Gene 
Symbol Gene Name Primer (5’3’) 
GenBank Accession 
Number 
F ATCTGCACTGGATTCAGGCG ZAG alpha-2-glycoprotein 1, zinc-binding 
R CTCCCCCCGACTTAGTCTCC 
CO699050 
F CAGCAAATTCTGGGCTTATGC ELOVL6 ELOVL family member 6, elongation of long chain 
fatty acids  R CCTAGTTCGGGTGCTTTGCTTA 
PMRNA17854 
F CCCCTGAGGATCATTGATCG PDK4 pyruvate dehydrogenase kinase, isozyme 4 
R TGGTGCCGTGGAGTATGTGT 
CX008060 
F CTGGAAATACCTAGTGGCCCC GPX7 glutathione peroxidase 7 
R GGGTCCCAAGCCCCTACTAC 
PMRNA6440 
F CCTCTGCCTCCCCATATGC CCL5 chemokine (C-C motif) ligand 5 
R GGGTAGTCGGCCGGAAAT 
NM_001003010 
F TGGTGCCTGAATCGGACTATT LOX lysyl oxidase 
R ATATGCATGGTGTCCCGTGTAG 
PMRNA1619 
F GAAGTCCTCCAGTTAGGCTCCTT PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 1 R GCTCGGAAACGCAGTCAGA 
CO704298 
F ACGAGGAGCACCCAGCCTAT OPA1 optic atrophy 1 (autosomal dominant) 
R TTCTACTCCTCGGGATTCAAGGT 
CO696931 
F GTGGCTGCTGTCCTTCCTAAA TREM2 triggering receptor expressed on myeloid cells 2 
R ACCCAGCGCATCATCCA 
PMRNA3184 
F CAAGCTCAAGGCATTCCTGTT GSTP glutathione S-transferase pi 
R CTGCTTCCTGTTGCCATTGAT 
PMRNA17710 
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Table 3.2:  Food intake, body weight, body composition, and body condition score (BCS) of control and ad libitum fed dogs 
Values are means (n=5 for ad libitum; n=4 for control). 
*BCS is based on a 9 point scale (1=extremely thin; 9=extremely obese). 
       P-value  
Treatment 0 wk 4 wk 8 wk 12 wk 24 wk SEM Time Treatment 
Treatment 
x time 
Ad libitum 137.1 358.8  314.0 256.7 281.3 21.6 Food intake (g/d) 
Control 140.5 147.8  143.1 153.8 140.0 19.3 
<0.01  <0.01 <0.01 
Ad libitum       8.36    10.72    11.78    12.18    14.64     0.34 Body weight (kg) 
Control        8.63      8.55      8.40      8.50      8.55     0.38 
<0.01  <0.01 <0.01 
Ad libitum        1.36      3.31      4.16      4.79      6.52     0.24 Fat mass (kg) 
Control        1.54      1.69      1.62      1.53      1.96     0.26 
<0.01  <0.01 <0.01 
Ad libitum        0.19      0.22      0.25      0.24      0.26 
 
    0.01 Bone mineral mass 
(kg) Control        0.18      0.20      0.19      0.18      0.19     0.01 
<0.01  <0.01 <0.01 
Ad libitum        6.17      6.36      6.69      6.39      6.85     0.28 Lean mass (kg) 
Control        6.16      6.14      6.12      6.28      6.06     0.25 
  0.35    0.33  0.09 
Ad libitum  0.24 0.12 0.05 0.10 0.02 Weight gain (kg) / 
Food intake (kg) Control  -0.02 -0.04 0.02 0.00 0.02 
 0.07 <0.01  <0.01 
Ad libitum      4.2    6.4    7.1    7.1    8.1     0.22 BCS* 
Control      4.4    4.4    4.2    4.2    4.2     0.24 
<0.01 <0.01 <0.01 
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Table 3.3: Fasting blood metabolite and hormone concentrations of control and ad libitum fed dogs 
Values are means (n=5 for ad libitum; n=4 for control). 
*NEFA= non-esterified fatty acid. 
       P-value 
 
Treatment 0 wk 4 wk 8 wk 12 wk 24 wk SEM Time Treatment 
Treatment x 
time 
Ad libitum     0.76     1.01   1.05   1.03   0.99   0.12 NEFA* (mEq/l) 
Control     0.81     0.88   0.68   0.52   0.65   0.13 
0.45 0.06          0.09 
Ad libitum 41.6 39.4 45.0 41.2 72.8    6.22 Triglycerides (mg/dl) 
Control 49.5 38.3 46.5 55.0 43.3  6.96 
0.02 0.82        <0.01 
Ad libitum 282 275 261 251 272  11 Fructosamine  
(µmol/l) Control 266 265 260 260 274  10 
0.04 0.77          0.43 
Ad libitum 65.2 78.4 75.6 70.6 74.8 
 
 3.6  Glucose (mg/dl) 
Control 62.3 66.5 70.8 68.0 62.5 
 
 4.1 
0.16 0.02          0.57 
Ad libitum 12.2 28.1 33.7 19.8 33.0  5.4 Insulin (pM) 
Control 17.1 24.2 22.3 19.6 11.8  6.0 
  0.18   0.12          0.21 
Ad libitum 35.7 42.2 41.5 48.2 37.8  4.0 Adiponectin (ng/ml) 
Control 35.1 34.1 34.2 36.8 41.2  4.5 
  0.12      0.37          0.05 
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Table 3.4:  Differentially expressed genes associated with metabolism, oxidation-reduction (redox), and mitochondrial fusion in 
subcutaneous adipose tissue of ad libitum fed dogs 
    Fold change 
Gene 
symbol Gene name Probe 
Functional 
Classification 4 wk 8 wk 12 wk 24 wk 
HK1 hexokinase 1 CfaAffx.21481.1.S1_s_at Metabolism 1.92 2.04 1.88 2.06 
G6PC glucose-6-phosphatase, catalytic subunit Cfa.204.1.S1_s_at Metabolism 0.04 0.18 0.04 0.07 
ACACA acetyl-Coenzyme A carboxylase alpha CfaAffx.27754.1.S1_s_at Metabolism 0.30 0.31 0.32 0.30 
ELOVL6 ELOVL family member 6, elongation of long 
chain fatty acids 
CfaAffx.17954.1.S1_at Metabolism 61.82 15.45 33.82 20.82 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 CfaAffx.4097.1.S1_s_at Metabolism 0.13 0.31 0.21 1.06 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 Cfa.2282.1.S1_at Metabolism 0.30 0.40 0.36 1.04 
ADRA2C adrenergic, alpha-2C-, receptor CfaAffx.22510.1.S1_at Metabolism 0.24 0.90 0.22 0.31 
ADRB2 adrenergic, beta-2-, receptor, surface Cfa.3770.1.S1_at Metabolism 0.19 0.37 0.18 0.17 
ADRB2 adrenergic, beta-2-, receptor, surface CfaAffx.28073.1.S1_s_at Metabolism 0.19 0.38 0.13 0.16 
ZAG alpha-2-glycoprotein 1, zinc-binding Cfa.11319.1.A1_at Metabolism 63.56 21.26 39.67 1.01 
PGC1α peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha 
CfaAffx.25283.1.S1_at Metabolism 0.34 0.50 0.22 0.99 
PGC1β peroxisome proliferator-activated receptor 
gamma, coactivator 1 beta 
CfaAffx.27981.1.S1_s_at Metabolism 0.45 0.76 0.36 0.59 
GPX1 glutathione peroxidase 1 Cfa.4561.1.A1_at Redox 1.31 1.38 1.38 1.39 
GPX7 glutathione peroxidase 7 CfaAffx.6540.1.S1_at Redox 2.03 2.55 1.54 1.08 
GSTM4 glutathione S-transferase mu 4 Cfa.17201.1.S1_at Redox 2.30 2.07 1.49 1.06 
GSTM4 glutathione S-transferase mu 4 CfaAffx.30320.1.S1_s_at Redox 1.30 2.46 2.16 1.61 
GSTO1 glutathione S-transferase omega 1 CfaAffx.16567.1.S1_s_at Redox 1.37 1.21 1.27 0.79 
GSTP Glutathione S-transferase P  CfaAffx.29492.1.S1_x_at Redox 2.53 2.53 1.96 2.04 
GSTP Glutathione S-transferase P  CfaAffx.17810.1.S1_x_at Redox 2.41 2.66 2.08 2.28 
GSTT2 Glutathione S-transferase theta 2 Cfa.14362.1.S1_s_at Redox 1.57 1.64 1.24 0.62 
NQO1 NAD(P)H dehydrogenase, quinone 1 CfaAffx.31023.1.S1_at Redox 1.56 1.72 1.40 1.64 
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Table 3.4 (cont.) 
 
      
MFN1 mitofusin 1 Cfa.19756.1.S1_at Mitochondrial 
fusion 
0.75 0.46 0.62 1.68 
OPA1 optic atrophy 1 (autosomal dominant) Cfa.1129.1.S1_at Mitochondrial 
fusion 
0.87 0.30 0.65 1.49 
OPA1 optic atrophy 1 (autosomal dominant) Cfa.1129.2.S1_at Mitochondrial 
fusion 
0.55 0.26 0.46 1.46 
OPA1 optic atrophy 1 (autosomal dominant) Cfa.1129.1.S1_s_at Mitochondrial 
fusion 
0.87 0.17 0.71 2.19 
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Table 3.5:  Differentially expressed genes associated with immune response and extracellular matrix (ECM) in subcutaneous adipose 
tissue of ad libitum fed dogs 
 
 
      
    Fold change 
Gene 
symbol Gene name Probe 
Functional 
classification 
4 wk 8 wk 12 wk 24 wk 
CCL5 chemokine (C-C motif) ligand 5 Cfa.21.1.S1_s_at Immune response 1.83 1.38 13.74 1.78 
CD97 CD97 molecule CfaAffx.25091.1.S1_s_at Immune response 1.93 2.08 1.68 1.85 
CD97 CD97 molecule Cfa.21259.1.S1_s_at Immune response 1.15 2.22 2.95 1.78 
CFH complement factor H Cfa.20016.1.S1_at Immune response 1.48 0.36 1.75 0.82 
CFH complement factor H Cfa.20016.1.S1_s_at Immune response 0.57 1.48 0.32 1.91 
CFI complement factor I Cfa.14495.2.S1_s_at Immune response 1.04 0.37 1.38 1.09 
IL10RB interleukin 10 receptor, beta Cfa.4778.1.A1_s_at Immune response 1.67 2.43 1.88 2.50 
MALT1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
CfaAffx.1126.1.S1_s_at Immune response 0.45 0.37 0.48 0.94 
SIKE1 suppressor of IKBKE 1 CfaAffx.15171.1.S1_s_at Immune response 0.76 0.47 0.67 1.01 
TREM2 triggering receptor expressed on myeloid 
cells 2 
CfaAffx.3284.1.S1_at Immune response 1.07 2.19 1.53 9.19 
LAMA3 laminin, alpha 3 Cfa.14.1.A1_at ECM 1.35 0.62 2.03 2.62 
NID1 nidogen 1 CfaAffx.17492.1.S1_s_at ECM 2.53 2.53 2.13 2.01 
NID2 nidogen 2 (osteonidogen) Cfa.20443.1.S1_s_at ECM 4.20 2.51 3.18 1.93 
ADAMTS2 ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
CfaAffx.1441.1.S1_at ECM 3.86 2.62 3.81 3.41 
ADAMTS2 ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
Cfa.6326.1.A1_s_at ECM 1.56 2.95 2.25 2.97 
ADAMTS2 ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
Cfa.6326.1.A1_x_at ECM 1.26 2.39 1.93 2.36 
ASPN asporin Cfa.4590.1.S1_s_at ECM 0.61 0.27 1.66 1.38 
ASPN asporin Cfa.533.1.S1_at ECM 0.51 0.70 0.31 1.77 
COL12A1 collagen, type XII, alpha 1 Cfa.10374.1.A1_at ECM 0.51 0.40 0.52 1.33 
COL23A1 collagen, type XXIII, alpha 1 CfaAffx.1328.1.S1_s_at ECM 2.36 1.87 1.43 1.37 
COL4A1 collagen, type IV, alpha 1 Cfa.208.1.A1_at ECM 2.01 1.79 1.49 1.27 
COL4A1 collagen, type IV, alpha 1 Cfa.15297.1.A1_at ECM 1.24 2.36 2.06 1.99 
COL4A1 collagen, type IV, alpha 1 CfaAffx.10085.1.S1_s_at ECM 1.46 2.75 2.20 1.82 
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Table 3.5 (cont.) 
 
 
COL4A2 collagen, type IV, alpha 2 Cfa.1455.1.A1_at ECM 1.91 1.74 1.51 1.36 
COL4A2 collagen, type IV, alpha 2 CfaAffx.10091.1.S1_s_at ECM 1.39 2.62 2.27 1.78 
FMOD fibromodulin Cfa.17831.1.S1_s_at ECM 7.94 3.29 3.25 1.82 
FMOD fibromodulin CfaAffx.14892.1.S1_at ECM 2.95 7.73 3.20 3.66 
LOX lysyl oxidase CfaAffx.1719.1.S1_at ECM 7.57 11.31 12.91 38.32 
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Table 3.6:  Differentially expressed genes associated with protein degradation and adipogenesis in subcutaneous adipose tissue of ad 
libitum fed dogs 
    Fold change  
Gene 
symbol Gene name Probe 
Functional 
classification 4 wk 8 wk 12 wk 24 wk 
PSMB3 proteasome (prosome, macropain) subunit, 
beta type, 3 
Cfa.11683.1.A1_s_at Protein 
degradation  
1.28 1.45 1.14 0.69 
PSMB3 proteasome (prosome, macropain) subunit, 
beta type, 3 
Cfa.12625.1.A1_x_at Protein 
degradation  
0.18 1.13 1.25 1.07 
PSMB5 proteasome (prosome, macropain) subunit, 
beta type, 5 
CfaAffx.17609.1.S1_s_at Protein 
degradation 
1.58 1.71 1.42 0.99 
PSMB6 proteasome (prosome, macropain) subunit, 
beta type, 6 
Cfa.2649.1.S1_s_at Protein 
degradation 
1.21 1.31 1.09 0.84 
PSMC1 proteasome (prosome, macropain) 26S 
subunit, ATPase, 1 
Cfa.868.1.S1_s_at Protein 
degradation 
1.55 1.82 1.18 1.19 
PSMC3 proteasome (prosome, macropain) 26S 
subunit, ATPase, 3 
Cfa.3960.1.A1_s_at Protein 
degradation 
1.27 1.31 1.14 0.92 
PSMC4 proteasome (prosome, macropain) 26S 
subunit, ATPase, 4 
Cfa.17798.1.S1_s_at Protein 
degradation 
1.47 1.82 1.27 0.94 
PSMC6 proteasome (prosome, macropain) 26S 
subunit, ATPase, 6 
Cfa.638.1.S1_at Protein 
degradation 
0.87 0.62 1 1.99 
PSMD4 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 4 
CfaAffx.19524.1.S1_s_at Protein 
degradation 
1.25 1.46 1.13 0.97 
PSMD8 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 8 
CfaAffx.9878.1.S1_s_at Protein 
degradation 
1.27 1.39 1.21 0.82 
PSMG3 proteasome (prosome, macropain) assembly 
chaperone 3 
Cfa.8226.1.A1_at Protein 
degradation 
1.15 1.47 0.99 0.72 
RUNX1T1 runt-related transcription factor 1; 
translocated to, 1 (cyclin D-related) 
Cfa.5127.1.A1_s_at Transcription 0.51 0.31 0.99 1.02 
XDH xanthine dehydrogenase CfaAffx.9452.1.S1_s_at Redox 0.19 0.26 0.2 0.17 
XDH xanthine dehydrogenase Cfa.12167.1.A1_at Redox 2.04 0.24 0.3 0.25 
XDH xanthine dehydrogenase CfaAffx.9444.1.S1_at Redox 2.06 0.24 0.31 0.24 
XDH nucleolar complex associated 3 homolog (S. 
cerevisiae) 
Cfa.12506.3.S1_at Cell 
differentiation 
0.8 0.28 1.27 1.05 
SMAD5 SMAD family member 5 CfaAffx.2515.1.S1_at Transcription 0.31 0.31 0.74 1.08 
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Table 3.6 (cont.) 
 
      
BMP2 bone morphogenetic protein 2 Cfa.7153.1.A1_s_at Signaling 0.33 0.57 0.44 1.16 
BMP2 bone morphogenetic protein 2 CfaAffx.9808.1.S1_at Signaling 1.16 0.45 0.62 0.47 
ID3 inhibitor of DNA binding 3, dominant 
negative helix-loop-helix protein 
Cfa.64.1.S1_at Transcription 0.51 0.63 0.6 0.39 
ID3 inhibitor of DNA binding 3, dominant 
negative helix-loop-helix protein 
CfaAffx.20523.1.S1_s_at Transcription 1.13 0.46 0.61 0.51 
TCF7L2 transcription factor 7-like 2 (T-cell specific, 
HMG-box) 
Cfa.3808.1.S1_s_at Transcription 0.76 0.46 0.99 1.13 
SFRP4 secreted frizzled-related protein 4 Cfa.12577.1.A1_at Signaling 2.31 0.71 7.62 1.21 
SFRP4 secreted frizzled-related protein 4 CfaAffx.6412.1.S1_at Signaling 1.2 2.3 0.78 7.46 
DKK2 dickkopf homolog 2 (Xenopus laevis) CfaAffx.17312.1.S1_at Signaling 4.41 2.53 3.05 6.68 
APC adenomatous polyposis coli Cfa.11080.1.S1_at Signaling 0.83 0.42 0.87 1.18 
APC adenomatous polyposis coli CfaAffx.11870.1.S1_s_at Signaling 0.23 0.85 0.32 0.87 
PPP2R5E protein phosphatase 2, regulatory subunit B', 
epsilon isoform 
Cfa.20148.1.S1_s_at Signaling 0.68 0.37 0.77 2.51 
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CHAPTER 4 
 
Subcutaneous and gonadal adipose tissue transcriptome differences in lean and obese  
 
female dogs 
 
Abstract  Adipose tissue depots are known to have unique metabolic and gene expression profiles in 
vivo and when cultured in vitro.  Differences in adipose depot function could be important in determining chronic disease risk.  Few comparisons of depot gene expression have been performed in the dog.  Utilizing microarray technology, our objective was to identify differentially expressed genes and enriched functional pathways between subcutaneous and gonadal adipose of lean and obese dogs.  Subcutaneous adipocytes of obese dogs were larger (P<0.05) than gonadal adipocytes of obese dogs and subcutaneous and gonadal adipocytes of lean dogs.  Because no depot x body weight status interactions were identified in the microarray data, depot differences were of greatest interest.  A total of 946 and 703 transcripts were differentially expressed (FDR P<0.05) between gonadal and subcutaneous adipose tissue in obese and lean dogs, respectively.  Of the adipose depot‐specific differences in gene expression, 162 were present in both lean and obese dogs, with the majority (85%) expressed in the same direction.  Both lean and obese dog gene lists had enrichment (P<0.05) of the complement and coagulation cascade, lysosomal, and systemic lupus erythematosus pathways.  The obese dogs had enrichment (P<0.05) of extracellular matrix‐receptor interaction and renin‐angiotensin system pathways.  The lean dogs had enrichment (P<0.05) of glutathione metabolism, focal adhesion, synthesis and degradation of ketone bodies and amino sugar metabolism. Obese dogs also had a larger representation of genes involved with the inflammatory response compared to lean dogs. 
   84 
Depot‐specific differences in adipose tissue inflammation, remodeling and metabolism may contribute to risk of chronic disease.  We have identified a core set of genes differentially expressed between subcutaneous and gonadal adipose tissue in both lean and obese dogs regardless of body weight.  These common genes contribute to depot specific differences of immune function, extracellular matrix remodeling and lysosomal function, and may contribute to the physiological differences noted between depots.   
 
Introduction 
 
Obesity is a major health problem for dogs.  Estimates of domestic dog obesity rates range from 
20-40% in western populations [1].  Overweight and obese dogs are at increased risk of oral 
disease, hypothyroidism, insulin resistance, pancreatitis, and cruciate ligament rupture [2].  The 
mechanisms by which adipose tissue contributes to chronic disease in the dog are unclear.    
 A greater understanding of how excess adipose tissue influences chronic disease 
development may lead to identification of biological factors having clinical relevance.  Adipose 
tissue is an active metabolic and endocrine tissue.  Canine adipose tissue produces and secretes 
adipokines and cytokines.  Production of monocyte chemotactic protein 1 (MCP-1), interleukin-
6, and tumor necrosis factor-α (TNFα) is increased by lipopolysaccharide (LPS) or TNFα in 
cultured canine adipocytes [3].  Obese dogs have decreased plasma concentrations of 
adiponectin, and increased plasma concentrations of leptin and TNFα [4, 5].  Adipose 
dysfunction and inflammation contribute to systemic changes in adipokines and cytokines; 
however, the clinical relevance and molecular mechanisms underlying such changes are not well 
understood in the dog. 
 Adipose tissue is heterogeneous with different depots having unique functional 
characteristics.  Yamamoto et al. reported that each adipose tissue depot in C57BL/6 mice has a 
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unique developmental gene signature and that this pattern of expression was similar to that of 
ob/ob mice [6].  To study depot differences in adipocyte biology, Perrini et al. isolated precursor 
stromal cells from the omental and subcutaneous adipose depots of humans, and differentiated 
them over a period of ~30 d [7].  In those adipocytes, depot differences in gene expression and 
function remained, with omental adipocytes having increased adiponectin release and insulin 
stimulated glucose uptake, while subcutaneous adipocytes had increased gene expression of 
CCAAT/enhancer binding protein alpha, adipocyte protein 2 and adiponectin.  These results 
imply that differences in depot metabolism and gene expression are, in part, due to innate 
differences in the preadipocyte populations.   
 In addition to being more metabolically active, visceral adipose tissue has higher levels of 
inflammation.  Visceral adipose tissue of obese mice has increased macrophage infiltration and 
crown-like structure formation as compared to subcutaneous adipose tissue [8].  Using DNA 
microarrays, Vohl et al. observed increased inflammatory gene expression in the human visceral 
adipose tissue transcriptome, as well as gene expression differences in cell differentiation, 
adipogenesis, regulation of lipolysis and other biological processes as compared to subcutaneous 
adipose tissue [9].  Analysis of human adipose depot transcriptome variation has revealed large 
differences among individuals, but much smaller differences between depots within the same 
individual [10].  Because the environment and genetics of humans are varied, utilizing a model 
with less genetic variation, and a more controlled environment may be useful in determining 
depot specific differences. 
 A limited number of studies have addressed depot specific gene expression differences in 
the dog.  Ryan et al. compared subcutaneous, omental, peri-renal, and falciform ligament adipose 
tissue expression of leptin, adiponectin, TNFα, interleukin-6, and MCP-1 in male dogs [3].  The 
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researchers reported modest differences in depot expression of leptin and MCP-1.  For these 
genes, differences were observed among visceral adipose tissue depots, but not for subcutaneous 
adipose tissue compared to all other depots [3].  Kim et al. demonstrated that feeding a 
moderate-fat (44%) diet for 12 wk did not significantly alter body weight, but increased visceral 
adiposity compared to control (chow-fed) dogs [11].  In a follow up study, Kabir et al. observed 
that feeding a moderate-fat (42%) diet for 12 wk did not significantly alter body weight, but did 
increase the ratio of visceral/subcutaneous adipose tissue gene expression of hormone sensitive 
lipase, lipoprotein lipase, and peroxisome proliferator-activated receptor γ compared to control 
(chow-fed) dogs [12].  After 12 wk of weight loss, visceral adipose tissue of obese dogs had 
decreased expression of sterol regulatory element binding transcription factor 1 and genes 
involved with lipid homeostasis, but subcutaneous adipose tissue was unchanged [13].  These 
studies indicate that differences in depot lipid metabolism may determine regional adipose tissue 
deposition in response to changes in dietary fat or increased calorie consumption in the dog.  
Although the studies above have documented specific differences in adipose tissue gene 
expression during weight loss or dietary intervention, global depot transcriptome differences 
remain unknown in the dog.  This study compares transcriptome profiles of gonadal and 
subcutaneous adipose tissue using microarray technology in lean and obese dogs.  Our study 
objectives were to identify differentially expressed genes and enriched pathways between 
adipose tissue depots and lean vs. obese dogs. 
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Methods 
 
Animals and diet  
The University of Illinois Animal Care and Use committee approved all animal care 
procedures prior to initiation of this experiment.  We previously performed a 24 wk weight-gain 
study with complete materials and methods are presented in Chapter 3 [14].  The adipose tissue 
samples collected at wk 24 from that study were analyzed in this experiment.  Briefly, nine intact 
female beagles (average age: 4.1 y) were housed in temperature-controlled rooms (22.2°C) in 
individual kennels (1.06 m × 1 m), with a 12-h light:12-h dark cycle at the Edward R. Madigan 
Laboratory on the University of Illinois campus.  Dogs were weighed and given a body condition 
score (9 point scale) weekly and daily food intake was recorded  [15].  After a baseline period of 
4 wk, dogs were randomized to either ad libitum feeding (n=5) or weight maintenance (control, 
n=4) and fed for 24 wk.  The diet contained 24.3% fat, 32.0% protein, and 6.7% total dietary 
fiber and 4.25 kcal/g metabolizable energy on a dry matter basis. 
As presented previously, dogs fed ad libitum gained a considerable amount of weight 
over the 24 wk study (obese: wk 0 = 8.36 ± 0.34 kg, wk 24 = 14.64 ± 0.34 kg), while the body 
weight of the lean group was unchanged.  Increased fat mass (~5.16 kg), accounted for most of 
the weight gained in obese dogs.  Indicators of blood glucose homeostasis were relatively 
unchanged, and no differences (P>0.05) in blood insulin concentrations (33.0 ± 5.4 pM vs. 11.8 
± 6.0 pM) were observed between obese and lean dogs.  Numerically greater blood leptin (12.9 ± 
1.32 ng/ml vs. 1.4 ± 1.48 ng/ml) and greater blood triglyceride (72.8 ± 6.22 mg/dl vs. 43.3 ± 6.96 
mg/dl) concentrations were noted in obese as compared to lean dogs at 24 wk. 
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Tissue collection 
At 24 wk, animals were fasted overnight prior to tissue collection.  Dogs were sedated 
with 0.2 mg/kg butorphanol (Fort Dodge Animal Health, IA), 0.2 mg/kg medetomidine (Webster 
Hormone and Steroid Biological Technology Co., Ltd., Shandong, China) and 0.04 mg/kg 
atropine (Med-Pharmex Inc., CA) for biopsy collection.  Anesthesia was maintained and 
isoflurane in 100% oxygen was used if necessary until the procedure was finished.  Each animal 
underwent an ovariohysterectomy.  After extraction of the ovaries and uterus, adipose tissue 
surrounding the broad ligament of the uterus was collected.  After ovariohysterectomy, an 
incision was made along the dorsal side of the body and subcutaneous adipose tissue was 
collected.  Samples were immediately flash frozen in liquid nitrogen and stored on dry ice until 
being transferred to -80°C. 
 
Adipocyte sizing 
Adipose tissue was fixed in formalin and embedded in paraffin wax.  5 µm sections were 
cut using a microtome.  Two 5 µm sections were stained with hemotoxylin and eosin.  Adipocyte 
area was calculated using Axiovision AC software and an AxioCam MRc5 (Zeiss, Obercochen, 
Germany). 
 
Adipose tissue RNA extraction 
Total cellular RNA was extracted from adipose tissue samples using the Trizol method 
(Invitrogen, Carlsbad, CA).  Samples were cleaned with the RNeasy mini kit and DNase treated 
(Qiagen, Valencia, CA).  RNA concentration and purity was determined using an ND-1000 
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spectrophotometer (Nanodrop Technologies, Wilmington, DE), and RNA quality was assessed 
using a 2100 Bioanalyzer (Agilent, Santa Clara, CA). 
  
Microarray analysis 
All RNA samples were analyzed by cDNA hybridization to the Affymetrix GeneChip® 
Canine Genome 2.0 Arrays (Affymetrix, Santa Clara, CA).  Hybridization reactions were 
performed using Affymetrix GeneChip Expression 3′-Amplification Reagents (One-Cycle Target 
Labeling and Control Reagents package) according to manufacturer instructions and as described 
by Swanson et al. [16].  After hybridization, the microarray chips were washed and stained using 
a streptavidin-conjugated phycoerythrin dye (Invitrogen) enhanced with biotinylated goat anti-
streptavidin antibody (Vector Laboratories, Burlingame, CA) using an Affymetrix GeneChip 
Fluidics Station 450 and Genechip Operating Software.  Images were scanned using an 
Affymetrix GeneChip scanner 3000. 
 
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR was used to validate a subset of differentially regulated genes based on 
microarray results. Gene-specific primers were designed for complement 3 (C3), complement 4 
(C4), complement 6 (C6), complement factor B (CFB), CD68, CD14, collagen, type 1, alpha 1 
(COL1A1), keratin 18 (KRT18), lymphocyte antigen 86 (LY86), lymphocyte antigen 96 (LY96), 
matrix metallopeptidase 2 (MMP2), matrix metallopeptidase 27 (MMP27), thrombospondin 4 
(THBS4), transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2), 
and WNT inhibitory factor (WIF1) using Primer Express 2.0 Software (Perkin Elmer, Boston, 
MA; Table 4.1).  Microarray data of these validation genes covered a wide range of expression 
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levels [Log2(FC) range -85.24 to 101.00], and these genes were chosen based on their association 
with biological processes including: immune function, extracellular matrix and remodeling.  
RNA was converted to cDNA using the ABI High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA).  Isolated cDNA was amplified using real time qRT-PCR 
on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems) with the following 
cycle: 2 min at 50°C, 10 min at 95°C, 40 cycles of 15s at 95°C and 1 min at 60°C, and a final 
dissociation stage of 15s at 95°C, 15s at 60°C, and 15s at 95°C to check for primer dimers.  The 
PCR mixture contained 10 ng of cDNA, 15 pmol of both forward and reverse primers, 5 ul of 
SYBR green (Applied Biosystems), and had a final volume of 10 ul.  Each sample was run in 
triplicate and expression of each gene was normalized to 18S expression. 
 
Statistics 
For microarray data, all quality control assessments, data processing and statistical 
analyses were done in R using packages from the Bioconductor project as indicated below 
[17,18].  All microarray data have been deposited in the Gene Expression Omnibus repository at 
the National Center for Biotechnology Information (NCBI) archives 
(http://www.ncbi.nlm.nih.gov/geo) under accession #GSE29280.  Quality control assessment 
was performed using affycoretools and showed that all arrays were of acceptable quality [19].  
The raw probe-level data were processed with the GeneChip Robust Multiarray Averaging 
(GCRMA) algorithm, which performs a GeneChip-based background-correction, does a quantile 
normalization between arrays and summarizes the multiple probes into one probe set value using 
a median polish algorithm [20].  To be considered for statistical testing, a probe set had to be 
called “present” (Affymetrix’s Call Detection Algorithm) on at least 1 array or “marginal” on at 
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least two arrays, and have at a mean GCRMA value greater than 3; 26,865 probe sets out of 
43,035 on the array passed these filters [21]. 
Testing for differential gene expression was done using the limma package to fit a mixed 
linear model while adjusting for the correlation due to individual dog  [22-24].  Within each 
treatment, pair-wise comparisons between the gonadal and subcutaneous fat types were pulled as 
contrasts from the model.  Raw p-values were corrected for multiple hypothesis testing using the 
FDR method [25].  Probe sets with FDR p-value < 0.05 and +/- 2 fold change were considered 
significant. 
To determine enriched pathways and assess gene function, lean and obese microarray 
transcript lists were loaded into the Database for Annotation, Visualization and Integrated 
Discovery (DAVID), and transcripts from the Affymetrix GeneChip® Canine Genome 2.0 Array 
were used as background [26-27].  Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway enrichment was analyzed separately in lean and obese dogs using EASE scoring, which 
uses a modified Fisher Exact Test [28].  For qRT-PCR data, the fixed effect of adipose depot, 
treatment and the interaction were tested, and animal was included in the model as a random 
effect.  For adipocyte size data, the fixed effects of adipose depot, treatment and the interaction 
were tested, and animal and number of cells counted per animal were included in the model as 
random effects. 
 
Results  
 
Adipocyte size 
Body weight and composition, and blood hormone and metabolite data are presented in Chapter 
3 [14].  Adipocyte size was greater (P<0.05) in subcutaneous as compared to gonadal adipose 
   92 
tissue and there was a depot by treatment interaction (P<0.05) (Figure 4.1).  Post hoc testing 
revealed that the depot by treatment interaction was driven by the greater (P<0.05) size of 
subcutaneous adipocytes in obese dogs, while all other adipocyte populations were not different 
in lean and obese dogs. 
 
Adipose tissue microarrays 
For adipose tissue microarrays, there were no significant (P>0.05) adipose depot by body 
weight status interactions.  Therefore, genes differentially expressed between subcutaneous and 
gonadal adipose tissue were of greatest interest.  A gene list comparing depot expression 
differences was generated and analyzed for each treatment group.  A total of 703 and 946 genes 
were differentially expressed (FDR P<0.05) between subcutaneous and gonadal adipose tissue in 
lean and obese dogs, respectively.  After removal of gene duplicates, 566 and 718 transcripts 
were differentially expressed between subcutaneous and gonadal adipose tissue in lean and obese 
dogs, respectively (Figure 4.2).  There was a subset of genes (162 genes) that were differentially 
expressed between depots in both treatment groups, with a majority (85%) expressed in the same 
direction in both lean and obese dogs.   
 KEGG pathway enrichment analysis was performed using DAVID for each treatment 
gene list separately [26, 27].  Lean dogs had 7 enriched (P<0.05) pathways, while obese dogs had 
5 enriched (P<0.05) pathways (Table 4.2 and 4.3; Appendix B).  Obese and lean dogs shared 
enrichment of the complement and coagulation cascades (Figure 4.3), lysosomal, and systemic 
lupus erythematosus pathways.  Obese dogs had enrichment of the extracellular matrix-receptor 
interaction and renin-angiotensin system pathways.  Lean dogs had enrichment of the glutathione 
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metabolism, focal adhesion, synthesis and degradation of ketone bodies, and amino sugar and 
nucleotide sugar metabolism pathways. 
Immune differences between subcutaneous and gonadal adipose tissue were apparent by 
over-representation of the complement and coagulation cascades and systemic lupus 
erythmatosis in both treatments.  Gonadal compared to subcutaneous adipose of lean and obese 
dogs had greater expression of CFB (fold change (FC) lean: 15.8, obese: 34.3 and -2.19), C3 (FC 
lean: 9.1, obese: 27.8), and the membrane attack complex component C6 (FC lean: 17.3, obese: 
19.6).  The Canine Genome 2.0 array contains 7 probe sets for CFB.  In obese dogs, two CFB 
probe sets had greater expression in gonadal adipose tissue, while one CFB probe set had lower 
expression in gonadal adipose.  As presented below, qRT-PCR data confirmed greater gonadal 
versus subcutaneous adipose tissue expression of CFB.  Obese dogs had greater gonadal 
compared to subcutaneous adipose expression of CFI (FC: 2.7), C7 (FC: 3.4), and precursor of 
C4 (FC: 3.1), but lower gonadal expression of C8 gamma polypeptide (FC: -4.4) as compared to 
subcutaneous adipose.  Lean dogs had lower expression of the classical complement cascade 
components, C1QA (FC: -2.9) and C1S (FC: -2.5) in gonadal as compared to subcutaneous 
adipose. 
Subcutaneous adipose of obese dogs was enriched (P<0.05) and lean dogs tended to be 
enriched (P<0.10, data not shown) in genes pertaining to the extracellular matrix-receptor 
interactions pathway and in extracellular matrix remodeling enzymes.  Both treatment groups 
had lower expression of MMP2 (FC lean: -16.0, obese: -12.2), MMP27 (FC lean: -18.6, obese: -
5.8), lysyl oxidase like 2 (FC lean: -6.2, obese: -3.9) and the MMP regulator TIMP 
metallopeptidase inhibitor 2 (FC lean: -3.0, obese: -2.1) in gonadal as compared to subcutaneous 
adipose tissue.  MMP9 (FC: -16.8) and lysyl oxidase (FC: -4.2) expression was lower in the 
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gonadal as compared to subcutaneous adipose tissue of obese dogs.  Expression of extracellular 
matrix genes was predominantly lower in gonadal as compared to subcutaneous adipose tissue in 
both treatments.  Obese dogs had lower expression of collagen type III, alpha 1 (COL3A1; FC: -
2.6), COL4A1 (FC: -2.2), and fibronectin (FC: -4.2) in gonadal as compared to subcutaneous 
adipose tissue.  Lean dogs had lower expression of COL6A1 (FC: -3.7) in gonadal as compared 
to subcutaneous adipose.  Both lean and obese dogs also had lower gonadal as compared to 
subcutaneous adipose expression of many extracellular matrix genes including extracellular 
matrix protein 1 (FC lean: -5.5, obese: -2.7), fibrillin 1 (FC lean: -4.1, obese: -2.9), 
microfibrillar-associated protein 2 (FC lean: -4.2, obese: -2.6), microfibrillar-associated protein 5 
(FC lean: -6.5, obese: -3.9), and thrombospondin 4 (FC lean: -12.0, obese: -26.9).  Laminin β1 
(FC lean: 3.0, obese: 3.5) expression was greater in gonadal as compared to subcutaneous 
adipose tissue in both lean and obese dogs. 
For the lysosomal pathway, obese dogs had more total genes differentially expressed 
between gonadal and subcutaneous adipose than lean dogs, including lipases, lysosomal 
membrane proteins and the lysosomal ATPase T-cell immune regulator 1 (FC: -2.6), which is 
required for acidification of the organelle.  Obese dog adipose tended (P<0.10, data not shown) 
to be enriched in the hematopoietic cell lineage pathway, and also had a greater representation of 
transcripts associated with the immune response.  Surprisingly, gonadal as compared to 
subcutaneous adipose tissue of obese dogs had lower expression of the macrophage markers 
CD68 (FC: -4.0), monocyte to macrophage differentiation-associated (FC: -3.5), and macrophage 
scavenger receptor 1 (FC: -3.2).  Gonadal as compared to subcutaneous adipose tissue in obese 
dogs also had lower expression of the antigen presentation protein CD80 (FC: -3.1), and LPS 
signaling genes CD14 (FC: -2.3), LY86 (FC: -3.7), LY96 (FC: -2.2), bactericidal/permeability-
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increasing protein (FC: -3.0), while gonadal as compared to subcutaneous adipose tissue had 
greater expression lipopolysaccharide binding protein (FC: 9.2). 
 
qRT-PCR 
Expression differences between adipose tissue depots was the predominant effect noted for 
validated genes.  CFB, C4, C3 and C6 had greater (P<0.05) expression in gonadal as compared 
to subcutaneous adipose tissue in lean and obese dogs (Figure 4.4).  CD14, CD68, LY86, and 
LY96 expression was lower (P<0.05) in gonadal as compared to subcutaneous adipose tissue in 
lean and obese dogs (Figure 4.5).  MMP2 and MMP27 expression was lower (P≤0.05) in gonadal 
as compared to subcutaneous adipose tissue in lean and obese dogs (Figure 4.6).  TMEFF2 
expression was lower (P<0.05), while KRT18 and WIF1 were greater (P<0.05) in gonadal as 
compared to subcutaneous adipose tissue in lean and obese dogs (Figure 4.7).   
There were limited differences observed between lean and obese dogs.  C4 had greater 
(P<0.05) and MMP27 tended to have greater (P=0.10) expression in lean dogs.  THBS4 had a 
treatment by depot interaction (P<0.05), with the difference in expression between gonadal and 
subcutaneous adipose tissue being greater in obese as compared to lean dogs.   The highest 
expression of THBS4 was observed in subcutaneous adipose of obese dogs, while gonadal 
adipose tissue of obese dogs had the lowest expression (Figure 4.6).  COL1A1 was not different 
(P>0.05) between adipose depots or treatments (Figure 4.6).  In general, qRT-PCR expression 
confirmed microarray data except in the case of COL1A1.   Microarray results for COL1A1 
indicated lower expression in gonadal as compared subcutaneous adipose tissue in lean and 
obese dogs.  qRT-PCR results indicated numerically lower gonadal as compared to subcutaneous 
adipose tissue expression in lean dogs, but greater gonadal as compared to subcutaneous tissue 
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expression in obese dogs.  Differential expression of C4, KRT18, CD14, CD68, LY86, and 
LY96 was only detected in obese dogs by microarray.  qRT-PCR results for these genes in lean 
and obese dogs revealed only depot differences for all genes except C4, which showed both 
treatment and depot differences.  These results indicate that although there were differences in 
the microarray gene lists generated from each treatment, these differences likely were not 
treatment differences, but represent depot differences in gene expression.  Gene expression 
differences detected by microarray were generally increased compared to qRT-PCR results.  The 
differences in expression between the two methods most likely arise from the background 
correction and normalization required for microarray analysis. 
 
Discussion  
 
 This study compares global gene expression profiles in whole gonadal and subcutaneous 
adipose tissue in intact female dogs.  It demonstrates that even though obesity affects adipose 
tissue function, there is a shared core set of genes that differentiate gonadal and subcutaneous 
adipose tissue depots in both lean and obese dogs.  Though obese and lean dogs shared only 162 
differentially expressed genes, these genes played an important role in enriched pathways 
identified by DAVID.   
In a recent review, Schaffler and Scholmeric highlighted the dual role of adipose tissue in 
metabolic homeostasis and innate immune function [29].  In our study, pathway analysis 
demonstrated multiple immune differences between gonadal and subcutaneous adipose tissue.  
Gonadal adipose in both lean and obese dogs showed increased expression of genes involved in 
the alternative pathway of the complement cascade and membrane attack complex.  In humans, 
visceral adipose tissue is enriched in expression of complement proteins, including those proteins 
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in the alternative pathway [30].  Complement proteins in adipose tissue are multifunctional, 
having immune and metabolic functions.  Carboxypeptidase N converts the C3 metabolite, C3a, 
into C3adesarg by the removal of an arginine residue.  Thus, C3a is inactivated and C3adesarg is 
able to exert its effects on adipocyte metabolism.  In 3T3-L1 adipocytes, C3adesarg increases 
triglyceride synthesis [31].  The absence of C3 and C3adesarg in C3 knockout mice has systemic 
effects, leading to reduced body fat mass and increased energy expenditure [32].   In our study, 
lean dogs had greater expression of the classical pathway of the complement cascade (e.g., 
C1QA, C1S) in subcutaneous as compared to gonadal adipose tissue.  Because complement is at 
the crossroads of innate immunity and metabolism, future studies investigating depot specific 
differences in expression of the complement cascade pathway and the functional implications of 
these differences on both the immune response and metabolism are warranted in the dog.  
Toll like receptor (TLR) signaling is another component of the innate immune system 
present in adipose tissue.  TLR4 is particularly important because of its ability to bind LPS, 
saturated fatty acids, and acyl-carnitines, which are fatty acid metabolites [33, 34].  In our study, 
subcutaneous as compared to gonadal adipose tissue had greater gene expression of macrophage 
markers and inflammatory signaling genes.  Surprisingly, qRT-PCR results indicate that 
differences in inflammatory gene expression among depots in lean dogs parallels that of obese 
dogs.  Our results were unexpected because subcutaneous adipose tissue has decreased crown-
like structure formation and presence of macrophages during diet-induced obesity in mice [35].  
We cannot distinguish the cell types contributing to differential gene expression of TLR 
signaling and macrophage marker genes in our study.  Our data indicate that there may be 
species or sex differences in the inflammatory profile of adipose depots in the dog.  Grove et al. 
reported up-regulation of inflammatory genes transcripts in the gonadal adipose tissue of male as 
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compared to female mice [36].  It may be important to understand species and sex differences in 
adipose depot function and physiology as they pertain to chronic disease risk.  It would also be 
useful to determine whether gene expression differences parallel differences in immune cell 
composition of the respective depots, and if these differences are present in other visceral depots 
of the dog.  
Extracellular matrix and its remodeling are important for adipocyte expansion and 
differentiation, and adipose tissue angiogenesis, and appear to be regulated differently depending 
upon depot [37].  In C57BL/6 mice, Strissel et al. demonstrated remarkable depot differences in 
adipocyte turnover and remodeling during diet-induced obesity, with the epididymal fat pad 
having rates of adipocyte turnover up to 80%, while inguinal fat had much lower rates (~4%) 
[35].  Contrary to our expectations, lean and obese dogs in the current study had greater 
expression of genes pertaining to extracellular matrix remodeling and extracellular matrix 
components in subcutaneous compared to gonadal adipose tissue.  Because the capacity for 
adipocytes to expand may be influenced by the production, composition, and remodeling of 
extracellular matrix, depot differences in our study may represent a larger capacity for 
subcutaneous adipose tissue to expand than gonadal adipose tissue.  It should be noted that the 
dogs used in our study were intact females and estrogen may have played a role in this process.  
The loss of estrogen through ovariectomy in rats results in a shift of adipose tissue storage from 
subcutaneous to visceral depots, a response that is resolved by administering estradiol [38].  
Matrix metalloproteinases and remodeling enzymes are both expressed by macrophages and 
adipocytes in adipose tissue.  It may be that differences in adipose tissue cellular composition 
were driving differences in remodeling and extracellular matrix gene expression in our study.  
Further investigation of the association of remodeling enzymes with fat pad cellular composition 
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is needed for a better understanding of depot differences and it would be useful to relate such 
differences to regional adipose tissue storage, sex and spay status of the dog. 
Lysosomes are intracellular organelles required for degradation of macromolecules, 
degradation of intracellular organelles through autophagy, and phagosome degradation of 
infectious agents.  Subcutaneous adipose tissue had greater expression of lysosomal genes in 
both lean and obese dogs, particularly the cathepsins and legumain.  Interestingly, knockout 
mouse models of lysosomal storage disease have lower body fat and altered energy expenditure 
[39].  Altered expression of lysosomal components may influence depot metabolism, but this is a 
largely unexplored field to date. 
With this study, we have demonstrated large differences in adipose depot gene 
expression, and have identified pathways relevant to both immunological and metabolic function 
of whole adipose tissue.  Although the gene expression differences are informative for adipose 
from a tissue perspective, we cannot attribute changes to specific cellular fractions or populations 
within the tissue.  It is possible that depot gene expression differences were driven by differing 
cell (e.g., adipocytes, macrophages, etc.) population sizes between subcutaneous and gonadal 
adipose depots in our study.  Although it is foreseeable that the gene expression differences 
identified herein are specific to the adipose depots analyzed, it is also probable that these 
pathways are regulated differently among other adipose depots.  As noted above, estrogen has a 
large influence on regional fat storage, so our results may not be applicable to male dogs or 
spayed females.  Despite these limitations, we have demonstrated a conserved set of genes and 
pathways that are likely of importance as it pertains immunologic and metabolic differences 
between subcutaneous and visceral adipose tissue regardless of body weight status in the dog.   
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Conclusions  
Large differences in gene expression profiles have been noted between adipose tissue depots of 
obese humans and rodents.  Here we show that in lean and obese dogs there is a shared core set 
of genes that may have a role in distinguishing adipose tissue depots and may explaining 
differences in depot physiology.  The depot specific differences we have identified may not only 
be important in overall depot homeostasis, but also of immunological importance, with visceral 
adipose tissue having a closer proximity to the foreign environment of the intestinal tract.  
Understanding the mechanisms driving gene expression in our study will be useful for 
understanding adipose depot biology, and how these differences influence the metabolic and 
inflammatory states of other tissues on a regional and systemic level. 
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Figure 4.1: Subcutaneous and gonadal adipocyte size of obese (n=4-5) and lean (n=3-4) dogs.  P-
values are provided for the treatment, depot and treatment x depot interaction effects. 
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Figure 4.2: Differentially expressed (FDR P<0.05) gene transcripts between gonadal and 
subcutaneous adipose tissue in lean and obese dogs.  Large circles denote the total genes 
differentially expressed in either the lean or obese group.  The center, overlapping circle entitled 
“shared”, indicates genes differentially expressed in both groups.  Red indicates within group 
expression of transcripts that had increased expression in gonadal compared to subcutaneous 
adipose tissue.  Blue indicates within group expression of transcripts that had decreased 
expression in gonadal compared to subcutaneous adipose tissue. 
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Figure 4.3: Complement cascade gene expression in lean and obese dogs (n=3-4).  Gene 
expression is presented as fold change over subcutaneous adipose tissue in lean and obese dogs, 
respectively. 
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Figure 4.4: Subcutaneous and gonadal adipose tissue gene expression of complement cascade 
genes in lean and obese dogs using qRT-PCR (n=3-4).  Gene expression is presented as fold 
change over lean dog subcutaneous adipose tissue expression, which was adjusted to 1 (CFB =  
complement factor B; C3 = complement 3; C4 = complement 4; and C6 = complement 6). 
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Figure 4.5: Subcutaneous and gonadal adipose tissue gene expression of inflammatory genes in 
lean and obese dogs using qRT-PCR (n=3-4).  Gene expression is presented as fold change over 
lean dog subcutaneous adipose tissue expression, which was adjusted to 1 (CD68 =  CD68 
antigen ; CD14 = CD14 antigen; LY86 = lymphocyte antigen 86; and LY96 = lymphocyte 
antigen 96). 
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Figure 4.6: Subcutaneous and gonadal adipose tissue gene expression of extracellular matrix and 
remodeling genes in lean and obese dogs using qRT-PCR (n=3-4).  Gene expression is presented 
as fold change over lean dog subcutaneous adipose tissue expression, which was adjusted to 1 
(MMP2 =  matrix metallopeptidase 2; MMP27 = matrix metallopeptidase 27; COL1A1 = 
collagen, type 1, alpha 1; and THBS4 = thrombospondin 4). 
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Figure 4.7: Subcutaneous and gonadal adipose tissue gene expression of KRT18 (Keratin 18), 
TMEFF2 (transmembrane protein with EGF-like and two follistatin-like domains 2) and WIF1 
(Wnt inhibitory factor 1) in lean and obese dogs using qRT-PCR (n=3-4).  Gene expression is 
presented as fold change over lean dog subcutaneous adipose tissue expression, which was 
adjusted to 1. 
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Table 4.1: Forward (F) and reverse (R) primers used for quantitative reverse transcriptase-PCR 
analysis 
 
Gene 
Symbol 
Gene Name 
Primer (5’è3’) REFSEQ # 
F TGGTCGTACTGCCCTTGACC C3 Complement 3 
R GGCGGAAGGAAGGAATGAAG XM_544932.2 
F GTCCTCCGAGAAGATGGCAG C4 Complement 4 
R GATGCTGGTCTCGAAGAGGC XM_538843.2 
F TGACACCTGCTACGACTGGG C6 Complement 6 
R ACACATTTGGAAACGGAGGC XM_536488.2 
F CCATCTGCTTCTCTCCTTCCC CD68 CD68 Molecule 
R TGTGTGAACCCGAAGCTGAG XM_844640.1 
F GCCCTGCGAAGTAGATGACG CD14 CD14 Molecule 
R TCCGTGAAGTTGCAGAAGCA XM_843653.1 
F GACACCCCTGAAGAGGTAGCC CFB Complement 
Factor B R GGTCTCAGTCAGGGACGACAG XM_532086.2 
F TGTGTCTGCGACAACGGC COL1A1 Collagen, type I, 
alpha 1 R TTCGTCGCAGATCACGTCAT NM_001003090.1 
F GGGAGAGCACCACAGTGGTC KRT18 Keratin 18 
R CAGCTTCTCCGATCTCAGCG XM_854071.1 
F TCCCCAGACTCCACAGGTGT LY86 Lymphocyte 
antigen 86 R GTGGCTACCAGGACATGCCT XM_535877.2 
F 
ATGAATTTACCAATGCGCAAAGA 
LY96 Lymphocyte 
antigen 96 
R AACATCATCAGATCCTCGGCA XM_848045.1 
F CTTTGCTCGTGCCTTCCAAG MMP2 Matrix 
metallopeptidase 2 R GAAAACCGCAGCGGAGTTAC XM_535300.2 
F TTGCCCAAAGCAAGAACAAGA MMP27 Matrix 
metallopeptidase 
27 R GCATTTCCCGAATTTTGCC XM_546548.2 
F ACTGGGTGGTGCTGAACCAA THBS4 Thrombospondin 4 
R CGCTGTTCATGGTCTGGACA XM_546047.2 
F ACATTTGCCAATTTGGTGCA TMEFF2 Transmembrane 
protein with EGF-
like and two 
follistatin-like 
domains 2 R ACCAGACATCCTCGGCATCT XM_536010.2 
F GCTGCAGGGCAGGAAGAAT WIF1 WNT inhibitory 
factor 1 R CAGGGAGCGTAAGGACAGGA XM_538269.2 
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Table 4.2: KEGG pathways enriched for transcripts differentially expressed between 
subcutaneous and gonadal adipose tissue in lean dogs 
 
KEGG Pathway Transcript 
Count 
P-Value Fold Enrichment 
Glutathione metabolism   6/47 0.01   5.11 
Systemic lupus erythematosus   8/140 0.01   3.25 
Focal adhesion 12/202 0.01   2.31 
Synthesis and degradation of ketone bodies   3/8 0.01 15.69 
Complement and coagulation cascades   6/62 0.03   3.54 
Amino sugar and nucleotide sugar 
metabolism   5/46 
0.03   4.36 
Lysosome   8/115 0.03   2.69 
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Table 4.3: KEGG pathways enriched for transcripts differentially expressed between 
subcutaneous and gonadal adipose tissue in obese dogs 
 
KEGG Pathway Transcript 
Count 
P-Value Fold Enrichment 
Systemic lupus erythematosus 10/140 <0.01 3.45 
Complement and coagulation cascades   9/62 <0.01 3.76 
Lysosome 12/115 <0.01 2.84 
ECM-receptor interaction   9/78   0.01 3.06 
Renin-angiotensin system   4/17   0.02 6.38 
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CHAPTER 5 
 
Skeletal muscle tissue transcriptome differences in lean and obese female dogs 
 
Abstract 
Skeletal muscle, as a large and insulin-sensitive tissue, is an important contributor to metabolic 
homeostasis and energy expenditure.  Obese dogs exhibit skeletal muscle insulin resistance, but 
the causes of these changes are unclear.  Only a limited number of studies have compared 
skeletal muscle gene expression of lean and obese dogs.  Using microarray technology, our 
objective was to identify genes and functional classes differentially expressed between lean and 
obese dogs.  Nine female beagles (4.09 ± 0.64 y; 8.48 ± 0.35 kg) were randomized to ad libitum 
feeding or body weight maintenance.  Skeletal muscle biopsies were collected at 0, 4, 8, 12 and 
24 wk.  Twenty-four wk skeletal muscle RNA samples were hybridized to Affymetrix Canine 
2.0 microarrays. Microarrays displayed 77 differentially expressed skeletal muscle transcripts 
between lean and obese dogs.  Alterations were observed in genes pertaining to the functional 
classes of signaling, transport, protein catabolism and proteolysis, protein modification, 
development, transcription and apoptosis, cell cycle and differentiation.  Genes differentially 
expressed in obese as compared to lean dog skeletal muscle indicate oxidative stress and altered 
skeletal muscle cell differentiation.  Many genes traditionally associated with lipid, protein and 
carbohydrate metabolism were not altered in obese as compared to lean dogs, but genes 
pertaining to endocannabinoid metabolism, insulin signaling, type II diabetes mellitus, and 
carnitine transport were differentially expressed.  The relatively small response of skeletal 
muscle could indicate that changes are occurring at a post-transcriptional level, or that other 
tissues are buffering skeletal muscle in our population.  Although only a limited number of 
differentially expressed genes were detected, these results highlight genes and functional classes 
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that may be important in determining the etiology of obesity-induced derangement of skeletal 
muscle function. 
 
Introduction  
Obesity has pleiotropic effects on energy metabolism, resulting in altered adipose, liver and 
skeletal muscle tissue function.  Skeletal muscle is a major contributor to whole body energy 
homeostasis because of its influence on basal metabolic rate, and insulin-stimulated glucose 
uptake.  Obesity is associated with changes in skeletal muscle that alter insulin signaling and 
glucose utilization, including altered serine and tyrosine phosphorylation of insulin receptor 
substrate-1 (IRS-1), and altered glucose transporter 4 (GLUT4) translocation.  The mechanisms 
leading to decrements in skeletal muscle metabolism with obesity are not well studied in the dog. 
 Few studies have focused on obesity-associated skeletal muscle gene expression 
differences in the dog.  Gayet et al. demonstrated that obese dogs have decreased skeletal muscle 
gene expression of peroxisome proliferator-activated receptor-γ, lipoprotein lipase (LPL) and 
GLUT4 as compared to lean control dogs [1].  These changes are associated with insulin 
resistance and indicate a reduced capacity for the uptake of energy substrates by skeletal muscle.  
In dogs, 14 wk of fat supplementation (6g/kg bacon grease) as compared to a non-supplemented 
control diet resulted in increased body weight, fat mass, and decreased insulin diffusion into the 
skeletal muscle interstitial space [2].  Obesity associated changes of skeletal muscle insulin 
diffusion may be mediated through exposure to non-esterified fatty acids (NEFA), because when 
NEFA were administered intravenously, insulin diffusion decreased as compared to saline 
control [3].  Altered access of insulin to skeletal muscle contributes to reduced skeletal muscle 
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glucose uptake and contributes to insulin resistance.  Currently, it is not clear how changes in 
insulin sensitivity progress, whether insulin access is reduced to skeletal muscle first, or if 
changes in gene expression preclude this event. 
 Microarray technology has been useful in determining differences in canine skeletal 
muscle function due to both diet and age, but has not been used to determine differences between 
lean and obese dogs [4].  Microarray profiling of skeletal muscle of insulin-resistant as compared 
to insulin-sensitive obese Pima Indians revealed global gene expression differences in functional 
categories pertaining to metabolism, transcription regulation and signaling, indicating that these 
differences may be contributing to the insulin-resistant phenotype within this population [5].  
Though these data are informative, cause and effect cannot be proven using this study design.  A 
time course of obesity-induced changes during high-fat (45%) feeding in APOE3 Leiden 
transgenic mouse skeletal muscle revealed a down-regulation of genes pertaining to lipid 
metabolism, acute phase response and inflammation [6].   
Although the previous studies indicate a role of skeletal muscle gene expression in 
insulin resistance and metabolism, other studies have had contrary results.  In C57BL/6 mice (9 
wk of age), 8 wk of high-fat (45%) feeding resulted in minor changes in skeletal muscle gene 
expression as compared to a low-fat (10%) control [7].  Interestingly in that same study, the 
effects of age (8 wk vs. baseline) on skeletal muscle gene expression were greater than those of 
diet (8 wk: high-fat vs. low-fat).  Gene expression profiling, using cDNA microarrays, was used 
to compare myotubes isolated from obese patients with type 2 diabetes vs. healthy obese controls 
(normal glucose tolerance and no family history of diabetes) [8].  In that study, expression 
profiles were not different, indicating that either insulin resistance associated with type 2 
diabetes was not due to changes at the gene expression level or that skeletal muscle was not 
 119 
driving the process.  Brons et al. fed a high-fat (60%), high-calorie (150% of caloric 
requirement) diet for 5 days to 26 young, healthy males and observed no alterations in peripheral 
insulin sensitivity or skeletal muscle gene expression, even though subjects had increased fasting 
glucose and hepatic glucose production [9].  These data indicate that the liver may drive initial 
changes in glucose homeostasis and that changes in peripheral insulin sensitivity occur later. 
 Because obesity is a major health problem in dogs, it will be useful to understand the 
functional differences of skeletal muscle between lean and obese dogs.  There have not been any 
published comparisons of lean and obese dog skeletal muscle tissue gene expression using 
microarrays.  We previously demonstrated that 24 wk of diet-induced obesity produced large 
changes in the subcutaneous adipose transcriptome, and at 24 wk obese dogs had higher blood 
triglycerides and leptin.  Because of the large differences observed in the subcutaneous adipose 
transcriptome and blood hormones and metabolites, our objective here was to identify skeletal 
muscle transcriptome differences between lean and obese beagles, which may be contributing to 
the obese phenotype.   
  
Methods 
Animals and diet 
The University of Illinois Animal Care and Use Committee approved all animal care procedures 
prior to initiation of this experiment.  We previously performed a 24 wk weight-gain study with 
complete materials and methods described in Chapter 3 [10].  During that study, skeletal muscle 
tissue samples were collected at wk 0, 4, 8, 12 and 24 and analyzed in this experiment.  Nine 
intact female beagles (average age: 4.1 y) were housed in temperature-controlled rooms (22.2°C) 
in individual kennels (1.06 m × 1 m), with a 12-h light:12-h dark cycle at the Edward R. 
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Madigan Laboratory on the University of Illinois campus.  Dogs were weighed and given a body 
condition score (9 point scale; [11]) weekly and daily food intake was recorded.  After a baseline 
period of 4 wk, dogs were randomized to either ad libitum feeding (n=5) or weight maintenance 
(control, n=4) and fed for 24 wk.  The diet contained 24.3% fat, 32.0% protein, and 6.7% total 
dietary fiber and 4.67 kcal/g metabolizable energy on a dry matter basis. 
 As presented in Chapter 3, dogs fed ad libitum gained a considerable amount of weight 
over the 24 wk study (obese: wk 0=8.36 ± 0.34 kg, wk 24=14.64 ± 0.34 kg), while the body 
weight of the lean group was unchanged [10].  Increased fat mass (~5.16 kg), accounted for most 
of the weight gain in obese dogs. Indicators of blood glucose homeostasis were relatively 
unchanged, and no differences in blood insulin concentrations (33.0 ± 5.4 pM vs. 11.8 ± 6.0 pM) 
were observed between obese and lean dogs, respectively.  Numerically greater blood leptin 
(12.9 ± 1.32 ng/ml vs. 1.4 ± 1.48 ng/ml) and greater blood triglyceride (72.8 ± 6.22 mg/dl vs. 
43.3 ± 6.96 mg/dl) concentrations were noted in obese as compared to lean dogs at 24 wk. 
 
Tissue collection 
At 0, 4, 8, 12 and 24 wk, animals were fasted overnight prior to tissue collection.  Dogs were 
sedated with 0.2 mg/kg butorphanol (Fort Dodge Animal Health, IA), 0.2 mg/kg medetomidine 
(Webster Hormone and Steroid Biological Technology Co., Ltd., Shandong, China) and 0.04 
mg/kg atropine (Med-Pharmex Inc., CA) for biopsy collection.  Anesthesia was maintained and 
isoflurane in 100% oxygen was used if necessary until the procedure was finished.  Skeletal 
muscle biopsies were collected from the latissimus dorsi muscle at each time point.  Samples 
were immediately flash frozen in liquid nitrogen and stored on dry ice until being transferred to -
80°C. 
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Skeletal muscle RNA extraction 
Total cellular RNA was extracted from skeletal muscle tissue samples using the Trizol method 
(Invitrogen, Carlsbad, CA).  Samples were cleaned with the RNeasy mini kit and DNase treated 
(Qiagen, Valencia, CA).  RNA concentration and purity was determined using an ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, DE), and RNA quality was assessed 
using a 2100 Bioanalyzer (Agilent, Santa Clara, CA). 
 
Microarray analysis 
Microarray analysis was performed on skeletal muscle RNA samples collected at 24 wk.  All 
RNA samples were analyzed by cDNA hybridization to the Affymetrix GeneChip® Canine 
Genome 2.0 Arrays (Affymetrix, Santa Clara, CA).  Hybridization reactions were performed 
using Affymetrix GeneChip Expression 3′-Amplification Reagents (One-Cycle Target Labeling 
and Control Reagents package) according to manufacturer instructions and as described by 
Swanson et al. [12].  After hybridization, the microarray chips were washed and stained using a 
streptavidin-conjugated phycoerythrin dye (Invitrogen) enhanced with biotinylated goat anti-
streptavidin antibody (Vector Laboratories, Burlingame, CA) using an Affymetrix GeneChip 
Fluidics Station 450 and Genechip Operating Software.  Images were scanned using an 
Affymetrix GeneChip scanner 3000. 
 
Quantitative real time polymerase chain reaction (qRT-PCR)  
qRT-PCR was used to validate a subset of differentially expressed genes at 24 wk based on 
microarray results.  Expression of validation genes and important metabolic mediators was also 
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analyzed at 0, 4, 8, 12, and 24 wk in order to ascertain how gene expression patterns changed in 
relationship to weight gain and blood hormone and metabolite.  Activin receptor IIB (ACVR2B), 
chemokine receptor-like 2 (CCRL2), cytokine inducible SH2-containing protein (CISH), 
glutathione-S-transferase alpha 4 (GSTA4), latent transforming growth factor beta binding 
protein 3 (LTBP3), suppressor of cytokine signaling 2 (SOCS2), signal transducer and activator 
of transcription 2 (STAT2) were chosen to validate microarray data because of their association 
with inflammation, oxidation-reduction, and myostatin signaling.  Though not differentially 
expressed at 24 wk as measured by microarray, branched chain amino acid aminotransferase 2 
(BCAT2), branched chain ketoacid dehydrogenase kinase (BCKDK), LPL, IRS-1, IRS-2, 
glycogen synthase 1 (GS1), uncoupling protein 2 (UCP2), uncoupling protein 3 (UCP3), 
GLUT4, and carnitine palitoyltransferase 1B (CPT1B) were chosen because of their integral 
roles in protein, carbohydrate and fat metabolism.  Gene-specific primers were designed for 
ACVR2B, CCRL2, CISH, GSTA4, LTBP3, SOCS2, STAT2, BCAT2, BCKDK, LPL, IRS-1, 
IRS-2, GS1, UCP2, UCP3, GLUT4, and CPT1B using Primer Express 2.0 Software (Perkin 
Elmer, Boston, MA; Table 5.1).  RNA was converted to cDNA using the ABI High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA).  Isolated cDNA was 
amplified using real time qRT-PCR on an ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems) with the following cycle: 2 min at 50C, 10 min at 95C, 40 cycles of 15s 
at 95C and 1 min at 60C, and a final dissociation stage of 15s at 95C, 15s at 60C, and 15s at 
95C to check for primer dimers.  The PCR mixture contained 10 ng of cDNA, 15 pmol of both 
forward and reverse primers, 5 ul of SYBR green (Applied Biosystems), and had a final volume 
of 10 ul.  Each sample was run in triplicate and expression of each gene was normalized to 18S 
expression. 
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Statistics 
All Quality Control assessments, data processing and statistical analyses for microarray data 
were done in R using packages from the Bioconductor project as indicated below [13, 14].  All 
microarray data have been deposited in the Gene Expression Omnibus repository at the National 
Center for Biotechnology Information (NCBI) archives (http://www.ncbi.nlm.nih.gov/geo) under 
accession #GSE29279.  QC assessment (affycoretools) showed that all arrays were of acceptable 
quality [15]. The raw probe-level data were processed with the GCRMA algorithm, which 
performs a GC-based background-correction, does a quantile normalization between arrays and 
summarizes the multiple probes into one probe set value using a median polish algorithm [16]. 
To be considered for statistical testing, a probe set had to be called “present” (Affymetrix’s Call 
Detection Algorithm) on at least 1 array or “marginal” on at least two arrays, and have at a mean 
GCRMA value greater than 3; 21,837 probe sets out of 43,035 passed these filters [17]. Testing 
for differential gene expression between obese and control dogs was done using the limma 
package to fit a linear model [18, 19].  Probe sets with raw P-value < 0.005 were considered 
significant. 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) and the 
Stanford SOURCE website (source.stanford.edu) were utilized to determine gene function [20, 
21].  For qRT-PCR validation of microarray data at 24 wk, the fixed effect of treatment was 
tested using ANOVA in the Mixed Models procedure of SAS (SAS Institute, Cary, NC).  To 
assess changes in gene expression over time, the fixed effects of treatment, time, and treatment x 
time were tested and animal was included as a random effect in a repeated measures ANOVA 
using the Mixed Models procedure of SAS (SAS Institute). Gene expression data for changes 
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over time of GSTA4, LTBP3, and CISH were not normally distributed, and a LOG10 
transformation was used to normalize the data. 
Results 
Skeletal Muscle Microarrays 
Body composition, body weight and blood hormone and metabolite data were presented in 
Chapter 3 [10].  A total of 81 differentially expressed (P<0.005) transcripts were detected in 
skeletal muscle of lean as compared to obese dogs.  After removal of duplicates, 77 genes 
transcripts remained.  Of the 77 transcripts, 44 were up-regulated and 33 were down-regulated in 
obese as compared to lean dogs.  Of the 77 transcripts, 55 were annotated genes.  Forty-nine out 
of the 55 annotated genes had ascribed functions and were functionally classified (Figure 5.1).  
The predominant functional classes of genes (Tables 5.2-5.5) differentiating skeletal muscle of 
lean and obese dogs included: signaling (7 genes); apoptosis, cell cycle; and differentiation (6 
genes); transport (6 genes); protein catabolism (5 genes); and protein modification (4 genes). 
 
Skeletal Muscle qRT-PCR 
qRT-PCR was performed on a subset of genes to validate skeletal muscle microarray 
data.  At 24 wk, obese dog skeletal muscle had lower (P<0.05) expression of SOCS2 and CISH 
as compared to that of lean dogs (Figure 5.2).  ACVR2B and CCRL2 gene expression was 
numerically lower in obese dog skeletal muscle, but did not reach significance (P>0.05, Figures 
5.2 and 5.3).  STAT2, GSTA4, and LTBP3 expression was higher (P<0.05) in skeletal muscle of 
obese as compared to lean dogs at 24 wk (Figures 5.2 and 5.3).  All qRT-PCR results had gene 
expression differences between obese and lean dogs in the same direction and of similar 
magnitude as microarray data. 
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Expression of validation genes was also tracked over time, in order to determine gene 
expression patterns in relation to changes in bodyweight and blood hormones and metabolites.  
SOCS2, CCRL2, and ACVR2B all presented treatment by time interactions (P<0.05; Figure 5.4).  
ACVR2B and CCRL2 interactions were driven by increased expression in the lean dogs at 12 wk 
and 24 wk.  The SOCS2 interaction was the result of increased expression in lean dogs at 24 wk.  
CISH was greater (P<0.05) in lean dogs, and exhibited a pattern similar to SOCS2 expression, 
with a large increase at 24 wk (data not shown).  STAT2 and GSTA4 had greater (P<0.05) gene 
expression in obese dogs, while there were no differences (P>0.05) noted over time for LTBP3 
expression (Figure 5.3; GSTA4 and LTBP3 data not shown).  Expression of BCAT2, BCKDK, 
CPT1B, GLUT4, GS1, IRS1, IRS2, LPL, UCP2, and UCP3 was not affected (P>0.05) by 
treatment. 
Discussion 
Here we have identified skeletal muscle gene expression profiles that differentiate obese and lean 
dogs.  In our study, functional classification revealed differences in signaling, cell growth, 
protein catabolism and transport, which may be of homeostatic relevance to obese dog skeletal 
muscle.  Surprisingly, there were few expression differences detected for genes involved in 
metabolism and the regulation of metabolism by qRT-PCR.   This may have been the result of a 
high capacity for adipose tissue expansion in our dog population, which may have buffered other 
tissues from nutrient excess.   The large transcriptome changes that occurred with adipose tissue 
expansion during obesity development, as described in Chapter 3, makes this a likely reason for 
the lack of change in skeletal muscle mRNA profiles [10]. 
 In our study, the functional class affected the most by obesity was that pertaining to 
signaling.  This was particularly apparent, as JAK-STAT signaling was the only over-represented 
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KEGG pathway detected by DAVID (data not shown).  JAK-STAT signaling is responsive to 
cytokines and growth factors, and thus is important for skeletal muscle growth and inflammation.  
In our study, obese dogs (24 wk) had lower expression of SOCS2, and CISH, suppressors of 
JAK-STAT signaling, and increased expression of the signaling protein STAT2 and the 
adipokine, leptin.  Leptin is secreted by adipocytes, and adipocytes in porcine trapezius muscle 
have been shown to express leptin [22].  Increased leptin expression with obesity in our study 
may be indicative of increased intramuscular fat in obese dogs, but intramuscular fat was not 
measured.  Alterations in JAK-STAT signaling may imply an altered capacity for 
growth/inflammatory signaling between obese and lean dogs.  SOCS2 is particularly important 
because it is a negative regulator of the growth hormone/IGF-1 axis, with knock-out mice 
exhibiting gigantism [23].  Interestingly, expression patterns over time indicate that altered 
SOCS protein expression was due to increased expression in the lean group at 24 wk, while 
altered STAT2 expression was due to increased expression in the obese group.  Because our 
study was performed over a limited period of time, it would be useful to examine these signaling 
genes during long-term chronic obesity, rather than after a relatively short period of rapid weight 
gain. 
 As presented in Chapter 3, there were no significant differences in lean body mass over 
the 24 wk study [10].  This may be explained by a lower proliferation of skeletal muscle cells.  
Lower expression of muscleblind-like, a candidate gene for myotonic dystrophy, and fms-related 
tyrosine kinase 1, the vascular endothelial growth factor receptor, in obese dogs may indicate 
decreased myogenesis and angiogenesisis as compared to lean dogs.  Along with lower 
expression of cell proliferation-associated genes, markers of entry into mitosis and cell cycle 
progression were also decreased in obese dogs.  These decreases in gene expression indicate a 
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reduced potential for cellular proliferation in obese as compared to lean dogs in our study, and 
may in part explain why we did not observe any significant differences in lean body mass. 
 As an insulin-sensitive tissue, skeletal muscle is important for glucose disposal and plays 
a large role in determining basal metabolic rate.  Skeletal muscle of obese dogs in our study 
exhibited differential expression of multiple genes that influence the capacity of glucose 
disposal.  The endocannabinoid system is important in determining feeding behavior and glucose 
disposal, and is altered by obesity.  Cannabinoid receptor 1 blockade has been shown to improve 
glucose homeostasis and body composition in rodents, and to decrease food intake and body fat, 
preferentially from the subcutaneous depot, in dogs [24, 25].   Although we did not detect 
alteration in endocannabinoid receptors, we did find that the 2-arachidonoyl-glycerol degrading 
enzyme, ABDH12, had higher expression (fold change) in obese dogs.  This increased 
expression could buffer skeletal muscle from the effects of the endocannabinoid system during 
obesity.  Insulin signaling is also affected by eukaryotic translation initiation factor 4E binding 
proteins (EIF4EBP).  In our study, EIF4BP1 was lower in obese as compared to lean dogs at 24 
wk.  The role of EIF4EBPs has been demonstrated by the EIF4EBP1 and EIF4EBP2 double-
knockout mice, which exhibit increased insulin resistance when fed a high-fat (60%) diet [26].  
Obese dogs in the current study had increased expression of phosphoprotein enriched in 
astrocytes 15 (PEA15), a gene that is normally associated with the central nervous system.  
Humans with type 2 diabetes exhibit increased expression of PEA15 in muscle, and this can 
occur very early in the disease process, making PEA15 a candidate gene for disease pathogenesis 
[27].  Obese dogs in our study had increased expression of PEA15, but the implications of such 
changes are unclear because although dogs become insulin-resistant, they generally do not 
transition from insulin resistance to type 2 diabetes.  These changes in gene expression may 
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affect skeletal muscle glucose metabolism, but further research is needed to clarify their roles in 
such processes. 
 Oxidative stress negatively affects skeletal muscle metabolism.  The generation of 
reactive oxygen species is a normal occurrence associated with aerobic metabolism and oxidative 
phosphorylation, but increased levels of oxidative stress are known to impair insulin sensitivity.  
GSTA4 is involved with the detoxification of 4-hyroxynonenal, and becomes localized in areas 
of oxidative stress in disease states [28].  In our study, skeletal muscle of obese dogs had a small 
increase in GSTA4 gene expression, which might indicate increased oxidative stress.  As 
mentioned above, leptin expression in skeletal muscle was higher in obese dogs and may reflect 
increased intramuscular lipid stores. Although intramuscular lipid stores may not be harmful, 
they may be associated with other toxic lipid metabolites associated with oxidative stress [29].    
Obese dogs also exhibited decreased expression of solute carrier family 22, member 5 
(SLC22A5), which actively transports carnitine from the blood into cells.  Noland et al. 
demonstrated that aging reduces skeletal muscle free carnitine concentrations in Wistar rats, a 
process that is accelerated by high-fat (45%) feeding [30].  In healthy male humans, insulin 
increases skeletal muscle SLC22A5 expression; so obese as compared to lean dog SLC22A5 
expression in our study may be due to decreased insulin sensitivity in the obese treatment [31].  
Because skeletal muscle free carnitine was not measured in our study, the influence of SLC22A5 
expression on carnitine and subsequent lipid metabolism in our dogs is unknown.  The dog is an 
efficient fat oxidizer, burning ~2X more fat at rest than less aerobic species [32,33].  Even 
though obese dogs in our study may have been accumulating intramuscular fat over time, they 
may have been buffered against the negative effects of excess intramuscular lipids because of 
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their efficient fatty acid oxidation.  Further investigation is needed to determine the impact of 
obesity on intramuscular fat and the health implications of ectopic fat accumulation in the dog. 
 As previously noted, adipose tissue had a large number of protein catabolism-associated 
genes altered during 24 wk of ad libitum feeding in dogs.  At 24 wk, skeletal muscle had a much 
smaller number of proteins affected in this functional class.  Of note, obese dogs had decreased 
expression of calpain 3.  Calpain 3 skeletal muscle gene expression is inversely related to 
adiposity and insulin resistance, which implies an association of obesity and its co-morbidities 
with altered protein catabolism [34].  Obese dogs also had increased expression of calpain, small 
subunit 1 and valosin containing protein, proteins involved with protein catabolism and 
autophagy.  Autophagy is a process that clears dysfunctional cellular organelles, and only a 
limited amount of research has examined how autophagy is affected by obesity in skeletal 
muscle.   
 Although we have identified differences in gene expression between lean and obese dogs, 
the functional implication of these differences are unclear because this was a cross-sectional 
study.  Our study also analyzed whole skeletal muscle tissue samples so gene expression changes 
may not be attributable to only myocyte populations.  As demonstrated by qRT-PCR data over 
the 24 wk study, differences in gene expression at the 24 wk time point were driven by changes 
both in the obese and lean groups.  Our gene expression data over time highlight the importance 
of longitudinal experiments and inclusion of appropriate control groups.  Because our study used 
female beagles, and estrogen is known to have a large impact on metabolism, our results may not 
be representative of male and spayed female dogs.  Even though this study has its limitations, it 
has highlighted genes and functional classes of importance in skeletal muscle of obese dogs. It 
will be important to conduct consequent longitudinal studies to determine causality, to ascertain 
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expression patterns of these genes during obesity development, and determine how these changes 
contribute to the obese phenotype and associated co-morbities.  It would be useful to perform 
future studies using a systems biology approach, taking into account important interactions 
among tissues (e.g., skeletal muscle, adipose, liver) during obesity development.  
 
Conclusion 
Skeletal muscle tissue is an important mediator of whole body glucose disposal.  Our results 
suggest that the skeletal muscle transcriptome exhibits a limited amount of change with short-
term weight gain and obesity in dogs.  Gene expression of obese dogs indicates increased 
oxidative stress, altered JAK-STAT signaling and altered fat and carbohydrate metabolism.  
Interestingly, it may be the presence of intramuscular fat driving these gene expression 
differences, as obese dogs had increased leptin expression compared to lean dogs.  These gene 
expression differences may be important in explaining the appearance and etiology of obesity 
associated co-morbidities in the dog. 
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Figure 5.1:  Functional gene classes altered by obesity in skeletal muscle.  Functional 
classification was determined using SOURCE, DAVID and NCBI resources. 
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Figure 5.2:  Skeletal muscle tissue gene expression of signaling and inflammatory genes in lean 
and obese dogs using qRT-PCR (n=4-5).  Gene expression is presented as fold change over lean 
dog expression, which was adjusted to 1 (SOCS2 = suppressor of cytokine signaling 2; CISH = 
cytokine inducible SH2-containing protein; STAT2 = signal transducer and activator of 
transcription 2; and CCRL2 = chemokine receptor-like 2; * difference (P<0.05) due to 
treatment). 
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Figure 5.3:  Skeletal muscle tissue gene expression of antioxidant- and myostatin-associated 
genes in lean and obese dogs using qRT-PCR (n=4-5).  Gene expression is presented as fold 
change over lean dog expression, which was adjusted to 1 (GSTA4 = glutathione-s-transferase 
alpha 4; LTBP3 = latent transforming growth factor beta binding protein 3; and ACVR2B = 
activin recepor II B; * difference (P<0.05) due to treatment). 
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Figure 5.4:  Skeletal muscle tissue gene expression of signaling, and inflammatory genes in lean 
and obese dogs at 0, 4, 8, 12, and 24 wk of ad libitum feeding using qRT-PCR (n=4-5).  Gene 
expression is presented as fold change over lean dog 0 wk expression, which was adjusted to 1 
(SOCS2 = suppressor of cytokine signaling 2; STAT2 = signal transducer and activator of 
transcription 2; and CCRL2 = chemokine receptor-like 2; and ACVR2B = activin recepor II B). 
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Table 5.1: Quantitative reverse transcriptase polymerase chain reaction primer sequences 
Gene Symbol Gene name Primer( 5'3') REFSEQ# 
ACVR2B activin A receptor, type IIB F TGGACCCGTGGATGAGTACA XM_542709.1 
R TGCTGGCCAATCTCTTCCTC  
BCAT2 
 
branched chain amino-acid transaminase 2 F GCAGCAAGAGGCGAAGAAGA XM_541509.2 
R CCGTACAGCCAGAGGACCTG  
BCKDK branched chain ketoacid dehydrogenase kinase F TCAGGATTTCAGACCGAGGC XM_536903.2 
R CCCGATCCAGGTCTTTGTGA  
CCRL2 chemokine (C-C motif) receptor-like  F TATTTTGCTACGCGCGAATG XM_541904.2 
 R TCCCCCTCTCTCCAGACCTT  
CISH cytokine inducible SH2-containing protein F CCTTCTCCAACCGGGTCTTT XM_541873.2 
R TGGGTTGAACGTGACCTCG  
CPT1B carnitine palmitoyltransferase 1B F AGCACATCTACCTGTCCGGG XM_538305.2 
R TGCGAATCAGGCGTTTCTTC  
GLUT4 solute carrier family 2 (facilitated glucose 
transporter), member 4 
F CAGTATATCGCGGAGGCCAT NM_001159327.1 
R AACCGCGAACAGAAGGAAGAC  
GSTA4 
 
glutathione S-transferase A4 F GCAGTGAAGCCCAAACTCCA XM_535577.2 
R GGATTCCATCCGGCCTCTT  
GYS1 glycogen synthase 1 F TAAGCCGCACTTTGTCCATG XM_849716.1 
R CCTCCCAATCCTCCAGTCCT  
IRS1 insulin receptor substrate 1 F GCAGTCGCGGAGGATATGAA XM_543274.2 
R CACGTTCTCAAAGGAAGCCG  
IRS2 insulin receptor substrate 2 F GCGCAGAACATCCACGAGA XM_542667.2 
R CTCCTTGAGCGCCTTCATG  
LPL lipoprotein lipase F TGCAACAACATGGGCTATGAG XM_854627.1 
R GCTGCCTCTTTTGGCTCTGA  
LTBP3 latent transforming growth factor beta binding 
protein  
F GAGACCACTGCGAGATCTACCC XM_540857.2 
R TGGAACTCGGCTGAGCTGTA  
SOCS2 suppressor of cytokine signaling 2 F ATGTGCAAGGATAAGCGGACA XM_539720.2 
R AACAGTGCCGTTCCGGG  
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Table 5.1 (cont.) 
 
  
STAT2 signal transducer and activator of transcription 2 F AATCCCGGATCCTGGAATTAA XM_538232.2 
R TGGATTTCACCAGCCTCTCC 
UCP2 uncoupling protein 2 F CAGCACCACAGGTGCCTTG NM_001003048.1 
  R ACTACATCTGTGGGCTGGGC  
UCP3 uncoupling protein 3 F CAAGCAGTTCTACACCCCCAA NM_001003047.1 
R CGCGTAGTGATGCTGGAGTG  
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Table 5.2:  Differentially expressed genes associated with apoptosis, cell cycle, and differentiation and signaling in skeletal muscle of 
obese as compared to lean dogs 
Gene symbol Gene name Probe Function Fold Change 
MBNL1 muscleblind-like  CfaAffx.13619.1.S1_at apoptosis, cell cycle, 
differentiation 
-2.11 
FLT1 fms-related tyrosine kinase 1  Cfa.19323.1.S1_s_at apoptosis, cell cycle, 
differentiation 
-1.59 
CCNE2 cyclin E2 CfaAffx.14834.1.S1_at apoptosis, cell cycle, 
differentiation 
-1.49 
LOC475196 zinc finger, C3HC type 1 CfaAffx.3142.1.S1_s_at apoptosis, cell cycle, 
differentiation 
-1.41 
PDCD7 programmed cell death 7 Cfa.691.1.A1_at apoptosis, cell cycle, 
differentiation 
 1.38 
PEA15 phosphoprotein enriched in astrocytes 15 CfaAffx.19351.1.S1_s_at apoptosis, cell cycle, 
differentiation 
 1.66 
CISH cytokine inducible SH2-containing protein CfaAffx.16086.1.S1_at signaling -21.05 
SOCS2 suppressor of cytokine signaling 2 CfaAffx.10255.1.S1_at signaling -4.95 
CCRL2 chemokine (C-C motif) receptor-like 2 CfaAffx.21295.1.S1_at signaling -2.60 
PDE4B phosphodiesterase 4B, cAMP-specific  Cfa.19191.1.S1_at signaling -1.78 
ACVR2B activin A receptor, type IIB CfaAffx.8479.1.S1_at signaling -1.63 
RAP1B RAP1B, member of RAS oncogene family Cfa.1011.1.S1_at signaling  1.56 
STAT2 signal transducer and activator of transcription 2 CfaAffx.27105.1.S1_s_at signaling  1.56 
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Table 5.3:  Differentially expressed genes associated with transport, development and transcription in skeletal muscle of obese  
 
as compared to lean dogs 
 
Gene symbol Gene name Probe Function Fold Change 
SLC22A5 solute carrier family 22, member 5 CfaAffx.2193.1.S1_s_at transport -2.63 
SLC7A2 solute carrier family 7 , member 2 CfaAffx.11313.1.S1_at transport -1.92 
RAB2B RAB2B, member RAS oncogene family Cfa.15246.1.A1_at transport  1.41 
TMCO3 transmembrane and coiled-coil domains 3 Cfa.9679.1.S1_at transport  1.56 
PRAF2 PRA1 domain family, member 2 Cfa.19173.1.S1_at transport  1.72 
SLC25A5 solute carrier family 25 , member 5 Cfa.1352.1.S1_s_at transport  1.81 
ZFAND5 zinc finger, AN1-type domain 5 CfaAffx.3616.1.S1_s_at development -1.52 
LTBP3 latent transforming growth factor beta binding protein 3 Cfa.17324.1.S1_s_at development  2.18 
TAGLN2 transgelin 2 Cfa.19077.1.S1_s_at development  3.26 
NRBF2 nuclear receptor binding factor 2 Cfa.19912.1.S1_s_at transcription -2.17 
MYNN myoneurin CfaAffx.756.1.S1_s_at transcription -1.77 
PAPOLA poly(A) polymerase alpha CfaAffx.27225.1.S1_s_at transcription -1.31 
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Table 5.4:  Differentially expressed genes associated with protein catabolism and protein modification in skeletal muscle of  
 
obese as compared to lean dogs 
 
Gene symbol Gene name Probe Function Fold Change 
CUL2 cullin 2 Cfa.19061.1.S1_s_at protein catabolism  -1.70 
CAPN3 calpain 3, (p94) CfaAffx.16858.1.S1_s_at protein catabolism  -1.57 
VCP valosin-containing protein CfaAffx.3906.1.S1_s_at protein catabolism   1.24 
PSMA5 proteasome (prosome, macropain) subunit, alpha type, 5 Cfa.9709.1.S1_s_at protein catabolism   1.27 
CAPNS1 calpain, small subunit 1 Cfa.16093.2.S1_s_at protein catabolism  1.30 
DOLK dolichol kinase Cfa.11380.1.A1_at protein modification  1.68 
OSTC oligosaccharyltransferase complex subunit Cfa.10288.1.S1_at protein modification  1.34 
TPST1 tyrosylprotein sulfotransferase 1 Cfa.10745.1.A1_at protein modification  1.88 
NNAT neuronatin CfaAffx.13891.1.S1_s_at protein modification  4.47 
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Table 5.5:  Differentially expressed genes in skeletal muscle of obese as compared to lean dogs 
 
Gene symbol Gene name Probe Function Fold Change 
CIB1 calcium and integrin binding 1  Cfa.15248.1.S1_s_at cell adhesion  1.53   
RFC2 replication factor C (activator 1) 2, 40kDa CfaAffx.18598.1.S1_s_at DNA replication -1.36 
ABHD12 abhydrolase domain containing 12 CfaAffx.7518.1.S1_at endocannabinoid 
regulation 
 1.46 
LOC609581 similar to Rab9 effector p40 Cfa.11793.1.A1_s_at endocytosis  1.60 
A2M alpha-2-macroglobulin Cfa.6037.1.S1_at immune response  1.57 
GAPDH glyceraldehyde-3-phosphate dehydrogenase CfaAffx.15326.1.S1_at metabolism -1.57 
LEP leptin CfaAffx.3412.1.S1_s_at metabolism  5.30 
TRDN triadin Cfa.1283.1.S2_s_at muscle contraction -2.13 
PDIA3 protein disulfide isomerase family A, member 3 Cfa.21639.1.S1_s_at protein folding  1.46 
BLVRA biliverdin reductase A CfaAffx.6160.1.S1_s_at oxidation-reduction  1.65 
GSTA4 glutathione S-transferase A4 Cfa.537.1.S1_at oxidation-reduction  1.95 
INTS8 integrator complex subunit 8 Cfa.344.1.A1_at RNA processing -3.11 
RRP1B ribosomal RNA processing 1 homolog B (S. cerevisiae) Cfa.14782.1.S1_s_at RNA processing -1.34 
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 
1 
Cfa.11962.1.A1_at translation -2.13 
PDXK pyridoxal kinase Cfa.20931.1.S1_s_at vitamin biosynthesis  1.71 
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CHAPTER 6 
 
Gonadal adipose tissue ZAG protein expression in a clinical population of dogs 
 
Abstract 
Zinc-alpha2 glycoprotein (ZAG) is a lipolytic adipokine.  ZAG expression is decreased in obese 
humans and rodents.  We previously demonstrated that ad libitum feeding and rapid weight gain 
caused a dramatic increase in subcutaneous adipose tissue ZAG expression.  As an obese body 
condition was reached, ZAG expression decreased to baseline levels, justifying further analysis.  
Thus, our objective was to determine whether ZAG protein expression was associated with body 
condition score (BCS) in a clinical dog population.  Adipose tissue samples were collected from 
discarded uterine tissue produced by routine spay procedures at the University of Illinois Small 
Animal Clinic.  The clinical population (n=27) analyzed had a BCS range of 2-6 (9 point scale) 
and body weight range of 3.0-29.5 kg.  ZAG expression was measured using Western blotting, 
and quantified by comparing band density of ZAG vs. A.  Linear regression was used to 
determine the effect of BCS and body weight on ZAG protein expression.  ZAG : cyclophilin A 
ranged from 0.68-3.90.  There was no effect (P>0.05; R2 = 0.017) of BCS or body weight on 
ZAG expression.  It may be that a wider range in body composition, including clinically obese 
dogs, is needed to determine the effect of obesity on ZAG expression.  ZAG protein expression 
may also be more affected by increased food intake or rapid weight gain, than body weight or 
BCS alone. 
 
Introduction 
Zinc-alpha2 glycoprotein (ZAG) is an adipokine secreted by adipose tissue.  It was first 
discovered in the urine of cancer patients with cachexia, and termed a lipid mobilizing factor [1].  
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Cachexia is characterized by muscle wasting and is often associated with the loss of adipose 
tissue stores.  During this condition, ZAG is thought to contribute to the loss of adipose tissue, as 
it is a lipid mobilizing factor that stimulates lipolysis.   
 Obese rodents and humans have decreased adipose tissue ZAG mRNA and protein 
expression [2-4].  It is unknown what mediates the down-regulation of ZAG expression in vivo.  
In cell culture studies, ZAG protein and mRNA expression is down-regulated by TNF-α 
treatment, and up-regulated by treatment with the peroxisome proliferator-activated receptor-γ 
agonist, rosiglitazone [3].  In Chapter 3 we found that ZAG mRNA was increased during a time 
of dramatic adipose tissue expansion and weight gain [5].  Adipose tissue ZAG expression may 
be a marker of adipose tissue homeostasis, with increased ZAG expression indicative of normal 
or expanding adipose tissue, while decreased expression may indicate adipose tissue dysfunction. 
 As an adipokine, ZAG has pleiotropic effects on the body.  ZAG likely influences 
adipose tissue locally in an autocrine manner, but other tissues as an endocrine hormone. Much 
of the research on the metabolic effects of ZAG has focused on brown adipose tissue and skeletal 
muscle because of their importance in maintaining energy homeostasis.  ZAG exerts effects on 
these tissues by signaling through the β3-adrenergic receptor [6].  Treatment of ob/ob mice with 
ZAG intraperitoneal injections (100 μg/day) decreased blood glucose, increased insulin 
sensitivity, and increased muscle mass and brown adipose tissue mass [7].   
 As mentioned previously in Chapter 3, we observed a large increase in adipose tissue 
ZAG mRNA expression at 4, 8 and 12 wk of ad libitum feeding.  At 24 wk, however, adipose 
tissue ZAG expression had returned to baseline (wk 0) levels.  Here we have analyzed gonadal 
adipose tissue ZAG protein expression in a clinical population.  Our goal was to collect gonadal 
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adipose tissue samples from ~30 dogs with wide range of a BCS.  We hypothesized that ZAG 
expression would be correlated with body condition score, have increased expression as  
BCS increased, but decreased expression in morbidly obese dogs. 
 
Methods 
Discarded gonadal adipose tissue was collected from 27 dogs undergoing ovariohysterectomy at 
the University of Illinois Small Animal Clinic from October 2010 to February 2011.  Adipose 
tissue was flash frozen in liquid nitrogen and transferred to dry ice until final storage at -80°C.  
Dog body weight was recorded and body condition scoring was done using a 9-point scale [8].  
Dog characteristics are listed in Table 6.1. 
 
Adipose tissue protein extraction 
A modified 2x adipose tissue protein extraction buffer containing 40 mM HEPES, 4 mM EGTA, 
100 mM NaF, 50 mM KCl, 0.4 mM EDTA and 100 mM B-glycerophosphate (pH 7.4) was 
prepared as described by Lynch et al [9].  For adipose tissue extraction, the 2x protein extraction 
buffer was diluted to 1x using water.  100x Pierce HALT protease and phosphatase inhibitors 
were diluted to 1x and PMSF was included at 1%, according to manufacturer instructions, in the 
1x protein extraction buffer. 
 Adipose tissue was ground in liquid nitrogen using a mortar and pestle, and 2 mg of 
tissue was added to 0.6 ml of protein extraction buffer.  Adipose tissue was then homogenized 
using the Tissuelyser II (Qiagen, Valencia, CA) system for two 1-min periods at 20 Hz.  After 
homogenization, adipose tissue protein extracts were centrifuged at 10,000g for 10 min at 4°C 
and the supernatant (soluble proteins) was collected.   
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Antibody generation 
A canine specific ZAG antibody was produced by the University of Illinois Immunological 
Resource Center.  A ZAG-specific protein sequence (cys-tyr-asp-ser-glu-thr-gly-lys-ala-ile-pro-
arg-tyr) was synthesized and purified using high-performance liquid chromatography by the 
University of Illinois Protein Sciences Facility.  The synthesized antibody was injected into a 
New Zealand rabbit 5 times (0 wk, 4 wk, 7 wk, 10 wk, 13 wk).  Blood was collected and 
antiserum extracted ~1wk after the final injection. 
 
Western blotting 
Soluble protein extract protein concentration was analyzed using the Bio-Rad Protein Assay 
(Bio-Rad, Hercules, CA).  45μg of protein was added to Laemeli buffer (Bio-Rad), for a final 
volume of 22μl.  Diluted samples were heated for 5 min at 100°C.  Samples were placed on ice 
until being loaded (20μl) on to a PAGE gel consisting of a 5% acrylamide stacking gel and 15% 
acrylamide resolving gel.  Once loaded, samples were run for 1 h at 200V in TRIS glycine SDS 
buffer (Bio-Rad).  Gels were next transferred to a polyvinylidene fluoride (PVDF) membrane 
(Bio-Rad) for 2h at 85V.  After transfer, the PVDF membrane was blocked in TRIS buffered 
saline (TBS) with 5% milk overnight.  After blocking, the PVDF membrane was then incubated 
with ZAG antibody (1:100 dilution) and cyclophilin A antibody (Santa Cruz Biotechnology; 
1:200 dilution) in TBS with 5% milk for 1h.  After incubation, PVDF membranes were washed 
using TBS with 0.1% tween for 1 min and 5 min.  Next the PVDF membrane was incubated with 
a rabbit specific 2° antibody (Invitrogen, Carlsbad, CA) containing alkaline phosphatase for 30 
min.  After incubation, the PVDF membrane was washed 4 times using TBS with 0.1% tween 
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for one 1m period and three 5 min periods.  The membrane was then rinse with water for 2 min.  
Next, the PDVF membrane was incubated in chromogenic substrate (Invitrogen) for ~25 min.  
The membrane was rinsed with water to stop the reaction and then an additional two times for 2 
min.  Next PVDF membranes were air dried for 20 min.  Images of PVDF membranes were 
taken with Grey Scale Digital Camera (model CFW-1312M, Bio-Rad) and analyzed with 
Quantity One software (Bio-Rad) for band density.  ZAG data are expressed as ZAG : 
cyclophilin A band density. 
 
Statistics 
To determine the effect of body weight and BCS on gonadal adipose tissue ZAG expression, 
linear regression was used (SAS Institute, Cary, NC).  A β value with P<0.05 was considered to 
be significant. 
 
Results 
Dogs of this clinical population were mostly mixed breed.  BCS ranged from 2-6 (Table 6.1), 
with the predominant scores in the normal range of 4-6 (22 of 29 dogs).  Body weight ranged 
from 3.0 -29.5 kg (Table 6.1).  Information regarding dog age was not available, but dogs ranged 
from puppies to adults.  Mean ZAG expression in this population was 1.5 (ZAG:cyclophilin A) 
and ranged from 0.68-3.90 (representative blot Figure 6.1).  Body weight and BCS had no effect 
(P=0.80 R2=0.017) on ZAG expression (Figure 6.2 and 6.3).   
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Discussion 
This is the first study to measure adipose tissue ZAG protein expression in the dog.  We 
previously found that subcutaneous ZAG mRNA expression was highly induced during ad 
libitum feeding and rapid weight gain, and that ZAG concentrations decreased as animals 
reached an obese BCS.  At 24 wk, gene expression of ZAG was not different between 
subcutaneous and gonadal adipose tissue depots, as measured by microarray (Chapter 4).  In this 
study, we hypothesized that ZAG concentrations would be positively associated with BCS, but 
decreased in morbidly obese dogs.  Zinc-alpha2 glycoprotein protein concentration was not 
associated with BCS or body weight in our dog population.  Because our population did not 
include any obese dogs, however, we could not test the effect of obesity on ZAG. 
 Studies focused on human adipose tissue have reported decreased ZAG protein 
concentration during obesity [8].  Non-obese subjects in that study had similar ZAG : cyclophilin 
A (average=1.0) compared to those observed in our study (average=1.54) [10].  There was a lot 
of inherent variability among dogs, as they varied by age and breed.  Although we did not have a 
reliable measure of age, it was apparent that some dogs were still growing puppies, and their 
uteri had not fully developed and had much less adipose tissue.  The effect of growth on ZAG 
expression has not been studied, but growth may partition energy away from gonadal adipose 
tissue, resulting in reduced depot size. 
 In Chapter 3, we observed large increases in ZAG expression with early weight gain and 
increasing BCS.  Because 24 wk ZAG expression was not different between subcutaneous and 
gonadal adipose tissue in Chapter 4, we felt that the use of gonadal adipose tissue, a byproduct of 
routine spays, would allow for adequate analysis. Zinc-alpha2 glycoprotein expression may be 
more responsive to dramatic changes in food intake and adipose tissue expansion.  We may have 
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not been able to detect differences in ZAG expression because the population available for this 
study were in the low range of BCS.  To fully understand how ZAG expression is affected by 
obesity status, a larger sample size of adult dogs would be needed that spanned the BCS range, 
including BCS 6-9.  BCS had no effect on ZAG expression in our population and larger 
differences in body composition and body condition score may be needed to observe differences 
in ZAG protein expression. 
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             Zinc alpha2-glycoprotein 
Cyclophilin A 
Figure 6.1: Representative western blot of gonadal adipose tissue zinc alpha2-
glycoprotein and cyclophilin A protein expression 
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Figure 6.2: Gonadal adipose tissue relative zinc alpha2 glycoprotein expression (ZAG; ZAG : 
cyclophilin A) in dogs (n=27) of varying body condition score (BCS).   
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Figure 6.3: Gonadal adipose tissue relative zinc alpha2 glycoprotein expression (ZAG; ZAG : 
cyclophilin A) in dogs (n=27) of varying body weight.   
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Table 6.1: Population characteristics 
Body weight (kg) Body condition score Breed 
6.9 2 Mixed breed 
3.0 3 Mixed breed 
3.6 3 Mixed breed 
            10.5 3 Mixed breed 
            21.8 3 Mixed breed 
6.7 4 Mixed breed 
8.9 4 Mixed breed 
9.1 4 Mixed breed 
            13.8 4 Mixed breed 
            14.5 4 Mixed breed 
            20.6 4 Mixed breed 
            21.6 4 Rottweiler 
            23.8 4 Mixed breed 
            26.1 4 Mixed breed 
            27.0 4 Mixed breed 
3.3 5 Mixed breed 
3.4 5 Mixed breed 
5.0 5 Mixed breed 
5.7 5 Mixed breed 
8.7 5 Beagle 
            10.0 5 Mixed breed 
            10.9 5 Mixed breed 
            13.6 5 Mixed breed 
            15.0 5 Mixed breed 
            15.0 5 Mixed breed 
            15.9 5 Mixed breed 
            29.5 6 American bulldog 
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CHAPTER 7 
Summary 
 A large portion of the canine population is obese and will experience increased incidence 
of chronic disease [1].  The molecular links between adipose and skeletal muscle tissue 
dysfunction and co-morbidities during obesity are unknown.  Here we have shown that the 
adipose tissue transcriptome undergoes dramatic changes in many physiologically relevant 
processes over 24 wk of ad libitum feeding.  We also demonstrated that there are large 
differences in adipose depot transcriptomes that may explain some of the functional differences 
noted between depots.  While large changes in adipose tissue mRNA transcript expression were 
detected, skeletal muscle had much fewer differentially expressed transcripts.  Our results 
highlight that adipose tissue must undergo dramatic changes in order to compensate for increased 
energy storage during obesity, large differences in depot function exist, and that changes in 
skeletal muscle are likely a combination of gene expression differences along with exposure to 
circulating non-esterified fatty acids (NEFA) and inflammatory mediators. 
 The objective of study 1 (Chapter 3) was to identify genes and functional gene classes 
differentially expressed over 24 wk of ad libitum feeding in the dog.  Ad libitum fed dogs gained 
a significant amount of body weight and fat mass.  Adipose tissue gene expression had dramatic 
changes with weight gain (1665 differentially expressed genes) over 24 wk of diet-induced 
obesity.  Functional classification of these genes revealed differences in many classes important 
for adipose tissue homeostasis including: extracellular matrix, metabolism, oxidation-reduction 
etc.  Because we fed both groups the same diet, it is unknown how these genes would respond to 
different diets, and translate to clinical populations. 
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The objective of study 2 (Chapter 4) was to identify genes and functional gene classes 
differentially expressed between subcutaneous and gonadal adipose tissue in lean and obese 
dogs.  Visceral adipose tissue is known to have increased inflammation and metabolic activity [2, 
3].  Here we have shown that there are marked differences between subcutaneous and gonadal 
adipose tissues, regardless of obesity status in the dog.  Contrary to the expected results, 
subcutaneous adipose tissue had higher expression of macrophage markers and 
lipopolysaccharide signaling components. This could be due to the effects of estrogen, as the 
dogs studied were intact female beagles, but could also represent species differences.  The 
alternative arm of the complement cascade had increased expression in visceral adipose tissue, 
which could function as both a potent mediator of innate immunity, but also influence 
metabolism through the metabolism of C3 to C3adesARG.  These differences likely reflect 
differences in depot specific metabolism and immune response. 
The objective of study 3 (Chapter 5) was to identify genes and functional gene classes 
differentially expressed in skeletal muscle between lean and obese dogs.  It is interesting to note 
that many other studies have reported either no changes or few changes in skeletal muscle gene 
expression using microarray technology [4-6].  These findings indicate that exposure to low-
grade inflammation and NEFA may play an important role in propagating skeletal muscle insulin 
resistance.  We did find alterations in genes that influence metabolism and insulin resistance, 
response to oxidative stress, and indicate increased lipid accumulation.  Further research to 
determine the importance of these genes on skeletal muscle function and how insulin resistance 
and oxidative stress is related lipid accumulation in skeletal muscle will be needed in the future.  
This may be particularly interesting in the dog because as a species they have a much lower 
respiratory quotient and utilize fat very efficiently compared to rodents and humans. 
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The objective of study 4 (Chapter 6) was to determine how gonadal adipose tissue ZAG 
protein expression differed with changing body weight and body condition score (BCS) in a 
clinical population.  Subcutaneous adipose tissue ZAG mRNA was dramatically increased with 
ad libitum feeding in Chapter 23 but expression had returned to basal levels by 24 wk.  Thus, 
determining how ZAG expression is influenced by BCS was warranted.  ZAG was unaffected by 
BCS in this population.  Our population was uncontrolled and did not include any obese dogs 
(BCS range was 2-6).  Future studies focused on dogs that are overweight and morbidly obese is 
needed. 
In our studies, we identified many genes and functional classes of importance to both 
adipose tissue and skeletal muscle homeostasis.  Follow-up studies are needed to determine the 
physiological relevance of these gene expression changes and how they relate to the clinically 
obese population.  We have begun this process by measuring ZAG protein expression in a 
clinical population, but it may also be useful to examine adipose tissue or whole body gene 
knockdown models in order to ascertain the relevance of these genes in normal and obese 
animals.  It may be useful to couple an obesity development experimental approach, with plasma 
metabolomics analysis to identify the association of tissue specific changes with plasma 
metabolites.  Although many of the functional classes altered by obesity were predictable, we 
have identified genes within these functional classes that have received little or no attention in 
previous obesity research, and are likely important to adipose tissue homeostasis.  An example of 
this is glutathione peroxidase 7, which we found to be induced in subcutaneous adipose tissue 
during the initial 12 wk of ad libitum feeding.  This enzyme has been linked to reducing 
oxidative stress of polyunsaturated fatty acids in other disease states, and may play an important 
role decreasing lipid oxidation in adipose tissue. 
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Although we observed large immunological gene expression differences between adipose 
tissue depots in both lean and obese beagles at 24 wk, over the time course of obesity 
development, few changes in inflammatory genes in subcutaneous adipose tissue were observed.  
This could be due to the depot measured, but also the diet fed.  Although the diet was high-fat 
(47%), it was formulated for working dogs and included ingredients that may reduce 
inflammation (e.g., fish oil).  It would be useful for future studies to compare diets formulated 
with saturated or polyunsaturated fats to determine the effect of fatty acid composition on the 
gene expression differences that we have observed. 
 Obesity induces both insulin resistance in the liver and skeletal muscle of the dog [7, 8].  
Global transcriptome analysis from our studies indicates a much larger response to weight status 
in adipose tissue than skeletal muscle, which agrees with past studies in mice and humans.  It 
may be that skeletal muscle is more sensitive to body weight change at the protein level, while 
adipose tissue, which undergoes remodeling and expansion, is more sensitive at the 
transcriptional level.  It is important to note that we did not measure liver gene expression in our 
studies.  We would expect changes in liver gene and protein expression with obesity, possibly 
contributing to obesity related co-morbidities.  Because adipose, skeletal muscle, and liver 
tissues are large contributors to systemic fuel utilization, it is important to understand how 
obesity affects macronutrient metabolism in all three organs. 
 Obesity and its co-morbidities are associated with altered tissue and systemic metabolism 
and inflammation.  We have identified many important functional processes in adipose tissue and 
skeletal muscle that are altered by obesity.  It should be recognized that the differences were in 
intact female dogs.  Estrogen plays a large role in metabolism and fat storage, and reduced 
estrogen in males and ovariectomized female rodents is associated with adipose tissue 
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inflammation [9, 10].  It would be particularly relevant to perform follow-up studies in male and 
spayed female dogs to determine the role of estrogen in depot-specific fat storage, as measured 
by MRI, depot immune cell composition and inflammation.  It would also be useful to determine 
the cellular fractions of adipose tissue that are responsible for these gene expression changes, and 
how the immune cell composition of canine adipose tissue varies over the course of obesity 
development.  Even though our studies have their limitations, we have identified genes and 
functional pathways in adipose tissue depots and skeletal muscle that have homeostatic roles at 
the tissue level, but likely are important to the systemic response to obesity and the development 
of co-morbidities.  Determining how these genes respond to different diets and physiological 
states will be important for the development of future obesity treatments in the dog. 
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Appendix A: Differentially expressed genes in ad libitum fed dogs during diet-induced obesity 
 
Probe Symbol Description Annotation Fold change 
    4 wk 8 wk 12 wk 24 wk 
CfaAffx.10479.1.S1_at VEZT 
vezatin, adherens junctions 
transmembrane protein Adherens junction 1.52 0.96 1.20 3.58 
Cfa.18570.1.S1_s_at AKAP1 A kinase (PRKA) anchor protein 1 Anchoring 0.48 0.77 0.37 0.53 
CfaAffx.26640.1.S1_s_at AKAP1 A kinase (PRKA) anchor protein 1 Anchoring 0.52 0.73 0.49 0.47 
Cfa.904.1.A1_at AKAP1 A kinase (PRKA) anchor protein 1 Anchoring 0.54 0.66 0.48 0.55 
Cfa.3287.1.A1_at PIGN 
phosphatidylinositol glycan anchor 
biosynthesis, class N Anchoring 0.77 0.43 0.96 1.30 
Cfa.1307.1.S1_at AKAP9 
A kinase (PRKA) anchor protein 
(yotiao) 9 Anchoring 0.81 0.43 0.67 1.09 
Cfa.227.1.S1_at AKAP12 A kinase (PRKA) anchor protein 12 Anchoring 1.25 0.78 1.49 1.39 
Cfa.11814.1.A1_at GPAA1 
glycosylphosphatidylinositol anchor 
attachment protein 1 homolog 
(yeast) Anchoring 1.49 1.51 1.49 1.26 
Cfa.3581.1.S2_at VEGFA vascular endothelial growth factor A Angiogenesis 0.54 0.62 0.41 0.55 
Cfa.3581.1.S1_s_at VEGFA vascular endothelial growth factor A Angiogenesis 0.56 0.85 0.30 0.37 
Cfa.4903.1.A1_at 
SERPINF
1 
serpin peptidase inhibitor, clade F 
(alpha-2 antiplasmin, pigment 
epithelium derived factor), member 
1 Angiogenesis 1.73 1.50 1.93 1.49 
CfaAffx.29358.1.S1_s_at 
SERPINF
1 
serpin peptidase inhibitor, clade F 
(alpha-2 antiplasmin, pigment 
epithelium derived factor), member 
1 Angiogenesis 2.33 2.01 2.70 1.92 
Cfa.110.1.S1_s_at BCL2 B-cell CLL/lymphoma 2 Apoptosis 0.43 0.73 0.31 0.45 
CfaAffx.16895.1.S1_s_at PDCD4 
programmed cell death 4 (neoplastic 
transformation inhibitor) Apoptosis 0.45 0.34 0.51 0.74 
Cfa.10871.1.A1_s_at 
TAX1BP
1 
Tax1 (human T-cell leukemia virus 
type I) binding protein 1 Apoptosis 0.57 0.27 0.48 1.11 
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Cfa.3565.1.S1_s_at C3VS 
uveal autoantigen with coiled-coil 
domains and ankyrin repeats Apoptosis 0.58 0.20 0.45 0.66 
CfaAffx.14399.1.S1_s_at SON SON DNA binding protein Apoptosis 0.63 0.46 0.85 1.01 
Cfa.10358.2.S1_s_at SON SON DNA binding protein Apoptosis 0.66 0.43 0.90 1.27 
Cfa.16935.1.S1_at BNIP1 
BCL2/adenovirus E1B 19kDa 
interacting protein 1 Apoptosis 0.66 0.92 0.47 0.57 
Cfa.10774.1.A1_at 
TAX1BP
1 
Tax1 (human T-cell leukemia virus 
type I) binding protein 1 Apoptosis 0.68 0.32 0.50 1.02 
CfaAffx.14389.1.S1_at SON SON DNA binding protein Apoptosis 0.71 0.35 0.84 1.53 
CfaAffx.1702.1.S1_s_at SON SON DNA binding protein Apoptosis 0.72 0.52 0.91 1.46 
Cfa.11224.1.A1_s_at TIAL1 
TIA1 cytotoxic granule-associated 
RNA binding protein-like 1 Apoptosis 0.75 0.78 0.84 1.30 
Cfa.8026.1.A1_at 
PPP1R13
B 
protein phosphatase 1, regulatory 
(inhibitor) subunit 13B Apoptosis 0.79 1.01 0.62 0.51 
Cfa.695.1.S1_at PPP3CC 
protein phosphatase 3 (formerly 
2B), catalytic subunit, gamma 
isoform Apoptosis 0.79 0.37 0.94 2.01 
CfaAffx.14149.1.S1_s_at RIPK2 
receptor-interacting serine-threonine 
kinase 2 Apoptosis 0.85 0.74 1.27 1.83 
Cfa.84.1.S1_at CASP3 
caspase 3, apoptosis-related cysteine 
peptidase Apoptosis 1.11 1.28 1.21 1.10 
Cfa.11640.1.S1_s_at BI-1 
Bax inhibitor-1 (BI-1) (Testis 
enhanced gene transcript) apoptosis 1.13 1.48 0.97 0.79 
CfaAffx.25232.1.S1_at 
MAGEH
1 melanoma antigen family H, 1 Apoptosis 1.17 1.69 1.32 0.88 
CfaAffx.3295.1.S1_s_at RRAGA Ras-related GTP binding A Apoptosis 1.27 1.51 1.15 0.75 
Cfa.6064.1.A1_at DAD1 defender against cell death 1 Apoptosis 1.30 1.37 1.41 1.20 
CfaAffx.17372.1.S1_s_at DAD1 defender against cell death 1 Apoptosis 1.45 1.63 1.53 1.16 
CfaAffx.17372.1.S1_at DAD1 defender against cell death 1 Apoptosis 1.48 1.58 1.51 1.18 
CfaAffx.3673.1.S1_s_at BAG1 BCL2-associated athanogene Apoptosis 1.54 1.88 1.45 1.36 
Cfa.2264.1.S1_at 
MAGED
1 melanoma antigen family D, 1 Apoptosis 1.80 1.66 2.03 1.64 
CfaAffx.24641.1.S1_s_at MAGED melanoma antigen family D, 1 Apoptosis 1.91 2.12 2.06 1.79 
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1 
Cfa.20792.1.S1_at 
BLOC1S
2 
biogenesis of lysosomal organelles 
complex-1, subunit 2 Apoptosis 2.90 1.92 2.20 1.99 
Cfa.20792.1.S1_s_at 
BLOC1S
2 
biogenesis of lysosomal organelles 
complex-1, subunit 2 Apoptosis 3.15 1.94 2.67 1.61 
CfaAffx.22169.1.S1_s_at AGFG2 ArfGAP with FG repeats 2 
ARF GTPase 
regulation 2.16 3.68 1.14 2.87 
CfaAffx.8878.1.S1_at SLITRK6 
SLIT and NTRK-like family, 
member 6 Axonogenesis 0.20 0.11 0.17 1.04 
CfaAffx.28191.1.S1_s_at ITGA2 
integrin, alpha 2 (CD49B, alpha 2 
subunit of VLA-2 receptor) Cell adhesion 0.39 0.12 1.09 0.74 
CfaAffx.4328.1.S1_at OMD osteomodulin Cell adhesion 0.57 0.09 0.80 1.65 
Cfa.1941.1.S1_at VCAM1 vascular cell adhesion molecule 1 Cell adhesion 0.60 0.31 0.93 1.04 
Cfa.1402.1.S1_at 
CTNNAL
1 catenin, alpha-like 1 Cell adhesion 0.74 0.24 0.76 1.21 
CfaAffx.17206.1.S1_s_at PPFIBP1 
PTPRF interacting protein, binding 
protein 1 (liprin beta 1) Cell adhesion 0.85 0.91 0.89 2.38 
Cfa.1266.1.A1_at JAM2 junctional adhesion molecule 2 Cell adhesion 0.87 0.53 1.24 0.75 
Cfa.5412.1.A1_at 
LOC4793
73 PDZ domain containing 3 isoform a cell adhesion 0.99 1.40 0.98 0.99 
Cfa.1988.1.S1_at SCARB2 
scavenger receptor class B, member 
2 Cell adhesion 1.30 1.16 1.35 1.08 
Cfa.10223.1.A1_at 
CERCA
M 
cerebral endothelial cell adhesion 
molecule Cell adhesion 1.95 1.74 2.06 1.01 
Cfa.2424.1.S1_at SVEP1 
sushi, von Willebrand factor type A, 
EGF and pentraxin domain 
containing 1 Cell adhesion 2.51 2.15 3.06 3.00 
CfaAffx.5312.1.S1_s_at SVEP1 
sushi, von Willebrand factor type A, 
EGF and pentraxin domain 
containing 1 Cell adhesion 2.85 2.44 3.62 3.30 
Cfa.10634.1.A1_at ITGA7 integrin, alpha 7 Cell adhesion 3.30 2.74 2.01 2.06 
CfaAffx.5336.1.S1_s_at SVEP1 
sushi, von Willebrand factor type A, 
EGF and pentraxin domain Cell adhesion 3.46 3.19 4.91 5.15 
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containing 1 
CfaAffx.1052.1.S1_s_at ITGA7 integrin, alpha 7 Cell adhesion 4.00 3.30 2.11 2.21 
CfaAffx.14209.1.S1_s_at THBS4 thrombospondin 4 Cell adhesion 
11.2
6 7.31 7.79 3.97 
CfaAffx.18523.1.S1_s_at CHEK2 
CHK2 checkpoint homolog (S. 
pombe) Cell cycle 0.28 0.33 0.39 0.39 
CfaAffx.18573.1.S1_s_at 
CCNDBP
1 cyclin D-type binding-protein 1 Cell cycle 0.43 0.54 0.35 0.42 
Cfa.17687.1.S1_at 
CCNDBP
1 cyclin D-type binding-protein 1 Cell cycle 0.44 0.47 0.42 0.67 
CfaAffx.3674.1.S1_s_at DBF4 DBF4 homolog (S. cerevisiae) Cell cycle 0.45 0.22 0.57 1.08 
CfaAffx.12618.1.S1_at ATR 
ataxia telangiectasia and Rad3 
related Cell cycle 0.47 0.14 0.70 1.93 
Cfa.3090.1.S1_at SESN1 sestrin 1 Cell cycle 0.51 0.45 0.66 0.70 
Cfa.15524.1.A1_s_at AHCTF1 
AT hook containing transcription 
factor 1 Cell cycle 0.51 0.27 0.52 1.02 
CfaAffx.27347.1.S1_at RPRD1A 
Regulation of nuclear pre-mRNA 
domain containing 1A Cell cycle 0.52 0.46 0.81 1.28 
Cfa.15281.1.S1_at CLIP1 
CAP-GLY domain containing linker 
protein 1 Cell cycle 0.54 0.27 0.56 1.28 
CfaAffx.28575.1.S1_at NIPBL Nipped-B homolog (Drosophila) Cell cycle 0.55 0.26 0.57 0.98 
Cfa.15098.1.A1_at SPIN2 Spindlin-like protein 2 (SPIN-2) Cell cycle 0.56 0.94 0.43 0.69 
CfaAffx.16837.1.S1_at SMC3 
structural maintenance of 
chromosomes 3 Cell cycle 0.62 0.23 0.58 0.79 
CfaAffx.12674.1.S1_s_at CLIP1 
CAP-GLY domain containing linker 
protein 1 Cell cycle 0.63 0.18 0.43 1.66 
Cfa.16649.1.S1_s_at STAG2 stromal antigen 2 Cell cycle 0.68 0.36 0.67 0.88 
CfaAffx.11926.1.S1_s_at 
MPHOSP
H8 M-phase phosphoprotein 8 Cell cycle 0.68 0.21 0.41 0.69 
CfaAffx.28426.1.S1_at STAG2 stromal antigen 2 Cell cycle 0.68 0.36 0.65 1.10 
Cfa.2504.1.A1_at 
MAD2L1
BP MAD2L1 binding protein Cell cycle 0.73 0.80 0.62 0.42 
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CfaAffx.21274.1.S1_at CCAR1 
cell division cycle and apoptosis 
regulator 1 Cell cycle 0.74 0.20 0.54 1.82 
CfaAffx.12000.1.S1_s_at STAG1 stromal antigen 1 Cell cycle 0.78 0.20 1.06 1.70 
CfaAffx.27898.1.S1_at RBBP8 retinoblastoma binding protein 8 Cell cycle 0.79 0.28 0.89 1.44 
Cfa.17828.1.S1_s_at TXNL4B thioredoxin-like 4B Cell cycle 0.83 1.19 0.58 0.51 
Cfa.20397.1.S1_s_at CEP63 centrosomal protein 63kDa Cell cycle 0.84 0.47 0.68 1.62 
Cfa.4773.1.S1_at SPIN1 spindlin 1 Cell cycle 0.85 1.48 1.46 1.54 
CfaAffx.11060.1.S1_s_at CEP63 centrosomal protein 63kDa Cell cycle 0.86 0.45 0.76 1.79 
Cfa.2964.1.A1_at CCPG1 cell cycle progression 1 Cell cycle 0.88 0.40 0.99 1.71 
CfaAffx.30973.1.S1_at TXNL4B thioredoxin-like 4B Cell cycle 0.88 1.21 0.48 0.48 
Cfa.5851.2.S1_s_at GSPT2 G1 to S phase transition 2 Cell cycle 0.99 1.12 1.61 1.15 
CfaAffx.4194.1.S1_at SPIN1 spindlin 1 Cell cycle 1.01 1.32 1.09 1.12 
Cfa.1521.1.S1_at NUSAP1 
nucleolar and spindle associated 
protein 1 Cell cycle 1.07 0.78 1.55 3.16 
CfaAffx.12330.1.S1_s_at NEK1 
NIMA (never in mitosis gene a)-
related kinase 1 Cell cycle 1.07 1.14 1.10 1.70 
Cfa.6041.1.A1_at 
MPHOSP
H8 M-phase phosphoprotein 8 Cell cycle 1.11 0.73 1.69 2.27 
CfaAffx.27516.1.S1_s_at PIN1 
peptidylprolyl cis/trans isomerase, 
NIMA-interacting 1 Cell cycle 1.19 1.39 1.06 0.73 
CfaAffx.25345.1.S1_s_at ERH 
enhancer of rudimentary homolog 
(Drosophila) Cell cycle 1.22 1.22 1.18 0.75 
CfaAffx.26219.1.S1_s_at CKS1B 
CDC28 protein kinase regulatory 
subunit 1B Cell cycle 1.32 1.48 1.17 0.77 
CfaAffx.18039.1.S1_s_at PPP1CA 
protein phosphatase 1, catalytic 
subunit, alpha isoform Cell cycle 1.56 1.82 1.12 0.58 
CfaAffx.2275.1.S1_at 8-Sep septin 8 Cell cycle 1.62 1.65 1.88 1.62 
CfaAffx.13468.1.S1_at INO80B INO80 complex subunit B Cell cycle 1.64 2.19 1.35 1.27 
Cfa.10960.1.S1_at 
CDK2AP
1 
cyclin-dependent kinase 2 
associated protein 1 Cell cycle 1.82 1.96 2.08 2.13 
Cfa.10960.2.A1_a_at 
LOC4774
52 
CDK2 (cyclin-dependent kinase 2)-
associated protein 1 Cell cycle 2.01 2.25 2.22 1.32 
Cfa.11204.1.A1_at LOC6095 response gene to complement 32 Cell cycle 2.46 2.18 1.60 1.91 
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34 
CfaAffx.7939.1.S1_at CGREF1 
cell growth regulator with EF-hand 
domain 1 Cell cycle 3.54 3.37 3.92 2.85 
Cfa.20275.1.S1_at 
LOC4750
95 Protein KIAA0196 Cell death 1.02 0.53 1.08 1.39 
CfaAffx.5908.1.S1_at IFRD1 
interferon-related developmental 
regulator 1 
Cell 
differentiation 0.46 0.66 0.38 1.25 
CfaAffx.7103.1.S1_at BBS7 Bardet-Biedl syndrome 7 
Cell 
differentiation 0.61 0.24 0.62 1.57 
CfaAffx.15352.1.S1_s_at TTC3 tetratricopeptide repeat domain 3 
Cell 
differentiation 0.63 0.19 0.76 1.89 
Cfa.11881.1.A1_s_at TTC3 tetratricopeptide repeat domain 3 
Cell 
differentiation 0.70 0.23 0.66 1.41 
Cfa.251.1.S1_at TTC3 tetratricopeptide repeat domain 3 
Cell 
differentiation 0.74 0.33 0.98 1.24 
CfaAffx.15350.1.S1_at TTC3 tetratricopeptide repeat domain 3 
Cell 
differentiation 0.79 0.44 0.92 1.16 
Cfa.12506.3.S1_at NOC3L 
nucleolar complex associated 3 
homolog (S. cerevisiae) 
Cell 
differentiation 0.80 0.28 1.28 1.05 
CfaAffx.9134.1.S1_s_at DZIP1 DAZ interacting protein 1 
Cell 
differentiation 1.07 0.47 1.22 1.53 
Cfa.19183.1.S1_s_at RNF114 ring finger protein 114 
Cell 
differentiation 1.18 1.61 0.92 0.39 
Cfa.19183.1.S1_at RNF114 ring finger protein 114 
Cell 
differentiation 1.19 1.70 0.81 0.36 
Cfa.10529.1.S2_at MTPN myotrophin 
Cell 
differentiation 1.26 1.78 1.42 1.30 
CfaAffx.10835.1.S1_s_at TBCB tubulin folding cofactor B 
Cell 
differentiation 1.42 1.60 1.51 1.03 
CfaAffx.9498.1.S1_at 
SPATA2
4 
TATA-binding protein-like factor-
interacting protein isoform 2 
Cell 
differentiation 1.76 1.54 0.93 0.63 
CfaAffx.2348.1.S1_s_at POLDIP3 
polymerase (DNA-directed), delta 
interacting protein 3 Cell growth 1.10 1.50 0.90 0.75 
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CfaAffx.16253.1.S1_at NDNL2 necdin-like 2 Cell growth 1.16 1.83 1.07 0.96 
Cfa.18110.1.S1_s_at GAS6 growth arrest-specific 6 Cell growth 2.15 2.93 1.98 1.80 
Cfa.3888.1.S1_at IGF1 
insulin-like growth factor 1 
(somatomedin C) Cell growth 2.68 1.35 1.87 1.19 
Cfa.3888.1.S1_s_at IGF1 
insulin-like growth factor 1 
(somatomedin C) Cell growth 3.33 1.36 2.29 1.64 
CfaAffx.20996.1.S1_at MIA3 
melanoma inhibitory activity family, 
member 3 Cell migration 1.10 0.71 1.20 1.49 
Cfa.6022.1.A1_at S100A2 S100 calcium binding protein A2 Cell migration 3.96 4.96 2.73 3.99 
Cfa.11453.1.A1_at IFT20 
intraflagellar transport protein 
IFT20 Cell projection 1.61 1.76 1.58 1.58 
CfaAffx.28507.1.S1_s_at IFT20 
intraflagellar transport protein 
IFT20 Cell projection 1.73 2.00 1.60 1.35 
Cfa.12215.1.A1_at 
LOC4759
35 
Interferon-induced transmembrane 
protein 3 (Interferon-inducible 
protein 1-8U) Cell proliferation 1.30 1.27 3.87 0.40 
Cfa.10769.1.S1_at S100A11 
Calgizzarin (S100 calcium-binding 
protein A11) (S100C protein) (MLN 
70) Cell proliferation 1.37 1.41 1.30 0.97 
Cfa.1482.1.A1_at SPARC 
secreted protein, acidic, cysteine-
rich (osteonectin) Cell proliferation 1.38 1.27 1.52 1.23 
CfaAffx.4671.1.S1_s_at LEPRE1 
leucine proline-enriched 
proteoglycan (leprecan) 1 Cell proliferation 1.70 1.43 1.77 1.16 
CfaAffx.27328.1.S1_s_at SPARC 
secreted protein, acidic, cysteine-
rich (osteonectin) Cell proliferation 2.12 1.87 2.24 1.54 
CfaAffx.5304.1.S1_at 
CLEC11
A 
C-type lectin domain family 11, 
member A Cell proliferation 2.35 1.35 6.65 1.70 
Cfa.13276.1.A1_at PALMD palmdelphin Cell shape 0.81 0.57 0.57 2.54 
CfaAffx.13127.1.S1_s_at LYSMD3 
LysM, putative peptidoglycan-
binding, domain containing 3 
Cell wall 
catabolism 0.89 0.90 0.91 1.33 
Cfa.20183.1.S1_at PCM1 pericentriolar material 1 Centrosome 0.57 0.26 0.69 1.03 
Cfa.20025.1.S1_s_at PCM1 pericentriolar material 1 Centrosome 0.66 0.20 0.42 1.15 
CfaAffx.22448.1.S1_s_at NIN ninein (GSK3B interacting protein) Centrosome 0.79 0.24 0.86 1.44 
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CfaAffx.28170.1.S1_at SMCHD1 
structural maintenance of 
chromosomes flexible hinge domain 
containing 1 
Chromosome 
organization 0.58 0.42 0.67 1.02 
CfaAffx.20439.1.S1_s_at HEBP1 heme binding protein 1 Circadian Rhythm 1.67 1.80 1.60 1.34 
CfaAffx.16573.1.S1_s_at FGD4 
FYVE, RhoGEF and PH domain 
containing 4 Cytoskeleton 0.43 0.33 0.41 0.74 
Cfa.19526.1.S1_s_at ACTN1 actinin, alpha 1 Cytoskeleton 0.83 0.97 0.91 1.82 
Cfa.15035.1.A1_at ABLIM1 actin binding LIM protein 1 Cytoskeleton 0.86 0.67 0.90 1.43 
Cfa.7570.1.A1_at TACC3 
transforming, acidic coiled-coil 
containing protein 3 Cytoskeleton 0.86 0.49 1.40 1.59 
Cfa.17259.1.S1_s_at 
CDC42B
PA 
CDC42 binding protein kinase alpha 
(DMPK-like) Cytoskeleton 0.94 0.67 0.88 2.39 
CfaAffx.19895.1.S1_s_at ABI2 abl-interactor 2 Cytoskeleton 1.08 1.27 0.67 1.02 
Cfa.11630.1.S1_s_at CNN3 calponin 3, acidic Cytoskeleton 1.15 0.93 1.06 0.42 
Cfa.11630.2.A1_s_at CNN3 calponin 3, acidic Cytoskeleton 1.22 0.96 1.11 0.41 
CfaAffx.23588.1.S1_s_at CC2D2A 
coiled-coil and C2 domain 
containing 2A Cytoskeleton 1.23 0.40 1.61 2.06 
CfaAffx.23231.1.S1_s_at ARPC1A 
actin related protein 2/3 complex, 
subunit 1A, 41kDa Cytoskeleton 1.27 1.26 1.08 0.77 
Cfa.12410.1.A1_at 
LOC4772
00 dynein, cytoplasmic, light chain 2A Cytoskeleton 1.30 1.43 1.34 1.27 
Cfa.20990.1.S1_at CTTN cortactin Cytoskeleton 1.31 1.45 1.83 2.33 
CfaAffx.23231.1.S1_at ARPC1A 
actin related protein 2/3 complex, 
subunit 1A, 41kDa Cytoskeleton 1.31 1.24 1.10 0.71 
Cfa.20990.1.S1_s_at CTTN cortactin Cytoskeleton 1.32 1.53 1.76 2.02 
CfaAffx.25218.1.S1_x_at TMSB10 thymosin, beta 10 Cytoskeleton 1.36 1.54 1.64 1.04 
CfaAffx.12186.1.S1_x_at 
LOC4772
00 dynein, cytoplasmic, light chain 2A Cytoskeleton 1.41 1.48 1.38 1.20 
CfaAffx.13363.1.S1_s_at EPB41L1 
erythrocyte membrane protein band 
4.1-like 1 Cytoskeleton 1.44 1.94 1.18 2.83 
CfaAffx.13353.1.S1_s_at EPB41L1 
erythrocyte membrane protein band 
4.1-like 1 Cytoskeleton 1.48 2.22 1.49 3.32 
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Cfa.4942.1.A1_s_at 
DYNC2H
1 
dynein, cytoplasmic, heavy 
polypeptide 2 Cytoskeleton 1.51 0.65 1.21 1.17 
CfaAffx.16438.1.S1_at SYNC 
syncoilin, intermediate filament 
protein Cytoskeleton 1.59 2.47 1.35 5.23 
CfaAffx.2583.1.S1_s_at EPB41L2 
erythrocyte membrane protein band 
4.1-like 2 Cytoskeleton 1.65 1.69 1.43 1.17 
CfaAffx.23260.1.S1_x_at ACTB actin, beta Cytoskeleton 1.77 1.77 1.18 0.51 
CfaAffx.23258.1.S1_x_at ACTB actin, beta Cytoskeleton 1.90 2.08 1.22 0.46 
CfaAffx.24565.1.S1_at FSCN1 
fascin homolog 1, actin-bundling 
protein (Strongylocentrotus 
purpuratus) Cytoskeleton 2.80 1.85 3.77 1.11 
Cfa.17000.1.S1_at 
LOC4772
99 
family with sequence similarity 48, 
member A isoform b Development 0.74 0.49 0.78 1.20 
Cfa.20193.1.S1_s_at 
DONSO
N downstream neighbor of SON Development 1.26 1.19 1.19 3.72 
Cfa.3110.1.A1_at AHNAK AHNAK nucleoprotein Development 2.91 3.94 2.01 2.52 
CfaAffx.24289.1.S1_s_at AHNAK AHNAK nucleoprotein Development 3.13 4.22 2.00 2.90 
CfaAffx.6861.1.S1_s_at REV3L 
REV3-like, catalytic subunit of 
DNA polymerase zeta (yeast) DNA metabolism 0.42 0.13 0.42 1.00 
CfaAffx.6855.1.S1_at REV3L 
REV3-like, catalytic subunit of 
DNA polymerase zeta (yeast) DNA metabolism 0.49 0.23 0.56 1.07 
CfaAffx.9967.1.S1_at ERCC5 
excision repair cross-
complementing rodent repair 
deficiency, complementation group 
5 DNA metabolism 0.69 0.38 0.83 1.05 
Cfa.507.1.A1_at RAD50 RAD50 homolog (S. cerevisiae) DNA metabolism 0.69 0.29 0.55 0.69 
CfaAffx.9298.1.S1_s_at EPC2 
enhancer of polycomb homolog 2 
(Drosophila) DNA metabolism 0.75 0.36 0.73 1.02 
Cfa.9489.1.A1_at PMS2 
PMS2 postmeiotic segregation 
increased 2 (S. cerevisiae) DNA metabolism 0.76 0.60 1.25 1.50 
Cfa.12802.1.A1_s_at PRKDC 
protein kinase, DNA-activated, 
catalytic polypeptide DNA metabolism 0.76 0.31 0.81 1.16 
CfaAffx.4865.1.S1_s_at MSH6 mutS homolog 6 (E. coli) DNA metabolism 0.87 0.34 0.76 1.14 
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Cfa.9287.1.A1_at PMS1 
PMS1 postmeiotic segregation 
increased 1 (S. cerevisiae) DNA metabolism 0.90 0.36 0.65 1.27 
Cfa.16932.1.S1_at TDG thymine-DNA glycosylase DNA metabolism 0.91 1.17 0.70 0.60 
CfaAffx.18623.1.S1_s_at RPA2 replication protein A2, 32kDa DNA metabolism 1.10 1.30 0.96 0.62 
Cfa.113.1.S1_s_at APTX aprataxin DNA metabolism 1.24 1.91 1.09 1.07 
Cfa.14349.1.A1_at REXO2 
REX2, RNA exonuclease 2 
homolog (S. cerevisiae) DNA metabolism 1.35 1.30 1.32 1.34 
CfaAffx.20883.1.S1_at REXO2 
REX2, RNA exonuclease 2 
homolog (S. cerevisiae) DNA metabolism 1.42 1.60 1.30 1.17 
CfaAffx.24959.1.S1_s_at DDB1 
damage-specific DNA binding 
protein 1, 127kDa DNA metabolism 1.44 1.71 1.27 1.13 
CfaAffx.24971.1.S1_at DDB1 
damage-specific DNA binding 
protein 1, 127kDa DNA metabolism 1.49 1.72 1.17 1.02 
CfaAffx.2719.1.S1_at 
LOC4762
97 RAD26L hypothetical protein DNA processing 0.58 0.39 0.43 1.89 
Cfa.11045.1.S1_s_at TOP2B 
topoisomerase (DNA) II beta 
180kDa DNA processing 0.72 0.29 0.70 1.08 
CfaAffx.14194.1.S1_s_at NBN nibrin DNA repair 0.72 0.23 0.64 1.88 
Cfa.1134.1.A1_at TOPBP1 
topoisomerase (DNA) II binding 
protein 1 DNA repair 0.85 0.45 0.95 1.66 
CfaAffx.22235.1.S1_at XRCC5 
X-ray repair complementing 
defective repair in Chinese hamster 
cells 5 (double-strand-break 
rejoining) DNA repair 0.86 0.60 0.68 0.68 
CfaAffx.17386.1.S1_s_at UNG uracil-DNA glycosylase DNA repair 1.83 2.07 0.88 0.57 
Cfa.6086.1.A1_s_at MCM8 
minichromosome maintenance 
complex component 8 DNA replication 0.64 0.30 0.64 2.07 
Cfa.6086.1.A1_at MCM8 
minichromosome maintenance 
complex component 8 DNA replication 0.69 0.39 0.69 1.16 
CfaAffx.738.1.S1_s_at GINS1 
GINS complex subunit 1 (Psf1 
homolog) DNA replication 1.32 2.23 1.08 1.12 
CfaAffx.8071.1.S1_at MCM10 
minichromosome maintenance 
complex component 10 DNA replication 3.84 3.14 1.29 1.09 
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Cfa.2466.1.S1_at FNBP1L formin binding protein 1-like Endocytosis 0.52 0.33 0.59 0.95 
Cfa.2584.1.A1_at ITSN2 intersectin 2 Endocytosis 0.71 0.51 0.79 1.16 
CfaAffx.6972.1.S1_s_at ITSN2 intersectin 2 Endocytosis 0.80 0.47 0.74 0.92 
CfaAffx.10118.1.S1_at POSTN periostin, osteoblast specific factor 
Extracellular 
matrix 0.37 0.13 4.63 1.06 
Cfa.10374.1.A1_at 
COL12A
1 collagen, type XII, alpha 1 
Extracellular 
matrix 0.51 0.40 0.53 1.33 
Cfa.4590.1.S1_s_at ASPN asporin 
Extracellular 
matrix 0.61 0.27 1.66 1.38 
Cfa.533.1.S1_at ASPN asporin 
Extracellular 
matrix 0.70 0.31 1.77 1.70 
CfaAffx.16274.1.S1_at FAP fibroblast activation protein, alpha 
Extracellular 
matrix 0.75 0.17 1.34 0.79 
CfaAffx.4106.1.S1_s_at ANXA2 annexin A2 
Extracellular 
matrix 1.29 1.31 1.43 1.43 
Cfa.14.1.A1_at LAMA3 laminin, alpha 3 
Extracellular 
matrix 1.34 0.62 2.02 2.63 
Cfa.1455.1.A1_at COL4A2 collagen, type IV, alpha 2 
Extracellular 
matrix 1.90 1.75 1.51 1.35 
Cfa.208.1.A1_at COL4A1 collagen, type IV, alpha 1 
Extracellular 
matrix 2.02 1.79 1.50 1.28 
Cfa.9487.1.A1_at MATN2 matrilin 2 
Extracellular 
matrix 2.07 2.39 2.34 2.37 
Cfa.15297.1.A1_at COL4A1 collagen, type IV, alpha 1 
Extracellular 
matrix 2.36 2.06 1.99 2.06 
CfaAffx.1328.1.S1_s_at 
COL23A
1 collagen, type XXIII, alpha 1 
Extracellular 
matrix 2.36 1.87 1.43 1.37 
Cfa.6326.1.A1_x_at 
ADAMT
S2 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
Extracellular 
matrix 2.39 1.94 2.35 2.06 
CfaAffx.17492.1.S1_s_at NID1 nidogen 1 
Extracellular 
matrix 2.54 2.54 2.13 2.01 
CfaAffx.10091.1.S1_s_at COL4A2 collagen, type IV, alpha 2 
Extracellular 
matrix 2.62 2.26 1.78 1.68 
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CfaAffx.10085.1.S1_s_at COL4A1 collagen, type IV, alpha 1 
Extracellular 
matrix 2.75 2.20 1.81 1.47 
Cfa.6326.1.A1_s_at 
ADAMT
S2 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
Extracellular 
matrix 2.94 2.24 2.96 2.17 
CfaAffx.21386.1.S1_at MATN2 matrilin 2 
Extracellular 
matrix 3.12 4.62 3.13 3.65 
CfaAffx.1659.1.S1_at MATN2 matrilin 2 
Extracellular 
matrix 3.54 6.24 3.70 5.56 
CfaAffx.1441.1.S1_at 
ADAMT
S2 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
Extracellular 
matrix 3.86 2.61 3.80 3.42 
Cfa.20443.1.S1_s_at NID2 nidogen 2 (osteonidogen) 
Extracellular 
matrix 4.21 2.51 3.18 1.93 
CfaAffx.1719.1.S1_at LOX lysyl oxidase 
Extracellular 
matrix 7.55 
11.2
7 12.91 38.21 
CfaAffx.14892.1.S1_at FMOD fibromodulin 
Extracellular 
matrix 7.74 3.20 3.65 1.48 
Cfa.17831.1.S1_s_at FMOD fibromodulin 
Extracellular 
matrix 7.94 3.29 3.25 1.82 
CfaAffx.29151.1.S1_s_at IDS iduronate 2-sulfatase 
Heparin sulfate 
degredation 1.25 1.81 1.63 2.16 
Cfa.1304.1.S1_at HGSNAT 
heparan-alpha-glucosaminide N-
acetyltransferase 
Heparin sulfate 
degredation 1.85 2.14 1.54 1.33 
CfaAffx.9000.1.S1_s_at HGSNAT 
heparan-alpha-glucosaminide N-
acetyltransferase 
Heparin sulfate 
degredation 1.89 2.11 1.40 1.15 
Cfa.14281.1.A1_at HGSNAT 
heparan-alpha-glucosaminide N-
acetyltransferase 
Heparin sulfate 
degredation 1.94 1.83 1.66 1.30 
CfaAffx.1126.1.S1_s_at MALT1 
mucosa associated lymphoid tissue 
lymphoma translocation gene 1 Immune response 0.45 0.37 0.48 0.94 
Cfa.468.2.A1_at NUDCD1 NudC domain containing 1 Immune response 0.65 0.34 0.58 2.02 
CfaAffx.15171.1.S1_s_at SIKE1 suppressor of IKBKE 1 Immune response 0.77 0.47 0.67 1.02 
CfaAffx.14233.1.S1_s_at PROS1 protein S (alpha) Immune response 0.98 0.67 2.30 1.16 
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Cfa.14413.1.S1_at PROS1 protein S (alpha) Immune response 1.02 0.64 2.18 1.35 
Cfa.14495.2.S1_s_at CFI complement factor I Immune response 1.03 0.37 1.38 1.10 
CfaAffx.3284.1.S1_at TREM2 
triggering receptor expressed on 
myeloid cells 2 Immune response 1.07 2.18 1.53 9.20 
CfaAffx.25616.1.S1_at IGBP1 
immunoglobulin (CD79A) binding 
protein 1 Immune response 1.20 1.24 1.09 0.82 
Cfa.17806.1.S1_at FCGRT 
Fc fragment of IgG, receptor, 
transporter, alpha Immune response 1.25 1.31 1.17 0.58 
CfaAffx.6384.1.S1_s_at FCGRT 
Fc fragment of IgG, receptor, 
transporter, alpha Immune response 1.31 1.34 1.14 0.58 
Cfa.17806.2.S1_s_at FCGRT 
Fc fragment of IgG, receptor, 
transporter, alpha Immune response 1.39 1.40 1.15 0.62 
CfaAffx.12741.1.S1_at PROCR 
protein C receptor, endothelial 
(EPCR) Immune response 1.42 1.10 0.89 0.46 
Cfa.20016.1.S1_s_at CFH complement factor H Immune response 1.49 0.32 1.90 1.07 
Cfa.20016.1.S1_at CFH complement factor H Immune response 1.49 0.36 1.75 0.82 
CfaAffx.14354.1.S1_at IFNGR2 
interferon gamma receptor 2 
(interferon gamma transducer 1) Immune response 1.65 1.85 1.25 0.90 
Cfa.4778.1.A1_s_at IL10RB interleukin 10 receptor, beta Immune response 1.67 2.42 1.88 2.49 
Cfa.21.1.S1_s_at CCL5 chemokine (C-C motif) ligand 5 Immune response 1.82 1.38 13.69 1.78 
CfaAffx.25091.1.S1_s_at CD97 CD97 molecule Immune response 1.94 2.08 1.68 1.86 
Cfa.21259.1.S1_s_at CD97 CD97 molecule Immune response 2.22 2.95 1.78 2.20 
Cfa.15481.1.A1_at C8G 
complement component 8, gamma 
polypeptide Immune response 3.76 3.94 3.21 3.04 
Cfa.8896.1.S1_at DDX3X 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, X-linked 
Interspecies 
interaction 0.78 0.36 0.80 1.29 
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CfaAffx.28948.1.S1_at NUBP1 
nucleotide binding protein 1 (MinD 
homolog, E. coli) Iron homeostasis 1.36 1.48 1.25 0.85 
Cfa.12245.1.A1_s_at HP haptoglobin Iron homeostasis 2.85 1.03 2.76 0.56 
Cfa.12245.2.A1_a_at HP haptoglobin Iron homeostasis 2.99 1.03 2.73 0.54 
Cfa.204.1.S1_s_at G6PC 
glucose-6-phosphatase, catalytic 
subunit Metabolism 0.04 0.18 0.04 0.07 
Cfa.14573.1.A1_s_at 
TMEM19
5 transmembrane protein 195 Metabolism 0.09 0.20 0.09 0.09 
CfaAffx.4097.1.S1_s_at PDK4 
pyruvate dehydrogenase kinase, 
isozyme 4 Metabolism 0.13 0.31 0.21 1.06 
Cfa.1794.1.S1_s_at 
TMEM19
5 transmembrane protein 195 Metabolism 0.15 0.23 0.12 0.13 
CfaAffx.261.1.S1_at NIACR1 niacin receptor 1 Metabolism 0.16 0.57 0.12 0.21 
CfaAffx.28073.1.S1_s_at ADRB2 adrenergic, beta-2-, receptor, surface Metabolism 0.19 0.38 0.13 0.16 
Cfa.3770.1.S1_at ADRB2 adrenergic, beta-2-, receptor, surface Metabolism 0.19 0.37 0.18 0.17 
Cfa.1794.1.S1_at 
TMEM19
5 transmembrane protein 195 Metabolism 0.20 0.26 0.16 0.14 
CfaAffx.22510.1.S1_at ADRA2C adrenergic, alpha-2C-, receptor Metabolism 0.25 0.90 0.22 0.31 
Cfa.13232.1.A1_at PFKFB1 
6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 1 Metabolism 0.25 0.35 0.26 0.65 
CfaAffx.12345.1.S1_s_at GLYAT glycine-N-acyltransferase metabolism 0.26 0.42 0.13 0.06 
Cfa.15689.1.A1_at PHYH phytanoyl-CoA 2-hydroxylase Metabolism 0.30 0.52 0.21 0.40 
CfaAffx.27754.1.S1_s_at ACACA 
acetyl-Coenzyme A carboxylase 
alpha Metabolism 0.30 0.31 0.32 0.30 
Cfa.2282.1.S1_at PDK4 
pyruvate dehydrogenase kinase, 
isozyme 4 Metabolism 0.30 0.40 0.36 1.04 
CfaAffx.3340.1.S1_s_at ACER2 alkaline ceramidase 2 Metabolism 0.30 0.61 0.21 1.03 
Cfa.9362.1.S1_at PSAT1 phosphoserine aminotransferase 1 Metabolism 0.30 0.52 0.23 0.30 
Cfa.8199.1.S1_at GLYAT glycine-N-acyltransferase metabolism 0.31 0.42 0.23 0.10 
CfaAffx.3267.1.S1_at PSAT1 phosphoserine aminotransferase 1 Metabolism 0.31 0.63 0.22 0.30 
CfaAffx.25228.1.S1_at PFKFB1 
6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 1 Metabolism 0.33 0.39 0.22 0.27 
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CfaAffx.25283.1.S1_at PGC1α 
peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha Metabolism 0.34 0.50 0.22 0.99 
CfaAffx.3267.1.S1_s_at PSAT1 phosphoserine aminotransferase 1 Metabolism 0.34 0.62 0.23 0.29 
CfaAffx.15618.1.S1_s_at MGEA5 
meningioma expressed antigen 5 
(hyaluronidase) Metabolism 0.39 0.28 0.54 0.65 
CfaAffx.27981.1.S1_s_at PGC1β 
peroxisome proliferator-activated 
receptor gamma, coactivator 1 beta Metabolism 0.45 0.76 0.36 0.59 
Cfa.14480.1.S1_at 
HSD17B
4 
hydroxysteroid (17-beta) 
dehydrogenase 4 Metabolism 0.49 0.50 0.46 0.75 
Cfa.12884.1.S1_at MGEA5 
meningioma expressed antigen 5 
(hyaluronidase) Metabolism 0.49 0.28 0.84 1.07 
Cfa.11382.1.A1_at ACSF2 
acyl-CoA synthetase family member 
2 Metabolism 0.55 1.37 0.62 1.37 
Cfa.10965.1.A1_at CDS1 
CDP-diacylglycerol synthase 
(phosphatidate cytidylyltransferase) 
1 Metabolism 0.56 0.45 0.99 1.96 
Cfa.5230.1.A1_at 
NOSTRI
N nitric oxide synthase trafficker Metabolism 0.56 0.28 0.45 1.05 
Cfa.19615.1.S1_s_at 
NOSTRI
N nitric oxide synthase trafficker Metabolism 0.56 0.37 0.47 0.91 
Cfa.3045.1.A1_s_at HACL1 2-hydroxyacyl-CoA lyase 1 Metabolism 0.58 0.88 0.35 0.44 
Cfa.17538.1.S1_s_at DDO D-aspartate oxidase Metabolism 0.60 0.71 0.31 0.18 
Cfa.11382.1.A1_s_at ACSF2 
acyl-CoA synthetase family member 
2 Metabolism 0.60 1.34 0.54 1.15 
Cfa.11067.1.A1_at THNSL1 
threonine synthase-like 1 (S. 
cerevisiae) Metabolism 0.63 0.36 0.50 2.23 
CfaAffx.28974.1.S1_at PPAP2B 
phosphatidic acid phosphatase type 
2B Metabolism 0.67 0.49 0.76 0.58 
Cfa.360.2.S1_at NCEH1 neutral cholesterol ester hydrolase 1 Metabolism 0.68 1.44 0.70 2.16 
Cfa.2440.1.A1_at FH fumarate hydratase Metabolism 0.69 0.65 0.68 0.59 
Cfa.10489.1.A1_s_at PPAP2B 
phosphatidic acid phosphatase type 
2B Metabolism 0.71 0.52 0.80 0.60 
Cfa.14944.1.A1_at AMT aminomethyltransferase Metabolism 0.72 0.78 1.07 1.35 
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CfaAffx.11739.1.S1_s_at PCCB 
propionyl Coenzyme A carboxylase, 
beta polypeptide Metabolism 0.73 0.97 0.60 0.46 
Cfa.18014.1.S1_s_at PCCB 
propionyl Coenzyme A carboxylase, 
beta polypeptide Metabolism 0.76 1.07 0.61 0.48 
CfaAffx.16200.1.S1_at COQ5 
coenzyme Q5 homolog, 
methyltransferase (S. cerevisiae) Metabolism 0.77 0.99 0.61 0.57 
Cfa.1282.1.A1_s_at PTGDS 
prostaglandin D2 synthase 21kDa 
(brain) Metabolism 0.82 0.36 1.09 0.21 
CfaAffx.23654.1.S1_s_at NCEH1 neutral cholesterol ester hydrolase 1 Metabolism 0.82 1.84 0.75 2.45 
Cfa.15097.1.A1_at ANAPC1 
anaphase promoting complex 
subunit 1 Metabolism 0.85 0.56 0.92 0.99 
CfaAffx.6429.1.S1_at PNPLA8 
patatin-like phospholipase domain 
containing 8 Metabolism 0.87 0.25 0.63 1.82 
CfaAffx.12124.1.S1_s_at AHCY adenosylhomocysteinase Metabolism 0.89 1.01 0.62 0.48 
CfaAffx.1276.1.S1_at CDO1 cysteine dioxygenase, type I Metabolism 0.89 0.41 0.55 0.12 
Cfa.6891.1.A1_s_at PRPS2 
phosphoribosyl pyrophosphate 
synthetase 2 Metabolism 0.90 1.62 1.05 0.99 
Cfa.8960.1.A1_at AHCY adenosylhomocysteinase Metabolism 0.91 0.96 0.68 0.43 
CfaAffx.22441.1.S1_s_at TPI1 triosephosphate isomerase 1 Metabolism 0.92 1.04 0.60 0.50 
CfaAffx.11397.1.S1_at GAPDHS 
glyceraldehyde-3-phosphate 
dehydrogenase, spermatogenic Metabolism 0.93 1.20 0.96 0.77 
Cfa.10953.1.S1_s_at HEXB 
hexosaminidase B (beta 
polypeptide) Metabolism 0.95 0.95 1.31 1.32 
Cfa.11250.1.A1_at PNPLA8 
patatin-like phospholipase domain 
containing 8 Metabolism 0.95 0.51 0.67 1.20 
Cfa.17440.1.S1_s_at GPD1L 
glycerol-3-phosphate dehydrogenase 
1-like Metabolism 1.00 1.29 0.92 0.53 
Cfa.2548.1.A1_at MECR 
mitochondrial trans-2-enoyl-CoA 
reductase Metabolism 1.03 1.07 0.89 0.51 
CfaAffx.9032.1.S1_at GPD1L 
glycerol-3-phosphate dehydrogenase 
1-like Metabolism 1.04 1.44 0.96 0.58 
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CfaAffx.7308.1.S1_x_at UQCR8 
Ubiquinol-cytochrome c reductase 
complex 11 kDa protein, 
mitochondrial precursor 
(Mitochondrial hinge protein) 
(Cytochrome C1, nonheme 11 kDa 
protein) (Complex III subunit VIII) Metabolism 1.09 1.06 0.70 0.56 
CfaAffx.6364.1.S1_at NOSIP 
nitric oxide synthase interacting 
protein Metabolism 1.09 1.40 0.98 0.64 
CfaAffx.19330.1.S1_at FABP2 
fatty acid binding protein 2, 
intestinal Metabolism 1.10 1.68 1.10 1.76 
CfaAffx.4005.1.S1_s_at 
rSULT1C
2 Sulfotransferase K1 (rSULT1C2) Metabolism 1.15 1.66 1.01 1.02 
CfaAffx.18110.1.S1_at MECR 
mitochondrial trans-2-enoyl-CoA 
reductase Metabolism 1.17 1.25 0.93 0.51 
Cfa.4397.1.A1_s_at ABAT 4-aminobutyrate aminotransferase Metabolism 1.19 1.18 1.40 0.47 
Cfa.5885.1.S1_s_at 
PAFAH1
B3 
platelet-activating factor 
acetylhydrolase, isoform Ib, subunit 
3 (29kDa) Metabolism 1.20 1.14 1.43 0.62 
CfaAffx.23254.1.S1_s_at QDPR quinoid dihydropteridine reductase Metabolism 1.27 1.29 1.07 0.72 
Cfa.17251.1.S1_at CS citrate synthase Metabolism 1.28 1.68 0.79 0.65 
CfaAffx.20168.1.S1_s_at FN3K fructosamine 3 kinase Metabolism 1.33 1.67 0.67 0.54 
Cfa.9367.1.A1_at SC4MOL sterol-C4-methyl oxidase-like Metabolism 1.34 1.57 1.62 2.32 
CfaAffx.10001.1.S1_s_at CDS2 
CDP-diacylglycerol synthase 
(phosphatidate cytidylyltransferase) 
2 Metabolism 1.37 2.52 1.13 1.12 
CfaAffx.30287.1.S1_at AHCYL1 adenosylhomocysteinase-like 1 Metabolism 1.37 1.57 1.29 1.51 
CfaAffx.3825.1.S1_at 
SIGMAR
1 
sigma non-opioid intracellular 
receptor 1 Metabolism 1.39 1.11 1.36 0.66 
Cfa.1199.1.A1_s_at ENO1 enolase 1, (alpha) Metabolism 1.52 1.29 1.51 1.36 
CfaAffx.25680.1.S1_s_at VKORC1 
vitamin K epoxide reductase 
complex, subunit 1 Metabolism 1.53 1.50 1.60 0.87 
Cfa.16191.1.A1_at MPDU1 
mannose-P-dolichol utilization 
defect 1 Metabolism 1.54 1.82 1.48 1.29 
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CfaAffx.25085.1.S1_s_at DEGS1 
degenerative spermatocyte homolog 
1, lipid desaturase (Drosophila) Metabolism 1.56 1.47 1.58 1.48 
Cfa.2052.1.A1_at ACOT9 acyl-CoA thioesterase 9 Metabolism 1.58 1.74 1.46 1.29 
CfaAffx.9756.1.S1_s_at P4HB 
prolyl 4-hydroxylase, beta 
polypeptide Metabolism 1.58 1.73 1.40 0.99 
CfaAffx.26366.1.S1_at 
LOC6111
34 cytochrome c oxidase, subunit 7a 3 Metabolism 1.58 1.89 1.66 1.09 
CfaAffx.20710.1.S1_s_at ACOT9 acyl-CoA thioesterase 9 Metabolism 1.59 1.79 1.44 1.31 
CfaAffx.19174.1.S1_at HMBS hydroxymethylbilane synthase Metabolism 1.60 1.54 1.22 0.67 
Cfa.18046.1.S1_s_at MPDU1 
mannose-P-dolichol utilization 
defect 1 Metabolism 1.62 2.04 1.48 1.28 
Cfa.5907.1.A1_at TPRA1 
transmembrane protein, adipocyte 
asscociated 1 Metabolism 1.62 1.25 1.23 0.59 
CfaAffx.11455.1.S1_at COX4I2 
cytochrome c oxidase subunit IV 
isoform 2 precursor Metabolism 1.63 1.31 1.50 0.77 
CfaAffx.20710.1.S1_at ACOT9 acyl-CoA thioesterase 9 Metabolism 1.68 1.94 1.68 1.39 
CfaAffx.28220.1.S1_s_at PEMT 
phosphatidylethanolamine N-
methyltransferase Metabolism 1.70 2.50 1.70 1.87 
CfaAffx.20834.1.S1_s_at PDK3 
pyruvate dehydrogenase kinase, 
isozyme 3 Metabolism 1.73 1.75 1.42 1.37 
CfaAffx.8748.1.S1_s_at RBKS ribokinase Metabolism 1.77 1.34 1.09 0.56 
Cfa.781.1.S1_at ENO1 enolase 1, (alpha) Metabolism 1.88 1.47 1.73 1.24 
CfaAffx.30133.1.S1_s_at ENO1 enolase 1, (alpha) Metabolism 1.90 1.51 1.72 1.27 
CfaAffx.17388.1.S1_at ABHD4 abhydrolase domain containing 4 Metabolism 1.90 2.10 1.64 1.65 
Cfa.18761.1.S1_s_at ABHD4 abhydrolase domain containing 4 Metabolism 1.90 2.21 1.64 1.70 
Cfa.11536.1.A1_at PGD phosphogluconate dehydrogenase Metabolism 1.92 1.77 1.68 1.52 
CfaAffx.21481.1.S1_s_at HK1 hexokinase 1 Metabolism 1.92 2.04 1.88 2.06 
Cfa.13103.1.A1_at INPPL1 
inositol polyphosphate phosphatase-
like 1 Metabolism 2.04 1.55 1.99 1.57 
CfaAffx.16230.1.S1_s_at 
ADIPOR
1 adiponectin receptor 1 Metabolism 2.07 2.45 1.61 1.43 
Cfa.11405.1.A1_at 
ALDH1L
2 
aldehyde dehydrogenase 1 family, 
member L2 Metabolism 2.11 2.31 2.32 3.67 
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Cfa.3555.1.S1_s_at GALK1 galactokinase 1 Metabolism 2.15 1.99 1.75 1.06 
CfaAffx.27412.1.S1_s_at GM2A GM2 ganglioside activator Metabolism 2.19 3.27 1.40 1.45 
Cfa.18420.1.S1_s_at ABHD4 abhydrolase domain containing 4 Metabolism 2.22 2.43 1.96 1.62 
CfaAffx.2829.1.S1_s_at AR 
Aldose reductase (AR) (Aldehyde 
reductase) Metabolism 2.23 2.67 1.49 2.04 
Cfa.12509.1.A1_s_at DSE dermatan sulfate epimerase Metabolism 2.28 1.70 2.57 2.60 
Cfa.15282.1.S1_at CYB5A cytochrome b5A microsomal variant Metabolism 2.41 2.84 1.80 2.47 
CfaAffx.3800.1.S1_s_at 
ALDH1L
2 
aldehyde dehydrogenase 1 family, 
member L2 Metabolism 2.43 2.66 2.57 5.07 
CfaAffx.9834.1.S1_s_at PYCR1 pyrroline-5-carboxylate reductase 1 metabolism 2.48 2.10 3.44 2.57 
Cfa.18811.1.S1_s_at DSE dermatan sulfate epimerase Metabolism 2.49 1.72 2.71 3.27 
CfaAffx.8336.1.S1_at PLCD1 phospholipase C, delta 1 Metabolism 2.52 2.19 1.71 1.49 
Cfa.20176.1.S1_s_at PGD phosphogluconate dehydrogenase Metabolism 2.68 2.58 2.20 1.85 
Cfa.19985.1.S1_s_at ASNS asparagine synthetase Metabolism 2.87 3.94 2.29 2.87 
Cfa.11979.1.A1_s_at LCAT lecithin-cholesterol acyltransferase Metabolism 2.88 3.55 2.02 1.89 
Cfa.5351.2.A1_at 
PPAPDC
1B 
phosphatidic acid phosphatase type 
2 domain containing 1B Metabolism 2.93 3.70 2.99 3.79 
CfaAffx.2482.1.S1_s_at ECHDC1 
enoyl Coenzyme A hydratase 
domain containing 1 Metabolism 3.39 3.09 3.17 1.98 
CfaAffx.9026.1.S1_s_at GDPD5 
glycerophosphodiester 
phosphodiesterase domain 
containing 5 Metabolism 3.48 2.59 2.18 1.95 
Cfa.14563.1.A1_s_at HGD 
homogentisate 1,2-dioxygenase 
(homogentisate oxidase) Metabolism 3.56 2.94 2.41 0.86 
CfaAffx.9594.1.S1_s_at INPPL1 
inositol polyphosphate phosphatase-
like 1 Metabolism 3.84 2.36 3.59 2.77 
Cfa.16941.1.S1_at PYCR1 pyrroline-5-carboxylate reductase 1 metabolism 4.52 3.49 6.63 3.65 
CfaAffx.16131.1.S1_s_at GPLD1 
glycosylphosphatidylinositol 
specific phospholipase D1 Metabolism 9.13 2.97 4.35 1.12 
CfaAffx.3412.1.S1_s_at LEP leptin Metabolism 
10.0
9 
12.8
4 6.84 13.47 
Cfa.15331.1.S1_at GPLD1 
glycosylphosphatidylinositol 
specific phospholipase D1 Metabolism 
14.3
6 5.72 6.14 1.54 
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Cfa.16237.1.S1_at ASIP 
agouti signaling protein, nonagouti 
homolog (mouse) Metabolism 
19.1
3 5.67 13.33 0.66 
CfaAffx.17954.1.S1_at ELOVL6 
ELOVL family member 6, 
elongation of long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3-like, yeast) Metabolism 
61.9
9 
15.4
2 33.78 20.77 
Cfa.11319.1.A1_at ZAG alpha-2-glycoprotein 1, zinc-binding Metabolism 
63.5
0 
21.2
5 39.78 1.02 
CfaAffx.411.1.S1_at FTSJD1 
FtsJ methyltransferase domain 
containing 1 Methylation 1.09 0.79 1.25 4.05 
Cfa.1129.2.S1_at OPA1 
optic atrophy 1 (autosomal 
dominant) 
Mitochondrial 
fusion 0.55 0.26 0.46 1.47 
Cfa.19756.1.S1_at MFN1 mitofusin 1 
Mitochondrial 
fusion 0.75 0.46 0.61 1.68 
Cfa.1129.1.S1_at OPA1 
optic atrophy 1 (autosomal 
dominant) 
Mitochondrial 
fusion 0.87 0.30 0.65 1.49 
Cfa.1129.1.S1_s_at OPA1 
optic atrophy 1 (autosomal 
dominant) 
Mitochondrial 
fusion 0.87 0.17 0.71 2.19 
Cfa.4389.1.A1_s_at MYL6 
myosin, light chain 6, alkali, smooth 
muscle and non-muscle 
Muscle filament 
sliding 1.28 1.41 1.22 0.94 
CfaAffx.24686.1.S1_at SNCG 
synuclein, gamma (breast cancer-
specific protein 1) 
Neurotransmitter 
secretion 2.63 8.46 2.33 6.04 
CfaAffx.2464.1.S1_at HINT3 
histidine triad nucleotide binding 
protein 3 
Nucleotide 
metabolism 0.58 0.90 0.36 0.60 
Cfa.20394.1.S1_at NUDT7 
nudix (nucleoside diphosphate 
linked moiety X)-type motif 7 
Nucleotide 
metabolism 0.87 0.57 1.44 1.26 
Cfa.17886.1.S1_at NUDT12 
nudix (nucleoside diphosphate 
linked moiety X)-type motif 12 
Nucleotide 
metabolism 0.96 0.68 0.68 0.95 
CfaAffx.2651.1.S1_s_at GUK1 guanylate kinase 1 
Nucleotide 
metabolism 1.13 0.90 1.16 0.65 
CfaAffx.30404.1.S1_s_at APRT adenine phosphoribosyltransferase 
Nucleotide 
metabolism 1.33 1.08 1.24 0.57 
CfaAffx.24152.1.S1_s_at CNP 
2',3'-cyclic nucleotide 3' 
phosphodiesterase 
Nucleotide 
metabolism 2.38 2.17 1.72 0.67 
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Cfa.17329.1.S1_s_at SYNE2 
spectrin repeat containing, nuclear 
envelope 2 
Nucleus 
Organization 0.66 0.31 0.66 0.68 
Cfa.9691.1.A1_at SYNE2 
spectrin repeat containing, nuclear 
envelope 2 
Nucleus 
Organization 0.69 0.40 0.67 0.74 
CfaAffx.1680.1.S1_s_at SYNE1 
spectrin repeat containing, nuclear 
envelope 1 
Nucleus 
Organization 0.72 0.44 0.86 1.29 
Cfa.11044.1.A1_at SYNE1 
spectrin repeat containing, nuclear 
envelope 1 
Nucleus 
Organization 0.74 0.50 0.88 1.24 
CfaAffx.1717.1.S1_s_at SYNE1 
spectrin repeat containing, nuclear 
envelope 1 
Nucleus 
Organization 0.75 0.41 0.86 1.40 
CfaAffx.9452.1.S1_s_at XDH xanthine dehydrogenase 
Oxidation-
reduction 0.19 0.26 0.20 0.17 
CfaAffx.9444.1.S1_at XDH xanthine dehydrogenase 
Oxidation-
reduction 0.24 0.31 0.24 0.17 
Cfa.12167.1.A1_at XDH xanthine dehydrogenase 
Oxidation-
reduction 0.24 0.30 0.25 0.18 
Cfa.12371.1.A1_s_at FMO4 flavin containing monooxygenase 4 
Oxidation-
reduction 0.34 0.37 0.31 0.32 
Cfa.3275.1.S1_at MT3 metallothionein 3 
Oxidation-
reduction 0.40 0.38 0.31 0.44 
CfaAffx.17765.1.S1_s_at TXNIP thioredoxin interacting protein 
Oxidation-
reduction 0.63 0.79 0.52 0.52 
Cfa.3978.1.S1_at OXR1 oxidation resistance 1 
Oxidation-
reduction 0.71 0.37 0.73 1.56 
Cfa.267.1.A1_at TXNIP thioredoxin interacting protein 
Oxidation-
reduction 0.74 0.78 0.73 0.81 
Cfa.16443.1.A1_s_at 
TXNDC1
2 
thioredoxin domain containing 12 
(endoplasmic reticulum) 
Oxidation-
reduction 1.02 0.90 1.11 0.70 
CfaAffx.6611.1.S1_s_at 
TXNDC1
2 
thioredoxin domain containing 12 
(endoplasmic reticulum) 
Oxidation-
reduction 1.20 1.16 1.13 0.68 
Cfa.33.1.S1_s_at TPMT thiopurine S-methyltransferase 
Oxidation-
reduction 1.23 0.56 1.21 2.52 
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Cfa.4561.1.A1_at GPX1 glutathione peroxidase 1 
Oxidation-
reduction 1.31 1.38 1.37 1.38 
Cfa.14458.1.S1_at TXNL5 thioredoxin-like 5 
Oxidation-
reduction 1.36 1.44 1.38 1.33 
CfaAffx.16567.1.S1_s_at GSTO1 glutathione S-transferase omega 1 
Oxidation-
reduction 1.37 1.21 1.28 0.79 
Cfa.977.1.S1_at PRDX4 peroxiredoxin 4 
Oxidation-
reduction 1.40 1.61 1.41 1.36 
Cfa.3121.4.S1_s_at PRDX6 peroxiredoxin 6 
Oxidation-
reduction 1.43 1.53 1.29 1.21 
Cfa.14903.1.S1_at TXNRD1 thioredoxin reductase 1 
Oxidation-
reduction 1.47 1.39 1.52 1.79 
CfaAffx.31023.1.S1_at NQO1 
NAD(P)H dehydrogenase, quinone 
1 
Oxidation-
reduction 1.55 1.71 1.41 1.63 
Cfa.14362.1.S1_s_at GSTT2 
Glutathione S-transferase theta 2 
(GST class-theta 2) 
Oxidation-
reduction 1.57 1.63 1.24 0.63 
Cfa.14458.1.S1_s_at TXNL5 thioredoxin-like 5 
Oxidation-
reduction 1.59 1.65 1.49 1.44 
CfaAffx.23907.1.S1_s_at DHRS7 
dehydrogenase/reductase (SDR 
family) member 7 
Oxidation-
reduction 1.65 1.83 1.41 1.68 
CfaAffx.6160.1.S1_s_at BLVRA biliverdin reductase A 
Oxidation-
reduction 1.75 1.82 1.72 1.59 
CfaAffx.10681.1.S1_s_at GSR glutathione reductase 
Oxidation-
reduction 1.79 2.35 1.46 1.06 
CfaAffx.20688.1.S1_s_at PRDX4 peroxiredoxin 4 
Oxidation-
reduction 1.81 1.96 1.61 1.66 
CfaAffx.20901.1.S1_at NNMT nicotinamide N-methyltransferase 
Oxidation-
reduction 1.82 1.09 3.67 0.95 
Cfa.14468.1.A1_s_at NNMT nicotinamide N-methyltransferase 
Oxidation-
reduction 1.93 1.29 4.56 1.12 
CfaAffx.6540.1.S1_at GPX7 glutathione peroxidase 7 
Oxidation-
reduction 2.03 2.55 1.54 1.08 
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Cfa.17201.1.S1_at GSTM4 glutathione S-transferase mu 4 
Oxidation-
reduction 2.30 2.07 1.50 1.06 
CfaAffx.17810.1.S1_x_at GSTP 
Glutathione S-transferase P (GST 7-
7) (Chain 7) (GST class-pi) 
Oxidation-
reduction 2.42 2.66 2.09 2.29 
CfaAffx.30320.1.S1_s_at GSTM4 glutathione S-transferase mu 4 
Oxidation-
reduction 2.46 2.16 1.61 1.20 
CfaAffx.29492.1.S1_x_at GSTP 
Glutathione S-transferase P (GST 7-
7) (Chain 7) (GST class-pi) 
Oxidation-
reduction 2.53 2.53 1.96 2.04 
Cfa.14564.1.S1_s_at BLVRB 
biliverdin reductase B (flavin 
reductase (NADPH)) 
Oxidation-
reduction 4.26 4.11 3.17 2.17 
Cfa.4088.1.A1_s_at EPHX1 
epoxide hydrolase 1, microsomal 
(xenobiotic) 
Oxidation-
reduction 4.53 2.38 3.07 1.48 
Cfa.4088.1.A1_at EPHX1 
epoxide hydrolase 1, microsomal 
(xenobiotic) 
Oxidation-
reduction 4.55 2.57 3.13 1.48 
CfaAffx.24797.1.S1_at EPHX1 
epoxide hydrolase 1, microsomal 
(xenobiotic) 
Oxidation-
reduction 5.08 2.94 3.51 1.66 
Cfa.770.1.S1_s_at FMO3 flavin containing monooxygenase 3 
Oxidation- 
reduction 0.32 0.42 0.20 0.38 
Cfa.16259.1.A1_at PTP4A1 
protein tyrosine phosphatase type 
IVA, member 1 Phosphorylation 0.50 0.81 0.54 0.92 
Cfa.20682.1.S1_at STK38L serine/threonine kinase 38 like Phosphorylation 0.59 0.31 0.70 1.55 
CfaAffx.1339.1.S1_s_at CLK4 CDC-like kinase 4 Phosphorylation 0.59 0.28 0.72 1.81 
Cfa.3071.1.S1_at CLK4 CDC-like kinase 4 Phosphorylation 0.74 0.38 0.77 1.18 
Cfa.524.1.S1_at PTPN13 
protein tyrosine phosphatase, non-
receptor type 13 (APO-1/CD95 
(Fas)-associated phosphatase) Phosphorylation 0.78 0.17 0.87 1.17 
Cfa.10083.1.S1_at TTBK2 tau tubulin kinase 2 phosphorylation 0.80 0.44 0.87 1.26 
CfaAffx.21189.1.S1_at PRKRIP1 
PRKR interacting protein 1 (IL11 
inducible) Phosphorylation 0.91 1.16 0.82 0.64 
Cfa.8254.1.A1_at PIK3R4 
phosphoinositide-3-kinase, 
regulatory subunit 4 Phosphorylation 0.95 0.72 1.10 1.79 
CfaAffx.10058.1.S1_at PIK3R4 
phosphoinositide-3-kinase, 
regulatory subunit 4 Phosphorylation 1.08 0.63 1.03 2.30 
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Cfa.20598.1.S1_at MTMR14 myotubularin related protein 14 Phosphorylation 1.32 1.29 1.10 0.65 
CfaAffx.13364.1.S1_at PTPMT1 
protein tyrosine phosphatase, 
mitochondrial 1 Phosphorylation 1.59 1.61 1.29 0.79 
CfaAffx.28815.1.S1_s_at PTPRS 
protein tyrosine phosphatase, 
receptor type, S Phosphorylation 1.63 4.74 1.43 1.67 
CfaAffx.26587.1.S1_s_at PTPN21 
protein tyrosine phosphatase, non-
receptor type 21 Phosphorylation 1.81 3.19 1.76 3.85 
CfaAffx.22249.1.S1_at DUSP19 dual specificity phosphatase 19 Phosphorylation 1.89 3.06 1.47 2.49 
Cfa.18545.1.S1_s_at MTMR14 myotubularin related protein 14 Phosphorylation 1.94 1.98 1.42 0.84 
CfaAffx.29674.1.S1_s_at OAZ1 ornithine decarboxylase antizyme 1 
Polyamine 
biosynthesis 1.18 1.31 0.99 0.85 
Cfa.2382.1.A1_at DAG1 
dystroglycan 1 (dystrophin-
associated glycoprotein 1) 
Protein complex 
assembly 2.42 3.24 1.66 2.41 
Cfa.2382.2.S1_at DAG1 
dystroglycan 1 (dystrophin-
associated glycoprotein 1) 
Protein complex 
assembly 2.66 3.51 1.73 2.57 
CfaAffx.17467.1.S1_at DAG1 
dystroglycan 1 (dystrophin-
associated glycoprotein 1) 
Protein complex 
assembly 2.71 3.49 1.67 3.39 
CfaAffx.26949.1.S1_s_at ASB2 
ankyrin repeat and SOCS box-
containing 2 
Protein 
degradation 0.11 0.45 0.04 0.06 
Cfa.13108.1.A1_at ASB2 
ankyrin repeat and SOCS box-
containing 2 
Protein 
degradation 0.11 0.38 0.03 0.06 
CfaAffx.26949.1.S1_at ASB2 
ankyrin repeat and SOCS box-
containing 2 
Protein 
degradation 0.20 0.51 0.07 0.13 
CfaAffx.5584.1.S1_at PM20D2 peptidase M20 domain containing 2 
Protein 
degradation 0.40 0.49 0.20 0.23 
CfaAffx.16074.1.S1_at DZIP3 
DAZ interacting protein 3, zinc 
finger 
Protein 
degradation 0.44 0.27 0.35 1.43 
CfaAffx.20016.1.S1_s_at HECTD1 HECT domain containing 1 
Protein 
degradation 0.53 0.24 0.46 0.72 
Cfa.1076.1.A1_s_at RBBP6 retinoblastoma binding protein 6 
Protein 
degradation 0.58 0.13 0.54 1.33 
CfaAffx.2954.1.S1_at UHRF2 
ubiquitin-like with PHD and ring 
finger domains 2 
Protein 
degradation 0.58 0.41 1.04 1.05 
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Cfa.3300.1.S1_s_at RBBP6 retinoblastoma binding protein 6 
Protein 
degradation 0.59 0.20 0.45 1.08 
CfaAffx.11061.1.S1_at LONRF1 
LON peptidase N-terminal domain 
and ring finger 1 
Protein 
degradation 0.60 0.46 0.53 1.38 
CfaAffx.19544.1.S1_s_at G2E3 
G2/M-phase specific E3 ubiquitin 
ligase 
Protein 
degradation 0.62 0.39 0.47 1.80 
CfaAffx.10834.1.S1_at USPL1 ubiquitin specific peptidase like 1 
Protein 
degradation 0.63 0.20 0.66 2.09 
CfaAffx.13089.1.S1_s_at USP25 ubiquitin specific peptidase 25 
Protein 
degradation 0.67 0.18 0.51 1.01 
CfaAffx.22836.1.S1_at USP48 ubiquitin specific peptidase 48 
Protein 
degradation 0.67 0.29 0.66 2.20 
Cfa.10093.1.A1_at USP48 ubiquitin specific peptidase 48 
Protein 
degradation 0.68 0.26 0.77 1.63 
Cfa.2155.1.S1_at VPRBP  Vpr-binding protein 
Protein 
degradation 0.71 0.63 0.71 1.03 
CfaAffx.1865.1.S1_at UBR5 
ubiquitin protein ligase E3 
component n-recognin 5 
Protein 
degradation 0.72 0.29 0.88 1.57 
Cfa.1083.1.S1_at YME1L1 YME1-like 1 (S. cerevisiae) 
Protein 
degradation 0.72 0.36 0.86 1.56 
CfaAffx.1869.1.S1_s_at UBR5 
ubiquitin protein ligase E3 
component n-recognin 5 
Protein 
degradation 0.74 0.32 0.81 1.25 
Cfa.2773.1.A1_at USP8 ubiquitin specific peptidase 8 
Protein 
degradation 0.78 0.39 0.78 1.17 
CfaAffx.16078.1.S1_s_at DZIP3 
DAZ interacting protein 3, zinc 
finger 
Protein 
degradation 0.83 0.55 0.70 2.24 
Cfa.20786.1.S1_at UBE2E1 
ubiquitin-conjugating enzyme E2E 1 
(UBC4/5 homolog, yeast) 
Protein 
degradation 0.86 0.54 0.99 1.96 
Cfa.638.1.S1_at PSMC6 
proteasome (prosome, macropain) 
26S subunit, ATPase, 6 
Protein 
degradation 0.87 0.61 1.00 1.98 
CfaAffx.5486.1.S1_s_at USP34 ubiquitin specific peptidase 34 
Protein 
degradation 0.88 0.37 0.93 1.34 
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Cfa.11165.1.A1_at CUL4A cullin 4A 
Protein 
degradation 0.93 0.71 0.80 1.84 
CfaAffx.5463.1.S1_at USP34 ubiquitin specific peptidase 34 
Protein 
degradation 0.95 0.48 1.07 1.37 
Cfa.16183.1.A1_s_at CPD carboxypeptidase D 
Protein 
degradation 0.98 0.36 0.95 0.93 
Cfa.20647.1.A1_s_at USP33 ubiquitin specific peptidase 33 
Protein 
degradation 1.02 0.60 0.78 4.18 
CfaAffx.9618.1.S1_s_at UBE2E1 
ubiquitin-conjugating enzyme E2E 1 
(UBC4/5 homolog, yeast) 
Protein 
degradation 1.03 1.08 1.20 1.55 
CfaAffx.13654.1.S1_s_at USP16 ubiquitin specific peptidase 16 
Protein 
degradation 1.04 0.34 0.62 2.24 
Cfa.4121.1.A1_at SPCS1 
signal peptidase complex subunit 1 
homolog (S. cerevisiae) 
Protein 
degradation 1.09 1.20 1.24 1.28 
Cfa.12625.1.A1_x_at PSMB3 
proteasome (prosome, macropain) 
subunit, beta type, 3 
Protein 
degradation 1.13 1.25 1.07 0.74 
Cfa.8226.1.A1_at PSMG3 
proteasome (prosome, macropain) 
assembly chaperone 3 
Protein 
degradation 1.15 1.48 1.00 0.72 
Cfa.734.1.A1_s_at NEDD8 
neural precursor cell expressed, 
developmentally down-regulated 8 
Protein 
degradation 1.16 1.33 1.20 0.90 
CfaAffx.14093.1.S1_s_at SPCS1 
signal peptidase complex subunit 1 
homolog (S. cerevisiae) 
Protein 
degradation 1.18 1.34 1.32 1.43 
Cfa.2649.1.S1_s_at PSMB6 
proteasome (prosome, macropain) 
subunit, beta type, 6 
Protein 
degradation 1.21 1.31 1.09 0.84 
Cfa.384.1.S1_at BLMH bleomycin hydrolase 
Protein 
degradation 1.24 1.56 1.22 1.10 
CfaAffx.19524.1.S1_s_at PSMD4 
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 4 
Protein 
degradation 1.25 1.46 1.12 0.96 
CfaAffx.7317.1.S1_at LRRC41 leucine rich repeat containing 41 
Protein 
degradation 1.25 1.33 1.00 0.64 
Cfa.11504.1.A1_s_at AUP1 ancient ubiquitous protein 1 
Protein 
degradation 1.26 1.28 1.11 0.75 
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Cfa.3960.1.A1_s_at PSMC3 
proteasome (prosome, macropain) 
26S subunit, ATPase, 3 
Protein 
degradation 1.26 1.31 1.14 0.92 
CfaAffx.9878.1.S1_s_at PSMD8 
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 8 
Protein 
degradation 1.28 1.39 1.21 0.82 
Cfa.11683.1.A1_s_at PSMB3 
proteasome (prosome, macropain) 
subunit, beta type, 3 
Protein 
degradation 1.28 1.46 1.14 0.69 
Cfa.18809.1.S1_at SCPEP1 serine carboxypeptidase 1 
Protein 
degradation 1.34 1.39 1.81 1.55 
Cfa.18986.1.S1_s_at SCPEP1 serine carboxypeptidase 1 
Protein 
degradation 1.40 1.66 2.02 1.91 
CfaAffx.811.1.S1_at UBE2I 
ubiquitin-conjugating enzyme E2I 
(UBC9 homolog, yeast) 
Protein 
degradation 1.43 1.77 1.42 0.92 
CfaAffx.18462.1.S1_at CSTA cystatin A (stefin A) 
Protein 
degradation 1.45 7.06 2.64 3.70 
Cfa.17798.1.S1_s_at PSMC4 
proteasome (prosome, macropain) 
26S subunit, ATPase, 4 
Protein 
degradation 1.48 1.81 1.27 0.94 
Cfa.17990.1.S1_s_at UFD1L ubiquitin fusion degradation 1-like 
Protein 
degradation 1.49 1.86 1.16 1.07 
CfaAffx.28126.1.S1_at GZMK 
granzyme K (granzyme 3; tryptase 
II) 
Protein 
degradation 1.50 1.50 4.32 1.15 
Cfa.868.1.S1_s_at PSMC1 
proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
Protein 
degradation 1.55 1.82 1.18 1.19 
CfaAffx.28683.1.S1_x_at NTAN1 N-terminal asparagine amidase 
Protein 
degradation 1.57 1.90 1.38 1.40 
CfaAffx.17609.1.S1_s_at PSMB5 
proteasome (prosome, macropain) 
subunit, beta type, 5 
Protein 
degradation 1.58 1.71 1.42 0.98 
Cfa.12436.1.A1_at PGCP plasma glutamate carboxypeptidase 
Protein 
degradation 1.76 2.42 1.51 1.79 
Cfa.20145.1.S1_s_at PGCP plasma glutamate carboxypeptidase 
Protein 
degradation 1.85 2.95 1.73 2.63 
Cfa.8595.2.A1_s_at PGCP plasma glutamate carboxypeptidase 
Protein 
degradation 1.85 2.80 1.78 2.55 
  192 
Cfa.12436.1.A1_s_at PGCP plasma glutamate carboxypeptidase 
Protein 
degradation 1.89 2.81 1.68 2.11 
CfaAffx.12642.1.S1_at PCSK1 
proprotein convertase 
subtilisin/kexin type 1 
Protein 
degradation 3.42 2.37 2.67 3.06 
CfaAffx.22502.1.S1_s_at CPZ carboxypeptidase Z 
Protein 
degradation 7.06 2.80 20.40 6.28 
Cfa.16255.1.S1_at DNAJB4 
DnaJ (Hsp40) homolog, subfamily 
B, member 4 Protein folding 0.61 0.33 0.62 1.64 
Cfa.11169.1.A1_at 
SDCCAG
10 
serologically defined colon cancer 
antigen 10 Protein folding 0.67 0.47 0.82 1.57 
Cfa.17565.1.S1_s_at PFDN2 prefoldin subunit 2 Protein folding 1.01 1.20 0.93 0.63 
CfaAffx.23819.1.S1_at DERL2 Der1-like domain family, member 2 Protein folding 1.18 1.44 1.16 0.78 
CfaAffx.958.1.S1_at NKTR 
natural killer-tumor recognition 
sequence Protein folding 1.28 1.13 1.19 2.14 
Cfa.21389.1.S1_at SELS selenoprotein S Protein folding 1.42 1.43 1.47 1.14 
CfaAffx.16529.1.S1_s_at SELS selenoprotein S Protein folding 1.60 1.73 1.63 1.12 
Cfa.3168.1.A1_at ERP29 endoplasmic reticulum protein 29 Protein folding 1.66 1.74 1.57 1.32 
CfaAffx.13881.1.S1_s_at ERP29 endoplasmic reticulum protein 29 Protein folding 1.96 2.17 1.66 1.21 
Cfa.16705.1.S1_at PPIF peptidylprolyl isomerase F Protein folding 2.13 1.37 0.90 0.50 
CfaAffx.13881.1.S1_at ERP29 endoplasmic reticulum protein 29 Protein folding 2.15 2.42 1.67 1.34 
CfaAffx.24044.1.S1_at PPIF peptidylprolyl isomerase F Protein folding 2.25 1.51 0.91 0.53 
Cfa.3766.1.S1_at CANX calnexin Protein folding 2.35 3.90 1.80 1.98 
Cfa.17636.1.S1_at HSPB2 heat shock 27kDa protein 2 Protein folding 3.15 3.09 2.13 1.56 
CfaAffx.881.1.S1_s_at HSPB2 heat shock 27kDa protein 2 Protein folding 3.20 3.62 2.08 1.64 
Cfa.307.4.S1_s_at CRYAB crystallin, alpha B Protein folding 4.62 6.06 2.50 2.76 
Cfa.11828.1.A1_at STOM stomatin 
Protein 
homooligomerizat
ion 2.32 3.12 1.57 2.79 
CfaAffx.6481.1.S1_s_at STOM stomatin 
Protein 
homooligomerizat
ion 2.90 4.88 1.79 4.75 
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Cfa.20891.1.S1_at STOM stomatin 
Protein 
homooligomerizat
ion 3.20 5.01 1.83 4.54 
Cfa.15635.1.A1_s_at NBEA neurobeachin 
Protein 
localization 0.72 0.25 0.83 0.94 
Cfa.15244.1.S1_at OGT 
O-linked N-acetylglucosamine 
(GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) 
Protein 
modification 0.57 0.29 0.84 1.26 
Cfa.1484.1.S1_at PAM 
peptidylglycine alpha-amidating 
monooxygenase 
Protein 
modification 0.63 0.36 1.07 1.30 
CfaAffx.10510.1.S1_s_at METAP2 methionyl aminopeptidase 2 
Protein 
modification 0.80 0.38 0.66 1.28 
Cfa.16311.1.S1_at DPM3 
dolichyl-phosphate 
mannosyltransferase polypeptide 3 
Protein 
modification 0.90 1.00 0.80 0.48 
CfaAffx.4666.1.S1_at ALG2 
asparagine-linked glycosylation 2, 
alpha-1,3-mannosyltransferase 
homolog (S. cerevisiae) 
Protein 
modification 1.12 1.55 0.92 0.82 
CfaAffx.9257.1.S1_at PPME1 
protein phosphatase methylesterase 
1 
Protein 
modification 1.16 1.74 1.08 1.24 
Cfa.9914.2.A1_s_at RPN1 ribophorin I 
Protein 
modification 1.39 1.38 1.25 0.87 
CfaAffx.16940.1.S1_s_at STT3A 
STT3, subunit of the 
oligosaccharyltransferase complex, 
homolog A (S. cerevisiae) 
Protein 
modification 1.42 1.48 1.28 1.05 
Cfa.2003.1.S1_at GGCX gamma-glutamyl carboxylase 
Protein 
modification 1.51 1.50 1.16 0.62 
CfaAffx.12436.1.S1_s_at GGCX gamma-glutamyl carboxylase 
Protein 
modification 1.52 1.61 1.02 0.72 
CfaAffx.3670.1.S1_at 
B4GALT
1 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 1 
Protein 
modification 2.21 1.95 2.50 1.88 
CfaAffx.2298.1.S1_at TTLL1 
tubulin tyrosine ligase-like family, 
member 1 
Protein 
modification 2.33 2.45 1.72 1.09 
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CfaAffx.8612.1.S1_s_at 
ST6GAL
NAC1 
ST6 (alpha-N-acetyl-neuraminyl-
2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-
sialyltransferase 1 
Protein 
modification 2.41 4.47 2.47 4.09 
Cfa.19120.1.S1_at 
B4GALT
1 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 1 
Protein 
modification 2.58 1.95 2.66 1.63 
CfaAffx.25978.1.S1_at APH1B 
anterior pharynx defective 1 
homolog B (C. elegans) Protein processing 1.17 1.30 1.13 2.72 
Cfa.589.1.S1_at GNPTAB 
N-acetylglucosamine-1-phosphate 
transferase, alpha and beta subunits Protein secretion 0.76 0.41 0.97 0.96 
Cfa.12996.1.A1_at WDR67 WD repeat domain 67 
Rab GTPase 
regulation 0.74 0.56 0.66 1.62 
Cfa.19504.1.S1_at USP6NL USP6 N-terminal like 
Rab GTPase 
regulation 1.36 0.62 1.35 2.26 
Cfa.10809.1.A1_at BMS1 
BMS1 homolog, ribosome assembly 
protein (yeast) Ribosome 0.67 0.33 0.72 1.05 
CfaAffx.11827.1.S1_at RRS1 
RRS1 ribosome biogenesis regulator 
homolog (S. cerevisiae) Ribosome 0.88 1.16 0.76 0.59 
CfaAffx.22271.1.S1_s_at EMG1 
EMG1 nucleolar protein homolog 
(S. cerevisiae) Ribosome 0.98 1.08 0.77 0.49 
Cfa.21167.1.S1_s_at GNL3L 
guanine nucleotide binding protein-
like 3 (nucleolar)-like Ribosome 1.34 1.84 1.41 1.61 
Cfa.15736.1.A1_at CCDC76 coiled-coil domain containing 76 RNA processing 0.46 0.24 0.56 1.93 
Cfa.20816.2.S1_at LARP7 
La ribonucleoprotein domain 
family, member 7 RNA processing 0.47 0.28 0.58 1.60 
CfaAffx.8460.1.S1_s_at DIS3 
DIS3 mitotic control homolog (S. 
cerevisiae) RNA processing 0.47 0.17 0.41 1.38 
Cfa.13271.1.A1_at FUSIP1 
FUS interacting protein (serine-
arginine rich) 1 RNA processing 0.51 0.39 0.74 1.55 
Cfa.15590.1.A1_s_at UTP20 
UTP20, small subunit (SSU) 
processome component, homolog 
(yeast) RNA processing 0.52 0.31 0.57 0.83 
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CfaAffx.30574.1.S1_at RNPC3 
RNA-binding region (RNP1, RRM) 
containing 3 RNA processing 0.53 0.27 0.67 1.45 
Cfa.2437.1.A1_at RNPC3 
RNA-binding region (RNP1, RRM) 
containing 3 RNA processing 0.56 0.39 0.58 1.19 
Cfa.1509.1.A1_s_at PRPF4B 
PRP4 pre-mRNA processing factor 
4 homolog B (yeast) RNA processing 0.58 0.26 0.73 1.34 
Cfa.19464.1.S1_s_at SFRS2IP 
splicing factor, arginine/serine-rich 
2, interacting protein RNA processing 0.60 0.12 0.50 1.53 
Cfa.6673.1.A1_s_at 
ZCCHC1
1 
zinc finger, CCHC domain 
containing 11 RNA processing 0.60 0.40 0.61 0.97 
Cfa.9849.2.S1_s_at WBP4 
WW domain binding protein 4 
(formin binding protein 21) RNA processing 0.60 0.37 0.60 1.85 
CfaAffx.8217.1.S1_s_at UPF2 
UPF2 regulator of nonsense 
transcripts homolog (yeast) RNA processing 0.62 0.26 0.52 1.41 
CfaAffx.14326.1.S1_s_at ZNF638 zinc finger protein 638 RNA processing 0.63 0.24 0.76 1.07 
Cfa.15590.1.A1_at UTP20 
UTP20, small subunit (SSU) 
processome component, homolog 
(yeast) RNA processing 0.63 0.41 0.62 0.71 
CfaAffx.1651.1.S1_at ZFC3H1 zinc finger, C3H1-type containing RNA processing 0.64 0.30 0.76 1.43 
CfaAffx.21846.1.S1_at CWC22 
CWC22 spliceosome-associated 
protein homolog (S. cerevisiae) RNA processing 0.65 0.23 0.44 1.28 
Cfa.15736.1.A1_s_at CCDC76 coiled-coil domain containing 76 RNA processing 0.65 0.49 0.62 1.32 
CfaAffx.5149.1.S1_at YTHDC1 YTH domain containing 1 RNA processing 0.65 0.43 0.72 1.09 
Cfa.19991.1.S1_at DDX20 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 20 RNA processing 0.66 0.49 0.89 1.10 
CfaAffx.25704.1.S1_at RBM25 RNA binding motif protein 25 RNA processing 0.67 0.20 0.71 1.60 
Cfa.2377.1.S1_at PRPF39 
PRP39 pre-mRNA processing factor 
39 homolog (S. cerevisiae) RNA processing 0.67 0.22 0.77 1.77 
Cfa.9139.1.A1_at SLU7 
SLU7 splicing factor homolog (S. 
cerevisiae) RNA processing 0.68 0.23 0.62 1.13 
Cfa.15319.1.A1_s_at SFRS2IP 
splicing factor, arginine/serine-rich 
2, interacting protein RNA processing 0.70 0.15 0.66 0.98 
CfaAffx.17058.1.S1_at RBM6 RNA binding motif protein 6 RNA processing 0.70 0.45 0.87 1.08 
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Cfa.17844.1.A1_at RNASEL 
ribonuclease L (2',5'-
oligoisoadenylate synthetase-
dependent) RNA processing 0.70 0.33 1.08 1.36 
Cfa.21637.1.S1_s_at SRRM2 serine/arginine repetitive matrix 2 RNA processing 0.73 0.56 0.92 0.99 
Cfa.1509.2.A1_at PRPF4B 
PRP4 pre-mRNA processing factor 
4 homolog B (yeast) RNA processing 0.73 0.36 0.71 0.81 
Cfa.2346.1.A1_s_at SKIV2L2 
superkiller viralicidic activity 2-like 
2 (S. cerevisiae) RNA processing 0.73 0.28 0.51 1.16 
Cfa.586.1.S1_at RBM5 RNA binding motif protein 5 RNA processing 0.74 0.68 0.91 0.90 
CfaAffx.13411.1.S1_at CUGBP1 
CUG triplet repeat, RNA binding 
protein 1 RNA processing 0.75 1.07 0.29 0.20 
Cfa.15731.1.S1_at RBM39 RNA binding motif protein 39 RNA processing 0.75 0.33 0.83 1.54 
Cfa.8055.2.A1_at FUSIP1 
FUS interacting protein (serine-
arginine rich) 1 RNA processing 0.77 0.52 1.09 1.89 
Cfa.3435.1.S1_s_at SF3B1 
splicing factor 3b, subunit 1, 
155kDa RNA processing 0.77 0.29 0.96 1.62 
CfaAffx.26538.1.S1_at LSM11 
U7 snRNA-associated Sm-like 
protein Lsm11 RNA processing 0.77 0.80 0.62 0.56 
Cfa.2751.1.S1_at SERBP1 
SERPINE1 mRNA binding protein 
1 RNA processing 0.77 0.45 0.71 0.86 
Cfa.11068.1.A1_s_at SSB 
Sjogren syndrome antigen B 
(autoantigen La) RNA processing 0.78 0.26 0.67 2.03 
Cfa.14782.1.S1_s_at RRP1B 
ribosomal RNA processing 1 
homolog B (S. cerevisiae) RNA processing 0.81 1.09 0.75 0.61 
CfaAffx.27139.1.S1_s_at INTS2 integrator complex subunit 2 RNA processing 0.82 0.45 1.03 2.48 
Cfa.9882.1.S1_at PAPOLA poly(A) polymerase alpha RNA processing 0.82 0.62 0.91 2.15 
Cfa.10443.1.A1_s_at GEMIN6 
gem (nuclear organelle) associated 
protein 6 RNA processing 0.86 0.82 0.67 0.64 
Cfa.4679.1.A1_s_at DICER1 dicer 1, ribonuclease type III RNA processing 0.88 0.52 0.79 1.31 
Cfa.5369.1.A1_at 
EXOSC1
0 exosome component 10 RNA processing 0.88 1.05 0.80 0.67 
CfaAffx.13302.1.S1_s_at AQR aquarius homolog (mouse) RNA processing 0.91 0.53 0.86 0.81 
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Cfa.3939.1.S1_at SART1 
squamous cell carcinoma antigen 
recognized by T cells RNA processing 0.99 1.16 0.67 0.58 
Cfa.8841.1.A1_s_at FBL fibrillarin RNA processing 0.99 0.99 0.81 0.60 
CfaAffx.6554.1.S1_s_at PRPF38A 
PRP38 pre-mRNA processing factor 
38 (yeast) domain containing A RNA processing 1.00 1.01 0.84 0.48 
CfaAffx.7536.1.S1_s_at SNRPD2 small nuclear ribonucleoprotein D2 RNA processing 1.03 1.02 0.88 0.60 
Cfa.18798.1.S1_at ARL6IP4 
ADP-ribosylation-like factor 6 
interacting protein 4 RNA processing 1.06 1.17 1.16 0.54 
Cfa.18383.1.S1_s_at THO4 
THO complex subunit 4 (Tho4) 
(Ally of AML-1 and LEF-1) 
(Transcriptional coactivator 
Aly/REF) (bZIP enhancing factor 
BEF) RNA processing 1.14 1.25 0.92 0.62 
CfaAffx.26542.1.S1_at THG1L 
tRNA-histidine guanylyltransferase 
1-like (S. cerevisiae) RNA processing 1.14 1.71 1.21 1.23 
CfaAffx.27630.1.S1_s_at IMP3 
IMP3, U3 small nucleolar 
ribonucleoprotein, homolog (yeast) RNA processing 1.14 1.30 1.04 0.64 
CfaAffx.15578.1.S1_at NPM3 nucleophosmin/nucleoplasmin, 3 RNA processing 1.19 1.55 0.98 0.72 
Cfa.18509.2.S1_a_at NAF1 
nuclear assembly factor 1 homolog 
(S. cerevisiae) RNA processing 1.19 1.71 0.89 0.86 
CfaAffx.15578.1.S1_s_at NPM3 nucleophosmin/nucleoplasmin, 3 RNA processing 1.25 1.43 0.95 0.71 
CfaAffx.9765.1.S1_at THO4 
THO complex subunit 4 (Tho4) 
(Ally of AML-1 and LEF-1) 
(Transcriptional coactivator 
Aly/REF) (bZIP enhancing factor 
BEF) RNA processing 1.28 1.55 0.94 0.60 
CfaAffx.7424.1.S1_s_at ISY1 
ISY1 splicing factor homolog (S. 
cerevisiae) RNA processing 1.34 1.44 1.29 1.03 
Cfa.6001.1.A1_at NCBP2 
nuclear cap binding protein subunit 
2, 20kDa RNA processing 1.40 1.35 1.27 0.76 
Cfa.19899.1.S1_s_at 
SNRNP4
0 
small nuclear ribonucleoprotein 
40kDa (U5) RNA processing 1.43 1.54 1.26 0.71 
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CfaAffx.17408.1.S1_at 
SNRNP4
0 
small nuclear ribonucleoprotein 
40kDa (U5) RNA processing 1.56 1.63 1.52 0.73 
Cfa.18171.1.S1_at NOL3 
nucleolar protein 3 (apoptosis 
repressor with CARD domain) RNA processing 3.23 6.03 2.02 1.15 
Cfa.3335.1.A1_at RBM28 RNA binding motif protein 28 RNA processing 3.26 2.37 2.54 1.97 
CfaAffx.3410.1.S1_at RBM28 RNA binding motif protein 28 RNA processing 4.21 3.07 2.43 1.58 
CfaAffx.6867.1.S1_at 
PRKAR2
B 
protein kinase, cAMP-dependent, 
regulatory, type II, beta Signaling 0.32 0.67 0.27 0.89 
Cfa.7153.1.A1_s_at BMP2 bone morphogenetic protein 2 Signaling 0.33 0.57 0.44 1.16 
CfaAffx.21915.1.S1_at SIK2 salt-inducible kinase 2 Signaling 0.34 0.69 0.25 0.64 
Cfa.2706.1.S1_s_at LIFR 
leukemia inhibitory factor receptor 
alpha Signaling 0.36 0.26 0.26 0.72 
CfaAffx.16437.1.S1_at CDON Cdon homolog (mouse) Signaling 0.38 0.41 0.66 0.80 
Cfa.9137.1.A1_s_at 
PRKAR2
B 
protein kinase, cAMP-dependent, 
regulatory, type II, beta Signaling 0.39 0.66 0.26 0.77 
CfaAffx.26265.1.S1_s_at ODZ2 
odz, odd Oz/ten-m homolog 2 
(Drosophila) Signaling 0.39 0.56 0.28 0.87 
Cfa.13931.1.A1_at 
PLEKHG
3 
pleckstrin homology domain 
containing, family G (with RhoGef 
domain) member 3 Signaling 0.40 0.53 0.33 0.30 
Cfa.1514.1.S1_at PIBF1 
progesterone immunomodulatory 
binding factor 1 Signaling 0.41 0.14 0.44 1.15 
CfaAffx.18296.1.S1_at GPR146 G protein-coupled receptor 146 Signaling 0.42 0.73 0.20 0.26 
CfaAffx.9808.1.S1_at BMP2 bone morphogenetic protein 2 Signaling 0.45 0.61 0.47 1.01 
CfaAffx.13770.1.S1_s_at PIK3C2A 
phosphoinositide-3-kinase, class 2, 
alpha polypeptide Signaling 0.45 0.31 0.52 1.82 
Cfa.20972.1.S1_s_at GKAP1 G kinase anchoring protein 1 Signaling 0.45 0.45 0.39 0.92 
Cfa.35.1.A1_s_at RHBG 
Rh family, B glycoprotein 
(gene/pseudogene) Signaling 0.47 0.58 0.17 0.12 
CfaAffx.10709.1.S1_s_at MITF 
microphthalmia-associated 
transcription factor Signaling 0.49 0.36 0.78 0.76 
Cfa.1514.1.S1_s_at PIBF1 
progesterone immunomodulatory 
binding factor 1 Signaling 0.50 0.34 0.42 0.77 
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CfaAffx.8844.1.S1_at 
RALGAP
A2 
GTPase activating Rap/RanGAP 
domain-like 1 isoform 2 Signaling 0.51 0.60 0.53 0.58 
CfaAffx.17516.1.S1_s_at PIK3CA 
phosphoinositide-3-kinase, catalytic, 
alpha polypeptide Signaling 0.51 0.18 0.47 2.37 
Cfa.2682.1.S1_s_at MITF 
microphthalmia-associated 
transcription factor Signaling 0.54 0.36 0.81 0.87 
CfaAffx.12643.1.S1_s_at GPR120 G protein-coupled receptor 120 Signaling 0.57 0.58 0.27 0.14 
CfaAffx.4016.1.S1_s_at GPR116 G protein-coupled receptor 116 Signaling 0.58 0.40 0.42 0.83 
Cfa.15610.1.A1_s_at GPR116 G protein-coupled receptor 116 Signaling 0.58 0.38 0.47 0.88 
Cfa.15610.1.A1_at GPR116 G protein-coupled receptor 116 Signaling 0.61 0.39 0.52 0.85 
CfaAffx.19259.1.S1_at ILKAP 
integrin-linked kinase-associated 
serine/threonine phosphatase 2C Signaling 0.63 0.71 0.53 0.48 
CfaAffx.10633.1.S1_s_at MAP4K3 
mitogen-activated protein kinase 
kinase kinase kinase 3 Signaling 0.63 0.39 0.69 2.04 
Cfa.20148.1.S1_s_at PPP2R5E 
protein phosphatase 2, regulatory 
subunit B', epsilon isoform Signaling 0.68 0.37 0.78 2.52 
CfaAffx.4803.1.S1_at RHOQ ras homolog gene family, member Q Signaling 0.68 0.33 0.77 2.35 
Cfa.4344.1.S1_at YWHAB 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
beta polypeptide Signaling 0.69 1.09 0.93 1.40 
CfaAffx.23894.1.S1_at STAT5B 
signal transducer and activator of 
transcription 5B Signaling 0.69 0.91 0.37 0.41 
Cfa.19720.1.S1_s_at 
ARHGEF
3 
Rho guanine nucleotide exchange 
factor (GEF) 3 Signaling 0.71 0.51 1.40 1.45 
Cfa.12558.1.A1_s_at PRKD1 protein kinase D1 Signaling 0.71 0.47 1.06 1.24 
Cfa.15734.1.A1_at OPHN1 Oligophrenin 1 Signaling 0.71 0.33 1.11 1.02 
Cfa.9474.1.A1_at 
CLEC12
A 
C-type lectin domain family 12, 
member A Signaling 0.76 0.38 2.18 1.14 
Cfa.8990.1.S1_at OPHN1 Oligophrenin 1 Signaling 0.77 0.42 1.18 1.51 
Cfa.3056.1.A1_at PRKRIR 
protein-kinase, interferon-inducible 
double stranded RNA dependent 
inhibitor, repressor of (P58 Signaling 0.77 0.35 0.83 1.75 
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repressor) 
Cfa.12563.1.A1_at MAP3K4 
mitogen-activated protein kinase 
kinase kinase 4 Signaling 0.80 0.51 0.93 1.00 
Cfa.17374.1.S1_s_at MACF1 
microtubule-actin crosslinking 
factor 1 Signaling 0.81 0.57 1.32 1.71 
CfaAffx.6904.1.S1_s_at OPHN1 Oligophrenin 1 Signaling 0.81 0.39 1.16 1.35 
CfaAffx.26751.1.S1_s_at 
ARHGAP
17 Rho GTPase activating protein 17 Signaling 0.81 1.00 1.30 1.37 
Cfa.3578.1.S1_at TEK TEK tyrosine kinase, endothelial Signaling 0.82 0.51 1.03 0.68 
Cfa.11080.1.S1_at APC adenomatous polyposis coli Signaling 0.83 0.42 0.87 1.18 
Cfa.10472.1.A1_s_at MACF1 
microtubule-actin crosslinking 
factor 1 Signaling 0.84 0.52 1.35 1.50 
Cfa.768.1.S1_at ZC3H15 
zinc finger CCCH-type containing 
15 Signaling 0.85 0.44 0.63 1.76 
CfaAffx.11870.1.S1_s_at APC adenomatous polyposis coli Signaling 0.86 0.32 0.87 1.73 
Cfa.18084.1.S1_s_at STAT1 
signal transducer and activator of 
transcription 1, 91kDa Signaling 0.86 1.30 0.99 1.99 
Cfa.2471.1.A1_s_at 
RAPGEF
2 
Rap guanine nucleotide exchange 
factor (GEF) 2 Signaling 0.91 0.51 0.88 1.01 
CfaAffx.15001.1.S1_s_at 
SPARCL
1 SPARC-like 1 (hevin) Signaling 0.92 0.19 0.68 1.41 
Cfa.10487.1.A1_at MACF1 
microtubule-actin crosslinking 
factor 1 Signaling 0.93 0.51 1.19 1.36 
CfaAffx.10207.1.S1_s_at PRKD3 protein kinase D3 Signaling 0.95 0.32 0.99 0.77 
CfaAffx.29105.1.S1_s_at ABR active BCR-related gene Signaling 0.98 1.72 0.99 0.78 
Cfa.3247.1.S1_at 
SPARCL
1 SPARC-like 1 (hevin) Signaling 0.99 0.26 0.77 1.32 
CfaAffx.30207.1.S1_at 
CTNNBI
P1 catenin, beta interacting protein 1 Signaling 1.05 1.63 0.92 0.72 
CfaAffx.4049.1.S1_at GPR111 G protein-coupled receptor 111 Signaling 1.10 1.43 1.19 0.90 
CfaAffx.21869.1.S1_at RANBP1 RAN binding protein 1 Signaling 1.14 1.12 1.05 0.59 
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CfaAffx.15058.1.S1_at BMP6 bone morphogenetic protein 6 Signaling 1.20 2.69 1.07 3.33 
Cfa.12086.1.S1_s_at CALM3 
calmodulin 3 (phosphorylase kinase, 
delta) Signaling 1.26 1.13 1.23 0.61 
CfaAffx.25055.1.S1_s_at CNIH4 cornichon homolog 4 (Drosophila) Signaling 1.30 1.31 1.16 0.82 
Cfa.13280.2.S1_s_at BCAR1 
breast cancer anti-estrogen 
resistance 1 Signaling 1.43 1.42 0.92 1.88 
Cfa.9484.1.A1_at CCM2 cerebral cavernous malformation 2 Signaling 1.46 1.33 1.49 0.81 
Cfa.465.3.S1_s_at ILK integrin-linked kinase Signaling 1.47 1.85 1.37 1.12 
CfaAffx.22957.1.S1_at 
GMF-
beta 
Glia maturation factor beta (GMF-
beta) Signaling 1.49 1.23 1.22 4.39 
Cfa.13073.1.A1_x_at PLP2 
proteolipid protein 2 (colonic 
epithelium-enriched) Signaling 1.50 2.21 1.20 1.08 
Cfa.5295.1.A1_at PLP2 
proteolipid protein 2 (colonic 
epithelium-enriched) Signaling 1.59 2.20 1.13 1.24 
CfaAffx.24207.1.S1_s_at PLP2 
proteolipid protein 2 (colonic 
epithelium-enriched) Signaling 1.65 2.43 1.14 1.38 
Cfa.18291.1.S1_s_at MAP2K3 
mitogen-activated protein kinase 
kinase 3 Signaling 1.65 1.84 0.94 0.54 
CfaAffx.9344.1.S1_s_at FARP1 
FERM, RhoGEF (ARHGEF) and 
pleckstrin domain protein 1 
(chondrocyte-derived) Signaling 1.65 2.10 2.16 2.49 
Cfa.8946.1.A1_at S100A10 S100 calcium binding protein A10 Signaling 1.72 1.67 1.82 1.95 
CfaAffx.4144.1.S1_s_at MAP4K4 
mitogen-activated protein kinase 
kinase kinase kinase 4 Signaling 1.74 1.46 1.52 0.96 
CfaAffx.20738.1.S1_s_at RGL1 
ral guanine nucleotide dissociation 
stimulator-like 1 Signaling 1.85 1.65 2.52 2.60 
CfaAffx.31281.1.S1_at GPR177 G protein-coupled receptor 177 Signaling 1.88 2.01 1.65 0.69 
Cfa.19694.1.S1_s_at NPR3 
natriuretic peptide receptor 
C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) Signaling 1.96 4.72 2.27 12.06 
CfaAffx.22099.1.S1_at 
RASGRP
2 
RAS guanyl releasing protein 2 
(calcium and DAG-regulated) Signaling 1.99 1.86 1.54 0.96 
  202 
CfaAffx.28818.1.S1_at NPR3 
natriuretic peptide receptor 
C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) Signaling 2.08 5.40 2.27 16.16 
Cfa.15687.1.A1_at ITSN1 intersectin 1 (SH3 domain protein) Signaling 2.26 2.61 2.08 2.33 
CfaAffx.6412.1.S1_at SFRP4 secreted frizzled-related protein 4 Signaling 2.29 0.78 7.46 1.31 
Cfa.12577.1.A1_at SFRP4 secreted frizzled-related protein 4 Signaling 2.32 0.71 7.64 1.21 
CfaAffx.22100.1.S1_s_at 
RASGRP
2 
RAS guanyl releasing protein 2 
(calcium and DAG-regulated) Signaling 2.35 2.22 1.70 1.07 
CfaAffx.8579.1.S1_at CXCR4 chemokine (C-X-C motif) receptor 4 Signaling 2.38 3.21 2.00 0.57 
Cfa.4658.1.A1_at PKIG 
protein kinase (cAMP-dependent, 
catalytic) inhibitor gamma Signaling 2.42 2.45 1.84 1.75 
CfaAffx.14915.1.S1_s_at PKIG 
protein kinase (cAMP-dependent, 
catalytic) inhibitor gamma Signaling 2.53 2.54 1.85 1.83 
Cfa.19694.1.S1_at NPR3 
natriuretic peptide receptor 
C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) Signaling 2.61 7.28 3.09 18.76 
Cfa.15085.1.A1_at YWHAG 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
gamma polypeptide Signaling 2.70 2.49 2.15 2.06 
Cfa.19694.2.A1_at NPR3 
natriuretic peptide receptor 
C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) Signaling 2.70 5.19 2.65 12.39 
Cfa.17582.1.S1_s_at 
RASGRP
2 
RAS guanyl releasing protein 2 
(calcium and DAG-regulated) Signaling 2.76 2.76 1.68 1.06 
Cfa.17582.1.S1_at 
RASGRP
2 
RAS guanyl releasing protein 2 
(calcium and DAG-regulated) Signaling 2.78 2.71 1.96 1.44 
CfaAffx.28688.1.S1_at PRLR prolactin receptor Signaling 2.99 6.48 2.21 2.44 
CfaAffx.20937.1.S1_at YWHAG 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
gamma polypeptide Signaling 3.10 3.31 2.44 2.30 
CfaAffx.16492.1.S1_at DNER delta/notch-like EGF repeat Signaling 3.67 11.2 2.08 10.53 
  203 
containing 9 
CfaAffx.17312.1.S1_at DKK2 
dickkopf homolog 2 (Xenopus 
laevis) Signaling 4.40 2.54 3.04 6.70 
Cfa.3643.1.S1_s_at PTH1R parathyroid hormone 1 receptor Signaling 6.45 4.37 3.08 1.99 
CfaAffx.4606.1.S1_at GABBR2 
gamma-aminobutyric acid (GABA) 
B receptor, 2 Signaling 8.92 4.42 3.82 1.58 
CfaAffx.28719.1.S1_s_at IGSF1 
immunoglobulin superfamily, 
member 1 Signaling 
32.1
2 
87.6
2 21.28 16.92 
CfaAffx.14682.1.S1_s_at 
SERPINB
6 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 6 
Thrombin 
inhibitor 1.81 1.57 1.91 1.32 
Cfa.6273.1.S1_at 
SERPINB
6 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 6 
Thrombin 
inhibitor 1.84 1.68 1.92 1.34 
Cfa.6273.1.S1_s_at 
SERPINB
6 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 6 
Thrombin 
inhibitor 2.03 1.90 2.08 1.49 
Cfa.3616.1.S1_at TJP1 
tight junction protein 1 (zona 
occludens 1) Tight junction 0.71 0.49 0.83 1.05 
Cfa.19555.1.S1_at MPDZ multiple PDZ domain protein Tight junction 0.88 0.36 0.99 0.97 
Cfa.1248.1.S1_at MPDZ multiple PDZ domain protein Tight junction 1.02 0.39 1.11 1.79 
CfaAffx.2515.1.S1_at SMAD5 SMAD family member 5 Transcription 0.30 0.31 0.74 1.08 
Cfa.20312.1.S1_at KLF11 Kruppel-like factor 11 Transcription 0.32 0.58 0.42 0.62 
CfaAffx.5517.1.S1_at ZNF292 zinc finger protein 292 Transcription 0.35 0.11 0.65 1.27 
CfaAffx.6041.1.S1_s_at KLF11 Kruppel-like factor 11 Transcription 0.35 0.72 0.47 0.73 
CfaAffx.27674.1.S1_x_at ZNF300 zinc finger protein 300 Transcription 0.36 0.23 0.44 1.19 
Cfa.15358.1.A1_at ELL2 
elongation factor, RNA polymerase 
II, 2 Transcription 0.37 0.35 0.33 0.60 
CfaAffx.15623.1.S1_s_at ZNF37A zinc finger protein 37A Transcription 0.38 0.22 0.40 1.47 
CfaAffx.30900.1.S1_at ZNF23 zinc finger protein 23 (KOX 16) Transcription 0.39 0.16 0.40 2.44 
CfaAffx.22707.1.S1_s_at ZNF674 zinc finger family member 674 Transcription 0.41 0.27 0.46 0.94 
CfaAffx.27633.1.S1_x_at ZNF300 zinc finger protein 300 Transcription 0.44 0.26 0.41 1.20 
Cfa.19342.2.A1_s_at RFC1 
replication factor C (activator 1) 1, 
145kDa Transcription 0.44 0.15 0.40 1.18 
CfaAffx.20523.1.S1_s_at ID3 
inhibitor of DNA binding 3, 
dominant negative helix-loop-helix Transcription 0.46 0.61 0.51 0.27 
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protein 
CfaAffx.10976.1.S1_at ZNF215 zinc finger protein 215 Transcription 0.46 0.44 0.45 0.53 
Cfa.2351.1.S1_at RFC1 
replication factor C (activator 1) 1, 
145kDa Transcription 0.47 0.24 0.41 0.60 
Cfa.15026.1.A1_s_at PHF20 PHD finger protein 20 Transcription 0.47 0.25 0.68 0.88 
Cfa.1602.1.A1_at PHF17 PHD finger protein 17 Transcription 0.47 0.36 0.59 0.68 
CfaAffx.4453.1.S1_at ZNF606 zinc finger protein 606 Transcription 0.48 0.29 0.43 1.95 
CfaAffx.25677.1.S1_s_at 
LOC6128
88 CG13624-PC, isoform C Transcription 0.49 0.20 0.61 1.27 
Cfa.64.1.S1_at ID3 
inhibitor of DNA binding 3, 
dominant negative helix-loop-helix 
protein Transcription 0.51 0.63 0.60 0.39 
Cfa.5127.1.A1_s_at 
RUNX1T
1 
runt-related transcription factor 1; 
translocated to, 1 (cyclin D-related) Transcription 0.51 0.31 0.98 1.02 
CfaAffx.13190.1.S1_s_at ZFHX4 zinc finger homeobox 4 Transcription 0.51 0.38 0.81 0.68 
CfaAffx.28793.1.S1_s_at NFIA nuclear factor I/A Transcription 0.51 0.52 0.40 0.60 
CfaAffx.24672.1.S1_at TSPYL2 TSPY-like 2 Transcription 0.52 1.12 0.62 1.76 
Cfa.1889.2.S1_s_at MTF2 
metal response element binding 
transcription factor 2 Transcription 0.52 0.19 0.65 1.18 
CfaAffx.30445.1.S1_at TTF1 
transcription termination factor, 
RNA polymerase I Transcription 0.53 0.42 0.77 1.08 
Cfa.1741.1.S1_s_at 
SMARC
AD1 
SWI/SNF-related, matrix-associated 
actin-dependent regulator of 
chromatin, subfamily a, containing 
DEAD/H box 1 Transcription 0.53 0.21 0.76 1.83 
Cfa.2221.1.A1_s_at 
LOC4768
00 EMSY protein Transcription 0.53 0.32 0.79 1.05 
CfaAffx.8351.1.S1_at MLL3 
myeloid/lymphoid or mixed-lineage 
leukemia 3 Transcription 0.55 0.36 0.85 1.03 
CfaAffx.9557.1.S1_x_at THR thyroid hormone receptor beta1 Transcription 0.55 0.41 0.55 0.63 
Cfa.19011.1.S1_at 
LOC6128
88 CG13624-PC, isoform C Transcription 0.56 0.30 0.61 1.03 
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Cfa.18921.1.S1_s_at TGS1 
trimethylguanosine synthase 
homolog (S. cerevisiae) Transcription 0.56 0.51 0.58 0.54 
CfaAffx.20312.1.S1_at ATF7IP 
activating transcription factor 7 
interacting protein Transcription 0.56 0.39 0.88 1.33 
CfaAffx.14872.1.S1_at BAZ2B 
bromodomain adjacent to zinc 
finger domain, 2B Transcription 0.57 0.23 0.57 1.63 
CfaAffx.20465.1.S1_s_at CIR1 corepressor interacting with RBPJ, 1 Transcription 0.57 0.34 0.72 1.08 
CfaAffx.30907.1.S1_s_at ZNF23 zinc finger protein 23 (KOX 16) Transcription 0.57 0.40 0.61 2.29 
Cfa.1994.1.A1_at CCNT2 cyclin T2 Transcription 0.57 0.32 0.80 1.29 
Cfa.19629.1.S1_s_at MLL5 
myeloid/lymphoid or mixed-lineage 
leukemia 5 (trithorax homolog, 
Drosophila) Transcription 0.57 0.44 0.67 1.38 
CfaAffx.17840.1.S1_s_at ARID4B 
AT rich interactive domain 4B 
(RBP1-like) Transcription 0.58 0.27 0.69 1.11 
Cfa.2221.1.A1_at 
LOC4768
00 EMSY protein Transcription 0.59 0.30 0.60 0.88 
Cfa.2477.1.S1_at BAZ2B 
bromodomain adjacent to zinc 
finger domain, 2B Transcription 0.59 0.37 0.64 1.14 
CfaAffx.10125.1.S1_at CEBPZ 
CCAAT/enhancer binding protein 
(C/EBP), zeta Transcription 0.59 0.26 0.39 1.05 
Cfa.1870.1.S1_at RLF rearranged L-myc fusion Transcription 0.60 0.17 0.50 0.82 
Cfa.9842.1.A1_s_at NCOA1 nuclear receptor coactivator 1 Transcription 0.60 0.51 0.71 0.93 
CfaAffx.31004.1.S1_s_at ZFHX3 zinc finger homeobox 3 Transcription 0.60 0.51 0.96 1.18 
CfaAffx.10691.1.S1_at 
LOC4845
60 
Hypothetical zinc finger protein 
KIAA1559 Transcription 0.61 0.46 0.70 2.03 
CfaAffx.7029.1.S1_s_at NCOA1 nuclear receptor coactivator 1 Transcription 0.61 0.53 0.64 1.04 
Cfa.16746.1.S1_at ZBTB11 
zinc finger and BTB domain 
containing 11 Transcription 0.61 0.30 0.63 1.52 
Cfa.9245.1.A1_at ZNF300 zinc finger protein 300 Transcription 0.61 0.15 0.75 1.69 
CfaAffx.24662.1.S1_s_at RFC1 
replication factor C (activator 1) 1, 
145kDa Transcription 0.62 0.23 0.39 0.69 
Cfa.12257.1.A1_at JARID2 
jumonji, AT rich interactive domain 
2 Transcription 0.62 0.65 0.87 0.82 
  206 
Cfa.20419.1.A1_s_at WASL Wiskott-Aldrich syndrome-like Transcription 0.63 0.50 0.81 1.01 
Cfa.1804.1.S1_at PSIP1 
PC4 and SFRS1 interacting protein 
1 Transcription 0.63 0.25 0.73 0.85 
Cfa.1108.1.S1_s_at ZNF331 zinc finger protein 331 Transcription 0.63 0.50 0.77 0.94 
CfaAffx.31203.1.S1_s_at ZZZ3 zinc finger, ZZ-type containing 3 Transcription 0.63 0.31 0.69 1.39 
Cfa.10740.2.A1_s_at RNF141 ring finger protein 141 Transcription 0.64 0.57 0.46 0.80 
CfaAffx.17985.1.S1_s_at BPTF 
bromodomain PHD finger 
transcription factor Transcription 0.64 0.21 0.86 1.37 
CfaAffx.15733.1.S1_at 
SMARC
AD1 
SWI/SNF-related, matrix-associated 
actin-dependent regulator of 
chromatin, subfamily a, containing 
DEAD/H box 1 Transcription 0.64 0.31 0.80 1.23 
Cfa.16375.1.S1_at MYCBP2 MYC binding protein 2 Transcription 0.65 0.29 0.76 1.02 
Cfa.1712.1.A1_at 
WHSC1L
1 
Wolf-Hirschhorn syndrome 
candidate 1-like 1 Transcription 0.65 0.38 1.00 1.12 
Cfa.11147.1.A1_at CIR1 corepressor interacting with RBPJ, 1 Transcription 0.66 0.24 0.60 1.32 
CfaAffx.5065.1.S1_at ZNF678 zinc finger protein 678 Transcription 0.66 0.59 0.64 1.39 
Cfa.1174.1.S1_at HLTF helicase-like transcription factor Transcription 0.66 0.30 0.76 1.72 
Cfa.20040.1.S1_s_at GPBP1 GC-rich promoter binding protein 1 Transcription 0.67 0.32 0.60 1.76 
Cfa.15585.1.A1_at NSD1 
nuclear receptor binding SET 
domain protein 1 Transcription 0.67 0.39 0.67 0.69 
Cfa.2506.1.S1_s_at UTP3 
UTP3, small subunit (SSU) 
processome component, homolog 
(S. cerevisiae) Transcription 0.67 0.75 0.66 0.68 
Cfa.1155.1.S1_at GPBP1 GC-rich promoter binding protein 1 Transcription 0.68 0.28 0.68 1.43 
CfaAffx.16988.1.S1_s_at TRIP11 
thyroid hormone receptor interactor 
11 Transcription 0.68 0.27 0.53 0.86 
CfaAffx.23612.1.S1_s_at MYST4 
MYST histone acetyltransferase 
monocytic leukemia 4 Transcription 0.69 0.42 0.85 1.08 
CfaAffx.8811.1.S1_at MED8 mediator complex subunit 8 Transcription 0.69 0.99 0.64 0.66 
CfaAffx.12161.1.S1_s_at KDM3A lysine (K)-specific demethylase 3A Transcription 0.69 0.27 0.81 1.22 
Cfa.9716.1.A1_s_at MYCBP2 MYC binding protein 2 Transcription 0.69 0.32 0.73 1.03 
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CfaAffx.15816.1.S1_s_at ZPF90 
Zinc finger protein 90 (Zfp-90) 
(Zinc finger protein NK10) Transcription 0.69 0.30 0.57 3.22 
Cfa.1985.2.S1_at UBP1 
upstream binding protein 1 (LBP-
1a) Transcription 0.69 0.82 1.07 1.58 
Cfa.20023.1.S1_s_at ZNF800 zinc finger protein 800 Transcription 0.70 0.69 0.77 1.88 
CfaAffx.20299.1.S1_s_at JMJD1C jumonji domain containing 1C Transcription 0.70 0.15 0.57 2.03 
CfaAffx.11615.1.S1_s_at CHD7 
chromodomain helicase DNA 
binding protein 7 Transcription 0.70 0.46 0.75 0.99 
Cfa.10398.1.A1_at NCOA1 nuclear receptor coactivator 1 Transcription 0.71 0.60 0.78 1.07 
CfaAffx.8351.1.S1_s_at MLL3 
myeloid/lymphoid or mixed-lineage 
leukemia 3 Transcription 0.71 0.40 0.94 0.99 
Cfa.936.1.S1_at 
SMARC
A5 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 5 Transcription 0.71 0.35 0.61 0.93 
CfaAffx.26204.1.S1_s_at 
CCDC10
1 coiled-coil domain containing 101 Transcription 0.71 0.92 0.66 0.46 
Cfa.10511.1.A1_at BBX bobby sox homolog (Drosophila) Transcription 0.71 0.36 1.15 1.40 
Cfa.2725.1.A1_at NARG1L NMDA receptor regulated 1-like Transcription 0.71 0.28 0.96 1.68 
Cfa.10566.1.A1_at NCOR1 nuclear receptor co-repressor 1 Transcription 0.72 0.55 0.68 0.86 
Cfa.3934.1.S1_at BCLAF1 
BCL2-associated transcription 
factor 1 Transcription 0.72 0.22 0.85 1.21 
CfaAffx.17879.1.S1_s_at ARID4B 
AT rich interactive domain 4B 
(RBP1-like) Transcription 0.73 0.21 0.77 0.98 
Cfa.10566.2.S1_a_at NCOR1 nuclear receptor co-repressor 1 Transcription 0.73 0.58 0.70 0.82 
Cfa.21375.1.S1_s_at AFF4 AF4/FMR2 family, member 4 Transcription 0.74 0.44 0.67 2.34 
CfaAffx.18001.1.S1_at BPTF 
bromodomain PHD finger 
transcription factor Transcription 0.74 0.36 0.87 1.50 
Cfa.16206.1.A1_s_at IWS1 IWS1 homolog (S. cerevisiae) Transcription 0.75 0.36 0.79 1.44 
Cfa.660.3.S1_s_at SLTM SAFB-like, transcription modulator Transcription 0.75 0.31 0.77 1.15 
Cfa.3808.1.S1_s_at TCF7L2 
transcription factor 7-like 2 (T-cell 
specific, HMG-box) Transcription 0.76 0.46 0.99 1.14 
CfaAffx.8009.1.S1_s_at ZNF283 zinc finger protein 283 Transcription 0.76 0.53 0.54 5.41 
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CfaAffx.7105.1.S1_s_at MLL5 
myeloid/lymphoid or mixed-lineage 
leukemia 5 (trithorax homolog, 
Drosophila) Transcription 0.76 0.55 0.80 1.20 
Cfa.1279.1.S1_at PNN pinin, desmosome associated protein Transcription 0.76 0.38 0.82 1.38 
Cfa.3949.1.A1_at CTCF 
CCCTC-binding factor (zinc finger 
protein) Transcription 0.76 0.55 1.00 1.13 
Cfa.11349.1.A1_at CCNL2 cyclin L2 Transcription 0.76 0.69 0.96 1.00 
Cfa.1872.1.S1_at ELF2 
E74-like factor 2 (ets domain 
transcription factor) Transcription 0.76 0.38 0.78 1.08 
Cfa.2025.1.A1_at ASCC3 
activating signal cointegrator 1 
complex subunit 3 Transcription 0.77 0.38 0.77 1.13 
Cfa.5314.1.A1_at ZBTB20 
zinc finger and BTB domain 
containing 20 Transcription 0.77 0.69 0.96 1.53 
Cfa.12313.1.A1_at TSHZ1 teashirt zinc finger homeobox 1 Transcription 0.77 0.91 1.18 1.21 
CfaAffx.11934.1.S1_at BTAF1 
BTAF1 RNA polymerase II, B-
TFIID transcription factor-
associated, 170kDa (Mot1 homolog, 
S. cerevisiae) Transcription 0.77 0.24 0.72 1.13 
Cfa.7590.1.A1_at RBBP7 retinoblastoma binding protein 7 Transcription 0.77 0.35 1.04 1.29 
CfaAffx.15494.1.S1_s_at BBX bobby sox homolog (Drosophila) Transcription 0.77 0.29 1.06 0.95 
CfaAffx.7191.1.S1_s_at PRDM5 PR domain containing 5 Transcription 0.78 0.20 0.88 1.03 
CfaAffx.12484.1.S1_s_at CGGBP1 CGG triplet repeat binding protein 1 Transcription 0.79 0.50 0.87 0.83 
CfaAffx.26383.1.S1_s_at 
DENND4
A 
DENN/MADD domain containing 
4A Transcription 0.79 0.24 0.56 1.23 
Cfa.15871.1.A1_at SRFBP1 
serum response factor binding 
protein 1 Transcription 0.79 0.19 0.53 1.84 
Cfa.2978.1.A1_at SLTM SAFB-like, transcription modulator Transcription 0.80 0.36 0.82 1.25 
Cfa.15377.1.A1_s_at FOXO1 forkhead box O1 Transcription 0.80 0.53 0.58 0.71 
Cfa.20155.1.S1_s_at BBX bobby sox homolog (Drosophila) Transcription 0.80 0.27 1.09 1.22 
CfaAffx.24187.1.S1_at KDM5A lysine (K)-specific demethylase 5A Transcription 0.80 0.41 0.94 1.12 
CfaAffx.20719.1.S1_at SETD2 SET domain containing 2 Transcription 0.80 0.49 0.71 0.84 
Cfa.10740.1.S1_at RNF141 ring finger protein 141 Transcription 0.80 0.60 0.57 0.90 
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CfaAffx.26436.1.S1_at TAF9B 
TAF9B RNA polymerase II, TATA 
box binding protein (TBP)-
associated factor, 31kDa Transcription 0.81 0.70 0.78 1.99 
CfaAffx.10766.1.S1_at ZNF382 zinc finger protein 382 Transcription 0.81 0.60 0.80 1.87 
Cfa.15175.1.A1_at KDM5A lysine (K)-specific demethylase 5A Transcription 0.82 0.45 0.97 1.07 
Cfa.9945.1.A1_at 
SMARC
AD1 
SWI/SNF-related, matrix-associated 
actin-dependent regulator of 
chromatin, subfamily a, containing 
DEAD/H box 1 Transcription 0.82 0.33 0.99 1.37 
CfaAffx.4357.1.S1_s_at POLR2B 
polymerase (RNA) II (DNA 
directed) polypeptide B, 140kDa Transcription 0.83 0.35 0.79 1.17 
Cfa.10607.1.A1_at SETD2 SET domain containing 2 Transcription 0.83 0.49 0.82 0.87 
Cfa.9106.1.S1_at PURA 
purine-rich element binding protein 
A Transcription 0.83 0.83 0.99 2.03 
Cfa.11331.1.A1_at HSF1 heat shock transcription factor 1 Transcription 0.84 0.95 0.71 0.53 
CfaAffx.15496.1.S1_s_at BBX bobby sox homolog (Drosophila) Transcription 0.84 0.26 1.01 0.99 
Cfa.5372.1.A1_at 
LOC6111
58 H2B histone family, member T Transcription 0.84 0.78 0.41 0.15 
CfaAffx.18384.1.S1_at MED18 mediator complex subunit 18 Transcription 0.85 0.92 0.78 0.49 
CfaAffx.18384.1.S1_s_at MED18 mediator complex subunit 18 Transcription 0.85 1.06 0.81 0.46 
CfaAffx.14793.1.S1_at CRY2 cryptochrome 2 (photolyase-like) Transcription 0.85 1.65 0.71 2.02 
Cfa.940.1.S1_s_at ZNF24 zinc finger protein 24 Transcription 0.85 0.37 0.85 1.27 
Cfa.20467.2.S1_a_at 
SUPT4H
1 
suppressor of Ty 4 homolog 1 (S. 
cerevisiae) Transcription 0.86 0.97 0.96 0.57 
CfaAffx.30853.1.S1_at MTF2 
metal response element binding 
transcription factor 2 Transcription 0.87 0.46 1.02 1.08 
CfaAffx.24012.1.S1_s_at PQBP1 polyglutamine binding protein 1 Transcription 0.88 1.13 0.76 0.54 
CfaAffx.23264.1.S1_s_at REST RE1-silencing transcription factor Transcription 0.89 0.41 0.95 1.74 
CfaAffx.8004.1.S1_s_at ZNF283 zinc finger protein 283 Transcription 0.90 0.81 0.78 2.21 
CfaAffx.23026.1.S1_at ZNF655 zinc finger protein 655 Transcription 0.94 0.83 0.85 2.71 
Cfa.19516.1.S1_s_at MYST2 MYST histone acetyltransferase 2 Transcription 0.95 1.48 0.88 0.83 
Cfa.16737.1.S1_at CHD4 
chromodomain helicase DNA 
binding protein 4 Transcription 0.95 0.91 1.15 0.69 
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Cfa.584.1.S1_at NFYB nuclear transcription factor Y, beta Transcription 0.96 0.85 0.97 2.91 
Cfa.20751.1.S1_s_at MTDH metadherin Transcription 0.96 0.69 1.01 1.77 
Cfa.7680.1.S1_s_at POLR2I 
polymerase (RNA) II (DNA 
directed) polypeptide I, 14.5kDa Transcription 0.99 1.08 0.86 0.58 
CfaAffx.6949.1.S1_s_at ZEB1 
zinc finger E-box binding 
homeobox 1 Transcription 1.01 0.41 0.99 1.59 
CfaAffx.23977.1.S1_at MED26 mediator complex subunit 26 Transcription 1.01 1.65 0.87 0.72 
Cfa.17790.1.S1_s_at MED28 mediator complex subunit 28 Transcription 1.02 1.07 0.83 0.42 
CfaAffx.4431.1.S1_s_at POLR1E 
polymerase (RNA) I polypeptide E, 
53kDa Transcription 1.03 1.20 0.75 0.65 
Cfa.17281.1.S1_s_at POLR1E 
polymerase (RNA) I polypeptide E, 
53kDa Transcription 1.08 1.37 0.77 0.58 
Cfa.14876.1.A1_at MED16 mediator complex subunit 16 Transcription 1.10 0.92 0.87 0.54 
Cfa.16406.1.S1_at GTF2H5 
general transcription factor IIH, 
polypeptide 5 Transcription 1.13 1.31 1.32 1.56 
CfaAffx.22988.1.S1_at MLX MAX-like protein X Transcription 1.15 1.35 0.85 0.60 
Cfa.20352.1.S1_at TEAD1 
TEA domain family member 1 
(SV40 transcriptional enhancer 
factor) Transcription 1.16 1.85 1.03 2.91 
CfaAffx.13134.1.S1_at POLR3G 
polymerase (RNA) III (DNA 
directed) polypeptide G (32kD) Transcription 1.21 1.42 0.98 2.88 
CfaAffx.29880.1.S1_s_at EDF1 
endothelial differentiation-related 
factor 1 Transcription 1.23 1.28 1.02 0.67 
CfaAffx.22988.1.S1_s_at MLX MAX-like protein X Transcription 1.23 1.46 0.91 0.67 
Cfa.2271.1.S1_at WWTR1 
WW domain containing 
transcription regulator 1 Transcription 1.25 1.16 1.07 2.50 
CfaAffx.6677.1.S1_at ZXDC ZXD family zinc finger C Transcription 1.27 1.63 1.23 0.87 
CfaAffx.13134.1.S1_x_at POLR3G 
polymerase (RNA) III (DNA 
directed) polypeptide G (32kD) Transcription 1.28 1.44 0.88 2.76 
CfaAffx.26936.1.S1_at PIAS2 
protein inhibitor of activated STAT, 
2 Transcription 1.30 2.03 1.89 3.23 
CfaAffx.20099.1.S1_s_at 
LOC4866
69 
H2A histone family, member J 
isoform 2 Transcription 1.33 1.11 1.08 0.46 
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Cfa.11131.1.A1_at PCGF3 polycomb group ring finger 3 Transcription 1.34 1.50 1.30 1.60 
CfaAffx.26998.1.S1_at SAP30L SAP30-like Transcription 1.41 1.74 1.05 1.53 
Cfa.749.1.A1_s_at 
MORF4L
1 mortality factor 4 like 1 Transcription 1.44 1.81 1.43 1.99 
CfaAffx.25621.1.S1_at PCGF3 polycomb group ring finger 3 Transcription 1.49 1.93 1.43 1.64 
CfaAffx.7382.1.S1_s_at POLR2D 
polymerase (RNA) II (DNA 
directed) polypeptide D Transcription 1.50 1.61 0.98 0.71 
CfaAffx.15240.1.S1_at HIF1AN 
hypoxia inducible factor 1, alpha 
subunit inhibitor Transcription 1.50 2.10 0.97 0.72 
Cfa.18719.1.S1_at HSBP1 heat shock factor binding protein 1 Transcription 1.50 1.75 1.47 1.45 
Cfa.15390.1.A1_at SETD7 
SET domain containing (lysine 
methyltransferase) 7 Transcription 1.51 1.25 1.45 2.09 
Cfa.3398.1.A1_s_at HMGN3 
high mobility group nucleosomal 
binding domain 3 Transcription 1.78 2.33 2.18 4.09 
CfaAffx.6497.1.S1_at SETD7 
SET domain containing (lysine 
methyltransferase) 7 Transcription 1.80 1.60 1.65 2.82 
Cfa.9171.1.A1_at SIRT5 
sirtuin (silent mating type 
information regulation 2 homolog) 5 
(S. cerevisiae) Transcription 2.07 2.20 1.67 1.64 
CfaAffx.15432.1.S1_s_at SIRT5 
sirtuin (silent mating type 
information regulation 2 homolog) 5 
(S. cerevisiae) Transcription 2.27 2.45 1.75 1.57 
Cfa.21155.1.S1_s_at PTRF 
polymerase I and transcript release 
factor Transcription 2.48 4.62 1.40 1.23 
Cfa.21126.1.S1_s_at EPRS glutamyl-prolyl-tRNA synthetase Translation 0.57 0.20 0.46 2.56 
Cfa.4495.1.A1_at 
MRPS18
A 
mitochondrial ribosomal protein 
S18A Translation 0.61 0.74 0.52 0.41 
CfaAffx.3815.1.S1_at 
MRPS18
A 
mitochondrial ribosomal protein 
S18A Translation 0.62 0.79 0.44 0.32 
CfaAffx.3815.1.S1_s_at 
MRPS18
A 
mitochondrial ribosomal protein 
S18A Translation 0.66 0.81 0.53 0.40 
Cfa.222.1.S1_s_at EPRS glutamyl-prolyl-tRNA synthetase Translation 0.75 0.25 0.82 1.64 
Cfa.18802.1.S1_s_at MRPL38 mitochondrial ribosomal protein Translation 0.80 0.98 0.64 0.51 
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L38 
Cfa.16750.1.S1_at EIF3A 
eukaryotic translation initiation 
factor 3, subunit A Translation 0.82 0.43 0.65 1.07 
Cfa.2263.1.A1_s_at DHX29 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 29 Translation 0.83 0.36 0.74 1.76 
CfaAffx.7986.1.S1_s_at ICT1 
immature colon carcinoma transcript 
1 Translation 0.83 1.13 0.72 0.56 
Cfa.795.1.A1_s_at RPL12 ribosomal protein L12 Translation 0.83 0.88 0.81 0.68 
CfaAffx.28280.1.S1_s_at FAU 
Finkel-Biskis-Reilly murine 
sarcoma virus (FBR-MuSV) 
ubiquitously expressed Translation 0.84 0.93 0.89 0.63 
Cfa.10645.1.S1_at RPL18A ribosomal protein L18a Translation 0.84 0.85 0.85 0.68 
Cfa.223.1.S1_at EIF3G 
eukaryotic translation initiation 
factor 3, subunit G Translation 0.84 0.99 0.73 0.56 
Cfa.14861.1.A1_s_at MRPL38 
mitochondrial ribosomal protein 
L38 Translation 0.85 0.97 0.73 0.54 
Cfa.14440.1.A1_at 
LOC4807
91 ribosomal protein S15a Translation 0.85 0.91 0.68 0.56 
CfaAffx.7985.1.S1_s_at ICT1 
immature colon carcinoma transcript 
1 Translation 0.85 1.11 0.77 0.55 
Cfa.18612.1.S1_at GATC 
glutamyl-tRNA(Gln) 
amidotransferase, subunit C 
homolog (bacterial) Translation 0.86 1.01 0.84 0.68 
CfaAffx.27415.1.S1_s_at EIF3G 
eukaryotic translation initiation 
factor 3, subunit G Translation 0.87 1.02 0.78 0.67 
Cfa.10201.2.S1_a_at RPL22 ribosomal protein L22 Translation 0.87 0.87 0.71 0.36 
CfaAffx.936.1.S1_at MRP63 mitochondrial ribosomal protein 63 Translation 0.88 1.20 0.76 0.54 
CfaAffx.16117.1.S1_s_at GATC 
glutamyl-tRNA(Gln) 
amidotransferase, subunit C 
homolog (bacterial) Translation 0.90 1.07 0.89 0.66 
Cfa.21459.1.S1_at RPLP1 ribosomal protein, large, P1 Translation 0.90 0.95 0.82 0.47 
Cfa.21459.1.S1_x_at RPLP1 ribosomal protein, large, P1 Translation 0.91 0.98 0.86 0.58 
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CfaAffx.18668.1.S1_s_at EIF4H 
eukaryotic translation initiation 
factor 4H Translation 0.92 1.14 0.91 0.57 
Cfa.4594.1.A1_x_at 
LOC4784
79 60S ribosomal protein L7a Translation 0.93 1.17 0.84 0.59 
CfaAffx.1572.1.S1_s_at 
MRPS18
B 
mitochondrial ribosomal protein 
S18B Translation 0.93 1.07 0.83 0.56 
CfaAffx.1572.1.S1_at 
MRPS18
B 
mitochondrial ribosomal protein 
S18B Translation 0.94 1.06 0.79 0.52 
Cfa.5875.2.A1_s_at MRPL22 
mitochondrial ribosomal protein 
L22 Translation 0.95 1.07 0.88 0.65 
CfaAffx.17037.1.S1_s_at EPRS glutamyl-prolyl-tRNA synthetase Translation 1.01 0.51 0.90 1.44 
Cfa.704.1.S1_at RPL35A ribosomal protein L35a Translation 1.08 1.37 0.96 0.69 
Cfa.9625.1.A1_s_at EPRS glutamyl-prolyl-tRNA synthetase Translation 1.08 0.25 0.83 1.62 
CfaAffx.16721.1.S1_s_at EIF3I 
eukaryotic translation initiation 
factor 3, subunit I Translation 1.12 1.22 0.90 0.65 
CfaAffx.16806.1.S1_at MRPL21 
mitochondrial ribosomal protein 
L21 Translation 1.13 1.17 0.99 0.61 
CfaAffx.12225.1.S1_x_at RPS29 ribosomal protein S29 Translation 1.16 1.54 1.01 0.83 
Cfa.1325.1.S1_s_at EPRS glutamyl-prolyl-tRNA synthetase Translation 1.17 1.18 0.94 0.65 
Cfa.3930.1.A1_at 
LOC4745
13 
eukaryotic translation initiation 
factor 3 subunit 6 interacting protein Translation 1.18 1.35 1.03 0.90 
CfaAffx.19863.1.S1_at MRPL9 mitochondrial ribosomal protein L9 Translation 1.19 1.30 0.95 0.68 
Cfa.1325.1.S1_at EPRS glutamyl-prolyl-tRNA synthetase Translation 1.23 1.27 1.00 0.62 
Cfa.15082.1.S1_s_at MRPL27 
mitochondrial ribosomal protein 
L27 Translation 1.24 1.46 1.16 0.72 
CfaAffx.24540.1.S1_x_at 
LOC4918
83 RNA binding motif protein 3 Translation 1.24 2.64 1.50 2.36 
Cfa.21102.1.S1_s_at EIF2B1 
eukaryotic translation initiation 
factor 2B, subunit 1 alpha, 26kDa Translation 1.36 1.75 1.04 0.99 
CfaAffx.10222.1.S1_at 
EIF4EBP
1 
eukaryotic translation initiation 
factor 4E binding protein 1 Translation 1.36 1.49 0.73 0.61 
Cfa.3792.1.A1_at SRP14 
signal recognition particle 14kDa 
(homologous Alu RNA binding Translation 1.39 1.48 1.42 1.23 
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protein) 
CfaAffx.12030.1.S1_at EIF2B1 
eukaryotic translation initiation 
factor 2B, subunit 1 alpha, 26kDa Translation 1.42 1.52 1.03 1.07 
CfaAffx.11089.1.S1_s_at SRP14 
signal recognition particle 14kDa 
(homologous Alu RNA binding 
protein) Translation 1.55 1.90 1.40 1.03 
CfaAffx.242.1.S1_s_at 
LOC4756
85 CG14903-PA Translation 1.72 2.14 1.29 0.94 
Cfa.5360.1.A1_at ANO3 anoctamin 3 Transport 0.26 0.22 0.19 0.17 
Cfa.15606.1.A1_s_at DOPEY1 dopey family member 1 Transport 0.47 0.27 0.45 0.57 
Cfa.4754.1.A1_s_at ABCA6 
ATP-binding cassette, sub-family A 
(ABC1), member 6 Transport 0.47 0.29 0.66 0.63 
CfaAffx.13523.1.S1_at SDAD1 SDA1 domain containing 1 Transport 0.51 0.18 0.45 1.47 
Cfa.4754.1.A1_at ABCA6 
ATP-binding cassette, sub-family A 
(ABC1), member 6 Transport 0.53 0.36 0.70 0.67 
Cfa.9228.1.A1_at SDAD1 SDA1 domain containing 1 Transport 0.53 0.23 0.52 1.00 
Cfa.3039.1.A2_at ATP1A1 
ATPase, Na+/K+ transporting, alpha 
1 polypeptide Transport 0.54 0.59 0.60 0.61 
CfaAffx.7739.1.S1_at 
SLC25A3
0 solute carrier family 25, member 30 Transport 0.55 0.86 0.31 0.46 
Cfa.10789.1.A1_s_at ABCA5 
ATP-binding cassette, sub-family A 
(ABC1), member 5 Transport 0.56 0.29 0.53 1.29 
Cfa.9228.1.A1_s_at SDAD1 SDA1 domain containing 1 Transport 0.57 0.21 0.58 1.29 
CfaAffx.5344.1.S1_at SLC4A4 
solute carrier family 4, sodium 
bicarbonate cotransporter, member 4 Transport 0.61 0.68 1.68 2.12 
Cfa.10962.1.A1_at STX16 syntaxin 16 Transport 0.62 0.62 1.01 1.09 
Cfa.10537.1.A1_at COG1 
component of oligomeric golgi 
complex 1 Transport 0.63 0.56 0.94 0.80 
Cfa.4112.1.S1_at AFTPH aftiphilin Transport 0.63 0.49 0.73 0.94 
CfaAffx.17086.1.S1_at ABCA9 
ATP-binding cassette, sub-family A 
(ABC1), member 9 Transport 0.63 0.38 0.95 0.66 
Cfa.1421.1.S1_at XPO1 exportin 1 (CRM1 homolog, yeast) Transport 0.64 0.38 0.81 1.01 
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Cfa.8017.1.A1_at HOOK2 hook homolog 2 (Drosophila) Transport 0.65 0.58 0.40 0.14 
Cfa.31.1.S1_s_at ANP32A 
acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member 
A Transport 0.66 1.10 0.86 2.89 
CfaAffx.28389.1.S1_s_at SGIP1 
SH3-domain GRB2-like 
(endophilin) interacting protein 1 Transport 0.66 0.21 0.85 1.79 
Cfa.5764.2.S1_s_at KIF5A kinesin family member 5A Transport 0.66 0.43 0.93 1.27 
Cfa.19362.1.S1_at STX12 syntaxin 12 Transport 0.66 0.88 0.58 0.53 
Cfa.10280.1.S1_at STX16 syntaxin 16 Transport 0.68 0.66 1.03 1.26 
Cfa.1729.1.A1_at STX12 syntaxin 12 Transport 0.68 0.79 0.60 0.55 
Cfa.3424.1.S1_at CCDC91 coiled-coil domain containing 91 Transport 0.68 0.36 0.59 1.69 
Cfa.17716.1.S1_s_at TMED5 
transmembrane emp24 protein 
transport domain containing 5 Transport 0.71 0.61 0.44 0.62 
CfaAffx.17010.1.S1_s_at ABCA8 
ATP-binding cassette, sub-family A 
(ABC1), member 8 Transport 0.72 0.40 0.85 0.64 
Cfa.12906.1.A1_s_at SLC39A8 
solute carrier family 39 (zinc 
transporter), member 8 Transport 0.73 0.72 0.69 0.48 
Cfa.2895.1.S1_at CSE1L 
CSE1 chromosome segregation 1-
like (yeast) Transport 0.73 0.37 0.79 1.06 
CfaAffx.4662.1.S1_s_at LRPPRC leucine-rich PPR-motif containing Transport 0.77 0.26 0.53 1.24 
Cfa.9711.1.A1_at STXBP5 
syntaxin binding protein 5 
(tomosyn) Transport 0.80 0.28 0.79 1.72 
CfaAffx.18629.1.S1_s_at 
RAB11FI
P2 
RAB11 family interacting protein 2 
(class I) Transport 0.83 0.33 0.83 1.53 
CfaAffx.21206.1.S1_s_at TPR 
translocated promoter region (to 
activated MET oncogene) Transport 0.88 0.36 0.75 0.80 
Cfa.5370.1.A1_s_at KPNB1 karyopherin (importin) beta 1 Transport 0.88 0.57 1.04 1.78 
Cfa.15237.2.S1_x_at GOLIM4 golgi integral membrane protein 4 Transport 0.89 0.76 0.76 1.85 
Cfa.10588.1.A1_at 
RAB11FI
P2 
RAB11 family interacting protein 2 
(class I) Transport 0.89 0.39 0.82 1.23 
Cfa.1429.1.S1_at SEC62 SEC62 homolog (S. cerevisiae) Transport 0.89 0.42 0.77 1.59 
CfaAffx.15878.1.S1_s_at SLC39 
solute carier family 39 (zinc 
transporter), member 10 Transport 0.90 0.22 1.41 1.78 
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CfaAffx.21206.1.S1_at TPR 
translocated promoter region (to 
activated MET oncogene) Transport 0.91 0.39 0.73 0.61 
Cfa.3946.2.S1_a_at SLC39 
solute carrier family 39 (zinc 
transporter), member 10 Transport 0.91 0.31 1.24 1.15 
CfaAffx.17850.1.S1_at PITPNC1 
phosphatidylinositol transfer 
protein, cytoplasmic 1 Transport 0.93 1.17 0.92 2.08 
Cfa.3804.1.S1_s_at SRP72 signal recognition particle 72kDa Transport 0.94 0.41 0.83 1.15 
Cfa.2073.1.S1_at SEC63 SEC63 homolog (S. cerevisiae) Transport 0.95 0.54 0.80 1.95 
Cfa.226.1.A1_at ATP2C1 
ATPase, Ca++ transporting, type 
2C, member 1 Transport 0.95 0.69 0.80 1.91 
CfaAffx.123.1.S1_at 
TRAPPC
5 
trafficking protein particle complex 
5 Transport 0.95 1.06 0.99 0.52 
Cfa.3810.1.S1_at SRP54 signal recognition particle 54kDa Transport 0.95 0.53 1.02 2.14 
Cfa.8566.2.S1_at 
SLC25A2
6 solute carrier family 25, member 26 Transport 0.96 1.43 0.41 0.27 
CfaAffx.12090.1.S1_at 
SNRNP3
5 
small nuclear ribonucleoprotein 
35kDa (U11/U12) Transport 0.97 1.21 1.00 0.64 
CfaAffx.27024.1.S1_s_at CLTC clathrin, heavy chain (Hc) Transport 0.99 0.43 1.09 1.44 
CfaAffx.9180.1.S1_s_at KCNE3 
potassium voltage-gated channel, 
Isk-related family, member 3 Transport 1.01 1.59 1.38 0.84 
Cfa.1346.1.A1_at VPS4A 
vacuolar protein sorting 4 homolog 
A (S. cerevisiae) Transport 1.02 1.15 0.79 0.56 
CfaAffx.30724.1.S1_s_at 
GABAR
APL2 
GABA(A) receptor-associated 
protein-like 2 Transport 1.03 1.20 1.08 0.76 
CfaAffx.31149.1.S1_at NUTF2 nuclear transport factor 2 Transport 1.04 1.05 0.89 0.63 
Cfa.2131.1.S1_at SNX3 sorting nexin 3 Transport 1.05 1.06 1.35 1.33 
Cfa.2091.1.S1_at SNX4 sorting nexin 4 Transport 1.07 0.56 0.96 1.84 
CfaAffx.12315.1.S1_at 
SLC25A3
6 solute carrier family 25, member 36 Transport 1.07 0.79 0.80 2.48 
Cfa.15193.1.S1_s_at SNX1 sorting nexin 1 Transport 1.07 1.12 1.12 0.74 
CfaAffx.31064.1.S1_s_at VPS4A 
vacuolar protein sorting 4 homolog 
A (S. cerevisiae) Transport 1.07 1.38 0.76 0.62 
CfaAffx.3454.1.S1_at APOL6 apolipoprotein L, 6 Transport 1.08 1.32 0.89 0.70 
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CfaAffx.14748.1.S1_at SLC40A1 
solute carrier family 40 (iron-
regulated transporter), member 1 Transport 1.09 1.41 2.44 1.05 
Cfa.754.1.S1_at SEC61G Sec61 gamma subunit Transport 1.09 1.39 1.13 1.29 
CfaAffx.6599.1.S1_s_at SNX3 sorting nexin 3 Transport 1.10 1.11 1.38 1.39 
Cfa.2307.1.S1_at MYO5A 
myosin VA (heavy chain 12, 
myoxin) Transport 1.14 0.57 1.32 2.24 
CfaAffx.1725.1.S1_s_at VPS13B 
vacuolar protein sorting 13 homolog 
B (yeast) Transport 1.14 1.00 1.41 1.86 
Cfa.1081.2.S1_at 
ATP6V1
D 
ATPase, H+ transporting, lysosomal 
34kDa, V1 subunit D Transport 1.15 1.16 1.23 1.29 
CfaAffx.12841.1.S1_at SLC9A9 
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 9 Transport 1.16 1.14 2.01 1.11 
CfaAffx.22786.1.S1_at VPS25 
vacuolar protein sorting 25 homolog 
(S. cerevisiae) Transport 1.17 1.07 1.07 0.50 
CfaAffx.22786.1.S1_s_at VPS25 
vacuolar protein sorting 25 homolog 
(S. cerevisiae) Transport 1.18 1.08 1.19 0.54 
Cfa.3802.1.S1_s_at RAB5C 
RAB5C, member RAS oncogene 
family Transport 1.18 1.79 1.45 4.99 
CfaAffx.9384.1.S1_s_at SLC4A7 
solute carrier family 4, sodium 
bicarbonate cotransporter, member 7 Transport 1.21 1.05 1.08 4.04 
Cfa.11730.1.A1_at 
LOC4808
83 
RAB2, member RAS oncogene 
family Transport 1.25 2.73 1.19 2.15 
CfaAffx.25418.1.S1_s_at 
ATP6V0
E1 
ATPase, H+ transporting, lysosomal 
9kDa, V0 subunit e1 Transport 1.25 1.46 1.18 0.92 
CfaAffx.25828.1.S1_at SNF8 
SNF8, ESCRT-II complex subunit, 
homolog (S. cerevisiae) Transport 1.28 1.16 1.12 0.63 
CfaAffx.2950.1.S1_s_at TOMM22 
translocase of outer mitochondrial 
membrane 22 homolog (yeast) Transport 1.30 1.47 1.05 0.76 
Cfa.4588.1.A1_at WIPI1 
WD repeat domain, 
phosphoinositide interacting 1 Transport 1.31 1.55 1.41 1.30 
Cfa.3799.1.A1_s_at LMAN2 lectin, mannose-binding 2 Transport 1.31 1.43 1.03 0.64 
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CfaAffx.14005.1.S1_s_at SSR3 
signal sequence receptor, gamma 
(translocon-associated protein 
gamma) Transport 1.31 1.52 1.36 1.38 
Cfa.21006.2.S1_s_at 
ATP6V0
B 
ATPase, H+ transporting, lysosomal 
21kDa, V0 subunit b Transport 1.32 1.28 1.34 0.79 
CfaAffx.25168.1.S1_at VTI1B 
vesicle transport through interaction 
with t-SNAREs homolog 1B (yeast) Transport 1.32 1.22 1.27 1.08 
CfaAffx.6410.1.S1_s_at 
STARD3
NL STARD3 N-terminal like Transport 1.34 1.69 1.46 1.14 
Cfa.17860.1.S1_s_at ERGIC1 
endoplasmic reticulum-golgi 
intermediate compartment (ERGIC) 
1 Transport 1.37 1.87 0.85 0.87 
Cfa.10602.1.A1_at YKT6 
YKT6 v-SNARE homolog (S. 
cerevisiae) Transport 1.39 1.29 1.49 1.04 
Cfa.7396.1.A1_at 
LOC6090
55 RER1 homolog Transport 1.41 1.66 1.23 0.89 
CfaAffx.23806.1.S1_s_at SLC3A2 
solute carrier family 3 (activators of 
dibasic and neutral amino acid 
transport), member 2 Transport 1.41 1.67 0.64 0.57 
Cfa.9192.1.A1_at MTCH2 
mitochondrial carrier homolog 2 (C. 
elegans) Transport 1.43 1.23 1.12 0.75 
Cfa.18078.1.S1_at RAB5B 
RAB5B, member RAS oncogene 
family Transport 1.45 1.75 0.67 0.58 
Cfa.17656.2.S1_a_at RAB1B 
RAB1B, member RAS oncogene 
family Transport 1.46 2.04 1.32 1.63 
CfaAffx.21620.1.S1_at SNX15 sorting nexin 15 Transport 1.46 1.51 1.31 0.94 
Cfa.3877.1.S1_s_at SEC61A1 
Sec61 alpha 1 subunit (S. 
cerevisiae) Transport 1.50 1.68 1.42 1.29 
CfaAffx.26600.1.S1_at RAB13 
RAB13, member RAS oncogene 
family Transport 1.52 1.48 1.31 0.85 
CfaAffx.29647.1.S1_s_at 
LOC6090
55 RER1 homolog Transport 1.53 1.93 1.25 0.84 
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CfaAffx.13322.1.S1_s_at MTCH2 
mitochondrial carrier homolog 2 (C. 
elegans) Transport 1.53 1.37 1.17 0.85 
CfaAffx.17267.1.S1_at WIPI1 
WD repeat domain, 
phosphoinositide interacting 1 Transport 1.55 2.23 1.42 1.18 
Cfa.10602.1.A1_s_at YKT6 
YKT6 v-SNARE homolog (S. 
cerevisiae) Transport 1.57 1.35 1.57 1.15 
Cfa.3895.1.A1_s_at Sec61b Sec61 beta subunit Transport 1.58 1.76 1.79 1.55 
CfaAffx.29647.1.S1_at 
LOC6090
55 RER1 homolog Transport 1.65 2.08 1.48 0.90 
CfaAffx.23861.1.S1_at 
KCNMB
3 
potassium large conductance 
calcium-activated channel, 
subfamily M beta member 3 Transport 1.65 3.15 1.10 3.35 
CfaAffx.9786.1.S1_s_at RAB1B 
RAB1B, member RAS oncogene 
family Transport 1.65 2.17 1.35 2.10 
CfaAffx.21601.1.S1_s_at TIMM8B 
translocase of inner mitochondrial 
membrane 8 homolog B (yeast) Transport 1.71 1.65 1.30 0.96 
Cfa.3406.1.S1_at ENSA endosulfine alpha Transport 1.75 1.81 1.66 1.80 
Cfa.8135.1.A1_at SORT1 sortilin 1 Transport 1.76 1.82 1.14 1.27 
CfaAffx.12608.1.S1_at SLC43A1 solute carrier family 43, member 1 Transport 1.87 1.74 1.71 0.87 
CfaAffx.9392.1.S1_s_at SLC4A7 
solute carrier family 4, sodium 
bicarbonate cotransporter, member 7 Transport 1.90 0.90 1.97 8.02 
Cfa.2217.1.A1_at TF transferrin Transport 2.03 1.46 2.34 0.65 
Cfa.2646.1.S1_at KDELR3 
KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum protein 
retention receptor 3 Transport 2.05 1.92 2.28 1.68 
CfaAffx.30350.1.S1_at SORT1 sortilin 1 Transport 2.20 2.09 1.43 1.25 
Cfa.6638.1.A1_at ABCB6 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 6 Transport 2.30 2.09 1.70 1.30 
Cfa.16809.1.S1_at SLC41A2 solute carrier family 41, member 2 Transport 2.43 1.61 2.78 4.16 
Cfa.20974.1.S1_at COPZ2 
coatomer protein complex, subunit 
zeta 2 Transport 2.49 2.84 2.78 2.62 
CfaAffx.2994.1.S1_s_at KDELR3 
KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum protein Transport 2.53 2.64 2.65 1.66 
  220 
retention receptor 3 
CfaAffx.10883.1.S1_s_at TF transferrin Transport 2.57 1.77 2.69 0.59 
CfaAffx.2291.1.S1_at SLC39A7 
solute carrier family 39 (zinc 
transporter), member 7 Transport 2.66 3.57 2.20 2.09 
CfaAffx.25723.1.S1_s_at COPZ2 
coatomer protein complex, subunit 
zeta 2 Transport 2.75 2.93 2.87 2.58 
CfaAffx.23290.1.S1_s_at ABCB6 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 6 Transport 2.91 2.55 1.90 1.78 
Cfa.18787.1.S1_s_at SLC39A7 
solute carrier family 39 (zinc 
transporter), member 7 Transport 3.14 4.60 2.61 2.39 
CfaAffx.27595.1.S1_at TRPV2 
transient receptor potential cation 
channel, subfamily V, member 2 Transport 3.27 2.33 3.14 2.12 
CfaAffx.28899.1.S1_at SLC9A6 
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 6 Transport 3.42 3.07 2.26 1.26 
Cfa.3.1.S1_s_at SLC46A2 solute carrier family 46, member 2 Transport 5.11 2.21 5.49 1.52 
CfaAffx.30158.1.S1_s_at SLC2A5 
solute carrier family 2 (facilitated 
glucose/fructose transporter), 
member 5 Transport 6.65 1.80 15.42 1.67 
CfaAffx.15696.1.S1_at WARS2 
tryptophanyl tRNA synthetase 2, 
mitochondrial TRNA acylation 1.32 1.82 0.99 0.86 
CfaAffx.14437.1.S1_at Unknown Unknown Unknown 0.06 0.10 0.09 0.06 
Cfa.10658.1.A1_at Unknown Unknown Unknown 0.07 0.07 0.07 0.09 
Cfa.10092.1.A1_at Unknown Unknown Unknown 0.16 0.28 0.13 0.31 
CfaAffx.30683.1.S1_at WDR34 WD repeat domain 34 Unknown 0.20 0.37 0.22 0.26 
Cfa.15087.1.A1_at Unknown Unknown Unknown 0.21 0.49 0.15 0.14 
Cfa.2419.1.S1_at CCDC18 coiled-coil domain containing 18 Unknown 0.25 0.07 0.17 0.80 
CfaAffx.27462.1.S1_at Unknown Unknown Unknown 0.26 0.13 0.18 0.09 
CfaAffx.1190.1.S1_s_at CCDC68 coiled-coil domain containing 68 Unknown 0.27 0.18 0.19 1.21 
Cfa.9535.1.A1_s_at Unknown Unknown Unknown 0.27 0.23 0.21 0.22 
CfaAffx.30843.1.S1_s_at CCDC18 coiled-coil domain containing 18 Unknown 0.27 0.10 0.13 0.65 
Cfa.13980.1.A1_at Unknown Unknown Unknown 0.27 0.27 0.25 0.64 
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CfaAffx.8971.1.S1_at EHD3 EH-domain containing 3 Unknown 0.28 0.49 0.22 0.23 
Cfa.2019.1.A1_at Unknown Unknown Unknown 0.30 0.59 0.25 0.59 
Cfa.11238.1.A1_at Unknown Unknown Unknown 0.30 0.23 1.19 0.28 
Cfa.15999.1.A1_at Unknown Unknown Unknown 0.33 0.18 0.29 0.74 
Cfa.13956.1.A1_at Unknown Unknown Unknown 0.34 1.11 0.46 0.72 
CfaAffx.8675.1.S1_at Unknown Unknown Unknown 0.34 0.27 0.37 0.27 
CfaAffx.28414.1.S1_at Unknown Unknown Unknown 0.35 0.35 0.31 0.49 
Cfa.13656.1.A1_at 
LOC6118
48 hypothetical protein LOC611848 Unknown 0.35 0.55 0.28 0.41 
Cfa.12455.1.A1_at Unknown Unknown Unknown 0.35 0.58 0.22 0.27 
Cfa.8610.1.A1_at Unknown Unknown Unknown 0.36 0.41 0.34 0.32 
CfaAffx.16809.1.S1_at 
ZMYND
8 
zinc finger, MYND-type containing 
8 Unknown 0.36 0.36 0.53 0.75 
Cfa.11775.1.A1_at Unknown Unknown Unknown 0.37 0.66 0.27 0.74 
Cfa.15555.1.A1_at Unknown Unknown Unknown 0.38 0.21 0.66 1.06 
CfaAffx.22840.1.S1_at CAR15 carbonic anhydrase 15 Unknown 0.38 0.15 1.74 0.16 
Cfa.10872.1.A1_at Unknown Unknown Unknown 0.39 0.84 0.47 0.69 
Cfa.15210.1.A1_at Unknown Unknown Unknown 0.39 0.95 0.52 0.65 
CfaAffx.25771.1.S1_at Unknown Unknown Unknown 0.39 0.44 0.23 0.16 
Cfa.9029.1.A1_at Unknown Unknown Unknown 0.40 0.53 0.36 0.44 
Cfa.4978.1.A1_at Unknown Unknown Unknown 0.41 0.80 0.31 0.91 
Cfa.2512.1.S1_at Unknown Unknown Unknown 0.42 0.34 0.50 1.06 
Cfa.19553.1.S1_at Unknown Unknown Unknown 0.42 0.27 0.45 1.59 
Cfa.15618.1.A1_at Unknown Unknown Unknown 0.42 0.76 0.33 0.82 
Cfa.12415.1.A1_at KLP-6 
Kinesin-Like Protein family 
member (klp-6) Unknown 0.42 0.24 0.48 0.87 
Cfa.21327.1.S1_at 
LOC4816
74 alpha-2u globulin PGCL4 Unknown 0.42 0.42 0.47 1.56 
Cfa.5310.1.A1_at Unknown Unknown Unknown 0.43 0.42 0.50 0.28 
Cfa.10375.1.A1_at Unknown Unknown Unknown 0.43 0.72 0.40 0.44 
Cfa.10375.2.A1_at Unknown Unknown Unknown 0.43 0.70 0.42 0.58 
CfaAffx.25758.1.S1_s_at Unknown Unknown Unknown 0.43 0.59 0.27 0.16 
Cfa.7204.2.A1_at Unknown Unknown Unknown 0.44 0.30 0.65 0.81 
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Cfa.9754.1.A1_at Unknown Unknown Unknown 0.44 0.28 0.29 0.53 
Cfa.11071.1.A1_at MAGEE2 melanoma antigen family E, 2 Unknown 0.44 0.50 0.49 0.59 
Cfa.14477.1.A1_at Unknown Unknown Unknown 0.44 0.29 0.43 0.15 
CfaAffx.1189.1.S1_at CCDC68 coiled-coil domain containing 68 Unknown 0.44 0.30 0.19 1.18 
Cfa.5104.1.A1_at Unknown Unknown Unknown 0.45 0.30 0.70 0.63 
CfaAffx.8025.1.S1_at FRMD4A FERM domain containing 4A Unknown 0.45 1.08 0.53 0.94 
Cfa.815.1.S1_at Unknown Unknown Unknown 0.45 0.18 0.60 1.11 
Cfa.6003.1.S1_at Unknown Unknown Unknown 0.46 0.91 0.33 0.38 
Cfa.3959.1.A1_at Unknown Unknown Unknown 0.46 0.30 0.45 0.83 
Cfa.6911.1.A1_at 
LOC4750
30 hypothetical LOC475030 Unknown 0.46 0.49 0.38 0.35 
CfaAffx.3427.1.S1_s_at Unknown Unknown Unknown 0.46 0.68 0.37 0.20 
CfaAffx.5057.1.S1_s_at Unknown Unknown Unknown 0.46 0.25 0.54 2.18 
Cfa.7796.1.A1_at Unknown Unknown Unknown 0.46 0.39 0.46 0.34 
Cfa.2721.1.A1_at Unknown Unknown Unknown 0.46 0.40 0.40 0.99 
Cfa.11492.1.A1_at Unknown Unknown Unknown 0.47 0.57 0.54 0.51 
Cfa.6911.1.A1_s_at 
LOC4750
30 hypothetical LOC475030 Unknown 0.47 0.57 0.42 0.44 
Cfa.2528.1.A1_at Unknown Unknown Unknown 0.47 0.73 0.35 0.43 
CfaAffx.7845.1.S1_s_at Unknown Unknown Unknown 0.47 0.48 0.69 0.66 
Cfa.5168.1.A1_at Unknown Unknown Unknown 0.47 0.85 0.33 0.54 
Cfa.8890.1.A1_at Unknown Unknown Unknown 0.48 0.33 0.64 1.50 
Cfa.1629.1.A1_at DMXL2 Dmx-like 2 Unknown 0.49 0.18 1.21 1.39 
Cfa.924.1.A1_at Unknown Unknown Unknown 0.50 0.13 0.43 1.49 
CfaAffx.25555.1.S1_s_at 
LOC4891
06 hypothetical LOC489106 Unknown 0.50 0.74 0.65 0.88 
CfaAffx.25498.1.S1_at 
LOC6130
08 Mblk1-related protein-1 isoform 1 Unknown 0.50 0.36 0.49 2.26 
CfaAffx.22691.1.S1_at 
CWF19L
2 
CWF19-like 2, cell cycle control (S. 
pombe) Unknown 0.50 0.20 0.39 0.57 
Cfa.1654.1.A1_at Unknown Unknown Unknown 0.50 0.52 0.55 0.86 
Cfa.8885.1.A1_at Unknown Unknown Unknown 0.51 0.47 0.59 0.89 
Cfa.13747.1.A1_at Unknown Unknown Unknown 0.51 0.21 0.91 0.59 
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CfaAffx.14739.1.S1_s_at Unknown Unknown Unknown 0.51 0.28 0.77 1.44 
Cfa.16559.1.A1_at Unknown Unknown Unknown 0.51 0.35 0.64 1.01 
Cfa.11540.1.A1_at Unknown Unknown Unknown 0.51 0.70 0.36 0.37 
Cfa.512.1.A1_at Unknown Unknown Unknown 0.51 0.75 0.42 0.63 
CfaAffx.15933.1.S1_at 
VKORC1
L1 
vitamin K epoxide reductase 
complex, subunit 1-like 1 Unknown 0.51 0.47 0.38 0.39 
Cfa.10157.1.S1_at 
LOC4781
82 NPD014 protein isoform 2 Unknown 0.51 0.51 0.71 1.86 
CfaAffx.20727.1.S1_s_at 
LOC6111
61 protein LOC611161 Unknown 0.51 0.26 0.93 1.88 
Cfa.3324.1.S1_at 
LOC4815
69 Protein C9orf72 homolog Unknown 0.51 0.61 0.44 0.59 
Cfa.14367.1.A1_at Unknown Unknown Unknown 0.52 0.38 1.22 0.85 
Cfa.2836.1.A1_at SFRS18 
splicing factor, arginine/serine-rich 
18 Unknown 0.52 0.19 0.43 1.05 
Cfa.3952.1.S1_at Unknown Unknown Unknown 0.52 0.29 0.45 0.98 
Cfa.11099.1.A1_at Unknown Unknown Unknown 0.52 0.76 0.61 0.57 
CfaAffx.8025.1.S1_s_at FRMD4A FERM domain containing 4A Unknown 0.52 0.92 0.59 0.76 
Cfa.1929.1.S1_at Unknown Unknown Unknown 0.53 0.85 0.78 0.97 
CfaAffx.24307.1.S1_at 
LOC4875
57 CG9005-PA Unknown 0.53 0.29 0.56 1.24 
Cfa.5303.1.A1_at Unknown Unknown Unknown 0.53 0.58 0.66 0.70 
CfaAffx.1769.1.S1_at SHANK3 
SH3 and multiple ankyrin repeat 
domains 3 (Shank3) (Proline-rich 
synapse associated protein 2) 
(ProSAP2) (SPANK-2) Unknown 0.53 0.60 0.69 0.76 
Cfa.122.1.S1_s_at BC3 zinc finger protein 252 Unknown 0.53 0.39 0.57 0.84 
Cfa.1783.1.A1_at Unknown Unknown Unknown 0.53 0.32 0.45 1.17 
Cfa.15540.1.A1_at Unknown Unknown Unknown 0.53 0.29 0.83 0.88 
Cfa.9172.1.S1_s_at 
LOC4788
66 CDC-like kinase 1 isoform 1 Unknown 0.54 0.25 0.66 1.65 
Cfa.2350.1.A1_at Unknown Unknown Unknown 0.54 0.23 0.47 0.54 
Cfa.10462.2.S1_at Unknown Unknown Unknown 0.54 0.94 0.60 0.89 
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Cfa.1695.1.S1_at Unknown Unknown Unknown 0.54 0.37 0.66 0.97 
Cfa.688.1.S1_at Unknown Unknown Unknown 0.54 0.50 0.73 1.55 
Cfa.9708.1.A1_at Unknown Unknown Unknown 0.54 0.38 0.94 1.25 
Cfa.2874.1.A1_at Unknown Unknown Unknown 0.54 0.32 0.48 0.98 
Cfa.9706.1.A1_a_at Unknown Unknown Unknown 0.54 0.40 0.63 1.07 
Cfa.17273.1.S1_s_at 
LOC4875
57 CG9005-PA Unknown 0.55 0.22 0.52 1.19 
CfaAffx.13565.1.S1_at CYYR1 cysteine/tyrosine-rich 1 Unknown 0.55 0.56 0.50 0.92 
Cfa.19575.1.A1_at Unknown Unknown Unknown 0.55 0.59 0.79 1.47 
Cfa.9312.1.A1_at Unknown Unknown Unknown 0.55 0.29 0.66 0.99 
Cfa.1777.1.A1_at Unknown Unknown Unknown 0.55 0.38 0.47 0.83 
Cfa.9399.1.A1_at Unknown Unknown Unknown 0.55 0.28 0.95 1.35 
CfaAffx.10308.1.S1_at CCDC41 coiled-coil domain containing 41 Unknown 0.56 0.14 0.41 1.46 
Cfa.2135.1.A1_at Unknown Unknown Unknown 0.56 0.29 0.39 0.83 
Cfa.2265.1.A1_at Unknown Unknown Unknown 0.56 0.44 0.57 1.26 
CfaAffx.9557.1.S1_at Unknown Unknown Unknown 0.56 0.44 0.67 0.55 
CfaAffx.14377.1.S1_at HELQ helicase, POLQ-like Unknown 0.56 0.32 0.61 1.43 
CfaAffx.23081.1.S1_at GORAB golgin, RAB6-interacting Unknown 0.57 0.37 0.85 2.09 
CfaAffx.10413.1.S1_at Unknown Unknown Unknown 0.57 0.46 0.90 1.32 
Cfa.605.1.S1_at Unknown Unknown Unknown 0.57 0.39 0.97 1.66 
Cfa.6429.1.A1_at Unknown Unknown Unknown 0.57 0.36 0.67 0.91 
Cfa.13476.1.A1_s_at Unknown Unknown Unknown 0.57 0.35 0.65 1.50 
Cfa.532.1.S1_at Unknown Unknown Unknown 0.57 1.31 0.71 0.86 
Cfa.10414.1.A1_at Unknown Unknown Unknown 0.57 0.33 0.80 2.13 
Cfa.20510.1.S1_at Unknown Unknown Unknown 0.58 0.27 0.54 0.79 
Cfa.3005.1.A1_at Unknown Unknown Unknown 0.58 0.34 0.77 1.21 
CfaAffx.28983.1.S1_at CCDC55 coiled-coil domain containing 55 Unknown 0.58 0.24 0.43 0.97 
Cfa.9622.1.A1_at Unknown Unknown Unknown 0.58 0.55 0.48 0.86 
CfaAffx.8023.1.S1_s_at FRMD4A FERM domain containing 4A Unknown 0.59 1.30 0.50 0.86 
Cfa.8563.1.A1_at Unknown Unknown Unknown 0.59 0.40 0.69 0.98 
Cfa.3063.1.S1_s_at ZUFSP 
zinc finger with UFM1-specific 
peptidase domain Unknown 0.59 0.18 0.82 2.12 
Cfa.14838.1.A1_at Unknown Unknown Unknown 0.59 0.39 0.68 0.80 
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Cfa.1286.1.A1_at Unknown Unknown Unknown 0.59 0.82 0.76 1.43 
Cfa.4940.1.A1_at Unknown Unknown Unknown 0.59 0.56 0.49 1.02 
Cfa.8062.1.A1_at Unknown Unknown Unknown 0.59 0.75 0.90 0.70 
Cfa.1943.1.A1_at Unknown Unknown Unknown 0.60 0.22 0.42 0.77 
Cfa.10504.1.S1_s_at 
LOC4783
35 CG30152-PA Unknown 0.60 0.75 0.61 0.65 
Cfa.15163.1.A1_at Unknown Unknown Unknown 0.60 0.57 0.77 2.12 
Cfa.16792.1.A1_at 
RMND5
A 
required for meiotic nuclear division 
5 homolog A (S. cerevisiae) Unknown 0.60 0.74 0.49 0.52 
CfaAffx.8655.1.S1_at FNDC4 
fibronectin type III domain 
containing 4 Unknown 0.60 0.25 0.35 0.23 
Cfa.9479.1.A1_at Unknown Unknown Unknown 0.61 0.20 1.22 1.54 
Cfa.4475.1.A1_at Unknown Unknown Unknown 0.61 1.04 0.55 0.98 
Cfa.16026.1.S1_at Unknown Unknown Unknown 0.61 0.22 0.83 0.71 
Cfa.9048.1.A1_at Unknown Unknown Unknown 0.61 0.35 0.62 0.77 
Cfa.342.1.A1_at 
LOC4776
50 CG6004-PB Unknown 0.61 0.25 0.97 1.16 
CfaAffx.6963.1.S1_at Unknown Unknown Unknown 0.61 0.43 0.57 1.89 
Cfa.15462.1.A1_at Unknown Unknown Unknown 0.61 0.39 0.29 0.20 
Cfa.2486.1.S1_at Unknown Unknown Unknown 0.61 0.33 1.02 0.67 
Cfa.2543.1.S1_at N4BP2L2 NEDD4 binding protein 2-like 2 Unknown 0.62 0.32 0.74 1.13 
Cfa.9343.1.A1_at Unknown Unknown Unknown 0.62 0.47 0.88 1.60 
CfaAffx.6011.1.S1_at Unknown Unknown Unknown 0.62 0.27 0.57 1.43 
Cfa.18839.1.S1_at Unknown Unknown Unknown 0.62 0.48 0.50 0.57 
Cfa.12118.1.A1_at Unknown Unknown Unknown 0.62 0.76 0.61 0.48 
CfaAffx.19999.1.S1_s_at BTNL9 butyrophilin-like 9 Unknown 0.62 0.51 0.37 0.73 
Cfa.9141.1.A1_at Unknown Unknown Unknown 0.62 0.58 0.76 0.76 
Cfa.19541.2.A1_at 
CCDC13
2 coiled-coil domain containing 132 Unknown 0.62 0.20 0.71 1.50 
Cfa.21322.1.A1_at Unknown Unknown Unknown 0.62 0.55 0.66 1.14 
Cfa.2763.1.S1_at Unknown Unknown Unknown 0.63 0.33 0.66 1.01 
Cfa.2353.1.A1_at Unknown Unknown Unknown 0.63 0.38 0.69 1.45 
CfaAffx.27678.1.S1_at LOC4798 CG8202-PA Unknown 0.63 0.59 0.45 0.23 
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25 
Cfa.2482.1.A1_at Unknown Unknown Unknown 0.63 0.37 0.72 1.44 
Cfa.18235.1.S1_at Unknown Unknown Unknown 0.63 0.22 0.77 1.90 
Cfa.15560.1.A1_at Unknown Unknown Unknown 0.63 0.51 0.64 1.05 
Cfa.3940.1.A1_at Unknown Unknown Unknown 0.63 0.36 0.74 0.95 
Cfa.283.1.A1_at RSRC2 arginine/serine-rich coiled-coil 2 Unknown 0.63 0.25 0.54 1.28 
Cfa.15370.1.A1_at Unknown Unknown Unknown 0.63 0.50 0.88 2.70 
Cfa.9644.1.A1_at Unknown Unknown Unknown 0.64 0.44 0.85 0.91 
CfaAffx.19832.1.S1_at TMEM57 transmembrane protein 57 Unknown 0.64 0.74 0.44 0.88 
CfaAffx.28552.1.S1_s_at 
LOC4793
61 hypothetical LOC479361 Unknown 0.64 0.32 0.83 1.30 
Cfa.2908.1.S1_at Unknown Unknown Unknown 0.64 0.48 0.72 0.85 
CfaAffx.21571.1.S1_at KLHL28 kelch-like 28 (Drosophila) Unknown 0.64 0.32 1.07 1.62 
Cfa.11072.1.A1_at Unknown Unknown Unknown 0.64 0.92 0.58 0.49 
Cfa.11254.1.A1_at Unknown Unknown Unknown 0.64 0.58 0.81 1.21 
Cfa.2270.1.A1_at Unknown Unknown Unknown 0.64 0.34 0.61 0.83 
Cfa.10685.1.A1_at Unknown Unknown Unknown 0.64 0.44 0.81 1.01 
Cfa.19467.1.S1_at Unknown Unknown Unknown 0.64 0.46 0.92 1.03 
Cfa.10444.1.A1_at Unknown Unknown Unknown 0.64 0.56 0.92 1.07 
Cfa.10519.2.S1_a_at TDRD3 tudor domain containing 3 Unknown 0.64 0.55 0.29 0.10 
Cfa.2764.1.S1_at Unknown Unknown Unknown 0.64 0.36 0.90 1.31 
Cfa.3388.1.A1_at Unknown Unknown Unknown 0.64 0.38 0.90 1.23 
Cfa.694.1.A1_at Unknown Unknown Unknown 0.65 0.43 0.71 1.10 
Cfa.2791.1.A1_at Unknown Unknown Unknown 0.65 0.18 0.73 1.17 
CfaAffx.6877.1.S1_at 
ANKRD5
0 ankyrin repeat domain 50 Unknown 0.65 0.17 0.70 0.94 
Cfa.9648.1.A1_at 
CWF19L
2 
CWF19-like 2, cell cycle control (S. 
pombe) Unknown 0.65 0.21 0.56 0.83 
Cfa.16304.1.A1_at Unknown Unknown Unknown 0.65 0.22 0.67 1.20 
Cfa.1958.2.A1_at Unknown Unknown Unknown 0.65 0.51 0.89 0.90 
Cfa.504.1.S1_at 
LOC4776
71 CG6454-PB, isoform B Unknown 0.65 0.23 0.73 1.51 
Cfa.1446.1.A1_at Unknown Unknown Unknown 0.65 0.40 0.63 0.84 
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Cfa.10964.1.A1_at Unknown Unknown Unknown 0.65 0.46 1.15 1.27 
Cfa.3390.1.A1_at Unknown Unknown Unknown 0.66 0.86 0.45 0.44 
Cfa.2380.1.A1_at Unknown Unknown Unknown 0.66 0.40 0.61 0.92 
CfaAffx.12588.1.S1_s_at RSRC2 arginine/serine-rich coiled-coil 2 Unknown 0.66 0.25 0.51 1.27 
Cfa.15056.1.A1_at Unknown Unknown Unknown 0.66 0.41 1.00 1.35 
Cfa.15123.1.A1_at Unknown Unknown Unknown 0.66 1.01 0.48 0.32 
Cfa.17088.2.S1_at 
LOC4756
15 
mitochondrial tumor suppressor 1 
isoform 4 Unknown 0.66 0.43 0.73 1.60 
Cfa.11621.1.A1_s_at Unknown Unknown Unknown 0.66 0.25 0.49 1.06 
CfaAffx.1302.1.S1_s_at YTHDC2 YTH domain containing 2 Unknown 0.66 0.34 0.79 1.10 
Cfa.15599.1.A1_at Unknown Unknown Unknown 0.66 0.50 0.82 0.62 
Cfa.21217.1.S1_at Unknown Unknown Unknown 0.66 0.40 1.01 0.93 
Cfa.16922.2.S1_a_at 
LOC4756
15 
mitochondrial tumor suppressor 1 
isoform 4 Unknown 0.66 0.28 0.88 1.00 
Cfa.10428.1.A1_at Unknown Unknown Unknown 0.67 0.23 0.74 2.45 
Cfa.2479.1.S1_at Unknown Unknown Unknown 0.67 0.42 0.69 1.28 
Cfa.1932.1.A1_at Unknown Unknown Unknown 0.67 0.73 0.52 0.63 
Cfa.473.1.A1_at Unknown Unknown Unknown 0.67 0.38 1.04 1.19 
Cfa.5473.1.A1_at Unknown Unknown Unknown 0.67 0.51 0.81 0.88 
Cfa.3102.1.A1_at Unknown Unknown Unknown 0.67 0.29 1.52 1.06 
Cfa.10861.1.A1_at Unknown Unknown Unknown 0.67 0.32 0.64 1.25 
CfaAffx.21268.1.S1_at Unknown Unknown Unknown 0.68 0.65 0.71 0.96 
Cfa.7687.1.A1_s_at Unknown Unknown Unknown 0.68 0.74 0.44 0.54 
CfaAffx.27349.1.S1_at Unknown Unknown Unknown 0.68 0.85 0.57 0.33 
Cfa.1085.1.A1_at Unknown Unknown Unknown 0.68 0.29 0.82 1.76 
Cfa.3063.1.S1_at ZUFSP 
zinc finger with UFM1-specific 
peptidase domain Unknown 0.68 0.31 0.71 1.31 
Cfa.608.1.S1_at Unknown Unknown Unknown 0.68 0.48 0.87 2.18 
Cfa.16752.1.S1_at Unknown Unknown Unknown 0.68 0.18 0.91 1.55 
CfaAffx.3613.1.S1_at Unknown Unknown Unknown 0.68 0.18 1.01 1.41 
Cfa.9663.1.S1_a_at Unknown Unknown Unknown 0.68 0.75 0.65 0.45 
Cfa.9094.1.A1_at Unknown Unknown Unknown 0.68 0.46 0.89 1.36 
CfaAffx.6143.1.S1_at Unknown Unknown Unknown 0.69 0.61 0.73 0.49 
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Cfa.16700.1.S1_at Unknown Unknown Unknown 0.69 0.26 0.79 1.44 
Cfa.7102.1.A1_at Unknown Unknown Unknown 0.69 0.71 0.85 1.54 
Cfa.3387.1.S1_a_at Unknown Unknown Unknown 0.69 0.25 0.70 1.50 
Cfa.13875.1.A1_at Unknown Unknown Unknown 0.70 0.46 1.07 0.92 
Cfa.600.1.S1_at Unknown Unknown Unknown 0.70 0.18 0.75 1.42 
Cfa.16814.1.S1_at Unknown Unknown Unknown 0.70 0.58 0.74 1.12 
Cfa.1673.1.A1_at Unknown Unknown Unknown 0.70 0.30 0.90 1.53 
Cfa.12395.1.A1_at Unknown Unknown Unknown 0.70 0.42 1.01 1.17 
Cfa.17128.1.S1_s_at Unknown Unknown Unknown 0.70 0.40 0.72 1.02 
CfaAffx.21207.1.S1_s_at Unknown Unknown Unknown 0.70 0.30 0.59 1.79 
Cfa.10420.1.A1_at Unknown Unknown Unknown 0.70 0.35 1.29 1.24 
Cfa.2516.1.S1_at 
LOC6129
36 hypothetical LOC612936 Unknown 0.71 0.83 0.91 1.35 
Cfa.2431.1.S1_at Unknown Unknown Unknown 0.71 0.34 0.92 1.46 
Cfa.682.1.A1_at Unknown Unknown Unknown 0.71 0.50 0.87 1.26 
Cfa.4400.1.A1_at Unknown Unknown Unknown 0.71 0.48 1.16 2.07 
Cfa.1946.1.A1_at HMCN1 hemicentin 1 Unknown 0.71 0.27 1.70 1.57 
Cfa.1047.1.A1_at Unknown Unknown Unknown 0.71 0.45 1.23 1.93 
Cfa.15321.1.S1_at Unknown Unknown Unknown 0.71 0.47 0.84 0.84 
Cfa.9339.1.A1_at DOCK11 dedicator of cytokinesis 11 Unknown 0.71 0.28 0.66 1.47 
Cfa.1887.1.A1_at Unknown Unknown Unknown 0.71 0.36 0.71 1.27 
CfaAffx.1905.1.S1_s_at Unknown Unknown Unknown 0.71 0.26 3.88 0.68 
Cfa.19327.1.A1_at Unknown Unknown Unknown 0.71 0.35 0.96 1.60 
Cfa.5610.1.A1_at Unknown Unknown Unknown 0.71 0.36 0.57 0.76 
CfaAffx.14736.1.S1_at Unknown Unknown Unknown 0.71 0.47 0.89 1.09 
Cfa.1938.1.A1_at Unknown Unknown Unknown 0.72 0.35 0.75 1.40 
Cfa.995.1.S1_s_at 
RMND5
A 
required for meiotic nuclear division 
5 homolog A (S. cerevisiae) Unknown 0.72 0.83 0.51 0.47 
Cfa.11075.1.A1_at LGALS8 
lectin, galactoside-binding, soluble, 
8 Unknown 0.72 0.48 1.15 1.58 
Cfa.3067.1.S1_at Unknown Unknown Unknown 0.72 0.40 0.64 0.51 
Cfa.517.1.A1_at Unknown Unknown Unknown 0.72 0.55 0.83 1.73 
Cfa.5021.1.A1_at Unknown Unknown Unknown 0.72 0.71 0.92 1.19 
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CfaAffx.9325.1.S1_at Unknown Unknown Unknown 0.73 0.80 0.95 0.54 
Cfa.545.1.S1_at Unknown Unknown Unknown 0.73 0.33 0.83 1.24 
CfaAffx.11057.1.S1_s_at 
LOC4773
27 RNA polymerase 1-3 isoform 2 Unknown 0.73 0.78 0.65 0.49 
CfaAffx.3798.1.S1_s_at 
LOC4867
57 ribonuclease P Unknown 0.73 0.87 0.65 0.36 
Cfa.5547.1.A1_at Unknown Unknown Unknown 0.73 0.38 1.17 1.16 
Cfa.10641.1.S1_s_at Unknown Unknown Unknown 0.73 0.80 0.89 1.11 
Cfa.4965.1.A1_at Unknown Unknown Unknown 0.73 0.35 0.79 1.48 
Cfa.9880.1.A1_at Unknown Unknown Unknown 0.73 0.44 0.70 1.49 
Cfa.16352.1.S1_at Unknown Unknown Unknown 0.73 0.45 0.81 1.04 
Cfa.5119.1.A1_at Unknown Unknown Unknown 0.73 0.45 1.18 0.91 
Cfa.19585.1.A1_at Unknown Unknown Unknown 0.73 0.48 0.78 1.36 
Cfa.10957.1.A1_at Unknown Unknown Unknown 0.74 0.14 0.54 1.02 
CfaAffx.21778.1.S1_at SESTD1 SEC14 and spectrin domains 1 Unknown 0.74 0.25 1.14 1.52 
Cfa.1184.1.S1_at Unknown Unknown Unknown 0.74 0.53 0.78 1.20 
Cfa.15534.1.A1_at GSE1 genetic suppressor element 1 Unknown 0.74 1.12 0.88 0.73 
Cfa.17118.1.S1_at 
FGFR1O
P2 FGFR1 oncogene partner 2 Unknown 0.74 0.29 0.84 1.13 
Cfa.272.1.A1_at Unknown Unknown Unknown 0.74 0.28 0.86 1.64 
Cfa.360.1.A1_at Unknown Unknown Unknown 0.74 1.10 0.71 1.71 
Cfa.1989.1.A1_at MUC17 mucin 17 Unknown 0.74 0.49 1.00 1.29 
Cfa.14537.1.A1_at Unknown Unknown Unknown 0.74 0.48 0.80 0.60 
Cfa.931.1.A1_at Unknown Unknown Unknown 0.74 0.44 0.82 0.99 
Cfa.12461.1.A1_at Unknown Unknown Unknown 0.74 0.97 0.61 0.59 
CfaAffx.13101.1.S1_s_at TRIM2 tripartite motif protein TRIM2 Unknown 0.75 0.60 1.38 1.76 
Cfa.2021.1.A1_at Unknown Unknown Unknown 0.75 0.42 0.57 0.78 
Cfa.19604.1.S1_at Unknown Unknown Unknown 0.75 0.31 0.61 1.31 
CfaAffx.24693.1.S1_at Unknown Unknown Unknown 0.75 0.48 0.75 1.10 
CfaAffx.21120.1.S1_s_at HMCN1 hemicentin 1 Unknown 0.75 0.27 1.53 0.98 
Cfa.20118.1.S1_s_at 
UHRF1B
P1L UHRF1 binding protein 1-like Unknown 0.75 0.39 0.52 2.82 
Cfa.12732.1.A1_at Unknown Unknown Unknown 0.75 0.44 0.73 0.77 
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Cfa.16353.1.S1_at Unknown Unknown Unknown 0.75 0.38 0.81 1.33 
Cfa.12963.1.A1_at Unknown Unknown Unknown 0.75 0.62 0.95 1.74 
CfaAffx.6704.1.S1_at Unknown Unknown Unknown 0.75 0.46 0.77 2.14 
Cfa.12171.1.A1_at PTCD3 Pentatricopeptide repeat domain 3 Unknown 0.75 0.50 0.72 0.94 
Cfa.10305.1.S1_at Unknown Unknown Unknown 0.75 0.35 0.71 1.53 
Cfa.1118.1.A1_at DOCK9 dedicator of cytokinesis 9 Unknown 0.76 0.34 1.03 1.35 
CfaAffx.7004.1.S1_s_at 
LOC4838
43 CG15133-PA Unknown 0.76 0.31 0.69 0.96 
Cfa.5568.1.A1_at Unknown Unknown Unknown 0.76 0.44 1.02 1.14 
Cfa.10621.1.S1_at Unknown Unknown Unknown 0.76 0.40 0.90 1.12 
CfaAffx.12331.1.S1_s_at Unknown Unknown Unknown 0.76 0.31 0.66 1.23 
Cfa.9563.1.A1_at Unknown Unknown Unknown 0.76 0.79 0.50 0.53 
Cfa.2861.1.S1_at Unknown Unknown Unknown 0.76 0.53 0.83 2.15 
Cfa.9692.1.A1_at Unknown Unknown Unknown 0.76 0.38 0.67 1.82 
Cfa.19431.1.S1_at Unknown Unknown Unknown 0.77 0.37 0.97 1.43 
CfaAffx.20364.1.S1_at Unknown Unknown Unknown 0.77 1.09 0.33 0.62 
Cfa.2346.3.A1_a_at Unknown Unknown Unknown 0.77 0.46 0.57 0.94 
Cfa.2558.1.A1_at Unknown Unknown Unknown 0.77 0.46 1.13 1.33 
Cfa.2882.1.S1_at Unknown Unknown Unknown 0.77 0.41 0.86 1.32 
Cfa.19454.1.S1_at Unknown Unknown Unknown 0.77 0.22 0.75 2.20 
Cfa.2927.1.S1_at Unknown Unknown Unknown 0.78 0.41 2.49 1.03 
Cfa.2075.1.A1_at 
THUMP
D3 THUMP domain containing 3 Unknown 0.78 0.40 0.77 1.21 
Cfa.2084.1.A1_at Unknown Unknown Unknown 0.78 0.54 0.73 1.30 
Cfa.12873.1.A1_at Unknown Unknown Unknown 0.78 0.44 0.76 1.13 
Cfa.16733.1.S1_at Unknown Unknown Unknown 0.78 0.42 0.58 1.02 
Cfa.2306.1.A1_at Unknown Unknown Unknown 0.78 1.19 0.71 1.46 
Cfa.9111.1.A1_at Unknown Unknown Unknown 0.78 0.45 0.89 1.33 
Cfa.9239.1.A1_at Unknown Unknown Unknown 0.78 0.46 0.91 1.49 
Cfa.4072.1.A1_at Unknown Unknown Unknown 0.79 0.43 1.13 2.06 
Cfa.14960.1.S1_at ATG2B 
ATG2 autophagy related 2 homolog 
B (S. cerevisiae) Unknown 0.79 0.41 0.79 1.40 
Cfa.13064.1.A1_at Unknown Unknown Unknown 0.79 0.51 0.79 1.09 
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Cfa.613.1.A1_at Unknown Unknown Unknown 0.79 0.38 1.54 1.96 
Cfa.3072.1.A1_at Unknown Unknown Unknown 0.79 0.36 0.79 1.01 
CfaAffx.3761.1.S1_s_at 
LOC4745
33 CG13957-PA Unknown 0.79 0.16 0.57 1.69 
Cfa.17776.1.S1_at LUC7L2 LUC7-like 2 (S. cerevisiae) Unknown 0.79 0.61 0.99 1.47 
Cfa.9770.1.A1_at Unknown Unknown Unknown 0.79 0.35 0.67 1.55 
Cfa.8906.1.A1_at Unknown Unknown Unknown 0.79 0.46 0.63 0.90 
Cfa.2755.1.A1_at Unknown Unknown Unknown 0.79 0.42 0.96 1.37 
CfaAffx.4415.1.S1_at 
TMEM13
1 transmembrane protein 131 Unknown 0.79 0.47 0.83 1.18 
Cfa.20746.1.S1_at Unknown Unknown Unknown 0.80 0.44 0.80 0.98 
CfaAffx.17782.1.S1_s_at HELZ helicase with zinc finger Unknown 0.80 0.50 0.75 1.15 
Cfa.2749.1.A1_at Unknown Unknown Unknown 0.80 0.66 1.22 2.07 
Cfa.2536.1.A1_at 
LOC4765
80 
retinoblastoma-associated protein 
140 Unknown 0.80 0.37 0.85 1.44 
Cfa.2519.1.A1_at Unknown Unknown Unknown 0.80 0.34 1.02 1.45 
Cfa.10913.1.A1_at Unknown Unknown Unknown 0.80 0.95 0.84 1.54 
Cfa.15214.1.A1_at Unknown Unknown Unknown 0.81 0.44 0.72 1.28 
Cfa.10474.1.S1_at Unknown Unknown Unknown 0.81 0.43 0.89 1.06 
Cfa.520.1.A1_at Unknown Unknown Unknown 0.81 0.53 0.89 1.16 
Cfa.1587.1.A1_s_at Buster3 
transposon-derived Buster3 
transposase-like Unknown 0.81 0.47 1.16 2.18 
Cfa.1382.1.A1_at Unknown Unknown Unknown 0.81 0.46 1.89 0.89 
Cfa.1768.1.A1_at 
LOC4793
61 hypothetical LOC479361 Unknown 0.81 0.35 0.86 1.34 
Cfa.18181.1.S1_at Unknown Unknown Unknown 0.82 0.43 0.93 1.08 
CfaAffx.3601.1.S1_at Unknown Unknown Unknown 0.82 0.43 0.78 2.64 
Cfa.11116.1.S1_at Unknown Unknown Unknown 0.82 0.45 0.85 1.67 
Cfa.15400.1.A1_at Unknown Unknown Unknown 0.82 0.72 1.27 2.10 
Cfa.3371.1.S1_at 
LOC4763
37 D19Bwg1357e protein Unknown 0.82 0.27 0.68 1.06 
Cfa.9444.1.A1_at GORAB golgin, RAB6-interacting Unknown 0.82 0.22 1.24 2.49 
Cfa.1767.1.A1_s_at CENPC1 centromere protein C 1 Unknown 0.82 0.29 0.60 1.78 
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Cfa.10578.1.A1_at Unknown Unknown Unknown 0.82 0.65 0.99 1.36 
CfaAffx.7578.1.S1_at CDADC1 
cytidine and dCMP deaminase 
domain containing 1 Unknown 0.82 0.35 0.78 1.56 
CfaAffx.1905.1.S1_at Unknown Unknown Unknown 0.82 0.39 4.98 0.66 
Cfa.2128.1.S1_at Unknown Unknown Unknown 0.83 0.38 1.10 1.27 
Cfa.3076.1.S1_at ZC3H13 
zinc finger CCCH-type containing 
13 Unknown 0.83 0.39 0.75 1.14 
CfaAffx.8742.1.S1_s_at HYI 
hydroxypyruvate isomerase 
homolog (E. coli) Unknown 0.83 0.89 0.57 0.40 
Cfa.1063.1.S1_at Unknown Unknown Unknown 0.83 0.40 1.02 1.66 
Cfa.8966.1.A1_s_at CEP192 centrosomal protein 192kDa Unknown 0.83 0.32 0.92 1.15 
Cfa.1769.2.A1_at Unknown Unknown Unknown 0.83 0.43 0.59 1.14 
CfaAffx.1657.1.S1_at 
TBC1D1
5 TBC1 domain family, member 15 Unknown 0.83 0.36 0.78 2.30 
CfaAffx.23684.1.S1_s_at 
LOC4803
40 Protein KIAA0586 Unknown 0.83 0.29 0.84 1.05 
CfaAffx.727.1.S1_x_at Unknown Unknown Unknown 0.83 0.92 0.77 0.67 
Cfa.10415.1.A1_at Unknown Unknown Unknown 0.83 0.22 1.58 1.95 
Cfa.2035.1.S1_at Unknown Unknown Unknown 0.84 0.62 0.83 2.05 
CfaAffx.17237.1.S1_x_at Unknown Unknown Unknown 0.84 1.01 0.72 0.55 
Cfa.12874.1.A1_at Unknown Unknown Unknown 0.84 0.55 0.81 1.63 
Cfa.6265.1.A1_s_at BOLA1 bolA homolog 1 (E. coli) Unknown 0.84 0.98 0.75 0.46 
Cfa.2053.2.A1_a_at REEP5 receptor accessory protein 5 Unknown 0.84 0.66 1.03 1.28 
Cfa.9550.1.A1_at Unknown Unknown Unknown 0.84 0.37 0.88 1.75 
Cfa.16544.1.A1_at Unknown Unknown Unknown 0.85 0.46 1.06 2.78 
Cfa.19536.1.S1_at Unknown Unknown Unknown 0.85 0.30 0.85 1.28 
CfaAffx.4158.1.S1_at 
LOC4752
37 hypothetical LOC475237 Unknown 0.85 1.13 0.77 0.63 
Cfa.9889.1.A1_at Unknown Unknown Unknown 0.85 0.46 0.94 1.55 
Cfa.5189.1.A1_at PHF20L1 PHD finger protein 20-like 1 Unknown 0.85 0.57 0.79 1.81 
Cfa.1473.1.A1_at Unknown Unknown Unknown 0.85 0.39 0.73 1.07 
Cfa.6384.1.A1_s_at MUC17 mucin 17 Unknown 0.85 0.51 1.03 1.23 
Cfa.4482.1.S1_at Unknown Unknown Unknown 0.86 0.26 0.77 0.82 
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CfaAffx.8726.1.S1_s_at HYI 
hydroxypyruvate isomerase 
homolog (E. coli) Unknown 0.86 0.96 0.53 0.31 
Cfa.2818.1.A1_at Unknown Unknown Unknown 0.86 0.71 1.19 1.43 
CfaAffx.3929.1.S1_at SAMD9L 
sterile alpha motif domain 
containing 9-like Unknown 0.86 0.17 1.13 1.17 
Cfa.217.1.S1_s_at TCTE1L 
t-complex-associated-testis-
expressed 1-like Unknown 0.87 0.34 0.75 2.66 
Cfa.1359.1.S1_at PLS3 plastin 3 (T isoform) Unknown 0.87 0.57 1.21 1.48 
Cfa.3336.1.A1_at Unknown Unknown Unknown 0.87 0.61 1.09 1.73 
Cfa.20039.1.S1_at Unknown Unknown Unknown 0.87 0.37 1.09 1.58 
Cfa.19538.1.S1_at DDX26B 
DEAD/H (Asp-Glu-Ala-Asp/His) 
box polypeptide 26B Unknown 0.87 0.30 1.47 2.23 
Cfa.3371.1.S1_s_at 
LOC4763
37 D19Bwg1357e protein Unknown 0.88 0.37 0.68 1.17 
Cfa.14852.1.A1_at Unknown Unknown Unknown 0.88 0.49 1.15 2.39 
Cfa.10312.1.A1_at Unknown Unknown Unknown 0.88 0.88 0.86 2.14 
Cfa.1760.1.A1_at Unknown Unknown Unknown 0.88 0.42 1.09 1.45 
Cfa.9122.1.A1_at Unknown Unknown Unknown 0.88 0.63 0.80 1.63 
Cfa.2716.1.A1_at Unknown Unknown Unknown 0.88 0.79 1.04 2.56 
CfaAffx.7425.1.S1_s_at Unknown Unknown Unknown 0.88 1.28 0.84 0.42 
CfaAffx.2564.1.S1_at Unknown Unknown Unknown 0.88 0.97 1.01 2.36 
Cfa.11109.1.A1_at Unknown Unknown Unknown 0.88 0.73 0.98 1.67 
Cfa.1812.1.A1_at Unknown Unknown Unknown 0.88 0.44 1.04 1.17 
CfaAffx.11721.1.S1_s_at Unknown Unknown Unknown 0.89 0.73 2.71 1.23 
CfaAffx.5223.1.S1_s_at SMEK2 
SMEK homolog 2, suppressor of 
mek1 (Dictyostelium) Unknown 0.89 0.28 0.74 2.51 
Cfa.1554.1.A1_at WDR47 WD repeat domain 47 Unknown 0.89 0.42 0.79 1.47 
CfaAffx.18289.1.S1_at OFD1 oral-facial-digital syndrome 1 Unknown 0.90 0.33 0.75 1.03 
Cfa.9354.1.A1_at 
LOC4780
15 
retinoblastoma-associated protein 
140 Unknown 0.90 0.56 1.12 1.27 
CfaAffx.31123.1.S1_at DDX28 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 28 Unknown 0.90 0.93 0.71 0.40 
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Cfa.14779.1.S1_at NF1-B 
Nuclear factor 1 B-type (Nuclear 
factor 1/B) (NF1-B) (NFI-B) (NF-
I/B) (CCAAT-box binding 
transcription factor) (CTF) 
(TGGCA-binding protein) Unknown 0.90 0.66 1.13 1.96 
Cfa.5832.2.S1_a_at Unknown Unknown Unknown 0.90 0.88 1.07 2.56 
Cfa.16195.1.S1_at Unknown Unknown Unknown 0.91 0.53 0.91 1.83 
Cfa.1250.1.S1_at Unknown Unknown Unknown 0.91 0.73 0.91 1.44 
CfaAffx.13722.1.S1_at Unknown Unknown Unknown 0.91 0.92 0.91 0.72 
Cfa.11656.1.A1_s_at STOML2 stomatin (EPB72)-like 2 Unknown 0.91 0.92 0.76 0.43 
Cfa.12899.1.A1_at Unknown Unknown Unknown 0.91 0.66 1.11 1.79 
CfaAffx.31101.1.S1_at SPATA1 spermatogenesis associated 1 Unknown 0.91 0.47 0.91 3.00 
Cfa.12811.1.A1_at Unknown Unknown Unknown 0.91 0.57 0.32 0.20 
Cfa.347.1.S1_at 
CTDSPL
2 
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide A) 
small phosphatase like 2 Unknown 0.91 0.37 0.85 1.85 
Cfa.17872.1.S1_at Unknown Unknown Unknown 0.91 0.58 0.87 1.49 
CfaAffx.4452.1.S1_at 
ANKRD3
9 ankyrin repeat domain 39 Unknown 0.91 1.08 0.77 0.54 
CfaAffx.10419.1.S1_s_at 
DNAJC1
3 
DnaJ (Hsp40) homolog, subfamily 
C, member 13 Unknown 0.92 0.24 1.05 1.69 
CfaAffx.5602.1.S1_s_at EHBP1 EH domain binding protein 1 Unknown 0.93 0.38 0.80 2.11 
Cfa.10579.1.A1_at Unknown Unknown Unknown 0.93 0.74 0.97 1.32 
CfaAffx.9661.1.S1_s_at ANKHD1 
ankyrin repeat and KH domain 
containing 1 Unknown 0.93 0.66 0.77 0.85 
Cfa.9814.1.A1_at Unknown Unknown Unknown 0.93 0.61 0.85 1.33 
Cfa.18023.1.S1_s_at 
LOC6118
31 hypothetical protein LOC611831 Unknown 0.93 0.72 0.90 0.45 
Cfa.20291.1.S1_at Unknown Unknown Unknown 0.94 0.35 1.31 1.74 
Cfa.2687.1.A1_at Unknown Unknown Unknown 0.94 0.29 0.78 2.16 
Cfa.10711.1.A1_at Unknown Unknown Unknown 0.95 0.43 0.83 1.25 
Cfa.10853.1.A1_at Unknown Unknown Unknown 0.95 0.26 0.92 1.56 
CfaAffx.24437.1.S1_s_at LOC4792 granule cell antiserum positive 14 Unknown 0.95 0.67 0.83 2.28 
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68 
Cfa.5968.1.A1_at Unknown Unknown Unknown 0.95 0.52 1.05 1.65 
Cfa.15208.1.A1_at Unknown Unknown Unknown 0.96 1.08 1.10 1.81 
Cfa.7942.1.A1_at Unknown Unknown Unknown 0.96 0.48 0.95 1.33 
CfaAffx.4869.1.S1_s_at Unknown Unknown Unknown 0.96 1.12 0.87 0.66 
CfaAffx.448.1.S1_x_at Unknown Unknown Unknown 0.96 0.84 0.93 1.07 
CfaAffx.5668.1.S1_s_at AVL9 AVL9 homolog (S. cerevisiase) Unknown 0.97 1.24 1.05 1.55 
Cfa.14735.1.A1_at Unknown Unknown Unknown 0.97 1.07 1.02 0.67 
Cfa.15578.1.A1_at Unknown Unknown Unknown 0.97 0.65 1.11 1.86 
Cfa.434.1.S1_at Unknown Unknown Unknown 0.97 0.68 0.85 3.01 
CfaAffx.5687.1.S1_s_at Unknown Unknown Unknown 0.98 1.10 0.84 0.68 
CfaAffx.10461.1.S1_at 
DNAJC1
3 
DnaJ (Hsp40) homolog, subfamily 
C, member 13 Unknown 0.98 0.45 1.04 1.43 
Cfa.1736.1.S1_at 
TMEM18
9-
UBE2V1 
TMEM189-UBE2V1 readthrough 
transcript Unknown 0.98 0.43 0.68 1.73 
Cfa.15360.1.A1_at Unknown Unknown Unknown 0.98 1.59 1.30 1.75 
CfaAffx.892.1.S1_at 
LOC6097
47 hypothetical protein LOC609747 Unknown 0.98 1.07 0.93 0.51 
Cfa.9501.1.A1_at Unknown Unknown Unknown 0.98 0.72 0.86 2.09 
Cfa.2108.1.A1_at Unknown Unknown Unknown 0.98 0.27 0.90 1.83 
CfaAffx.28438.1.S1_at Unknown Unknown Unknown 0.99 0.71 1.07 2.05 
CfaAffx.26385.1.S1_at 
LOC4767
03 UPF0139 protein CGI-140 Unknown 0.99 0.96 1.10 0.49 
Cfa.2513.1.A1_s_at 
LOC6123
96 
ubiquitin specific protease 9, X-
linked isoform 2 Unknown 0.99 0.53 0.86 1.14 
Cfa.9520.1.A1_at Unknown Unknown Unknown 0.99 0.86 1.19 1.68 
Cfa.12830.1.A1_at Unknown Unknown Unknown 0.99 0.49 1.25 0.94 
Cfa.2499.1.S1_at Unknown Unknown Unknown 0.99 0.83 0.87 1.87 
Cfa.1008.1.A1_s_at Unknown Unknown Unknown 0.99 0.50 1.09 1.54 
CfaAffx.19712.1.S1_at Unknown Unknown Unknown 1.00 1.46 1.03 1.83 
Cfa.2015.1.A1_at Unknown Unknown Unknown 1.00 0.55 1.43 1.89 
CfaAffx.11394.1.S1_s_at Unknown Unknown Unknown 1.01 1.33 0.83 0.65 
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Cfa.406.1.S1_at Unknown Unknown Unknown 1.01 0.58 0.94 1.14 
Cfa.3064.1.A1_at Unknown Unknown Unknown 1.01 0.62 0.82 0.45 
CfaAffx.15531.1.S1_s_at GDAP2 
ganglioside induced differentiation 
associated protein 2 Unknown 1.01 0.78 1.25 1.15 
Cfa.8830.1.A1_a_at 
LOC4798
25 CG8202-PA Unknown 1.02 0.84 0.88 0.51 
Cfa.10542.1.S1_at UBAP1 ubiquitin associated protein 1 Unknown 1.02 1.70 0.86 0.66 
Cfa.1441.1.S1_at Unknown Unknown Unknown 1.02 0.39 1.37 1.21 
Cfa.11354.1.A1_s_at Unknown Unknown Unknown 1.02 1.01 1.06 0.76 
Cfa.3231.1.S1_at CCDC56 coiled-coil domain containing 56 Unknown 1.03 1.07 0.92 0.57 
Cfa.4689.1.A1_at Unknown Unknown Unknown 1.03 1.49 1.26 1.22 
Cfa.19444.1.S1_at Unknown Unknown Unknown 1.04 0.36 1.16 1.80 
Cfa.9779.1.A1_at Unknown Unknown Unknown 1.05 0.45 1.07 1.63 
Cfa.13504.1.A1_at Unknown Unknown Unknown 1.06 1.67 1.32 2.50 
Cfa.1161.1.S1_at Unknown Unknown Unknown 1.06 0.53 0.87 2.07 
CfaAffx.27494.1.S1_at MORC4 
MORC family CW-type zinc finger 
4 Unknown 1.06 1.00 1.11 1.52 
Cfa.1657.1.S1_at Unknown Unknown Unknown 1.06 0.69 1.06 2.82 
Cfa.2523.1.S1_at Unknown Unknown Unknown 1.07 0.32 3.74 1.19 
Cfa.4869.1.A1_s_at 
TMEM14
7 transmembrane protein 147 Unknown 1.09 0.94 1.07 0.59 
Cfa.10442.1.A1_at Unknown Unknown Unknown 1.09 0.22 1.27 2.01 
Cfa.12423.2.A1_at CBWD2 COBW domain containing 2 Unknown 1.09 1.38 1.18 1.90 
Cfa.9952.1.A1_at Unknown Unknown Unknown 1.09 1.56 0.97 2.13 
Cfa.11409.1.S1_s_at 
LOC4775
69 hypothetical LOC477569 Unknown 1.10 1.11 1.01 0.54 
Cfa.2549.1.A1_s_at Unknown Unknown Unknown 1.10 1.19 1.18 0.79 
CfaAffx.7333.1.S1_at Unknown Unknown Unknown 1.12 0.30 4.87 0.81 
CfaAffx.7724.1.S1_at 
TMEM12
6B transmembrane protein 126B Unknown 1.12 1.59 1.10 0.77 
Cfa.12862.1.S1_at Unknown Unknown Unknown 1.13 0.59 1.00 1.64 
Cfa.4340.1.S1_at Unknown Unknown Unknown 1.13 1.56 1.73 2.22 
CfaAffx.27678.1.S1_s_at LOC4798 CG8202-PA Unknown 1.13 1.00 0.85 0.44 
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25 
CfaAffx.24047.1.S1_at 
ZCCHC2
4 
zinc finger, CCHC domain 
containing 24 Unknown 1.13 2.09 1.13 6.88 
Cfa.2274.1.A1_at Unknown Unknown Unknown 1.13 1.36 1.30 1.77 
Cfa.15922.1.S1_at 
LOC6079
11 CG5057-PA Unknown 1.14 1.61 1.13 1.03 
Cfa.15212.1.A1_at Unknown Unknown Unknown 1.14 1.37 0.98 0.79 
Cfa.14203.1.A1_at Unknown Unknown Unknown 1.14 0.93 1.02 0.77 
CfaAffx.19604.1.S1_x_at 
LOC4823
54 CG17059-PA Unknown 1.14 1.14 1.04 0.64 
CfaAffx.26385.1.S1_s_at 
LOC4767
03 UPF0139 protein CGI-140 Unknown 1.15 1.13 1.25 0.67 
Cfa.1684.1.S1_at Unknown Unknown Unknown 1.15 1.95 1.33 4.16 
Cfa.13620.2.A1_at NAT5 
N-acetyltransferase 5 (GCN5-
related, putative) Unknown 1.16 1.74 1.02 0.82 
Cfa.10094.1.A1_at Unknown Unknown Unknown 1.16 1.06 1.63 1.52 
CfaAffx.15852.1.S1_s_at CCDC56 coiled-coil domain containing 56 Unknown 1.16 1.31 1.03 0.55 
Cfa.13620.2.A1_s_at NAT5 
N-acetyltransferase 5 (GCN5-
related, putative) Unknown 1.16 1.38 1.03 0.92 
Cfa.9894.1.A1_s_at Unknown Unknown Unknown 1.16 1.43 1.01 0.72 
Cfa.20266.1.S1_at Unknown Unknown Unknown 1.17 1.36 1.28 2.31 
CfaAffx.23773.1.S1_at Unknown Unknown Unknown 1.18 2.16 1.51 2.25 
Cfa.2986.1.A1_at MYO1B myosin IB Unknown 1.18 0.38 1.28 1.36 
Cfa.13782.1.A1_at Unknown Unknown Unknown 1.19 0.76 1.04 1.26 
CfaAffx.27804.1.S1_s_at Unknown Unknown Unknown 1.19 1.09 3.19 1.22 
Cfa.4496.1.S1_at Unknown Unknown Unknown 1.20 0.51 1.15 1.84 
Cfa.357.1.A1_at Unknown Unknown Unknown 1.20 0.56 1.83 1.67 
Cfa.11126.1.A1_at Unknown Unknown Unknown 1.20 0.55 1.43 2.75 
CfaAffx.27689.1.S1_s_at TTC19 tetratricopeptide repeat domain 19 Unknown 1.21 1.81 0.92 1.17 
Cfa.20536.1.S1_at Unknown Unknown Unknown 1.21 1.76 1.09 2.05 
Cfa.7392.1.A1_at Unknown Unknown Unknown 1.21 0.96 1.74 0.77 
Cfa.10255.1.A1_s_at MYO1B myosin IB Unknown 1.21 0.50 1.46 1.53 
Cfa.20323.1.S1_at Unknown Unknown Unknown 1.21 0.50 0.80 2.83 
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Cfa.14738.1.A1_at Unknown Unknown Unknown 1.22 0.53 1.86 1.81 
Cfa.10469.1.A1_at 
LOC6096
88 hypothetical protein LOC609688 Unknown 1.22 0.46 1.47 1.68 
Cfa.12222.1.A1_at NKG7 natural killer cell group 7 sequence Unknown 1.22 1.12 2.57 1.00 
Cfa.561.1.S1_at Unknown Unknown Unknown 1.22 1.53 1.09 0.90 
CfaAffx.790.1.S1_s_at 
LOC6078
74 hypothetical protein LOC607874 Unknown 1.23 1.26 1.29 1.53 
CfaAffx.17653.1.S1_s_at Unknown Unknown Unknown 1.23 1.36 1.09 0.73 
CfaAffx.16189.1.S1_s_at 
LOC6079
11 CG5057-PA Unknown 1.24 1.65 1.14 1.04 
Cfa.9154.1.A1_at Unknown Unknown Unknown 1.24 1.84 1.60 5.02 
Cfa.17944.1.S1_s_at WRB tryptophan rich basic protein Unknown 1.25 1.86 1.22 1.07 
Cfa.10255.1.A1_at MYO1B myosin IB Unknown 1.26 0.48 1.45 1.31 
Cfa.5401.1.A1_at Unknown Unknown Unknown 1.26 1.80 1.65 7.47 
CfaAffx.12389.1.S1_s_at Unknown Unknown Unknown 1.26 1.26 1.24 1.14 
Cfa.17018.1.S1_at Unknown Unknown Unknown 1.27 1.41 0.92 0.47 
Cfa.29.1.S1_at 
LOC4035
31 hypothetical protein LOC403531 Unknown 1.27 1.47 0.83 0.64 
Cfa.1619.1.S1_s_at 
TMEM18
3A transmembrane protein 183A Unknown 1.27 1.24 1.13 0.73 
Cfa.11259.1.A1_at Unknown Unknown Unknown 1.28 1.83 1.56 2.10 
Cfa.619.1.A1_at Unknown Unknown Unknown 1.28 0.87 0.92 2.51 
CfaAffx.17680.1.S1_x_at Unknown Unknown Unknown 1.28 1.28 0.93 0.43 
CfaAffx.26418.1.S1_s_at 
LOC4801
36 
Protein C1orf43 (Hepatitis C virus 
NS5A-transactivated protein 4) 
(NICE-3 protein) (S863-3) Unknown 1.29 1.74 0.95 0.81 
Cfa.3217.2.S1_at Unknown Unknown Unknown 1.30 1.36 1.46 1.94 
Cfa.8736.1.A1_at Unknown Unknown Unknown 1.30 1.96 1.25 1.59 
Cfa.9677.1.A1_at Unknown Unknown Unknown 1.31 1.74 1.03 0.96 
CfaAffx.135.1.S1_at Unknown Unknown Unknown 1.31 1.49 1.23 0.92 
Cfa.5822.1.A1_at Unknown Unknown Unknown 1.34 1.03 1.49 2.25 
Cfa.12423.2.A1_s_at CBWD2 COBW domain containing 2 Unknown 1.34 1.53 1.48 1.70 
CfaAffx.16169.1.S1_at Unknown Unknown Unknown 1.35 2.10 1.19 1.44 
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CfaAffx.30489.1.S1_s_at COX4NB COX4 neighbor Unknown 1.35 1.47 1.02 0.71 
Cfa.10334.1.A1_at Unknown Unknown Unknown 1.35 1.03 1.85 2.13 
Cfa.3200.1.S1_at Unknown Unknown Unknown 1.36 1.50 1.17 0.85 
Cfa.612.1.A1_at Unknown Unknown Unknown 1.37 1.25 1.39 1.94 
Cfa.21169.1.S1_s_at 
CCDC10
9A coiled-coil domain containing 109A Unknown 1.37 1.39 1.27 1.25 
Cfa.20251.2.S1_at UBAC2 UBA domain containing 2 Unknown 1.38 1.63 1.23 1.01 
Cfa.17111.1.S1_at Unknown Unknown Unknown 1.38 1.71 1.35 1.44 
CfaAffx.7266.1.S1_s_at 
LOC6077
44 hypothetical protein LOC607744 Unknown 1.38 1.74 1.60 1.01 
CfaAffx.14005.1.S1_at Unknown Unknown Unknown 1.39 1.50 1.43 1.31 
Cfa.6676.1.S1_s_at 
TMEM20
8 transmembrane protein 208 Unknown 1.40 1.47 1.36 0.90 
Cfa.2446.1.S1_at Unknown Unknown Unknown 1.40 1.86 1.08 1.17 
Cfa.19700.1.S1_s_at Unknown Unknown Unknown 1.41 1.74 0.85 0.38 
CfaAffx.17246.1.S1_at Unknown Unknown Unknown 1.41 1.42 1.47 1.30 
CfaAffx.28227.1.S1_at Unknown Unknown Unknown 1.43 1.67 5.10 1.26 
CfaAffx.13938.1.S1_s_at 
TMEM19
2 transmembrane protein 192 Unknown 1.43 1.89 0.95 0.69 
Cfa.3033.1.A1_at Unknown Unknown Unknown 1.44 1.57 1.87 1.77 
Cfa.5302.1.A1_at Unknown Unknown Unknown 1.45 2.12 1.36 4.15 
CfaAffx.7071.1.S1_s_at Unknown Unknown Unknown 1.47 1.66 1.35 1.56 
CfaAffx.6771.1.S1_s_at Unknown Unknown Unknown 1.49 1.43 1.98 2.48 
CfaAffx.12621.1.S1_s_at LETMD1 LETM1 domain containing 1 Unknown 1.49 2.73 0.87 0.47 
CfaAffx.11484.1.S1_at IMPAD1 
inositol monophosphatase domain 
containing 1 Unknown 1.50 1.97 1.68 1.95 
Cfa.2750.1.A1_at Unknown Unknown Unknown 1.50 2.19 2.02 4.80 
CfaAffx.26728.1.S1_s_at CALML4 calmodulin-like 4 Unknown 1.51 1.99 1.73 1.23 
Cfa.13544.1.A1_at TSPAN9 tetraspanin 9 Unknown 1.52 1.70 1.43 1.40 
Cfa.3200.1.S1_s_at Unknown Unknown Unknown 1.52 1.62 1.30 1.29 
Cfa.15718.1.S1_at Unknown Unknown Unknown 1.53 1.47 1.31 1.15 
CfaAffx.413.1.S1_s_at Unknown Unknown Unknown 1.54 1.58 1.71 1.25 
CfaAffx.18042.1.S1_s_at LOC6072 CG10581-PA Unknown 1.59 1.73 1.41 1.46 
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37 
Cfa.5605.1.A1_at TCTN2 tectonic family member 2 Unknown 1.60 1.23 1.78 0.95 
CfaAffx.3629.1.S1_at Unknown Unknown Unknown 1.62 1.80 1.43 1.61 
CfaAffx.12624.1.S1_s_at LETMD1 LETM1 domain containing 1 Unknown 1.63 2.84 0.82 0.46 
Cfa.318.1.A1_at Unknown Unknown Unknown 1.63 1.62 1.85 1.65 
Cfa.10216.1.A1_a_at 
LOC6072
37 CG10581-PA Unknown 1.64 1.80 1.40 1.39 
CfaAffx.10845.1.S1_at WDFY4 WDFY family member 4 Unknown 1.64 3.13 1.69 3.01 
Cfa.11798.1.A1_at Unknown Unknown Unknown 1.65 1.70 1.55 1.28 
Cfa.13913.1.A1_at Unknown Unknown Unknown 1.66 1.63 2.00 1.80 
CfaAffx.2185.1.S1_at 
LOC4812
08 Protein C22orf8 Unknown 1.67 5.60 1.90 4.81 
Cfa.7065.2.A1_at Unknown Unknown Unknown 1.68 2.35 1.62 2.58 
Cfa.10891.1.A1_at 
TMEM21
8 transmembrane protein 218 Unknown 1.68 2.63 1.71 2.43 
Cfa.15718.1.S1_s_at Unknown Unknown Unknown 1.69 1.75 1.39 1.17 
CfaAffx.9510.1.S1_s_at MEMO1 mediator of cell motility 1 Unknown 1.71 1.80 1.64 1.70 
CfaAffx.10845.1.S1_s_at WDFY4 WDFY family member 4 Unknown 1.71 3.13 1.67 3.38 
CfaAffx.26728.1.S1_at CALML4 calmodulin-like 4 Unknown 1.71 2.33 1.55 1.11 
Cfa.9445.1.A1_at CALML4 calmodulin-like 4 Unknown 1.72 2.18 1.87 1.45 
Cfa.4318.1.S1_s_at 
TMEM16
0 transmembrane protein 160 Unknown 1.73 2.08 1.77 1.12 
CfaAffx.29216.1.S1_at HMGB3 high-mobility group box 3 Unknown 1.74 1.99 1.93 4.78 
Cfa.5660.1.A1_at Unknown Unknown Unknown 1.76 1.74 1.76 1.52 
CfaAffx.12132.1.S1_s_at Unknown Unknown Unknown 1.78 2.17 1.99 1.07 
Cfa.19037.1.S1_at Unknown Unknown Unknown 1.78 1.71 1.52 1.14 
Cfa.4682.1.A1_at Unknown Unknown Unknown 1.79 1.32 2.17 1.48 
Cfa.8972.1.S1_at 
LOC4785
84 
growth and transformation-
dependent protein Unknown 1.79 1.87 1.50 1.88 
CfaAffx.1452.1.S1_s_at PPM1H 
protein phosphatase 1H (PP2C 
domain containing) Unknown 1.80 2.27 1.67 2.05 
CfaAffx.5847.1.S1_at 
LOC6081
73 hypothetical protein LOC608173 Unknown 1.80 1.70 1.45 0.95 
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Cfa.20604.1.S1_at Unknown Unknown Unknown 1.80 2.03 1.59 1.47 
Cfa.14716.1.A1_at 
LOC4755
40 testis-specific histone 2b Unknown 1.82 1.96 2.00 3.83 
CfaAffx.20175.1.S1_at 
LOC4035
31 hypothetical protein LOC403531 Unknown 1.82 2.21 1.01 0.53 
Cfa.10237.1.S1_at Unknown Unknown Unknown 1.83 2.07 1.74 1.31 
Cfa.14628.1.A1_at Unknown Unknown Unknown 1.84 1.60 1.65 1.41 
Cfa.526.1.A1_at Unknown Unknown Unknown 1.84 0.77 1.70 3.40 
Cfa.5855.1.A1_at Unknown Unknown Unknown 1.85 1.96 1.83 1.48 
CfaAffx.1907.1.S1_s_at CW-1 
Cytoplasmic dynein light chain (T-
complex testis-specific protein 1 
homolog) (Protein CW-1) Unknown 1.88 2.03 1.84 1.21 
Cfa.12161.1.A1_at 
PRKCDB
P 
protein kinase C, delta binding 
protein Unknown 1.90 1.76 1.64 1.20 
Cfa.20978.1.S1_s_at 
PRKCDB
P 
protein kinase C, delta binding 
protein Unknown 1.90 1.59 1.58 0.96 
Cfa.9272.1.A1_at Unknown Unknown Unknown 1.91 2.15 1.52 1.34 
Cfa.2050.2.A1_at Unknown Unknown Unknown 1.91 1.73 1.97 1.72 
Cfa.5665.1.A1_at Unknown Unknown Unknown 1.92 2.13 1.60 1.53 
Cfa.12014.1.A1_a_at CW-1 
Cytoplasmic dynein light chain (T-
complex testis-specific protein 1 
homolog) (Protein CW-1) Unknown 1.94 2.08 1.82 1.36 
Cfa.6830.1.A1_at Unknown Unknown Unknown 1.99 2.55 1.62 1.75 
Cfa.14322.1.A1_at Unknown Unknown Unknown 2.00 2.61 1.41 1.32 
CfaAffx.2199.1.S1_at 
LOC4812
10 CG9646-PA Unknown 2.02 2.21 2.14 6.47 
Cfa.7651.1.S1_at Unknown Unknown Unknown 2.04 2.32 1.52 2.21 
Cfa.9578.1.A1_at Unknown Unknown Unknown 2.05 2.21 2.20 3.72 
CfaAffx.17082.1.S1_s_at 
TMEM21
8 transmembrane protein 218 Unknown 2.05 3.98 1.86 2.36 
CfaAffx.25721.1.S1_at PAPLN 
papilin, proteoglycan-like sulfated 
glycoprotein Unknown 2.07 3.70 2.39 2.60 
Cfa.9724.1.A1_at Unknown Unknown Unknown 2.09 1.84 1.73 5.89 
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CfaAffx.11275.1.S1_s_at Unknown Unknown Unknown 2.12 2.62 1.58 1.36 
CfaAffx.14696.1.S1_at 
TMEM45
A transmembrane protein 45A Unknown 2.13 1.47 3.25 1.97 
CfaAffx.26190.1.S1_s_at 
LOC4803
96 CG5780-PA Unknown 2.14 2.56 1.83 1.36 
Cfa.15784.1.A1_at Unknown Unknown Unknown 2.14 2.46 2.25 2.80 
Cfa.5059.1.A1_at Unknown Unknown Unknown 2.14 2.43 1.95 4.62 
Cfa.15460.1.A1_at CENPP centromere protein P Unknown 2.15 2.20 1.13 0.95 
Cfa.14576.1.A1_at Unknown Unknown Unknown 2.16 1.89 2.84 1.17 
Cfa.528.1.S1_at Unknown Unknown Unknown 2.17 2.38 2.13 1.72 
Cfa.1498.1.A1_at Unknown Unknown Unknown 2.22 2.67 2.05 4.21 
Cfa.2465.1.A1_at AGPHD1 
aminoglycoside phosphotransferase 
domain containing 1 Unknown 2.24 3.04 1.48 1.83 
Cfa.8072.1.A1_at Unknown Unknown Unknown 2.24 2.09 1.77 1.41 
Cfa.12038.1.A1_at 
LOC4803
96 CG5780-PA Unknown 2.24 2.51 1.83 1.55 
CfaAffx.17035.1.S1_at Unknown Unknown Unknown 2.27 2.64 2.38 2.16 
Cfa.15428.1.A1_at Unknown Unknown Unknown 2.31 2.05 1.92 1.49 
CfaAffx.11718.1.S1_s_at Unknown Unknown Unknown 2.36 3.63 2.21 2.81 
CfaAffx.18465.1.S1_at 
HSPA12
A heat shock 70kDa protein 12A Unknown 2.36 5.14 1.77 3.70 
CfaAffx.12039.1.S1_at TMEM22 transmembrane protein 22 Unknown 2.37 1.22 1.98 1.28 
Cfa.10071.1.A1_at Unknown Unknown Unknown 2.43 2.07 2.28 1.57 
CfaAffx.953.1.S1_s_at HMGB3 high-mobility group box 3 Unknown 2.47 3.36 2.12 6.50 
CfaAffx.11724.1.S1_s_at Unknown Unknown Unknown 2.51 3.03 1.89 2.56 
Cfa.18386.1.S1_s_at PDLIM4 PDZ and LIM domain 4 Unknown 2.53 1.28 1.64 0.56 
CfaAffx.2165.1.S1_s_at PDLIM4 PDZ and LIM domain 4 Unknown 2.58 1.32 1.87 0.81 
Cfa.11829.1.A1_s_at Unknown Unknown Unknown 2.60 3.81 2.40 3.44 
Cfa.10899.1.A1_at Unknown Unknown Unknown 2.64 2.68 5.38 2.40 
Cfa.528.2.S1_a_at Unknown Unknown Unknown 2.65 3.97 2.86 1.96 
Cfa.14981.1.S1_at Unknown Unknown Unknown 2.66 2.42 1.95 1.19 
Cfa.14981.1.S1_s_at Unknown Unknown Unknown 2.66 2.22 1.94 1.17 
Cfa.3073.1.A1_at Unknown Unknown Unknown 2.75 2.41 2.31 1.98 
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CfaAffx.17681.1.S1_x_at Unknown Unknown Unknown 2.78 2.68 2.37 2.48 
Cfa.16704.1.S1_at Unknown Unknown Unknown 2.79 4.65 2.72 4.16 
CfaAffx.3092.1.S1_x_at Unknown Unknown Unknown 2.80 2.63 2.38 2.72 
CfaAffx.22872.1.S1_s_at Unknown Unknown Unknown 2.85 4.36 2.49 5.50 
Cfa.10704.1.S1_at Unknown Unknown Unknown 2.86 3.33 2.12 1.65 
Cfa.14829.1.A1_at Unknown Unknown Unknown 2.91 2.46 2.75 2.80 
CfaAffx.1802.1.S1_s_at 
GRAMD
3 GRAM domain containing 3 Unknown 2.92 2.37 2.27 1.66 
Cfa.8366.1.A1_at Unknown Unknown Unknown 2.93 4.53 2.17 3.37 
Cfa.12855.1.A1_at Unknown Unknown Unknown 2.94 6.45 4.09 11.33 
CfaAffx.24121.1.S1_at 
LOC6105
26 Protein C10orf57 homolog Unknown 3.04 3.21 2.36 1.41 
Cfa.2495.1.S1_at Unknown Unknown Unknown 3.15 2.10 2.39 2.04 
Cfa.13067.1.A1_at Unknown Unknown Unknown 3.17 3.50 2.64 2.61 
Cfa.8312.1.A1_at Unknown Unknown Unknown 3.25 2.63 3.19 3.19 
CfaAffx.23941.1.S1_s_at Unknown Unknown Unknown 3.45 3.81 2.20 1.76 
CfaAffx.2246.1.S1_at Unknown Unknown Unknown 3.65 2.92 2.61 2.17 
CfaAffx.7944.1.S1_at Unknown Unknown Unknown 3.90 2.25 3.64 1.69 
CfaAffx.19953.1.S1_at Unknown Unknown Unknown 4.29 4.83 4.17 3.61 
Cfa.6341.1.A1_at 
PDZK1IP
1 PDZK1 interacting protein 1 Unknown 4.30 2.18 2.23 0.54 
CfaAffx.22032.1.S1_s_at Unknown Unknown Unknown 4.48 2.14 1.14 1.04 
CfaAffx.6961.1.S1_s_at 
PDZK1IP
1 PDZK1 interacting protein 1 Unknown 4.49 1.88 2.20 0.62 
Cfa.16302.1.A1_at Unknown Unknown Unknown 4.80 3.72 4.72 6.06 
Cfa.17639.1.S1_s_at LCR 
Lung carbonyl reductase [NADPH] 
(NADPH-dependent carbonyl 
reductase) (LCR) (Adipocyte P27 
protein) (AP27) Unknown 5.17 6.07 1.93 1.90 
Cfa.14409.1.A1_at Unknown Unknown Unknown 7.39 5.10 4.92 2.15 
Cfa.11741.1.A1_s_at Unknown Unknown Unknown 9.10 2.64 8.44 2.27 
Cfa.11186.1.A1_at Unknown Unknown Unknown 
11.2
0 
55.6
8 4.08 47.13 
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Cfa.12107.1.A1_at Unknown Unknown Unknown 
11.9
8 7.26 2.97 4.64 
CfaAffx.21494.1.S1_at TPRG1 tumor protein p63 regulated 1 Unknown 
12.2
9 
15.5
3 7.64 5.88 
CfaAffx.28624.1.S1_s_at UGT3A2 
UDP glycosyltransferase 3 family, 
polypeptide A2 Unknown 
16.6
0 
22.8
0 9.57 8.62 
Cfa.13159.1.A1_at Unknown Unknown Unknown 
17.2
5 
25.2
2 8.66 8.01 
Cfa.3358.1.S1_at Unknown Unknown Unknown 
17.7
1 5.20 13.43 7.62 
Cfa.125.1.S1_s_at EDN1 endothelin 1 Vasoconstriction 0.32 0.50 0.38 0.59 
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Appendix B: Enriched KEGG pathway gene transcripts differentially expressed between gonadal and subcutaneous adipose tissue in 
lean and obese dogs 
 
    Fold Change 
KEGG Pathway Probe Symbol Description Obese Lean 
Amino sugar and nucleotide sugar 
metabolism CFA.16909.1.S1_S_AT NANS 
N-acetylneuraminic acid 
synthase  -3.51 
Amino sugar and nucleotide sugar 
metabolism CFAAFFX.29683.1.S1_AT RENBP renin binding protein  -4.04 
Amino sugar and nucleotide sugar 
metabolism CFAAFFX.29579.1.S1_S_AT AMDHD2 
amidohydrolase domain 
containing 2  -2.24 
Amino sugar and nucleotide sugar 
metabolism CFA.12553.1.A1_S_AT GFPT2 
glutamine-fructose-6-phosphate 
transaminase 2  -5.48 
Amino sugar and nucleotide sugar 
metabolism CFA.1666.1.S1_AT GNPNAT1 
glucosamine-phosphate N-
acetyltransferase 1  -2.72 
Amino sugar and nucleotide sugar 
metabolism CFAAFFX.1631.1.S1_S_AT GFPT2 
glutamine-fructose-6-phosphate 
transaminase 2  -6.32 
Amino sugar and nucleotide sugar 
metabolism CFAAFFX.22817.1.S1_AT GNPNAT1 
glucosamine-phosphate N-
acetyltransferase 1  -2.39 
Complement and coagulation 
cascades CFA.15714.1.A1_AT KLKB1 
kallikrein B, plasma (Fletcher 
factor) 1 2.97  
Complement and coagulation 
cascades CFAAFFX.7180.1.S1_S_AT C5AR1 
complement component 5a 
receptor 1 -3.94 -5.29 
Complement and coagulation 
cascades CFA.21548.1.S1_S_AT LOC481722 
similar to Complement C4 
precursor 3.06  
Complement and coagulation 
cascades CFA.4812.1.A1_AT C6 complement component 6 25.23 13.89 
Complement and coagulation 
cascades CFA.13217.1.A1_S_AT C3 complement component 3 40.97 12.29 
Complement and coagulation 
cascades CFA.13267.1.A1_S_AT C3 complement component 3 24.98 8.73 
Complement and coagulation 
cascades CFAAFFX.28463.1.S1_AT C3 complement component 3 21.29 7.04 
Complement and coagulation 
cascades CFA.5944.1.A1_AT RDBP RD RNA binding protein 3.26 3.40 
Complement and coagulation CFA.15481.1.A1_AT C8G complement component 8, -4.38  
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cascades gamma polypeptide 
Complement and coagulation 
cascades CFA.13267.2.S1_S_AT C3 complement component 3 27.75 9.53 
Complement and coagulation 
cascades CFA.6458.1.A1_S_AT CFB complement factor B 36.71 18.20 
Complement and coagulation 
cascades CFA.3834.1.S1_AT C5AR1 
complement component 5a 
receptor 1 -2.75 -4.61 
Complement and coagulation 
cascades CFAAFFX.28425.1.S1_S_AT C6 complement component 6 25.65 19.68 
Complement and coagulation 
cascades CFA.19007.1.S1_S_AT C7 complement component 7 3.80  
Complement and coagulation 
cascades CFAAFFX.28437.1.S1_S_AT C7 complement component 7 2.98  
Complement and coagulation 
cascades CFA.18884.1.S1_S_AT C3 complement component 3 35.86 11.44 
Complement and coagulation 
cascades CFA.1379.1.S1_AT C1QA 
complement component 1, q 
subcomponent, A chain  -2.93 
Complement and coagulation 
cascades CFA.13268.1.A1_AT C6 complement component 6 5.72  
Complement and coagulation 
cascades CFA.15539.1.A1_S_AT KLKB1 
kallikrein B, plasma (Fletcher 
factor) 1 4.65  
Complement and coagulation 
cascades CFA.12240.1.A1_AT C3 complement component 3 15.75 5.81 
Complement and coagulation 
cascades CFA.8846.1.A1_S_AT CFB complement factor B 31.91 13.42 
Complement and coagulation 
cascades CFA.10821.1.A1_S_AT C1S 
complement component 1, s 
subcomponent  -2.53 
Complement and coagulation 
cascades CFAAFFX.17824.1.S1_S_AT CFI complement factor I 2.66  
Complement and coagulation 
cascades CFA.18899.1.S1_S_AT HEATR7B2 
HEAT repeat family member 
7B2 22.42 13.25 
Complement and coagulation 
cascades CFA.14267.1.S1_AT CFB complement factor B -2.20  
Complement and coagulation 
cascades CFA.13268.1.A1_S_AT C6 complement component 6 21.61 18.44 
ECM-receptor interaction CFA.10634.1.A1_AT ITGA7 integrin, alpha 7 -2.59  
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ECM-receptor interaction CFA.3707.3.S1_S_AT FN1 fibronectin 1 -4.74  
ECM-receptor interaction CFA.14626.1.S1_AT COL3A1 collagen, type III, alpha 1 -2.64  
ECM-receptor interaction CFA.18707.1.S1_S_AT LAMB1 laminin, beta 1 3.54  
ECM-receptor interaction CFA.100.1.S1_AT COL1A1 collagen, type I, alpha 1 -2.96  
ECM-receptor interaction CFA.3800.2.S1_AT CD44 
CD44 molecule (Indian blood 
group) -3.82  
ECM-receptor interaction CFA.3800.1.S1_S_AT CD44 
CD44 molecule (Indian blood 
group) -3.42  
ECM-receptor interaction CFA.15297.1.A1_AT COL4A1 collagen, type IV, alpha 1 -2.15  
ECM-receptor interaction CFAAFFX.14209.1.S1_S_AT THBS4 thrombospondin 4 -26.88  
ECM-receptor interaction CFAAFFX.1052.1.S1_S_AT ITGA7 integrin, alpha 7 -2.91  
ECM-receptor interaction CFA.3112.1.S1_AT SDC4 syndecan 4 2.48  
ECM-receptor interaction CFA.21446.1.S1_AT SDC4 syndecan 4 3.16  
Focal adhesion CFAAFFX.18556.1.S1_AT FIGF c-fos induced growth factor  3.20 
Focal adhesion CFA.20235.1.S1_S_AT FYN 
FYN oncogene related to SRC, 
FGR, YES  -2.26 
Focal adhesion CFAAFFX.25315.1.S1_S_AT ACTN1 actinin, alpha 1  -2.66 
Focal adhesion CFAAFFX.14209.1.S1_S_AT THBS4 thrombospondin 4  -12.02 
Focal adhesion CFA.1262.1.S1_S_AT COL1A2 collagen, type I, alpha 2  -2.56 
Focal adhesion CFA.100.1.S1_S_AT COL1A1 collagen, type I, alpha 1  -12.38 
Focal adhesion CFA.16248.1.S1_AT CCND1 cyclin D1  -3.84 
Focal adhesion CFA.3524.1.S2_AT EGF 
epidermal growth factor (beta-
urogastrone)  -7.68 
Focal adhesion CFA.1011.1.S1_AT RAP1B 
RAP1B, member of RAS 
oncogene family  -2.17 
Focal adhesion CFA.100.1.S2_AT COL1A1 collagen, type I, alpha 1  -14.38 
Focal adhesion CFA.6798.1.A1_S_AT ITGA11 integrin, alpha 11  -2.24 
Focal adhesion CFAAFFX.6036.1.S1_S_AT CAV2 caveolin 2  2.96 
Focal adhesion CFA.18707.1.S1_S_AT LAMB1 laminin, beta 1  2.98 
Focal adhesion CFA.1262.1.S2_AT COL1A2 collagen, type I, alpha 2  -5.99 
Focal adhesion CFA.100.1.S1_AT COL1A1 collagen, type I, alpha 1  -4.49 
Focal adhesion CFA.1262.1.S2_S_AT COL1A2 collagen, type I, alpha 2  -6.05 
Glutathione metabolism CFAAFFX.30320.1.S1_S_AT GSTM1 glutathione S-transferase mu 1  2.54 
Glutathione metabolism CFA.13231.1.A1_AT GSTM1 glutathione S-transferase mu 1  3.39 
Glutathione metabolism CFAAFFX.21677.1.S1_S_AT GSTT1 glutathione S-transferase theta 1  4.41 
Glutathione metabolism CFA.14362.1.S1_S_AT LOC477558 similar to Glutathione S-  4.23 
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transferase theta 2 
Glutathione metabolism CFAAFFX.1833.1.S1_AT RRM2B 
ribonucleotide reductase M2 B 
(TP53 inducible)  2.16 
Glutathione metabolism CFAAFFX.455.1.S1_S_AT LOC477558 
similar to Glutathione S-
transferase theta 2  2.73 
Glutathione metabolism CFA.878.1.A1_AT GSTM3 
glutathione S-transferase mu 3 
(brain)  2.86 
Glutathione metabolism CFA.4791.1.A1_AT GSTT1 glutathione S-transferase theta 1  4.21 
Glutathione metabolism CFA.17201.1.S1_AT GSTM1 glutathione S-transferase mu 1  2.30 
Glutathione metabolism CFA.878.1.A1_S_AT GSTM3 
glutathione S-transferase mu 3 
(brain)  3.29 
Glutathione metabolism CFA.20798.1.S1_AT ANPEP 
alanyl (membrane) 
aminopeptidase  -4.33 
Lysosome CFAAFFX.23020.1.S1_AT NAGLU N-acetylglucosaminidase, alpha- -2.83  
Lysosome CFAAFFX.18787.1.S1_AT CTSK cathepsin K -3.09 -3.72 
Lysosome CFA.13105.1.A1_AT   -2.08 -2.22 
Lysosome CFAAFFX.19926.1.S1_S_AT LOC480283 
similar to Adapter-related 
protein complex 4 sigma 1 
subunit 2.02 2.83 
Lysosome CFA.11935.1.A1_AT LGMN legumain -2.26 -2.77 
Lysosome CFA.8631.1.A1_AT LGMN legumain -3.38 -3.68 
Lysosome CFAAFFX.15770.1.S1_S_AT CTSD cathepsin D -2.87  
Lysosome CFA.588.1.S1_AT CTSK cathepsin K -2.84 -3.49 
Lysosome CFA.13370.1.A1_AT CD68 CD68 molecule -4.01  
Lysosome CFA.11351.1.A1_S_AT  TCIRG1 -2.41  
Lysosome CFAAFFX.26400.1.S1_S_AT MAN2B1 
mannosidase, alpha, class 2B, 
member 1  -2.25 
Lysosome CFA.809.1.A1_AT   -2.29  
Lysosome CFA.14639.1.S1_AT SLC11A1 
solute carrier family 11, member 
1 -3.60  
Lysosome CFA.102.1.S1_S_AT PLA2G15 phospholipase A2, group XV -2.03  
Lysosome CFAAFFX.14173.1.S1_S_AT CTSC cathepsin C -2.63  
Lysosome CFA.11351.1.A1_AT TCIRG1 
T-cell, immune regulator 1, 
ATPase, H+ transporting, 
lysosomal V0 subunit A3 -2.77  
Lysosome CFAAFFX.24089.1.S1_AT LIPA lipase A, lysosomal acid, -2.49  
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cholesterol esterase 
Lysosome CFA.9432.1.A1_AT AP3B2 
adaptor-related protein complex 
3, beta 2 subunit -5.31  
Lysosome CFAAFFX.17218.1.S1_AT LGMN legumain -2.04 -2.49 
Lysosome CFA.17547.1.S1_AT CTSD cathepsin D -3.24 -2.14 
Lysosome CFA.20896.1.S1_S_AT LGMN legumain -2.09  
Renin-angiotensin system CFA.13105.1.A1_AT   -2.08  
Renin-angiotensin system CFAAFFX.18739.1.S1_S_AT  31.35  
Renin-angiotensin system CFA.3774.1.A1_S_AT ANPEP 
alanyl (membrane) 
aminopeptidase -4.75  
Renin-angiotensin system CFA.3982.1.A1_AT AGT angiotensinogen  17.29  
Renin-angiotensin system CFA.3646.1.S1_AT AGT angiotensinogen  18.29  
Renin-angiotensin system CFA.13894.1.S1_S_AT MME 
membrane metallo-
endopeptidase -3.95  
Renin-angiotensin system CFA.20798.1.S1_AT ANPEP 
alanyl (membrane) 
aminopeptidase -3.78  
Synthesis and degradation of ketone 
bodies CFAAFFX.28412.1.S1_S_AT OXCT1 3-oxoacid CoA transferase 1  3.54 
Synthesis and degradation of ketone 
bodies CFA.21053.1.S1_S_AT OXCT1 3-oxoacid CoA transferase 1  3.70 
Synthesis and degradation of ketone 
bodies CFA.14368.1.A1_AT HMGCS2 
3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 
(mitochondrial)  3.39 
Synthesis and degradation of ketone 
bodies CFAAFFX.28412.1.S1_AT OXCT1 3-oxoacid CoA transferase 1  6.62 
Synthesis and degradation of ketone 
bodies CFAAFFX.20668.1.S1_AT BDH1 
3-hydroxybutyrate 
dehydrogenase, type 1  3.53 
Systemic lupus erythematosus CFAAFFX.25315.1.S1_S_AT ACTN1 actinin, alpha 1  -2.66 
Systemic lupus erythematosus CFA.17841.1.S1_S_AT ACTN4 actinin, alpha 4 2.43  
Systemic lupus erythematosus CFA.10821.1.A1_S_AT C1S 
complement component 1, s 
subcomponent  -2.53 
Systemic lupus erythematosus CFA.13217.1.A1_S_AT C3 complement component 3 40.97 12.29 
Systemic lupus erythematosus CFA.13267.1.A1_S_AT C3 complement component 3 24.98 8.73 
Systemic lupus erythematosus CFAAFFX.28463.1.S1_AT C3 complement component 3 21.29 7.04 
Systemic lupus erythematosus CFA.13267.2.S1_S_AT C3 complement component 3 27.75 9.53 
Systemic lupus erythematosus CFA.18884.1.S1_S_AT C3 complement component 3 35.86 11.44 
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Systemic lupus erythematosus CFA.12240.1.A1_AT C3 complement component 3 15.75 5.81 
Systemic lupus erythematosus CFA.4812.1.A1_AT C6 complement component 6 25.23 13.89 
Systemic lupus erythematosus CFAAFFX.28425.1.S1_S_AT C6 complement component 6 25.65 19.68 
Systemic lupus erythematosus CFA.13268.1.A1_AT C6 complement component 6 5.72 19.68 
Systemic lupus erythematosus CFA.13268.1.A1_S_AT C6 complement component 6 21.61 18.44 
Systemic lupus erythematosus CFA.19007.1.S1_S_AT C7 complement component 7 3.80  
Systemic lupus erythematosus CFAAFFX.28437.1.S1_S_AT C7 complement component 7 2.98  
Systemic lupus erythematosus CFA.15481.1.A1_AT C8G 
complement component 8, 
gamma polypeptide -4.38  
Systemic lupus erythematosus CFA.3596.2.S1_AT CD80 CD80 molecule -3.10  
Systemic lupus erythematosus CFA.173.1.A1_S_AT FCGR1A 
Fc fragment of IgG, high affinity 
Ia, receptor (CD64) -3.41  
Systemic lupus erythematosus CFA.18899.1.S1_S_AT HEATR7B2 
HEAT repeat family member 
7B2 22.42 13.25 
Systemic lupus erythematosus CFA.14716.1.A1_AT LOC475540 
similar to testis-specific histone 
2b -2.05  
Systemic lupus erythematosus CFAAFFX.791.1.S1_S_AT LOC478743 similar to Histone H2B 291B  2.75 
Systemic lupus erythematosus CFAAFFX.17229.1.S1_X_AT LOC478743 similar to Histone H2B 291B  2.34 
Systemic lupus erythematosus CFA.21548.1.S1_S_AT LOC481722 
similar to Complement C4 
precursor 3.06  
Systemic lupus erythematosus CFAAFFX.17944.1.S1_X_AT LOC483168 
similar to Histone H2A.o 
(H2A/o) (H2A.2) (H2a-615)  7.69 
Systemic lupus erythematosus CFAAFFX.17974.1.S1_AT LOC483173 
similar to H2B histone family, 
member F  2.92 
Systemic lupus erythematosus CFA.5372.1.A1_AT LOC611158 
similar to H2B histone family, 
member T 4.46   
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